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ABSTRACT 
 
 
 
 Since Alexander Fleming first noted the killing of a bacterial culture by a mold, 
antibiotics have revolutionized medicine, being able to treat, and often cure life-threatening 
illnesses and making surgical procedures possible by eliminating the possibility of 
opportunistic infection.  However, during the past 30 years many of the infections that were 
once easily cured by the proper antibiotic are no longer so due to a precipitous rise in multi-
drug resistant organisms.  This rise in multi-drug resistant organisms poses a grave threat to 
the medical advances that have been made in the past century and underscores the need for 
new antibiotics.  We have developed two promising candidates for pharmaceutical 
applications, compounds 72 and 71, which are derived from nonactin, a biologically active 
natural product.     
 Nonactin 40, an ionophore macrotetrolide antibiotic that is produced by Streptomyces 
griseus ETH A7796, is an ideal candidate for the synthesis of new antimicrobial drugs.  This 
secondary metabolite is composed of two units of (+)-nonactic acid 49 and two units of (–)-
nonactic acid 50.  Whereas nonactin does not possess a synthetically useful chemical 
„handle‟, the nonactic acid subunits do.  Through methanolysis of this structure and the 
separation of the two enantiomers, followed by a series of transformations, easily 
iii 
 
diversifiable scaffolds have been synthesized, which allows for the relatively rapid synthesis 
of chemically diverse libraries. 
From a small library of compounds that were synthesized, the compounds, 72 and 71 
were found to show promising activities against vancomycin-resistant Enterococcus faecalis 
(VRE) and methicillin-resistant Staphylococcus aureus (MRSA).  Compounds 88 and 90 
were shown to be the active enantiomers.  It was also shown by making the 1,4-substituted 
triazoles and the 1,5-substituted triazoles 91, 92 that only the 1,4-substituted triazoles gave 
the aforementioned activities.  These results illustrate the vital importance of stereochemistry 
and regiochemistry.   
To establish the importance of the nonactic acid moiety itself in the triazoloester 
compounds, analogues of these compounds were made by replacing the nonactic acid moiety 
with a cyclohexane moiety, specifically starting with both trans and cis 4-cyclohexanol-
carboxylic acid.  Neither the cis nor the trans analogues 131, 132, 142, 143, 151, 152, 160, 
161 of either of the regioisomers of the compounds made to mimic 72 and 71 gave the 
activities of their nonactate-containing counterparts. 
As an alternative to chemical synthesis we investigated biotransformation of nonactic 
acid analogs by Streptomyces griseus.  While we were unable to generate new nonactin 
analogues we did discover an inhibitor of nonactin biosynthesis 186 and we were able to set 
limits on precursor directed biosynthesis in S. griseus.       
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The Missing Piece 
 
 
In the fire the stone, 
 
Turned in the pyre a bone, 
 
Seasoned with the spice of ash. 
 
In the hearth the cauldron, 
 
Melted in the crucible this dust, 
 
Out of the brazen kettle, 
 
Arose a thing of brain, bone, and flesh. 
 
And in the dark stumbled „round, 
 
Until the morning light was found, 
 
Though by all this amalgam had every part, 
 
It fell at the door to dust for lack of a heart. 
 
 
 
       Joshua Bryant Phillips
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CHAPTER 1 
 
 
INTRODUCTION AND BACKGROUND OF ANTIBIOTICS 
 
 
 
1.1  Origin and history of antibiotics 
 
1.1.A  Definitions 
 
An antibiotic is defined as a compound that kills or inhibits the growth of bacteria.[8, 
9]  Some antibiotics are bactericidal and others are bacteriostatic.[3, 8]    Antibiotics include 
antibacterial agents such as penicillin, antifungals such as rifamycin, and antiprotozoal 
compounds such as tetracycline.  They may be natural, synthetic, or semi-synthetic 
compounds which are derived from natural products and chemically modified.  Chemical 
compounds that inhibit the growth or kill an organism are known collectively as 
antimicrobials.[9]  Antimicrobials include antibacterials, antifungals, antiparasitics and 
antiprotozoal.[9]  Compounds that kill microorganisms are bactericidal, while those that 
impede their growth are bacteriostatic agents.[8]   
 Before the isolation of antibiotics, infections had been treated orally and topically 
with a wide range of plants and molds in the Chinese, Greek, Egyptian, and Arab 
cultures.[10, 11]  Modern medicine has since then isolated many of the naturally occurring 
antibiotic compounds that elicited the antibacterial, antifungal, or antiparasitic and 
antiprotozoal activity.  Antibiotics were known originally as antibiosis, a term coined by 
French bacteriologist Vuillemin which meant „against life‟ to describe the antibacterial 
nature of these compounds.[12]  Antibiosis was first described in 1877 by Louis Pasteur and 
Robert Koch when they noted that the growth of Bacillus anthracis was inhibited by an 
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airborne strain of bacillus.[13]  In 1942 these compounds were renamed antibiotics (anti 
„against‟, bios „life‟) by the American microbiologist Selman Wakeman.[12, 14]    
 
1.1.B  Arsenicals and sulfonamides:  development of the first synthetic antibiotics 
 
 Salvarsan 1a, 1b arguably, became the world‟s first antibiotic compound used to treat 
a specific disease and was instrumental in ushering in the age of antibiotics.  Paul Ehrlich, 
working with a team of scientists that included bacteriologist, Sahachiro Hata, and chemist 
Alfred Bertheim, set out to find a „magic bullet‟, a compound that could affect only the target 
organism and not the host.[15]  Ehrlich had noticed in his days as a medical student that 
certain dyes could be used to stain certain microorganisms which lead to this novel idea.[15]  
Putting this idea into practice, he lead a his team to find a compound that would kill 
Trepnema pallidum, the parasite thought responsible for causing syphilis, and not affect the 
host.[15]  Salvarsan was discovered in 1909 during the synthesis and testing of organoarsenic 
compounds by Ehrlich and Bertheim.[15]   
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Figure 1.1:  Structures of Salvarsan.  Salvarsan consists of a mixture of cyclic arsenicals (1a 
and 1b).[1] 
 
As described by Yarnell, A. et al., it was found that a single dose of the compound 
cured syphilis in rabbits.  Salvarsan was placed on the market in 1910 for the treatment of 
syphilis and was used into the 1940‟s, until the discovery and use of penicillin made 
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salvarsan obsolete by virtue of its superior bioavailability and lower toxicity.  Despite 
difficulties in treatment using salvarsan, the pharmaceutical became the world‟s first 
blockbuster drug.[15]         
Cresol, an antiseptic, was the standard treatment for wounds inflicted in war.[2]  
Cresol, however, failed to prevent infection.[2]  Due to the serious nature of the injuries and 
their frequency, the need for antibiotic research and development was spurred.  It was said in 
1914 by the Director General of the British Army Medical Service that “We have in this war 
gone straight back to all the septic infections of the Middle Ages.”[2, 16]  Sulfonamides 
became the first antimicrobial drugs and the first of the synthetic antibiotics after 
salvarsan.[17]   
 This powerful new class of compounds was developed under the auspices of Heinrich 
Horlein of the Friedrich Bayer Company.[2]  Heinrich Horlein was inspired by the work of 
Ehrlich and devised a plan similar to Ehrlich‟s to develop synthetic antibacterial 
compounds.[2, 18]  Domagk, who tested the newly synthesized compounds in vitro and in 
vivo using animals, was added to Horlein‟s team in 1927.[2]  The sulfonamide class of 
antibiotics would prove useful with the discovery of Prontosil 2 in 1932.   
N
N
H2NO2S
NH2
NH2
2, Prontosil  
 
Figure 1.2:  Structure of Prontosil 2.  
 
Prontosil 2 is also called sulfonamidochrysoidine and was synthesized in 1932 by 
Mietzsch and Klarer.[2]  Gerhard Domagk tested the compound against bacterial infections 
in mice and found the compound to be effective in the elimination of the infection, 
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specifically Streptococcus hemolyticus, a highly virulent Streptococcal strain.[2, 19]  
Prontosil 2 became the first medicine discovered that could treat a range of bacterial 
infections in vivo and the first commercially available antibacterial antibiotic.[19]  Gerhard 
Domagk received the 1939 Nobel Prize for Medicine for his discovery.  Prontosil 2 has 
activity against a wide range of Gram-positive cocci, with the exception of Enterobacteria.  
Sulfonamidochrysoidine was later found to be metabolized to sulfanilamide 4 by Jacques and 
Therese Trefouel at the Pasteur Institute in 1936.  Sulfanilamide 4 had been discovered in 
1909 by Paul Gelmo at the University of Vienna.  Though its antimicrobial potential had not 
been discovered, sulfanilamide is cheaply produced and allows for ease of conjugation onto 
other molecules.  Therefore, though Prontosil 2 failed to have exclusivity due to newer 
sulfonamides and the active component was a well-established compound, the discovery of 
Prontosil 2 ushered in the concept of „pro-drugs‟ and the „sulfa drugs‟ of which bactrim 
(sulfamethoxazole 3) would be a much later descendent.   
H2N S
HN
O
O
O
N
3, sulfamethoxazole
 
 
Figure 1.3:  Structure of Sulfamethoxazole 3. 
 
It was also the first of the „wonder drugs‟. 
 
S NH2
O
O
NH2
4, Sulfanilamide  
Figure 1.4:  Structure of Sulfanilamide 4. 
Sulfaniliamide 4 was marketed in the United States, France, and Britain in the early 
part of 1937.  By the Spring of 1937, any skepticism concerning chemotherapy had withered 
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away.[20]  The biologically active sulfonamide compounds were useful antimicrobial drugs, 
a lead to the discovery of „bioactivation‟, and were the first of the synthetic antibiotic 
pharmaceuticals.  The sulfonamide itself was a compound widely used in dye manufacture, 
easy to conjugate to other compounds, and cheaply produced.  Antibiotic sulfonamides are 
competitive inhibitors of the enzyme, dihydropteroate synthase, DHPS.[17]  This inhibition 
of DHPS causes the inhibition of bacterial purine synthesis.[21-23]  Sulfonamide spectrum of 
activity consists of Gram-positive cocci, such as Streptococci.[2] 
 
1.1.C  Beta-lactam antibiotics 
As the discovery of the sulfonamide compounds became the first class of synthetic 
antimicrobials, the discovery of beta-lactam antibiotics marked the beginning of the naturally 
derived antibiotic compounds.  Beta-lactam structures consist of a beta-lactam in a [3.2.0] 
bicyclic system. 
Beta-lactam antibiotics act as bacteriocidal agents on Gram-positive bacteria and are 
divided into three categories based on structure: penams, penems, and cephems.[24, 25]  
Specifically, this class of antibiotics inhibits cell wall synthesis by targeting enzymes on the 
outer face of the cytoplasmic membrane, called peptidoglycan transpeptidases, which aid in 
the synthesis of the cell wall.[26]  The beta-lactam antibiotics include several families of 
antibiotic compounds.  These are the pencillins, monobactams, carbapenes, and 
cephalosporins.  The first discovered compound in this class was the antibiotic compound, 
penicillin.   
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Figure 1.5:  Penicillins, the structures of Penicillin F 5a and G 5b.[2] 
Penicillin G 5b, or rather the effect, of the compound produced by a penicillian was 
discovered through serendipity by Alexander Fleming in 1928.[27]  A petri dish which had 
been inoculated with Staphylococcus and accidently left uncovered in the basement of St. 
Mary‟s Hospital in London became contaminated with a blue-green mold.  It was observed 
that a halo of inhibited bacterial growth formed around the mold.  Alexander Fleming 
concluded that the mold was producing a compound that lysed the Staphylococcus and, 
therefore killed them.  This substance he named the „mould broth filtrate‟ as penicillin from 
the name of the fungus.[28]  A pure culture of the mold was grown and found to be 
Penicillium notatum.[2, 29]  Fleming halted his research in 1931 after concluding that 
penicillin did not remain in the body long enough to be of value.  Three years later he 
returned to it and attempted to enlist someone in deciphering its structure which was finally 
accomplished in the early 1940‟s.[30]   
After the end of WWII, the total synthesis of penicillin was completed by John C. 
Sheehan at MIT.[31]  The synthetic method for the production of penicillin, however, did not 
allow for large scale production.  Synthesis in drug production coupled with the production 
of natural products from fermentation became significantly important in the development of 
better antibiotics.  As Fleming had observed, penicillin is not retained long in the human 
body.  Its rapid renal clearance and the difficulties in large scale production did not allow 
penicillin to become a marketable drug.  Within three to four hours after dosing, 
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approximately 80% of the compound was eliminated from the body through urination.  As in 
early trials of the drugs, the patients urine was collected the compound extracted so that it 
could be reused.  Infected patients who were given penicillin 5b had shown remarkable 
improvement, but due to the difficulties in the first attempts to isolate the drug from the 
filtrate of broth cultures of Penicillium notatum the patients would sicken and die when the 
last of the penicillin 5b was used.   
Though penicillin 5b had been used successfully in the 1944 to treat soldiers, 
specifically amputees, the rapid loss of penicillin 5b posed a significant problem.  An 
urisosuric agent called probenecid was found that could competitively inhibit the secretion of 
penicillin 5b via the organic acid transporter responsible for the elimination of penicillin 5b.  
The drugs were given together, thus establishing a synergistic strategy in drug development.  
The application of two drugs was not an optimal solution and other penicillins 5b were 
sought after.  The establishment of the structure of penicillin 5b and discovery of others led 
to the isolation of 6-APA, the pharmacophore of penicillin 5b, which in turn allowed for the 
semi-synthesis of penicillin 5b analogs.  Among these analogs was ampicillin 6 which gave a 
broader spectrum of activity. 
H
N
O N
S
NH2
O
O
OH
H
6, ampicillin
 
Figure 1.6:  Structure of Ampicillin 6. 
   Penicillins 5a, 5b are wide spectrum antibiotics that are bacteriocidal against Gram-
positive organisms. The mechanism of action of the penicillins 5b is the inhibition of cell 
walls synthesis which occurs by the inhibition of formation of peptidoglycan cross-linking in 
the cell wall.  Cross-linking is inhibited by the binding and inactivation of the transpeptidases 
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by penicillin 5b or other beta-lactam, also known as the penicillin binding protein, PBP.  The 
bacteria die via cytolysis caused by osmotic pressure. 
 
1.1.D  Cephalosporins 
 The Cephalosporins 7 are another class of beta-lactam antibiotics and are part of 
subgroup of beta-lactams called cephems.[32]  Cephalosporins 7 are composed of a beta-
lactam in a [4.2.0] bicyclic system. 
N
S
H
O
H
N
R2
OHO
R1
O
7, cephalosporin moiety  
Figure 1.7:  General Structure of Cephalosporins 7. 
Cephalosporin C was discovered by the Italian scientist Giuseppe Brotzu in 1948.[33]  
Cephalosporins were isolated from cultures of Cephalosporium acremonium in Sardinia.[33]  
Members of this antibiotic class are bactericidal and disrupt the synthesis of the 
peptidoglycan layer of bacterial cell walls in the same manner as the rest of the beta-lactam 
antibiotics.[32]  Cephalosporins 7, however, show a greater resistance to beta-lactamases, 
otherwise known as penicillinases.[32]  Several generations of cephalosporins 7 have 
allowed for an increase in their spectrum of activity.  Cephalosporin structure 7 can be 
modified to alter the antibacterial activity or pharmacokinetic profile.[32]  The acyl side 
chain at position 7 can be altered to change antibacterial activity and pharmacokinetics can 
be change by chemical modification to the 3-position.[32]  The first generation of 
cephalosporins was active against Gram-positive bacteria, including penicillin resistant 
Staphylococci and Streptococci.  Successive generations have shown activity against Gram-
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negative bacteria, however, in doing so, the activity against Gram-positive bacteria has 
decreased.  Activity against Gram-positive bacteria encapsulates the spectrum of activity of 
second and third generation cephalosporins.  Third generation cephalosporins are able to 
penetrate the CNS which allows for their use against meningitis caused by H. influenza, 
meningococci, and pneumococci.[32]  Some members of this class also have 
antipseudomonal activity.  The fourth generation of cephalosporins shows broad spectrum 
activity being effective against Gram-positive bacteria as with first generation 
cephalosporins, but also have activity against meningitis, and against Pseudomonas 
aeruginosa.[32]       
    
1.1.E  Carbacephems 
The carbacephems are beta-lactam antibiotics and are a subclass of the 
cephalosporins.  Carbacephems, a member of the cephem class, are synthetically made and 
based upon the structure of cephalosporins.  The basic structure of the carbacephems is 
altered from that of the cephalosporins and that of other cephems in that a carbon is 
substituted for the sulfur.  A bacteriostatic effect is achieved by these synthetic structures by 
the inhibition of cell wall synthesis, which prevents cell division.  However, unlike the other 
lactams, it does not lyse and kill the bacterium.  An example of this class of antibiotics is 
Loracarbef 8, also referred to as Lorabid.  This compound is more chemically stable than the 
widely used second generation cephalosporin, Cefaclor. 
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8, Lorabid  
Figure 1.8:  Structure of Loracarbef (Lorabid) 8, a carbacephem. 
 
1.1.F  Carbapenems 
N
H
O
CO2H
9, carbapenem moiety  
Figure 1.9:  General Structure of the Carbapenems 9. 
 The carbapenems 9 are natural product analogues, based off the structure from 
Thienamycin 10.[34]   
N
CO2H
O
OH
HH
S
NH2
10, Thienamycin  
Figure 1.10:  Structure of Thienamycin 10. 
Carbapenems 9 are composed of an unsaturated five-membered carbon ring which is fused to 
one carbon and a nitrogen on the beta-lactam ring.[34]  Thienamycin 10 is a natural product 
produced from Streptomyces cattelya and was the first described carbacephem.[34, 35]  This 
compound, however, is chemically unstable and titers of this compound in fermentation are 
low.  Carbapenems 9 are synthetically made via total synthesis.  Carbapenems 9 have activity 
against Gram-positive and Gram-negative bacteria, having the broadest spectrum of activity 
in the beta-lactam antibiotic family.[34]  They are also beta-lactamase resistant.[34]  
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Intracellular bacteria are not affected by carbapenems 9 due to the bioavailability of 
carbapenems.[36]   
 
1.1.G  Monobactams 
The remaining class of beta-lactam antibiotics is the monobactams, which, unlike the 
other beta-lactams, have only a single four membered beta-lactam ring which is unattached to 
any other ring in the molecule.[37, 38]  They are characterized by the presence of the 2-
oxoazetidine-1-sulfonic acid moiety.[37]  These compounds have been recently isolated from 
gram-negative bacteria.[38]  Naturally occurring monobactams exhibit weak antibacterial 
activity, however, derivatives of these compounds are potent antibiotics.[37] 
N
HN
SO3HO
ON
N
S
NH2
O
OH
O
11, Aztreonam  
Figure 1.11:  Structure of Aztreonam 11, a monobactam antibiotic. 
Aztreonam 11 is synthetically produced.[37]  Monobactams are only effective against 
Gram-negative bacterium, including Pseudomonas aeruginosa.[37, 38]  Aztreonam 11 is also 
bactericidally effective against E. coli, Klebsiella, Proteus, Citrobacter, Enterobacter, and 
Serratia species.[39]  Their mechanism of action is the inhibition of the mucopeptide 
synthesis in the bacterial cell wall which blocks peptidoglycan cross-linking. 
 
1.1.H  Aminoglycosides 
Aminoglycosides consist of multifunctional hydrophilic sugars which are derived 
from Streptomyces and Micromonospora.[40]  They are protein synthesis inhibitors which 
12 
 
function by binding to the 30S ribosomal subunit.[41]  A binding affinity for nucleic acids is 
also a characteristic of these antibiotics due to their polycationic nature.  The majority of 
aminoglycosides are bactericidal.[40]  Aminoglycosides are active against Gram-negative 
bacilli, including aerobic bacteria, such as Enterobacter, Pseudomonas, and 
Acinetobacter.[17] 
Streptomycin 12 was first of the aminoglycosides antibiotics to be discovered. 
HO
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Figure 1.12:  Structure of Streptomycin 12, an aminoglycoside. 
Streptomycin was isolated by Albert Schatz at Rutgers University in 1943 from Streptomyces 
griseus.[42]  Streptomycin 12 is a bactericidal natural product and was the first antibiotic 
used to cure tuberculosis.[43]  It is effective at inhibiting Gram-positive and Gram-negative 
bacteria and, therefore, classified as a broad spectrum antibiotic.  This antibiotic inhibits the 
binding of formyl-methionyl-tRNA to the 30S subunit by binding to the 30S subunit of the 
bacterial ribosome, therefore, inhibiting protein synthesis.[44]  Streptomycin 12 is also used 
to restrict the growth of fungi and algae. 
 
1.1.I.  Macrolides 
 Macrolides are members of a class of natural product antibiotics called polyketides.  
These antibiotics consist of a large macrocyclic lactone which is usually 14, 15, or 16-
membered and two sugars, desosamine and cladinose.[45]  Macrolides are protein synthesis 
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inhibitors and may have three different mechanisms of action.[45]  They have been shown to 
inhibit ribosomal translocation, cause premature dislocation of peptidyl-tRNA from the 
ribosome, and inhibit the peptidyl of the peptidyl-tRNA from adding to the next amino acid 
in the sequence by inhibiting the peptidyltransferase.[45]  Macrolides bind close to the 
peptidyl transferase center on the 50S ribosomal subunit.[45-48]  In general, macrolides have 
a medium spectrum of activity, which is slightly greater than that of penicillin and are used 
for patients with a penicillin allergy.[49]  Specifically, macrolides have activity against 
Staphylococci, beta-hemolytic Streptococci, Pneumonococci, Enterococci, Chlamydia, 
Mycoplasm, and Mycobacteria.[49]  Commonly, they are used to treat respiratory infections.  
Erythromycin 13, azithromycin 15, clarithromycin 14, and telithromycin 16 are members of 
this class.   
O
O
HO
OH
OH
O O
O
O
O
N
HO
O
OH
13, Erythromycin  
Figure 1.13:  Structure of Erythromycin 13, a macrolide antibiotic. 
 Discovered by Eli Lilly in 1949 by J.M. McGuire, erythromycin 13 is a natural 
product macrolide antibiotic that was isolated from Saccharopolyspora erythraea.  
Erythromycin 13 contains a 14-membered ring and is composed of two sugars, cladinose and 
desosamine.[45, 50]  As with other macrolides antibiotics, erythromycin 13 interferes with 
protein synthesis by binding to the 50s subunit of the bacterial 70s rRNA complex and causes 
interference with aminoacyl translocation.[45]  This results in blockage of the entry way into 
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the large ribosomal subunit and, therefore, inhibits the production of useful proteins.[45, 51-
53]  Therefore the origin of antimicrobial activity is causing a lack of functional proteins 
necessary for life processes.  Erythromycin 13 is not a particularly effective antibiotic and, 
therefore, not a first line drug.[49]  It is quickly eliminated from the body by demethylation 
in the liver and is inactivated by gastric acid.[49]  High doses are necessary and common side 
effects are diarrhea and nausea.[49]  Due to the low acid tolerance, clarithromycin 14 was 
invented which is more acid stable.[49, 54]  The C-6 hydroxyl group of erythromycin is 
substituted for a methoxy group which prevents the erythromycin 13 base from becoming the 
hemiketal intermediate via degradation.  The gastrointestinal side-effects of erythromycin 13  
are thought to originate from the production of the hemiketal intermediate, which induce 
stomach motility.[55]  
OH
O
O
O
HO OCH3
O O
HO N(CH3)2
O
O
OCH3
OH
14, Clarithromycin  
Figure 1.14:  Structure of Clarithromycin 14. 
 Azithromycin 15 is another member of the macrolides class of antibiotics, which is 
semisynthetic analogue of erythromycin 13.[49]  The macrocycle ring is modified by the 
inclusion of a methyl amine and removal of the ketone at the 9a position of the aglycone ring 
giving a 15-membered ring in place of the 14-membered erythromycin macrocycle.[49, 56]   
This places azithromycin 15 into a subclass of macrolides antibiotics called azalides.  
Azithromycin 15 was discovered in 1980 by Pliva, a Croatian pharmaceutical company.  By 
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binding to the 50S subunit of the bacteria ribosome, the translation of mRNA is 
inhibited.[56]  This caused the inhibition of protein synthesis which prevents the growth of 
the bacteria.[56]  Though azithromycin 15 shares a similar spectrum of activity with 
erythromycin 13, azithromycin is more effective against certain strains of Gram-negative 
species.[56]  Azithromycin 15 is effective against Staphylococcus aureus and several species 
of Streptococcus including pyrogenes, agalactiae, and pneumonia.[56]  It is also effective 
against Mycoplasma pneumonia, Chlamydia, and Haemophilus.[56]   
N
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15, Azithromycin  
Figure 1.15:  Structure of Azithromycin 15. 
To treat respiratory tract infections caused by macrolide-resistant strains, ketolides 
were developed, such as telithromycin 16.[3, 49]   
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16, Telithromycin  
Figure 1.16:  Structure of Telithromycin 16, a ketolide antibiotic, related to macrolides 
antibiotics[3] 
 
Ketolides are structurally related to macrolides, but differ in the removal of the L-cladinose 
sugar and the oxidation of the 3-hydroxy to 3-keto.[3, 49, 57]  Ketolide antibiotics also 
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prevent protein synthesis via blocking of the ribosomal exit channel, but have activity against 
macrolide-resistant strains.[3] 
 
1.1.J.  Ansamycins 
 Ansamycins were discovered in 1959 by Sensi et al.  These compounds are natural 
products, one that is produced from the Actinomycete, Amycolatopsis mediterranei.[58]  This 
family of secondary metabolites contains several classes, each one a derivative with the 
primary structural characteristic of this unique family.  The primary structural characteristic 
is the presence of an aromatic unit, bridged by an aliphatic chain.[59]  Each structural 
derivative of this primary scaffolding engenders a new class.  Examples of these are 
rifamycin and naphthomycin which contain a naphthalene ring or a naphthoquinone ring.[60]  
Another class includes the ansamycins, ansamitocin and geldanamycin 17 in which the 
primary aromatic moiety is composed of a benzoquinone ring or a benzene ring.[60]   
O
O
H3CO
H
N
H3CO
O
OH
O
H3CO
NH2
O
17, Geldanamycin  
Figure 1.17:  Structure of Geldanamycin 17, a benzoquinone ansamycin 
 Ansamycins have shown potency against a wide spectrum of Gram-positive and 
Gram-negative bacteria.  Potent mycobacterial activity has been demonstrated by the 
rifamycin subclass of ansamycins and it is in wide spread use to combat fungal infections in 
immunocompromised patients, such as those with AIDS, as well as leprosy, and importantly 
17 
 
tuberculosis.[61]  Lastly antiviral activity has also been demonstrated against bacteriophages 
and poxviruses.  This gives ansamycins a wide spectrum of activity. 
 The rifamycin subclass of ansamycin antibiotics were discovered by Group Lepetit 
SpA, an Italian pharmaceutical company in Milan by Piero Sensi and Pinhas Margalith in 
1957.  Rifamycins were isolated from Streptomyces mediterranei, a soil bacterium.  Over the 
years this species has been renamed several times and now includes the names Nocardia 
mediterranei and Amycolatopsis rifamycinica, which is perhaps the most recent 
nomenclature and was given in 2004.   
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18, Rifamycin B  
Figure 1.18:  Structure of Rifamycin B 18.      
 Rifamycin B 18 is able to inhibit DNA-dependent RNA synthesis via the binding to 
prokaryotic RNA polymerase.[62]  By binding to the polymerase, its steric bulk physically 
blocks chain elongation of the oligonucleotide.[63]   In HIV-compromised patients, 
tuberculosis, leprosy, and mycobacterium avium complex, as well as intestinal infections 
caused by Escherichia coli have all been treated with rifamycins. 
 
1.1.K.  Tetracyclines 
 Tetracyclines are a family of broad-spectrum, bacteriostatic antibiotics that were 
discovered in 1945 by Benjamin Minge Duggar.[64, 65]  Structurally, the tetracycline 
antibiotics are uniquely defined for the presence of four hydrocarbon rings (A, B, C, and D) 
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and are derivatives of polycyclic naphthacene carboxamide.[4]  These polyketide antibiotics, 
which are isolated from a Streptomyces species, comprise a very large group of antibiotics.  
The first of these antibiotics to be discovered was Aureomycin which was discovered in the 
late 1940s.  Aureomycin, otherwise known as 7-chlorotetracycline 19, was isolated in the 
Lederle Laboratories from a soil-bacterium called Streptomyces aureofaciens.[4]   
Cl
OH O OH O
CONH2
OH
N(CH3)2OHH3C
19, 7-Chlortetracycline
OH
 
Figure 1.19: Structure of 7-Chlorotetracycline 19.[4] 
Oxytetracycline was later isolated by A.C. Finlay et al. from Streptomyces rimosus.  
They are natural products and inhibit protein synthesis.[64, 65]  Tetracyclines prevent the 
docking of amino-acylated tRNA to the ribosomal acceptor (A) site by binding to the 30S 
bacterial ribosome subunit.[4, 17]  Tetracyclines are used in the treatment of skin infections 
such as acne and rosacea as well as anthrax, plague, and Legionnaires‟ disease.  In general 
tetracyclines are also employed as the primary class of antibiotics to treat infections such as 
urethritis, typhus, and spirochetal infections.      
 Tetracycline 20, the tetracycline antibiotic, was also discovered by Benjamin Duggar 
and described in 1948.   
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Figure 1.20:  Structure of Tetracycline 20, a tetracycline antibiotic.[4] 
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It is used to treat a variety of Gram-positive and Gram-negative infections.[4]  Certain 
protozoa are also treatable with tetracycline.  Cholera was once widely treated with 
tetracycline.  It is also used to treat common acne and rosacea.  The discovery of this family 
of antibiotics was a precipitous event in that it lead to a cascade of chemically altered 
antibiotics and is noted as one of the most important discoveries in the field.        
 
1.1.L.  Tigecycline 
 Tigecycline 22 is a derivative of minocycline 21 and is related structurally to 
tetracyclines.[5, 66]   
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Figure 1.21: Structure of Minocycline 21.[4] 
Tigecycline is a glycylcycline antibiotic and was developed by Wyeth in 2005.[5, 67, 68]  
Tigecycline 22 is a protein synthesis inhibitor and possesses a wide spectrum of activity.[3, 
66, 69]  It is bacteriostatic.[69]  This antibiotic binds to the 30S ribosomal subunit and blocks 
aminoacyl-tRNA molecules entry into the A site of the 30S ribosomal subunit which 
prevents translation.[5, 69, 70]  Activity has been documented against Gram-positive and 
negative bacteria including anaerobes, methicillin-resistant Staphylococcus aureus, 
Staphylococcus epidermidis, vancomycin-resistant Enterococcus faecalis, vancomycin-
resistant Enterococcus faecium, and drug resistant strains Actinetobacter baumannii.[3, 5]  
This member of the new class of antibiotics, glycylcyclines, possesses a central four-ring 
carbocyclic skeleton and is therefore related to the tetracyclines. 
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Figure 1.22:  Structure of Tigecycline 22, a glycylcycline.[5]   
Tigecycline 22 is used for intravenous therapy for serious bacterial infections, among them, 
complicated skin, soft tissue, and intra-abdominal infections.[5, 70]  It is mainly 
bacteriostatic; however, it has been shown to have bactericidal activity. 
 
 1.1.M.  Glycopeptides 
 Glycopeptides are a class of antibiotics that consists of glycosylated cyclic or 
polycyclic nonribosomal peptides.[71]  One of two core linear heptapeptide structures forms 
the backbone of these antibiotics.[71]  This unique class inhibits peptidoglycan synthesis and 
therefore inhibits the construction of the cell wall.  Interference with the construction of the 
bacterial cell wall is accomplished by two mechanisms.  First, the glycopeptides inhibit 
transpeptidases which causes a lack of tensile strength in the cell wall resulting from a lack of 
cross-linked peptidoglycan necessary for the integrity of the organism.[71]  Secondly, 
glycopepides prevent the growth of the peptidoglycan chain via the inhibition of 
transglycosylase.[71]  Glycopeptides effectively target Gram-positive cocci.[71]  Bacterial 
species that are susceptible to this class are Staphylococci, Streptococci, Clostridia, and 
Enterococci.[71]  In Enterococci, these antibiotics are bacteriocidal, but are bacteriostatic in 
all almost all other species.  Vancomycin 23 is a member of this class and has the distinction 
of being a last line of defense antibiotic, specifically for use against drug and multi-drug 
resistant species such as MRSA.[72] 
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Vancomycin 23, a natural glycopeptide antibiotic, was isolated by E.C. Kornfeld 
from Amycolatopsis orientalis, a soil bacterium found in Borneo.[73]   
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Figure 1.23:  Structure of Vancomycin 23, a glycopeptide antibiotic. 
The antibiotic disrupts the synthesis of the cell wall in Gram-positive bacteria by inhibiting 
the assimilation of N-acetylglucosamine and N-acetylmuramic acid peptide subunits into the 
peptidoglycan matrix.  Due to the side effects, such as ear and kidney damage as well as local 
pain and thrombophlebitis, and the prevention of the rise of vancomycin 23 resistant bacterial 
strains it is used as a drug of last resort.[73-76]  The first use of the drug was the treatment of 
penicillin-resistant Staphylococcus aureus to combat beta-lactam resistant strains.[73, 74] 
 
1.1.N.  A lipopeptide antibiotic, daptomycin 
 Daptomycin 24 was discovered by Eli Lilly and marketed by Cubist in 2003 under the 
name Cubicin.[77-80]  It is a novel lipopeptide antibiotic and a natural product.[81-88]  
Notably, it the first natural product in 41 years to be categorized under a new structural 
class.[79, 80]  Daptomycin 24 is produced by Streptomyces roseosporus.[81-88]   
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Figure 1.24:  Structure of Daptomycin 24, a lipopeptide antibiotic 
Daptomycin 24 consists of a 13-member amino acid cyclic lipopeptide with a decanoyl side-
chain.[89]  The mechanism of action of this novel compound is to bind to the bacterial cell 
membrane.[89]    Its unique structure confers upon it this novel mechanism.[89]  It is 
believed that the insertion of the lipophilic daptomycin tail into the bacterial cell membrane 
causes rapid membrane depolarization and potassium efflux which leads to the inhibition of 
DNA, RNA, and protein synthesis.[3, 89-91]  This leads to cell death and, therefore, 
daptomycin 24 is bactericidal.[89-91]  Daptomycin 24 has a very narrow spectrum of 
activity, only being active against Gram-positive organisms.[81-88]  This cyclic lipopeptide 
has been shown to be effective against Enterococci, Staphylococcus, Corynebacteria, and 
Streptococci.  The current main use of daptomycin 24 is to treat skin and skin structure 
infections.[92]    
 
1.1.O.  Quinolones and fluoroquinolones 
 Quinolones are synthetic broad spectrum antibiotics that were first synthesized in an 
attempt to make a synthetic form of chloroquine 26 which was used in World War II to treat 
malaria.[17]  Chloroquine 26 was discovered in 1934 at Bayer by Hans Andersag.  In the 
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process of this synthesis, nalidixic acid 25 was discovered and became the blueprint for the 
quinolone family of antibiotics.   
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Figure 1.25:  Structure of Nalidixic Acid 25 and Chloroquine 26.[6] 
Quinolones prevent DNA replication.[17, 93]  Through porins in the outer membrane of 
bacterial cells, the quinolones diffuse through the plasma membrane and then selectively 
complex reversibly with DNA gyrase and topoisomerase IV.[94, 95]  These enzymes are 
necessary for chromosomal decatenation, replication, and transcription.  The bacteriostatic 
action is theorized to be caused by the slow reversible complex formation.[96]  Higher 
concentrations of quinolones will have a bactericidal effect, depending upon the 
bacteriostatic or bactericidal effect of an individual quinolone, as some inhibit growth and are 
less effective in causing cell death.[96, 97]  Quinolones also induced DNA lesions causing 
cell death by triggering the SOS response.[96, 98] 
 The fluoroquinolones 27 are a subclass of the quinolone antibiotics.  The main 
difference between the two structures is the presence of a fluorine atom attached to the 
central ring system.  This constituent is attached at either the 6 or 7 carbon atom position.  
Like the quinolones, the fluoroquinones 27 are synthetic.  Fluroroquinolone antibiotics, as 
with the quinolones, originated from nalidixic acid, which was then employed in 1962 to 
treat urinary tract infections.[6, 99, 100] 
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Figure 1.26:  General Structure of Fluoroquinolones 27. 
The fluoroquinones‟ 27 bactericidal activity originates from its mechanism of action.   The 
inhibition of the topoisomerase IV enzyme and DNA gyrase causes inference with DNA 
replication in bacteria.[6]  Since human cells lack these topoisomerases, fluoroquinones 27 
are specific for bacterial strains and, due to the interference with DNA replication, they are 
also bactericidal.[6, 101, 102]  Interference with DNA replication imbues fluoroquinones 27 
with a broad spectrum of activity.  Effective bactericidal activity has been established against 
Gram-positive and Gram-negative bacteria.   
Ciprofloxacin 28 is a member of the fluoroquinolones 27, a second generation 
compound which was patented in 1983 by Bayer.  Like the rest of the fluoroquinolones 27, 
ciprofloxacin is synthetic and inhibits DNA replication as well as transcription via the 
inhibition of DNA gyrase and topoisomerase IV.[103]  Ciprofloxacin 28 is used to treat 
urinary tract infections, bacterial diarrhea, gonorrhea, and community-acquired pneumonia. 
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Figure 1.27:  Structure of Ciprofloxacin 28, a fluoroquinolone 27.[6]   
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1.1.P.  Oxazolidinones 
 The oxazolidinone class of antibiotics were discovered in 1956.[104, 105]  
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29, 2-Oxazolidone  
Figure 1.28:  The 2-Oxazolidone 29 Identifying Structure. 
Members of this class are synthetic antibacterials, the first of which was cycloserine. 
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Figure 1.29:  Structure of Cycloserine 30. 
This compound was developed as second-line drug in the treatment of tuberculosis.[106] 
 The mechanism behind the oxazolidinones antibacterial activity is the disruption of 
translation of mRNA into proteins in the ribosome.[107, 108]  Oxazolidinones disrupts 
protein synthesis initiation complexes by interaction with the 23S ribosomal RNA on the 50S 
ribosomal subunit near the 30S ribosomal subunit in which the formation occurs.[3, 107, 
109]  Oxazolidinones are unique in this aspect in that unlike other protein synthesis 
inhibitors, they inhibit the initiation of protein synthesis, not the elongation process.[3, 110]  
It is theorized that these antibiotics prevent tRNA from entering the A site of the 50S 
ribosomal subunit by binding to the P site on the 50S ribosomal subunit, therefore causing 
the tRNA to dislodge from the ribosome completely.[111]     
Oxazolidinones have been found to be effective against Gram-positive, specifically 
MRSA, and limited Gram-negative bacteria.[107, 110, 111]  Like vancomycin 23, these 
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antibiotics are considered as last line defense against drug resistant organisms.  Posizolid 31 
and Linezolid 32 are members of this class. 
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Figure 1.30:  Structure of Posizolid 31. 
 Linezolid 32 is a mostly bacteriostatic drug that was discovered in 1996 at Upjohn 
Laboratories.[111-113]  This synthetic antibiotic was the first commercial available antibiotic 
and is used as a second line defense against multi-drug resistant Gram-positive strains, such 
as community-acquired pneumococcal pneumonia.[104, 105, 111, 114] 
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Figure 1.31:  Structure of Linezolid 32. 
The main mechanism of activity is the inhibition of protein synthesis.  Linezolid 32 has been 
found to be effective against MRSA, VRE, and Streptococci strains.[110, 115]  Surgical 
infections such as S. epidermidis can be treated with Linezolid 32.[111, 116, 117] 
 
1.1.Q.  Polypeptide antibiotics 
 The polypeptide antibiotics, such as Bacitracin 33, Gramicidin, and Polymyxin 34, 
mainly consist of repeated chains of amino acids.  The compounds are used topically for treat 
of ear and eye infections. 
27 
 
 Bacitracin 33 was first isolated by John T. Goorley from a Bacillus subtilis strain 
found in a compound fracture of the tibia in a female patient called Tracy I.[118, 119]  
Isolation gave a mixture of related cyclic polypeptides.  Bacitracin 33 was isolated from this 
mixture in 1945.[118]  Bacitracin 33 is a natural product antibiotic and is produced by strains 
of Bacillus licheniformis.[120]  
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Figure 1.32:  Structure of Bacitracin 33. 
The natural product interferes the production of bacterial cell walls by preventing 
peptidoglycan subunits from being transported outside of the inner membrane.[121]  The 
main mechanism of action occurs by inhibiting the dephosphorylation of the C55-isoprenyl 
pyrophosphate.[120, 121]  This prevents the synthesis of the bacterial cell wall in Gram-
positive organisms by inhibiting the regeneration of the lipid carrier which necessary for the 
cyclic synthesis of peptidoglycan.[120, 122, 123]  Bacitracin 33 is used to treat topical 
infections when combined with other topical antibiotics such as polymyxin B 34.  Eye and 
skin infections are treated with this polypeptide antibiotic and on small wounds to prevent 
infection. 
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 Gramicidin was discovered by Rene Dubos in 1939 in the isolation of tyrothricin.  
Tyrothricin is composed of a mixture of linear pentadecapeptides, which are gramicidins A, 
B, and C.[124-126]  It is also comprised of gramicidin S and tyrocidins, which are backbone-
cyclized cationic decapeptides.[124-126]  This natural product mixture was isolated from 
Aneurinibacillus migulanus.[124]  Collectively, they act to form a channel in the bacterial 
cell wall which results in the destruction of the ion gradient via an increase in 
permeability.[124, 127-131]  Gramicidin acts to form a beta-helix in the hydrophobic interior 
of the cellular lipid bilayer, which then dimerizes to span the entire width of the 
membrane.[124, 127-131]  Monovalent cations are able to travel between the extracellular 
space and the cell‟s cytoplasm without control.[124, 127-131]  This bactericidal mixture is 
applied topically and is potently active against a broad spectrum of Gram-positive and Gram-
negative organisms.[124]  Gramicidin S is a particular potent antibiotic however it may only 
be used topically due to its hemolytic effects.[124]  Gram-positive bacilli are not affected by 
Gramicidin; however Gram-negative Neisseria stains are susceptible to these collective 
compounds. 
  Polymyxins 34 are produced by Bacillus polymyxa, a Gram-positive bacteria.[132]  
A pentabasic decapeptide with a cycloheptapeptide ring and a C9 or C10 fatty acid chain 
constitute this antibiotic class.  These compounds are surfactant-like in that their hydrophobic 
substituents cause damage to the cell membrane which results in cell death.  Polymyxins 34 
have a narrow spectrum of activity, specifically against Gram-negative species.[133, 134]  In 
Gram-negative bacterial species, disturbances caused by the binding by the cationic 
polypeptide polymyxins 34 to the anionic lipopolysaccharides molecules in the outer 
membrane increase the permeability of the membrane.[135, 136]  It has been hypothesized 
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that polymyxin may act on more than one target since cell death has been observed to take 
place before an increase in membrane permeability occurs.[137]  A member of this subclass 
is Polymyxin B 34. 
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Figure 1.33:  Structure of Polymyxin B 34, a cyclic polypeptide.    
 
1.1.R.  Chloramphenicol 
 Chloramphenicol 35 is a natural product bacteriostatic antimicrobial compound.  
David Gottlieb isolated the compound from Streptomyces venezuelae and used it to treat 
infection beginning in 1949.[138]  Chloramphenicol 35 is a broad spectrum antibiotic, able to 
effectively treat Gram-positive and Gram-negative bacterial infections.[139]  The compound 
is a protein synthesis inhibitor via the inhibition of peptide bond formation.  
Chloramphenicol inhibits peptidyltransferase activity of the bacterial ribosome via binding to 
the 50S ribosomal subunit.[17] 
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Figure 1.34:  Structure of Chloramphenicol 35.  
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1.1.S.  Trimethoprim 
 Trimethoprim 36 is a synthetic bactericidal antibiotic.  Trimethoprim 36 was 
developed by GlaxoSmithKline and has been used in the United Kingdom since 1969.  
Potent, selective, and a competitive inhibitor of bacterial dihydrofolate reductase, 
Trimethoprim 36 acts to affect methyl transfer reactions due to the depletion of 
tetrahydrofolate.[17]  This interferes with thymine synthesis by inhibiting folic acid synthesis 
by the disruption of dihydrofolate reductase.[17]  It is therefore classified as a nucleic acid 
inhibitor.[17]   
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Figure 1.35:  Structure of Trimethoprim 36. 
 
1.2  Rise of antibiotic resistant strains 
 
1.2.A.  Introduction to antimicrobial resistance 
 
 As early as when the first „sulfa drugs‟ and penicillins were being administered to 
patients, scientists and physicians have noted this ability of microorganisms to develop 
resistance to antimicrobial compounds.[140]  An example of penicillin resistance is S. 
pneumonia, whose resistance was first detected in 1967, and has become increasingly 
prevalent worldwide.[140]  However, in recent years, the world has seen a precipitous rise in 
resistant strains.[141]  Such resistant strains are resistant to one or more compounds that had 
previously been effective at treating and curing the infection.[141]  In a 2004 report from the 
IDSA (Infectious Disease Society of America), approximately 2 million individuals in the 
United States alone will acquire a bacterial infection.[141]  Out of these infected people, 
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approximately 90,000 will succumb to the infection.[141]  Bacterial strains that are resistant 
to one or antimicrobials make up more than 70 percent of these 2 million infections.[141]  
 As the number of bacterial and other microorganism such as fungi and protozoa, 
become immune to antibiotics, antifungal, or antiprotozoal pharmaceuticals, the approval rate 
for new antimicrobials diminished.  Particularly, though new antimicrobial drugs are being 
synthesized, few new mechanisms of action have been discovered.[142]              
 
1.2.B.  Acquisition of antimicrobial resistance 
 
 Antimicrobial resistance is acquired through three main factors: plasmid exchange, 
random mutation, and zoonotic transfer. 
 Plasmid exchange is the lateral gene transfer of DNA or RNA via plasmids.[143]  
Resistance genes may be transferred from one microorganism to another microorganism and 
does not involve the mechanism of heredity.[143]  Due to this process, one strain in which a 
particular antibiotic is effective may become resistant to that antibiotic via the acquisition of 
resistance genes from another resistant strain.  Therefore, any resistant strains that exist in the 
environment may pass along their resistance, producing drug and multi-drug resistant 
organisms.[3]  Plasmid exchange is very common among bacteria and is one of the most 
important causes of increased drug resistance.  
 Horizontal gene transfer can occur through three main mechanisms.[144]  These 
mechanisms are transformation, transduction, and conjugation.[144]  Transformation is the 
genetic alteration of a cell from uptake and expression of foreign genetic material, which 
may be either RNA or DNA.[144, 145]  Transduction is the process in which bacterial DNA 
is moved from one bacterium to another by a bacterial virus, a bacteriophage.[144, 145]  The 
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last of these is bacterial conjugation in which through direct cell-to-cell contract, genetic 
material is transferred.[144, 145] 
 Random mutation is a randomly derived change to the nucleotide sequence of the 
genetic material of an organism.[144]  On the small scale random mutations include point 
mutations, insertions, and deletions.[144]  Point mutations are mutations in which only a 
single base pair is altered or changed.[144, 145]  These mutations may be caused by two 
main processes.  Errors during the replication of DNA may cause the incorrect insertion of a 
base in the polynucleotide chain during DNA replication.[144, 145]  Secondly, DNA bases 
may be changed directly via contact with chemical compounds.[144, 145]  Insertions are the 
process in which segments of additional genetic material are added into the DNA 
sequence.[144, 145]  Insertions are often caused by transposable elements, which are 
stretches of DNA that may move from one site on the chromosome to another.[144, 145]  
Insertions also may occur, though infrequently, through mistakes in DNA or RNA replication 
or recombination, or through exposure to acridines.  Deletions may occur during insertion of 
a new DNA or RNA sequence.[144, 145]  Deletion is the removal of a stretch of 
polynucleotide in the DNA or RNA segment.[144, 145]  Deletions may be caused by 
exposure to acridines, mistakes in DNA or RNA replication, and commonly occur as part of 
insertion mutations or transposition mutations.[144, 145]    
On the large scale random mutations include amplifications, deletions, chromosomal 
translocations, interstitial deletions, and chromosomal inversions.  Amplifications are the 
production of additional copies of a nucleotide sequence.[145]  These extra sequences are 
found either in intrachromaosomal or extrachromosomal DNA or RNA.[145]  Chromosomal 
translocations occur when a segment of genetic material detaches from the chromosome and 
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attaches to another.[144]  Chromosomal inversions are the inversion of a segment of a 
chromosome into the same site.[144] 
Zoonotic transfer of bacterial resistance relates to zoonosis, which is the infection of a 
human being with a disease that can be transmitted from a non-human animal.  Humans can 
contract zoonotic diseases through direct contact with wild or domestic animals.  Such labors 
as pig farming and ranching can result in zoonotic transfer.  Dairies, fairs, soil, and food and 
water contaminated with animal feces are also highly likely sources of zoonoses.  Zoonoses 
included bacteria, viruses, fungi, parasites, and prions.  Examples of zoonotic diseases are 
anthrax, brucellosis, bubonic plague, and toxoplasmosis.  Animals treated for certain 
infections with antibacterials or antiviral drugs may develop resistance strains.  These drug 
resistant strains can then infect humans, causing a disease that may be very difficult to treat.  
Zoonotic antibiotic resistant infections are also on the rise, due to the overuse of antibiotics in 
humans and the use of antibiotics in agriculture and veterinary medicine.  Furthermore, the 
resistance genes in zoonotic bacterial strains may be able to cross into an unrelated bacterial 
strain through plasmid exchange.      
 
1.2.C.  The mechanisms of antimicrobial resistance 
 
 Antimicrobial resistance is obtained through four main processes.  These processes 
are drug modification or inactivation, alteration of the target site, alteration of the metabolic 
pathway, and reduced drug accumulation in the infected host.[3, 142, 143]  
 
34 
 
1.2.D.   Antimicrobials and resistance mechanisms  
 
1.2.D.1.  Beta-Lactam resistance 
 
 The primary cause of resistance to beta-lactam antibiotics is the catalytic function of 
beta-lactamases.[17, 146]  Inactivation of this family of antibiotics is caused by the 
enzymatic hydrolysis of the beta-lactam ring.[146]  Current theory holds that these beta-
lactamases evolved from penicillin-binding proteins.[146-152]  Beta-lactamases are 
categorized into four classes, A, B, C, and D.[17, 146, 153-155]  Each of these classes 
represents a different catalytic mechanism by which the lactamases cleave the beta-lactam 
and, therefore, enable resistance to this family of antibiotics.[146]  A series of enzymes 
named extended-spectrum beta-lactamases (ESBLs) are also problematic and over 250 
variants have been detected.[17]  Therefore, strains of Enterobacteria can become resistance 
to cefotaxime, ceftriaxone, and ceftazidime.[17]  To make matters worse, other species can 
easily acquire these enzymes.[17]   
 
1.2.D.2.  Aminoglycoside resistance 
 
 The roots of aminoglycoside resistance lies in four general mechanisms.[156]  
Altered uptake, target modification, chemical modification, and antibiotic efflux all 
contribute to the growing resistance to aminoglycosides.[156]   
Uptake of aminoglycosides requires energy in order for transportation across the cell 
membrane.[157]  Mutations that can confer aminoglycoside resistance are, therefore, those 
which can alter the membrane potential.[156, 157]   
Target modification of the point in which the aminoglycoside antibiotic acts occurs 
through two mechanisms which are the methylation of the 16S rRNA and point mutation of 
ribosomal proteins or ribosomal RNA.[107, 156]   
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Chemical modification is possibly the most important mechanism in conferring 
resistance to aminoglycosides.[17, 156]  A series of enzymes that act to adenylate, acetylate, 
or phosphorylate antibiotics are responsible for this resistance.[156]  These enzymes are O-
phosphotransferases, N-acetyltransferases, and O-nucleotidyltranferases.[17, 156]  The sheer 
number and diversity of these enzymes in addition to enzyme inhibitor transportation across 
the cellular membrane, provide enormous challenges for the development of inhibition of 
these enzymes.[156]   
Antibiotic efflux is also of great important and mostly a problem in Gram-negative 
organisms.[156]  This mechanism of resistance exists due to the presence of the tripartite 
resistance-nodulation-division (RND) family of efflux proteins.[156]  In Gram-negative 
organisms, such as E. coli, AcrAD, a TolC-associated aminoglycoside efflux pump is 
responsible for the export of the aminoglycoside from the cytoplasm and periplasm.[156]       
 
1.2.D.3.  Quinolone resistance 
 
 As previously stated in the mechanism of action by quinolones, the targets of action 
are DNA gyrase and topoisomerase IV.[107]  Target modification of either of these targets 
can result in resistance.[107]  Point mutation can achieve this effect through a change in a 
single amino acid.[107]  Mutations in the amino terminal domains of GyrA or ParC, as well 
as in GyrB and ParE have been shown to cause quinolone resistance.[107, 158]  Changes in 
topoisomerase IV has the most effect in Gram-positive organisms, whereas, a mutation to the 
DNA gyrase elicits resistance more in Gram-negative species.[107, 159]  Resistance in 
quinolones, with the exception of Qnr, plasmid mediated, proteins, is entirely 
chromosomal.[17, 160-164]  Qnr proteins have the ability to protect DNA gyrase from 
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quinolones and have reached a wide distribution a variety of bacterial genera and plasmid 
environments .[17, 162]       
 
1.2.D.4.  Rifamycin resistance 
 
 Rifamycin resistance occurs due to mutations in the rpoB gene, specifically those 
which encode amino acid changes in the beta-subunit of the RNA polymerase.[107, 165]  
The highly conserved regions in which the mutations take place in the rpoB gene are thought 
to be involved in the polymerase antitermination process.[107, 165, 166]  Connection 
between these mutations and the resistance effects have yet to be fully made, though it is 
theorized that they reduced the RNA polymerase affinity for rifampin.[107]  E. coli, S. 
aureus, Mycobacterium leprae, S. pneumonia, Neisseria meningitides, and M. tuberculosis 
have all been shown to acquire resistance to rifamycins, specifically rifampin, through 
mutations in similar regions of the rpoB gene.[107, 147, 167-172] 
 
1.2.D.5.  Oxazolidinone resistance 
 
 The origin of oxazolidinone resistant strains is still under investigation.[107]  It is 
deemed unlikely that mutation is responsible as multiple genomic copies of rRNA genes are 
present in most human pathogens including staphylococci and enterococci.[107]  Linezolid, 
the only oxazolidinone antibiotic in clinical use, has met with resistance in strains of 
VRE.[107, 147, 173, 174]  Selective pressure in general has been ruled the most likely 
mechanism in which oxazolidinone resistance has been acquired by the vancomycin resistant 
Enterococcus faecalis.[107, 147]  There is also a rough correlation between clinical isolates 
of E. faecalis which have a G2576T mutation on the 23S rRNA genes and the level of 
oxazolidinone resistance.[147, 175]  Linezoid is the only oxazolidinone approved for clinical 
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use and is used to combat hospital acquired VRE nosocomial infections.[147]  Current large 
surveillance studies have reported that linezoid resistance is rare in Enterococci.[176-180]        
 
1.2.D.6.  Macrolide resistance 
 
 Macrolide resistance stems from posttranscriptional alteration of a specific base of 
rRNA that results in ribosomes with reduced drug affinity.[107, 181]  Methylation of an 
adenine at position 2058 of 23S rRNA occurs through the action of erythromycin resistance 
methylase.[107]  Dimethylation at this locus engenders a high-level resistance to all 
generations of macrolides antimicrobials.[107, 182]  Telithromycin, the only clinically 
available ketolide, is relatively unaffected by the monomethylation of A2058, but 
dimethylation of the site results in resistance.[107, 183]  Macrolide resistance in Gram-
positive bacteria can result from efflux mediated by mef genes.[147, 184]    
 
1.2.D.7. Glycopeptide resistance 
 
 Vancomycin resistance is achieved through the substitution of D-lactate for the 
terminal D-alanine of the peptide side chain.[107, 185]  Vancomycin resistance in MRSA 
strains has been attributed to several abnormalities in these strains.[107]  Enhanced autolysis, 
increased production of PBP-2, and cytoplasmic cell wall precursor monomer UDP-N-
acetylmuramyl-pentapeptide, and enhanced incorporation of N-acetylglucosamine into the 
bacterial cell wall contribute to the glycopeptide resistance in methicillin resistant 
Staphylococcus aureus.[107, 186]  In addition, the theory of the „false target model‟ has been 
put forth due to the increased numbers of uncrosslinked pentapeptide chains which retain 
their binding affinity for vancomycin and the increase in cell wall thickness.[107, 187, 188]  
Non-critical binding of vancomycin to these targets may act to protect the active site of the 
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transglycosylase enzymes near the cell membrane.[107, 188]  Vancomycin resistance has 
become increasingly widespread.[147, 189]  In 2003, it was reported that 28.5% of 
enterococci infections in hospitalized patients in the U.S. intensive care units were 
vancomycin resistant, according to the National Nosocomial Infections Surveillance 
System.[147, 190]  In 2004, an independent study that the percentage of E. faecium isolates 
that were vancomycin resistant was 72%.[176]  Contamination of some hospital rooms has 
become so extreme as to warrant four hour long cleaning procedures and the gastrointestinal 
systems of patients that acquire VRE may persist in this condition for years.[147, 191, 192]       
 
1.2.D.8.  Tetracycline resistance 
 
 TetM, TetO, and OtrA are tetracycline resistance proteins that protect ribosomes from 
tetracycline, through interaction with the bacterial ribosome.[107, 147, 193-197]  Research 
into the function of TetM suggests that it acts catalytically with tetracycline in addition to 
elongation factor, EF-G.[107, 198, 199]  TetM does not prevent the binding of tetracyclines, 
but does catalytically control the release of tetracycline from the ribosome as well as acting 
as a competitive inhibitor.[107, 200]  Drug efflux is also a main cause of tetracycline 
resistance which takes placed in enterococci.[17, 107, 147]  Tigecycline has been developed 
which can treat most tetracycline resistant strains.[17, 201, 202]  Inhibitors of Tet efflux 
proteins have also been a recent development in combating tetracycline resistance.[17, 203] 
 
1.2.D.9.  Trimethoprim resistance 
 
 Exogenous acquisition of drug-resistant dihydrofolate reductases on transposons or 
plasmids are the most common way a species will acquire trimethoprim resistance.[17, 107, 
204-207]  Family 2 dihydrofolate reductases are subdivided into three classes.[107, 207]  All 
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classes in this family of DHFRs have exceedingly high levels of resistance to trimethoprim 
38.[107, 208, 209]  These trimethoprim resistance DHFRs are encoded by genes on mobile 
genetic elements.[107, 207]  These included plasmids and transposons which are able to 
easily spread among bacteria.[107, 207]       
 
1.2.D.10. Lipopeptide resistance 
 
 Resistance to the lipopeptide, daptomycin, has been noted in a few cases since its 
employ into clinical use.[147, 210]  Lipopeptides may disrupt cell integrity which results in 
cell depolarization.[147, 211]  Due to a lack of pertinent information concerning the 
mechanism of action of daptomycin, no resistance mechanism has been put forth.[147]   
 
1.2.D.11.  Chloramphenicol resistance 
 
 Chloramphenicol acetyltransferases inactivate chloramphenicol.[17, 147, 212]  These 
enzymes are encoded on by genes on conjugative and non-conjugative resistance 
plasmids.[147, 213-215]  They may also be present on the enterococci chromosome.[147, 
213-215]  Energy-driven efflux of chloramphenicol has also been documented.[147, 216]   
 
1.2.D.12.  Fluoroquinolone resistance 
 
 One mechanism or a combination of both mechanisms, infer fluoroquinolone 
resistance in Gram-negative species.[147]  Drug efflux and mutation are responsible for 
fluoroquinolone resistance, particularly in Enterococcus.[147, 216]  Mutations in the genes 
that code for the topoisomerase target proteins impart resistance as do mutations in parC 
which encode for the A subunit of DNA gyrase, and subunits of gyrA and topoisomerase 
IV.[147, 217-221]  Further mutations in the emeA gene and efrB gene that encode for an 
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enterococcus efflux pump and an ABC efflux pump respectively cause an increase in uptake 
and export of the fluoroquinolone antibiotics.[147, 222-224]    
 
1.3  Modern drug discovery methods 
 
1.3.A.  Introduction 
 
 Drug discovery consists of several lines of investigation including natural product 
screening, synthesis, combinatorial chemistry, combinatorial biosynthesis, and the use of 
synthesis, specifically combinatorial chemistry in conjunction with natural product screening.   
 Natural product screening is the isolation and characterization of potentially 
pharmaceutically active biological molecules.[225]  These molecules are derived from an 
enumerable number of sources, which include bacteria, fungi, molds, plants, and marine 
organisms.  Synthesis is the artificial construction of both novel molecules and biological 
molecule mimics using chemical techniques.  Combinatorial chemistry is the use of synthesis 
to create large libraries of compounds.[226]  Combinatorial libraries mostly consist of small, 
stereochemically poor products.  Combinatorial biosynthesis is the use of knowledge of the 
biosynthetic pathway, such as a polyketide biosynthesis pathway for the synthesis of a 
macrolide like erythromycin, to alter it chemically in vivo.[227]  These alterations involve 
the addition and/or insertion of plasmid DNA or RNA into the producing strain of bacteria.  
Such genetic alterations are commonly achieved with the introduction of a plasmid carrying 
the desired segment.  Combinatorial chemistry in conjunction with natural product screening 
can be used to synthesize complex and difficult to synthesize natural products, allowing for 
the efficient production of large libraries of compounds.[228]  Combinatorial chemistry does 
not involve genetic change, simply the use of a natural product as a scaffold which can be 
elaborated using organic synthetic techniques to introduce foreign moieties for ease of 
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chemical modification.  The introduction of easily modifiable chemical moieties is key to the 
production of large and quickly synthesized natural product analogue libraries.        
 
1.3.B.  Natural product screening 
 
 Compounds produced in nature were among the first substances used to combat 
infection.[11]  These substances were derived from flora and fauna.  This pharmacopeia of 
folklore medicines has been used as a standard medicinal arsenal for centuries.[11]  Modern 
chemical techniques isolate the active component or components of various biological 
entities such as plants and molds.  Thus, natural product research continues to be an active 
area of drug discovery.  Many of the antibiotics previously mentioned, such as the pencillins 
and macrolides, are secondary metabolites of mold and bacteria respectively.   
 In the past 20 years, a major shift has occurred away from natural products and 
toward combinatorial libraries due to the advent of high throughput screening (HTS). [228] 
High throughput screening allows for the screening of large libraries of compounds that can 
be provided through combinatorial synthesis.[228]  The value of natural products has not 
been in question; the efficiency in investigation of natural products has. 
Natural products are compounds that are often low in sulfur and halogens and often 
contain such chemical groups as carboxylic acids, alcohols, esters, amides, and ethers.  
Natural products on average contain a fairly high number of ring structures.  These structures 
are secondary metabolites (i.e. products from metabolic pathways that are necessary for the 
sustainment of life for an organism), and are often stereochemically rich.  High numbers of 
chiral centers in conjunction with hydrogen bond donors allow for complex three dimension 
structures that can interact with target enzymes within organisms.[228]  Some natural 
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products, such as those produced by microorganisms, can be synthesized in large quantities 
via culture and subsequent fermentation.   
 
1.3.C.  Synthesis 
 
 Synthesis is the mechanism by which molecules can be made artificially.  Synthesis 
includes natural product synthesis, combinatorial synthesis, target oriented synthesis, and 
diversity oriented synthesis.  Natural product synthesis, also called total synthesis, includes 
all synthetic steps necessary to re-create a natural product.  Examples of this are the total 
synthesis of Taxol 37 and platencin 38.[229, 230]   
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Figure 1.36:  Structure of Taxol 37. 
Taxol 39 is a diterpene which produced by plants of the genus Taxus and isolated from the 
bark of T. brevifolia.  Taxol is used as a treatment of ovarian and breast cancers.[231] 
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Figure 1.37:  Structure of Platencin 38. 
Platencin 38 is a potent inhibitor of bacterial fatty acid biosynthesis (Fab) and displays a 
broad-spectrum of activity against drug resistant pathogens such as methicillin-, macrolide-, 
and linezolid-resistant S. aureus, vancomycin intermediate S. aureus, vancomycin-resistant 
enterococci, and Streptococcus pneumonia.[232]  Target oriented synthesis is the synthesis of 
a particular compound designed to bind to bind to specific receptor sites that have been 
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characterized in advance.  Diversity-oriented synthesis is the synthesis of many compounds, 
varying in chemical groups, topography, stereochemistry, and regiochemistry.  The aim of 
diversity-oriented synthesis is the construction of a variety of structures to test against a 
variety of targets in order to establish activity. 
 
1.3.D.  Combinatorial synthesis 
 
 Combinatorial synthesis is used to construct large libraries of compounds that have a 
low molecular weight, are stereochemically poor, uncomplicated and have a diversity of 
functional groups.[233]  Combinatorial chemistry can exploit solid supports for ease of 
purification or can be free in solution.   
 
1.3.E.  Combinatorial biosynthesis 
 
 One significant problem in natural products research is the lack of selective chemical 
„handles‟, or in other words, functional groups that provide for ease of structural 
diversification of the natural product.  The lack of chemical „handles‟ limits the synthesis of 
derivatives and analogues, which may be necessary in order to produce a product that has 
greater bioavailability, acid stability, activity, limits toxicity, and resists quick elimination 
from the body.  Combinatorial biosynthesis can provide a way around this dilemma. 
 Combinatorial biosynthesis is the combinatorial construction of secondary metabolite 
biosynthesis gene clusters with the goal of generating new “non-natural” natural products.  
By using genetic recombinatorial techniques, changes can be made to the order in which the 
end product is assembled and, therefore, produce a novel natural product in vivo or a 
derivative of an already existing entity.[228, 234]   
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1.3.F.  Natural products in combinatorial synthesis 
 
 Natural products are often stereochemically rich, topographically complex, contain 
ring structures, and can be produced through culture and fermentation processes, which 
eliminates the need for complex, time-consuming syntheses of similar compounds.[228]  
However, natural product isolation lacks the chemical diversity, large library synthesis, and 
high-throughput screening available in combinatorial synthesis.[228]  A combination of these 
methods involves creating natural product-like compounds.  After extraction of the desired 
natural product from fermentation, this product may be subjected to synthetic modification to 
create easily modifiable chemical moieties which can be exploited through combinatorial 
chemistry.[228]  Once the natural product-like scaffold has been synthesized, thousands to 
millions of compounds can be synthesized using simple chemical techniques.  Increases in 
the number of different moieties can be used to synthesize ever greater numbers of natural-
product-like molecules that combine the chemical diversity of combinatorial compounds with 
the high rate of biological activity of natural products.[233]  Not only is this harnessing of 
potentially vast libraries of biologically produced complex entities the latest evolution of 
combinatorial and natural product synthesis, it provides a strong and compelling strategy in 
modern drug discovery.[228]  
 
1.4 Summary 
 Highly efficient combinatorial synthesis combined with scaffolds derived from 
nonactin, a natural product, was used to make triazoloester libraries of potentially 
antimicrobial compounds.  The triazoloester library was assayed for antimicrobial activity.  
The impact of stereochemistry and structure on the biological activity of compounds 
exhibiting antimicrobial activity was studied as well as the necessity of the natural product 
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component of the antimicrobial active compounds for biological activity.  Though many 
compounds can be synthesized from a single scaffold, the development of more than one 
scaffold from a single natural product is advantageous in the search for antibiotic 
compounds.  Therefore, other scaffolds were synthesized from nonactin and libraries of 
compounds produced from these scaffolds.  Finally, the synthesis of analogues of nonactin 
was attempted in order to develop a library from this ionophore antibiotic.        
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CHAPTER 2 
 
METHYL NONACTATE AS A NATURAL PRODUCT SCAFFOLD FOR 
COMBINATORIAL SYNTHESIS 
  
 
 
2.1  Why is methyl nonactate a good scaffold? 
 
 
O
OH O
OMe
45, Methyl Nonactate  
 
Figure 2.1: Structure of methyl (±)-nonactate 45, post-primary scaffold for the triazoloester 
nonactic acid analogue libraries. 
  
Methyl nonactate 45 and, therefore, nonactic acid 49, 50 are highly useable and 
valuable structures for drug discovery.[235]  Methyl nonactate 45 is a stereochemically rich 
structure (Figure 2.1).  Gram quantities of highly pure enantiomers of methyl nonactate 46, 
48 can be produced through the addition of racemic methyl nonactate to a fermentation of 
Rhodococcus  and can then be used to synthesize enantiomerically pure primary scaffolds of 
the triazoloester nonactic acid analogue libraries (Scheme 2.1).[7]   
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Figure 2.2:  Enantiomers of nonactic acid and methyl nonactate. 
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Chemical „handles‟ available on this structure make methyl nonactate 45 a compound 
from which many analogue scaffolds can be made and from these scaffolds, large derivative 
libraries.   
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Scheme 2.1:  Overall scheme of triazoloester library synthesis from 46 and 48.   
 The secondary alcohol was conveniently available for esterification, which led to 
ester scaffolds, from which further modification could be initiated on the carboxylic acid 
(Scheme 2.1).  The carboxylic acid was reduced to a primary alcohol, which was substituted 
with azide after tosylation.  This allowed for the formation of substituted triazoles using 
terminal alkynes using the Huisgen‟s 1,3-dipolar cycloaddition reaction under Sharpless 
conditions, which regioselectively formed 1,4-triazoles (Scheme 2.1).[236, 237] 
The stereochemically rich structure 40 is available on the gram scale, which is made 
by Streptomyces griseus and extracted using standard procedures.  Synthesis of the plus and 
minus nonactic acid 49, 50 is complicated, uses many steps, and results in low yields of the 
final products, resulting in only milligrams for use in scaffold synthesis.[238]  Biosynthesis 
using fermentation cultures to produce nonactin 40  (Figure 2.3) followed by purification via 
crystallization, methanolysis, chromatographic separation, and stereoisomer separation via 
Rhodococcus (Scheme 2.2) is cost and time efficient as well as productive, producing 
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material 49, 50 in gram scale quantities.[7]  Gram scale quantities are essential not only for 
the production of libraries from nonactic acid and nonactic acid analogue scaffolds, but for 
the mass scale production of commercial pharmaceutical compounds that may come from 
these libraries.  High production of these compounds at lower cost and with less time will 
help make potential drugs more affordable and, therefore, commercially attractive. 
 
2.2    How do we make methyl nonactate? 
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Figure 2.3:  Naturally occurring macrotetrolides 39, most importantly nonactin 40. 
 
The parent compound of a group of ionophore (Na
+
 and K
+
) antibiotics called 
macrotetrolides 39 (Figure 2.3) is nonactin 40, which is produced by Streptomyces griseus 
ETH A7796.[239]  Acetate, propionate, and succinate are known to be units in the polyketide 
biosynthesis pathway that assemble to form nonactin 40.[239, 240]  The nonactin 40 
structure is a cyclic tetraester ionophore which is composed of four monomeric subunits, two 
plus enantiomers of nonactic acid 49 and two minus enantiomers of nonactic acid 50 (Figure 
2.3).[238, 241, 242]  The plus and minus subunits 49,50 are alternately joined to form a 32-
   R1 R2 R3 R4 
Nonactin (40) Me Me Me Me 
Monactin (41) Me Me Et Me 
Dinactin (42)  Et Me Et Me 
Trinactin (43)  Et Et Et Me 
Tetranactin (44) Et Et Et Et 
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membered macrocycle.[238, 241]  Though each subunit is chiral, the S4 symmetry of the 
nonactin macrotetrolide 40 makes nonactin achiral, a meso compound.[238, 241]   
Nonactin 40 has been shown to have both antibiotic and antitumor activity.[241, 243]  
It possesses antitumor activity against mammalian cell lines in vitro and in mice, against 
Crocker sarcoma 180.[240]  Nonactin 40 has also been shown to be an inhibitor of the 170-
kDa P-glycoprotein-mediated efflux of 4-O‟-tetrahydropyranyldoxorubicin in multidrug-
resistant erythroleukemia K562 cells at subtoxic concentrations.[240]  Highly purified 
nonactin 40 is also commercially important for use in ammonium-sensitive electrodes.[235]         
Fermentation of Streptomyces griseus yields nonactin 40, which is isolated from the 
fermentation by standard natural product extraction and isolation procedures.[235]  The 
methods in Dinges J.M. et al. detail the extraction of the secondary metabolite from cell paste 
with acetone.  After evaporation, the concentrated residue of the macrotetrolide mixture is 
then fractionated on a silica gel column and crystallized using standard methods to give 
nonactin crystals.  The nonactin crystals are then subsequently recrystallized several times 
until a high purity is reached.  A typical fermentation yields 5-10 g of nonactin 40 per 
liter.[235]    
Methanolysis of the nonactin tetramer gives two plus and two minus nonactate 
subunits 49,50.[235]  Methanolysis is carried out by refluxing nonactin 40 in 5% H2SO4 / 
MeOH for 12 hours.  The nonactate subunits 49, 50 provide a powerful scaffold.   
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Scheme 2.2:  The Rhodococcus erythropolis enzymatic separation of methyl (±)-nonactate 
45 into 46 and 48.[7] 
 
Perhaps the most important aspect to the nonactate scaffold 45 and its production 
from Streptomyces griseus also presents one of the most important problems.  The 
stereochemistry provided by the natural product subunit is set biologically instead of 
chemically, but a racemic mix of the plus and minus enantiomers 45 is given by the 
methanolysis of nonactin 40.  In order to meet the requirements of the study of 
stereochemically pure natural product libraries and the requirements of drug testing, the 
enantiomers were separated from each other.  Enantiomers, however, have identical chemical 
properties, and, therefore, identical polarities which do not allow for their separation via 
chromatography on silica gel.  A common, but costly way to separate out enantiomers is the 
use of Mosher‟s ester to create diastereomers, which can be separated by chromatography on 
silica gel due to their distinct and different chemical properties.  Mosher‟s ester, however, is 
commercially very costly to buy.  This cost limits the amount of material that can be 
separated.  Therefore, in order to separate out the plus and minus nonactic acid stereoisomers 
49, 50 another method was developed that would allow separation and purification on a gram 
scale and avoid expensive reagents.  Racemic methyl nonactate 45 in shake flask cultures of 
Rhodococcus erythropolis allows for an efficient resolution (Scheme 2.2).[7]  Rhodococcus 
erythropolis selectively oxidizes the secondary alcohol of the methyl (–)-nonactate 48, 
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making a ketone under aerobic conditions.  The differences in polarity between the alcohol 
and the ketone functional groups allow for separation of the enantiomers on a silica gel 
column.  The oxidized minus methyl nonactate 47 can then be reduced under anaerobic 
conditions by Rhodococcus erythropolis to give methyl (–)-nonactate 48.  Therefore, both 
enantiomers of methyl nonactate can be separated from each other in excellent yields and 
with enantiomeric purity.[7]  Rhodococcus fermentation is exceptionally cost effective and 
the separation method can be applied to grams of the racemic starting material.   
 
2.3 Conclusion 
 
 Methyl nonactate is a versatile scaffold for the synthesis of libraries.  It is a 
stereochemically complex molecule with readily modifiable alcohol and ester groups.   It is 
derived from fermentation and methanolysis as opposed to a lengthy and expensive 
synthesis.  The ability to separate out the enantiomers with inexpensive Rhodococcus 
fermentation makes methyl nonactate ideal for use in drug discovery. 
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CHAPTER 3 
 
SYNTHESIS AND EVALUATION OF A COMBINATORIAL LIBRARY BASED 
UPON METHYL NONACTATE 
 
 
 
3.1 Introduction 
 
The primary library was created via the synthesis of an analogue to nonactic acid, 
which was developed as an azidoalcohol nonactic acid analogue scaffold 55.  Through a 
short series of steps, all of which had good to excellent yields, the azidoalcohol 55 was 
synthesized.  The azide and the secondary alcohol are easily modified by well-known 
synthetic techniques to produce triazoloesters (Scheme 3.1). 
 
Scheme 3.1:  Overall scheme for the synthesis of the racemic triazoloester library from 45. 
 To build the triazoloester library, the secondary alcohol of the azidoalcohol nonactic 
acid analogue scaffold 55, which was synthesized from 45, was first esterified with a series 
of acyl chlorides, followed by the formation of a substituted triazole from the primary azide 
(Scheme 3.2).        
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3.2 Generation of scaffold material 
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Scheme 3.2:  Synthesis the azidoalcohol (±)-nonactic acid analogue scaffold 55. 
The azidoalcohol (±)-nonactic acid analogue scaffold 55 was synthesized with a 
36.2% overall yield from methyl (±)-nonactate 45 (Scheme 3.2).  The secondary alcohol of 
45 was then THP protected using DHP in dichloromethane.  The THP protection of the 
secondary alcohol went smoothly and quickly.  The protection produced diastereomers which 
were purified and collected as a whole with minimal separation.  The primary alcohol 52 
from the reduction of the ester was purified by flash chromatography and dried to produce 
the protected nonactate alcohol.  This primary alcohol 52 was then activated with pTsCl and 
pyridine into order to allow for the substitution of the alcohol for an azide.  The protection of 
the secondary alcohol was necessary in order to assure that only the primary alcohol would 
be tosylated and replaced by azide.  Though it has been shown that reduction of nonactate to 
a diol can be easily done, the following tosylation would depend upon a selective activation 
of a primary alcohol which was not a good strategy.  The latter approach has been shown to 
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be slower, and does not produce high yields.  Protection of the secondary alcohol is therefore 
necessary and uses an inexpensive and efficient method.  The tosylation of the primary 
alcohol 53 was then followed by the azide substitution with sodium azide in DMF at 80 
o
C 
which quickly afforded the protected azide 54.  The last remaining step was the 
straightforward removal of the THP protecting group by hydrochloric acid in methanol to 
give 55.  The reaction was almost immediate but was given time to ensure good yields.  With 
the removal of the THP group, the purification of the target scaffold produced was very 
simple and done by chromatography on silica gel.  Each step is high yielding and efficient.   
 
3.3 Diversification of scaffold 55 to generate a combinatorial library 
 
The azidoalcohol nonactic acid analogue scaffold 55 was used as the primary scaffold 
for the synthesis of a library of triazoloester (±)-nonactic acid analogue compounds.  The 
secondary alcohol and the primary azide provide chemical handles for derivatization.  
Esterification of the secondary alcohol allows for derivatization of one side of the scaffold 
(Scheme 3.3).  Huisgen 1,3-dipolar cycloaddition under Sharpless conditions to the primary 
azide provides derivatization of the other side of the scaffold via the synthesis of substituted 
triazoles in a regiospecific manner (Scheme 3.4).  In the formation of the triazoloester library 
the secondary alcohols were esterified forming azidoester nonactic acid analogues 56.  The 
azidoester nonactic acid analogues then underwent the Huisgen‟s 1,3-dipolar cycloadditions 
to produce the triazoloester nonactic acid analogue derivatives 62.  For the initial prototype 
library we chose five terminal alkynes and five acyl halides to give twenty-five possible 
library members.  The identity of the appended structures is shown in Table 3.1.  Out of the 
twenty-five possible structures, ten of these compounds were chosen for synthesis. 
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 Table 3.1: Chart of triazoloester compounds and numbering scheme. 
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Scheme 3.3:  Synthesis of the azidoester (±)-nonactic acid analogue scaffolds 56. 
These reactions were carried out at room temperature and easily finished within three 
hours.  The percent yields of these reactions were generally 70-90% (Figure 3.1). 
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Figure 3.1:  Overall yields of azidoester nonactic acid analogue scaffolds from 45.  
 
 
Scheme: 3.4: Synthesis of the racemic triazoloester nonactic acid analogue library 62. 
The azidoester scaffold 56 was used to make each of the final derivatives compounds, 
the triazoloesters (Scheme 3.4).  This second reaction performed was the 1,3-Huisgen dipolar 
cycloaddition in which to each azidoester 56 a monosubstituted alkyne was added, followed 
by 0.3 M copper sulfate in solution and a 1.1 M ascorbic acid solution.  These conditions are 
commonly known as Sharpless conditions which act to control the regiospecificity of the 
reaction and improve the reaction rate.  The percent yield of product 62 of these reactions 
generally exceeded 90% (Figure 3.2). 
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Figure 3.2: Overall yields of triazoloester (±)-nonactic acid analogue library from 45.  
 
 
3.4 Biological evaluation of initial library 
 
The 72, 71, and 67 compounds were shown by assay, which was performed by 
Adrienne Smith, Dr. Erin Bolstad, and Dr. Brooke Martin, to be the most active members of 
the 25 membered of the triazoloester (±)-nonactic acid analogue library (Figure 3.2).  These 
compounds were tested against B. subtilis, B. anthracis, S. aureus, S. aureus (MRSA), and 
Ent. faecalis (VRE).  
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ORO N3
 
 
R Compound B. subtilis S. aureus 
H 55 Inact. Inact. 
Ac 57 Inact. Inact. 
COtBu 58 Inact. Inact. 
COCH2CH2CHCH2 59 Inact. Inact. 
COCH2CH2CO2Me 60 Inact. Inact. 
Bz 61 Inact. Inact. 
 
Table 3.2:  Inactivities of azidoester compounds. 
 
 Alamar-blue assays on the azidoesters revealed that they have no antibacterial activity 
in B. subtilis or S. aureus (Table 3.2).[244]  Since no azidoester showed any significant 
activity as did the original scaffold, only potential for the triazoloesters remained.      
ORO N3
 
 
  IC50 IC99 
R Compound MCF10 (calc.) 
H 55 791 ± 62 983 ± 62 
OAc 57 685 ± 1125 720 ± 1126 
COtBu 58 741 ± 18 926 ± 18 
COCH2CH2CHCH2 59 704 ± 85 895 ± 86 
COCH2CH2CO2Me 60 816 ± 56 1039 ± 56 
Bz 61 769 ± 35 999 ± 35 
 
Table 3.3:  MCF10 IC50 (µM) and IC99 (µM) values for azidoester compounds. 
 
 Cytotoxicity assays against the MCF10 breast cell line showed that none of the 
azidoesters had any significant cytotoxicity (Table 3.3).[245]      
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Compound 
1
R 
2
R B. subtilis S. aureus 
63 Ac tBu Inact. Inact. 
66 tBu  Inact. Inact. 
65  tBu Inact. Inact. 
68 CO2Me  F  
Inact. Inact. 
72 Ph 2-pyridyl 94 1500 
64 Ac  1125 Inact. 
69 tBu mPhNHAc Inact. Inact. 
67   62 1000 
71 CO2Me  mPhNHAc 375 750 
70 Ph mPhNHAc Inact. Inact. 
     
Table 3.4:  MIC (µM) values of racemic triazoloester compound library. 
 
 Alamar Blue Assay of the ten triazoloester compounds synthesized from the 
azidoalcohol scaffold 55 showed antibacterial activity for three compounds.  72 showed 
activity against B. subtilis at 94 µM and against S. aureus at 1500 µM.  67 had effective 
antibacterial activity against B. subtilis at 62 µM and against S. aureus at 1000 µM.  The lead 
compound, 71, showed antibacterial activity against B. subtilis at 375 µM and against S. 
aureus at 750 µM (Table 3.4). 
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Compound R1 R2 IC50 (MCF10) IC99 (calc.) 
63 Ac tBu 716 ± 50 875 ± 50 
66 tBu  114 ± 5.6 129 ± 5.7 
65  tBu 407 ± 39 541 ± 40 
68 CO2Me  F  
767 ± 44 998 ± 44 
72 Ph 2-pyridyl 291 ± 74 965 ± 109 
64 Ac  481 ± 1.4 540 ± 1.4 
69 tBu mPhNHAc 140 ± 17 228 ± 18 
67   247 ± 19 349 ± 19 
71 CO2Me  mPhNHAc 758 ± 35 1017 ± 46 
70 Ph mPhNHAc 693 ± 83 1198 ± 88 
 
Table 3.5:  IC50 (µM) and IC99 (µM) values for the triazoloester compound library. 
 
 The degree of cytotoxicity for the triazoloester compounds differed greatly.  The 
bactericidal compounds 72 and 71, showed the highest IC99 values for cytotoxicity.  As the 
ratio of bactericidal activity compared to cytotoxicity was the greatest for 72 and 71, these 
became the lead compounds (Table 3.5).  These compounds became the focus of SAR studies 
in order to increase the bactericidal potency of the compounds and decrease their 
cytotoxicity.  
 As shown in Figure 3.3, B. subtilis exposed to varying concentrations of the 72 
compound with a DMSO carrier resulted in an effect similar to plasmolysis.[244]  The SEM 
images of B. subtilis exposed to concentrations of 72 show a „shriveling‟ of the plasma 
membrane with discontinuities present at the cell poles (Figure 3.3). Osmotic perturbations 
were ruled out by measuring MIC values over a wide range of NaCl concentrations.  It was 
found that the MIC values were independent of ionic strength.       
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Figure 3.3: SEM images of B. subtilis after treatment with 72. 
 
 
3.5 Evaluation of scaffold stereochemistry upon antibacterial activity 
 
One of the most important aspects of the developmental plan in the projects 
synthetics schemes is stereochemistry.  Stereochemistry played a prominent role in the 
projects for several reasons, the first being that for the development of any pharmaceutical 
both enantiomers must be tested to know the biological activities of each stereoisomer.  
Thalidomide was an anti-nausea medication given to pregnant women to alleviate morning 
sickness.[246]  One enantiomer of thalidomide was found to be responsible for the anti-
nausea effect, the other enantiomer proved to be a powerful teratogen that caused severe 
developmental defects.[246]  The cellular component that a drug interacts with: efflux 
pumps, enzymes, etc, determines its activity or inactivity.  One of the major goals of this 
research is not only the discovery of new powerful antibiotics, but antibiotics that will be 
selective.  Therefore, in order to discover which if not both enantiomers of the racemic 72 
and 71 triazoloester compounds is responsible for their antibacterial behavior, 81 and 79 
were synthesized using an azidoalcohol (–)-nonactic acid analogue scaffold 77 which was 
synthesized from (–)-nonactic acid 48.  The (–)-nonactate was separated out of the racemic 
stock according to the aforementioned Rhodoccocus procedure.[7]    
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Scheme: 3.5: Synthesis of the azidoalcohol (–)-nonactic acid analogue scaffold 77. 
The scaffold 77 was derived from (–)-nonactic acid.  The secondary alcohol of the 
methyl (–)-nonactate starting material was THP protected using DHP and a catalytic amount 
of pTsOH at room temperature in methylene chloride for 5 hours.  The eastern ester portion 
of the molecule was then reduced to primary alcohol 74 using lithium aluminum hydride in 
THF at room temperature for 12 hours and tosylated with pTsCl in pyridine at room 
temperature for 5 hours to give 75.  The tosylate 75 then served as a leaving group for the 
introduction of azide via sodium azide in DMF at 100 ⁰C for 3 hours.  Deprotection of the 
secondary alcohol was achieved by stirring at room temperature with 6 M HCl in methanol 
and water at room temperature for 3 hours.  This resulted in the nonactic acid analogue 
scaffold 77 derived from (–)-nonactic acid.  The yields of this synthesis scheme matched well 
with those of the synthesis scheme for the racemic compound. 
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Scheme 3.6: Synthesis of the 71 triazoloester nonactic acid analogue 79. 
From the azidoalcohol nonactic acid analogue scaffold 77 the triazolo-ester nonactic 
acid analogue 79 was synthesized (Scheme 3.6).  As with the racemic scaffold, the secondary 
alcohol was esterified using methyl 4-chloro-4-oxobutyrate in pyridine at room temperature 
for 3 hours.  The azide of the resultant azidoester 78 was then reacted with N-(3-ethynyl-
phenyl)-acetamide in a Huisgen 1,3-dipolar cycloaddition reaction with Sharpless conditions.  
The reaction was carried out in a shaker at 37 ⁰C for 12 hours.  Initial addition of the 
components turned the mixture a yellow-orange color, clouded with undissolved solid.  After 
12 hours, the solid disappeared from the mixture but an insoluble residue clung to the glass 
of the vial.  However, both reactions were high yielding and the products were easy to purify 
by chromatography on silica gel.   
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Scheme 3.7: Synthesis of the triazoloester (–)-nonactic acid analogue 81.  
To synthesize the minus 72 triazoloester nonactic acid analogue 81, the azidoalcohol 
77 derived from (–)-nonactic acid was esterified with benzoyl chloride in pyridine at room 
temperature for 3 hours (Scheme 3.7).  Dipolar cycloaddition under Sharpless conditions was 
used to synthesize the triazole 81 by the addition of 2-ethynyl-pyridine to the azidoester 80 in 
5:1 ethanol in water (Scheme 3.7).  The solution turned a dark olive green with solid 
suspensions; the solution was then shaken at 37 ⁰C for 12 hours.  As with the 72 solution, a 
thin solid residue clung to the glass of the vial after rinsing with ethyl acetate.  The 
benzoylation was high yielding but purification was troublesome as the product spot 
coincided closely with leftover benzoyl chloride on separation followed on a thin layer 
aluminum-backed silica-gel chromatography plate.  The triazole formation reaction was high 
yielding and purification was simple using chromatography on silica gel which gave pure 81.   
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Scheme 3.8: Synthesis of the azidoalcohol (+)-nonactic acid analogue scaffold 86. 
Compound 86, derived from methyl (+)-nonactate 46, was generated using methods 
similar to those employed in generating 77.  The secondary alcohol of methyl (+)-nonactate 
46 was THP protected 82 with DHP and pTsOH at room temperature for 5 hours.  The 
product of the reaction was reduced by lithium aluminum hydride in THF at room 
temperature for 12 hours to a primary alcohol 83.  The yield over these two steps was 67%.  
The easily purified product 83 was then tosylated to give 84 with a 73.4% yield, which then 
underwent nucleophilic substitution with sodium azide in DMF at 80 ⁰C for 5 hours to give 
the THP-protected primary azide 85, a process that gave a yield of 80%.  In the final step, the 
secondary alcohol was deprotected with 6 M HCl in water and methanol at room temperature 
for 12 hours, giving a final 67% yield of the plus azido-alcohol nonactic acid analogue 
scaffold 86.      
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Scheme 3.9: Synthesis of the 72- triazoloester (+)-nonactic analogue 88. 
 Analogue 88 was synthesized by an almost identical method to that of 81.  Benzoyl 
chloride was added to 86 with pyridine at room temperature for 3 hours giving a 77.5% yield 
of the ester analogue 87.  Compound 87 was then used in a second reaction after purification 
with 2-ethynyl-pyridine, 1.1 M ascorbic acid in water, 0.3 M copper sulfate in water, 5:1 
ethanol in water solution, which was shaken at 37 ⁰C for 12 hours.  This gave a product 88 
yield of 74.4% after chromatography of silica gel.    
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Scheme 3.10: Synthesis of the 71-triazoloester (+)-nonactic acid analogue 90. 
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The plus 71 triazoloester nonactic acid analogue 90 was synthesized by methods 
almost identical to that of the minus stereoisomer 79.  Methyl 4-chloro-4-oxobutyrate in 
pyridine was added to the plus azidoalcohol nonactic acid analogue 86 at room temperature 
for 3 hours giving a 66% yield after chromatography on silica gel.  N-(3-ethynyl-phenyl)-
acetamide was then added in a 5:1 ethanol to water solution to the resulting azidoester 89 
followed by 1.1 M ascorbic acid in water and 0.3 M copper sulfate in water.  The solution 
was then shaken at 37 ⁰C for 12 hours, giving an 81% yield of 90 after purification. 
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 88 81 72 90 79 71 
Organism (+) (–) Racemic (+) (–) Racemic 
B. cereus 1500 Inact. 1500 187 Inact. 375 
B. subtilis 47 Inact. 94 187 Inact. 375 
B. anthracis 750 Inact. 1500 375 Inact. 750 
S. aureus 750 Inact. 1500 750 Inact. 750 
E. faecalis van
R
 62 Inact. Nd 125 Inact. nd 
 
Table 3.6:  MIC (µM) Values of 72 and 71. 
 
 Compounds 72 and 71 both showed significant antibacterial activity against a range 
of organisms.  Table 3.6 highlights the importance of stereochemistry in drug design.  The 
racemic compounds 72 and 71, showed activity as did the plus enantiomer.  The minus 
enantiomers 81 and 79 showed no activity.  This assayed proved that it is the plus enantiomer 
of 72 and 71 that are antibacterial.  
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Strain 88 81 90 79 
B. anthracis 750 Inactive 375 Inactive 
B. cereus 1500 Inactive 187 Inactive 
B. subtilis 47 Inactive 187 2000 
E. faecalis 500 Inactive 250 nd 
E. faecalis van
R
 62 Inactive 125 Inactive 
S. aureus 750 Inactive 750 Inactive 
S. aureus MRSA 125 Inactive 250 750 
S. epidermidis 250 Inactive 250 nd 
S. pyogenes 64 Inactive 125 nd 
 
Table 3.7:  MIC (µM) Values for 88, 81, 90, and 79. 
 
 Compounds 88, 81, 90, and 79 were tested against a wide range of pathogens (Table 
3.7).  Significant antibacterial activity was show against B. subtilis, E. faecalis van
R
, S. 
aureus MRSA, S. epidermidis, and S. pyogenes for compound 88.  The minus enantiomer 81 
of 88 was found to be completely inactive against all the pathogens it was tested against.  
Compound 90 was found to have antibacterial activity against B. cereus, B. subtilis, E. 
faecalis, E. faecalis van
R
, S. aureus MRSA, S. epidermidis, and S. pyogenes.          
Modern drug discovery dictates that both enantiomers of a racemic mix must be 
tested for activity in order to determine which enantiomer gives rise to the biological action 
and, in the course of testing, determine the safety of each enantiomer.  The Rhodococcus 
fermentation (Scheme 2.1) has allowed for the resolution of nonactic acid.  Once the 
enantiomers had been separated, the pure enantiomers of 71 and 72 were synthesized and 
tested for activity.  The assay showed very low activity for 81 and 79.  The plus enantiomers, 
however, showed a marked increase in potency compared to that of the 50/50 mixture.  This 
increase was double the activity of its racemic counterparts (Table 3.6). 
In summary, this library was generated using a biologically active natural product, 
nonactin 40, from which the methyl nonactate scaffold 45 was generated.  This scaffold was 
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then used to generate the azidoalcohol nonactate scaffold 55 which was used in turn to 
synthesize a  library of compounds, in which members of which were shown to have 
antimicrobial activity.  Pure plus and minus enantiomers of the azidoalcohol nonactate 
scaffold 86, 77 were synthesized and the enantiomerically pure antimicrobial compounds 
generated from each enantiomer.  Assays revealed the plus enantiomer was responsible for 
the activity.    
Though not entirely conclusive, the activity of only the plus enantiomer points to the 
specificity of the target site for these two compounds.  It may also be noteworthy that out of 
only ten of the triazoloester nonactic acid analogue derivatives synthesized (Figure 3.2) two 
were found to have good activity.  
 
3.6 Regiochemistry 
 
Regiospecificity is also a major consideration for drug development just as 
stereospecificity is.  Interactions between a potential drug and its binding site depend greatly 
on the molecular weight of the drug, its polarity, how lipophilic or hydrophilic it is, surface 
topology, weak or strong interactions and therefore binding with the drug target in order for 
the drug to fit in the right „pocket‟.  The stereospecificity of the nonactic acid analogue 
libraries can be controlled by the separation of enantiomers, and the organic synthesis tools 
used to make analogues with respect to making epimers.  Regiospecificity in these analogues 
can also be controlled by the single site of regiodiversity.  This site is the triazole made from 
the azide portion on the eastern side of the azido-esters such as 60 and 61.  Using Sharpless 
conditions, the 1,4-triazole regioisomer dominates over the 1,5-triazole regioisomer in such a 
way by virtue of the reaction mechanism.  The binding to the copper ligand to the terminal 
end of the alkyne allows for the reaction to proceed only one way by generating a copper 
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acetylide species.  This gives the 1,4-triazole as the exclusive product.  Under thermal 
conditions however the reaction favors the formation of the 1,5-triazole even with Sharpless 
conditions.  In order to determine if regiospecificity is important to the triazoloester nonactic 
acid analogue libraries, both regioisomers were synthesized.     
 
Scheme 3.11: Synthesis of the 1,5-triazoloester (+)-nonactic acid analogue 91. 
 
Starting from a racemic amount of the azidoalcohol nonactic acid analogue scaffold 
55, the secondary alcohol was esterified with benzoyl chloride in pyridine at room 
temperature for 3 hours (Scheme 3.11).  The product 61 was purified by chromatography on 
silica gel and used directly in the dipolar cycloaddition (Scheme 3.11).   
In the attempt to form the 1,5-triazole, the ester was added to a 5:1 ethanol to water 
solution and 1.1 M ascorbic acid in water was added, as was 0.3 M copper sulfate in water, 
along with 2-ethynyl-pyridine.  The reaction was heated around 100 ⁰C for 12 hours.  The 
yield of the final product 91 of the reaction was 69%.   
The IR, MS, and NMR data support the conclusion that the product of this reaction is 
a triazolo-ester nonactic acid analogue compound.  The only spectral differences in 91 were 
changes in the aromatic region of the 1H NMR and those of the single proton attached to the 
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triazole.  It was thought that the chemical shift of the triazole proton was shifted relative to 
that of the 1,4-triazole.  However, it remained inconclusive by virtue of reliance on chemical 
shift data.  Therefore, a 2D-NOE was run so that a through space correlation could be seen 
between the pyridine protons and the neighboring methyl group.  Unfortunately no 
correlation was ever noted.  A similar 2D-NOE was run on a sample of 72 but no correlation 
was noted between the 2-position methyl group and the triazolo proton.  Since one of these 
interactions must exist, the logical conclusion is that the 2D-NOE was in some way faulty, 
possibly due to insufficient deoxygenation of the sample or because the positions of the 
protons relative to each other are too far away, resulting in little or no signal.    
 
Scheme 3.12: Synthesis of the 1,5-triazoloester (+)-nonactic acid analogue 92. 
The racemic analogue 55 was used to synthesize the racemic 1,5-triazole 92 (Scheme 
3.11).  The primary azide of the nonactic acid analogue 60 underwent dipolar cycloaddition 
reaction efficiently.  The solution was stirred for 12 hours at 100 ⁰C, giving a final yield of 
92 after purification by chromatography on silica gel of 86.3%.  
Compound 91 and 92 were analyzed with a 2D-NOE as well as 71 and 72.  Neither of 
the aforementioned correlations was seen.  Again, this is most likely due to either insufficient 
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deoxygenation of the sample or because the actual positions of the groups are too far apart to 
observe NOE.        
No significant biological activity was noted for the putative 1,5-triazoloester (±)-
nonactic acid analogue regioisomers 91 and 92. 
 
3.7 Attempts to generate libraries from homononactic acid 
 
Up till now, methyl nonactate 45 has been used as the primary scaffold in the 
synthesis of the major library.  Methyl homononactate 93 is also a product of the 
methanolysis of the macrotetrolide mix which is separated out by chromatography on silica 
gel.  In order test the flexibility of the site of biological activity, the homologous 
azidoalcohol nonactic acid analogue scaffold 97 (Scheme 3.13) was made as well as their 
corresponding esters 98-102 (Figure 3.4).  This particular synthetic scheme remains 
unfinished, the ultimate goal of which is to obtain the 72 and 71 homononactic acid analogue 
products 104, 103 (Figures 3.6 and 3.5).  These would then be assayed for biological activity 
and compared with the biological data obtained for 72 and 71.  This data would give a better 
idea as to the nature of the site which the compounds target.       
 
Scheme 3.13: Synthesis of the azidoalcohol homononactic acid analogue scaffold 97. 
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Azidoalcohol homononactic acid analogue scaffold 97 was synthesized from methyl 
homononactate 93 (Scheme 3.13).  As with the primary nonactic acid analogue scaffold 55, 
the secondary alcohol was THP-protected.  Methyl homononactate 93 was added to 
methylene chloride, followed by DHP and pTsOH, and stirred for 5 hours at room 
temperature.  During the reaction an increasing amount of polymeric product is produced in 
the reaction as a brown to black material that remains suspended in the reaction.  Within the 
5 hour time frame, the reaction remained fairly clear.  Due to the diastereomers produced in 
the production of the THP protected product, the residue of the reaction was partially purified 
by chromatography on silica gel and used directly in the following reaction.  The ester of the 
semi-pure THP protected product was then reduced to the primary alcohol by lithium 
aluminum hydride in THF and stirred at room temperature for 12 hours.  This gave the 
product with a 73% yield of 94 after purification on silica gel.  The primary alcohol 94 was 
then tosylated with pTsCl and pyridine and stirred in methylene chloride at room temperature 
for 12 hours giving a 78% yield after purification.  The tosylated product 95 was then added 
to DMF with sodium azide at 100 ⁰C for 24 hours which gave the azido product 96.  The 
yield after chromatography on silica gel was 84.5%.  The secondary alcohol was then 
deprotected with 6 M HCl in water and methanol at room temperature for 3 hours, resulting 
in a 70% yield 97 after purification by chromatography on silica gel.   
Once the azidoalcohol homononactic acid analogue scaffold 97 had been synthesized, 
it was esterified and the 1,4-triazoles would then be synthesized to make the homologous 72 
and 71-triazoloester nonactic acid analogues 104, 103.  The synthesis of 104 and 103 remains 
incomplete.   
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Figure 3.4: Overall yields of azidoester homononactic acid analogue scaffold library 98, 99, 
100, 101, 102. 
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Scheme 3.14: Synthesis of the 72-intermediate azidoester homononactic acid analogue 102. 
 
The azidoalcohol homononactic acid analogue scaffold 97 was esterified with 
benzoyl chloride in pyridine at 37 ⁰C for 12 hours (Scheme 3.14).  The purification of the 
azidoester product 102 by chromatography on silica gel was difficult due to similar polarities.  
The final yield was 41%.    
 
Scheme 3.15: Synthesis of the 71-intermediate azidoester homononactic acid analogue 101. 
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The azidoalcohol homononactic acid analogue scaffold 97 was esterified with methyl 
4-chloro-4-oxobutryate in pyridine at 37 ⁰C for 12 hours (Scheme 3.15).  Unlike the 72-
homononactic acid analogue azidoester 102, the 71-homononactic acid analogue azidoester 
101 was simple to purify by chromatography on silica gel and gave a 66.1%% yield. 
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Figure 3.5: 71-triazoloester homononactic acid analogue 103. 
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Figure 3.6: 72-triazoloester homononactic acid analogue 104. 
 
Due to a shortage of the compound, the triazoloesters 103,104 were never completed.  
It remains unknown and part of a future synthesis to determine the utility of homononactic 
acid analogue libraries. 
The azidoalcohol homononactic acid analogue scaffold 97 presented no biological 
activity against B. subtilis. 
 
3.8 Conclusion 
 Triazoloester derivatives were synthesized from methyl nonactate, the product from 
the methanolysis of nonactin, and assayed for antibacterial activity and cytotoxicity.  Out of 
the ten triazoloesters, two possessed significant antibacterial activity, 72 and 71.  In time-kill 
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assays, it was found that they are bactericidal.  SEM showed a „shriveling‟ of B. subtilis in 
varying concentrations of 72, which may indicate the target of action of the triazolo-ester 
compounds to be the cytoskeleton.  Compounds 88 and 90 were shown to be the active 
enantiomers.  Compounds 81 and 79 had no antibacterial activity.  Regioisomers of 72 and 
71 were made.  It was found that the 1,4-triazole regioisomer of 72 and 71 was the active 
regioisomer.  The 1,5-triazole regioisomer of 72 and 71 showed no antibacterial activity.  
Homologs of 72 and 71 are as of yet incomplete. 
 Triazoloesters, by virtue of their bactericidal activity against S. aureus and E. faecalis 
as well as against other pathogens (Table 3.7) and their relatively low cytotoxicity have great 
potential for the development of new potent antibacterial compounds.  Compounds 71 and 72 
have shown great promise (Table 3.7) as antibacterial compounds and were later used as 
leads in SAR studies to produce even more potent compounds.  To date, these compounds 
have undergone testing in animals and are proceeding to the next phase toward clinical 
studies.       
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CHAPTER 4 
 
 
SYNTHESIS OF THE BIS-TRIZAZOLE NONACTIC ACID ANALOGUE LIBRARY 
 
 
 
4.1 Synthesis of the bis-azide (±)-nonactic acid analogue scaffolds 
 
The biological activity exerted by the (+)-72 and 71 nonactic acid analogue 
compounds 88, 90 has made the starting subunit, methyl nonactate 45 an attractive building 
block for making libraries of potentially active compounds.  The azidoalcohol nonactic acid 
analogue scaffold 55 has lead to the triazoloester libraries which have shown even more 
promise through the continuation and expansion of the primary library (Figure 3.2).  This 
primary scaffold 55, however, is not the only scaffold that can be developed from methyl 
nonactate 45.  In this study, both the primary and secondary alcohols were transformed to 
azides to make an easy one step derivatization scaffold in which two triazoles could be made.  
Alkyne addition to this scaffold 115 produced the bis-triazole library 116 (Scheme 4.1). 
O
OH
OMe
O
O
N
N
N N
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45 116, bis-triazole library
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Scheme 4.1:  Overall scheme for the racemic bis-triazole library 116 from 45. 
  This downside to this scaffold is that both moieties on either end are the same.  The 
advantage to this scaffold is that it greatly simplifies and shortens the scheme to make the 
scaffold, eliminates the esterification process that can be difficult, increases the overall yield, 
and allows for easy purification.  The more scaffolds that can be made from methyl nonactate 
45, the more attractive methyl nonactate 45 becomes for drug discovery.  
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Scheme 4.2: Synthesis of the bis-azide (±)-nonactic acid analogue scaffold 115. 
The bis-azide (±)-nonactic acid analogue scaffold 115 was synthesized from methyl 
(±)-nonactate 45 (Scheme 4.2).  The methyl (±)-nonactate 45 was reduced by lithium 
aluminum hydride in THF to give the diol 113 with a 99% yield.  The diol 113 was then 
tosylated with pTsCl in pyridine.  DMAP was added and the solution was stirred for 12 hours 
at room temperature giving a 39% yield of 114 after purification by column chromatography 
on silica gel.  In the final step, sodium azide was added to the bis-tosylate product 114 in 
DMF at 80 ⁰C for 12 hours, which resulted in an inversion of stereochemistry at C8 with an 
80.5% yield after purification of the bis-azide nonactic acid analogue scaffold 115. 
The bis-azide nonactic acid analogue scaffold 115 showed no biological activity. 
 
 
4.2 Synthesis of the bis-triazole (±)-nonactic acid analogue library 
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Scheme 4.3:  Synthesis of bis-triazole (±)-nonactic acid analogue library 116. 
Libraries of bis-triazole (±)-nonactic acid analogue compounds 116 can be made 
through a dual Huisgen 1,3-dipolar cycloaddition on the bis-azide (±)-nonactic acid analogue 
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scaffold 115.  In order to ensure the regiochemistry of the products, the 1,4-triazoles were 
made using Sharpless conditions at 37 ⁰C.  Due to limited amounts of the material available, 
only five of the bis-triazole products (Figure 4.1) were synthesized.      
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Figure 4.1:  Overall yields for bis-triazole (±)-nonactic acid analogue library. 
Each of the five compounds 117, 118, 119, 120, and 121, were synthesized by the 
addition of the bis-azide scaffold 115 to a 5:1 ethanol in water solution.  To each of the five 
solutions prepared one of the previously used alkynes (Table 3.1) were added in excess, 
followed by 0.3 M copper sulfate in water and 1.1 M ascorbic acid in water.  The solution 
was shaken at 37 ºC for 12 hours.  Each compound was purified by chromatography on silica 
gel.   
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The yield of the bis-triazole product 117, 24.9%, was the lowest out of the five bis-
triazoles synthesized possibly due to the steric hindrance caused by the tert-butyl groups.  
118, 119, and 120 were obtained with a 56%, 61%, and a 63.4% yield respectively.  A 99% 
yield of 121 was obtained.   This may be due to electron donation into the ring and, therefore, 
into the alkyne.    
4.3 Conclusions 
 
 The bis-triazole nonactic acid analogue library (Figure 4.1) was synthesized for two 
main purposes.  The first of these purposes was to demonstrate that not one, but many 
different scaffolds could be synthesized from a single natural-product derivative.  More than 
one scaffold allows for the possibility of parallel syntheses, even syntheses that use the 
addition of similar chemical moieties.  The second purpose in their construction, with the 
success of the first scaffold in mind, and the results that showed the importance of the 
nonactic acid moiety, was to synthesize more potentially active compounds.  Though these 
compounds did not show any significant useful biological activity, 118 did show a curious 
cytotoxic activity against normal mammalian cells over that of cancer cells.  This preliminary 
finding has not yet been replicated or explored. 
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CHAPTER 5 
 
 
CYCLOHEXANE ANALOGUE LIBRARY OF 72 AND 71 
 
 
 
5.1 Introduction 
 
The importance of the natural product component to the antimicrobial activity 
exhibited by 72 and 71 was determined by the replacement of the nonactic acid analogue 
scaffold with that of a cyclohexane chemically similar moiety (Figure 5.1a).   
 
 
 
 
 
 
 
 
 
Figure 5.1a:  Comparison of 72 and 71 to cyclohexane analogues 131 and 132. 
The cyclohexane moiety would approximate the spacing and stereochemistry of the 
natural product component of 72 and 71.  The reasoning behind this replacement is not only 
to determine if the natural product component is necessary for biological activity, but if 
replacement of this moiety is possible using an inexpensive commercially available 
compound.     
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Figure 5.1b:  72 and 71 Comparison to the cyclohexane analogue library. 
The cyclohexane analogue libraries of the 72 and 71 were synthesized to illustrate not 
just the importance of incorporating natural products, but the importance of the nonactic acid 
subunit itself (Figure 5.1).  Cis and trans cyclohexanes were used to mimic the 
stereochemistry of the azidoalcohol nonactic acid analogue scaffolds 77, 86 in the synthesis 
of the 72 and 71 compounds.     
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5.2 Synthesis of the Cis-4-azidomethyl-cyclohexanol scaffold 
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Scheme 5.1: Synthesis of the cis-4-azidomethyl-cyclohexanol scaffold 128. 
A series of synthetic steps were executed to synthesize the cis-4-azidomethyl-
cyclohexanol scaffold 128 (Scheme 5.1).  The starting material for the synthesis was cis-4-
hydroxycyclohexane-1-carboxylic acid 122 which was added to 5% sulfuric acid in methanol 
and stirred at room temperature, then refluxed for 5 hours.  The methyl ester 123 was purified 
by chromatography on silica gel to give an 84% yield.  The secondary alcohol 123 was 
protected by a THP group.  The impure product 124 was reduced by lithium aluminum 
hydride in THF at room temperature for 12 hours.  The two step reaction gave a 90% yield 
after purification by chromatography on silica gel.  This gave a THP-protected secondary 
alcohol and a primary alcohol 125.  The primary alcohol was then tosylated with pTsCl in 
pyridine at room temperature for 12 hours.  The product 126 was purified by chromatography 
on silica gel to give a 69% yield.  The tosylate was then substituted with azide.  The tosylate 
product 126 in DMF with sodium azide was warmed to 80 ⁰C, and stirred for 5 hours which 
gave an 82% yield of the primary azide product 127 after purification by chromatography on 
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silica gel.  The 4-azidomethyl-cyclohexanol 128 was obtained by the deprotection of the 
secondary alcohol with 6 M HCl in water and methanol at room temperature after 3 hours.  
The final reaction gave a 90.3% yield of 128.  This scaffold was obtained without any 
changes in the cis structure of the starting material to give the cis-4-azidomethyl-
cyclohexanol product 128.     
In order to approximate the structures and chemical reactivity of 72 and 71, the 
methyl 4-chloro-4-oxobutyrate and benzoyl chlorides were used to synthesize the 
corresponding esters in respect to the 72 and 71 products (Scheme 5.2). 
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Scheme 5.2: Synthesis of the cis-4-azidomethyl-ester-cyclohexane scaffolds 129, 130. 
 128 was added to pyridine and methyl 4-chloro-4-oxobutyrate and stirred for 3 hours 
then purified by chromatography on silica gel which gave 129 at 55% yield.  Esterification 
reactions with methyl 4-chloro-4-oxobutryate often gave a good deal of dark residue which 
was easily separated from the product.  130 was obtained with an 81% yield in a similar 
reaction with the exception of using benzoyl chloride in place of methyl 4-chloro-4-
oxobutyrate.  Excess benzoyl chloride proved to be difficult to remove via chromatography 
on silica gel as it often coincided with 130. 
85 
 
Once the esters were synthesized the 72 and 71-like cyclohexane analogues could be 
synthesized.  Each ester 129 and 130 underwent a dipolar cycloaddition using Sharpless 
conditions, with N-(3-ethynyl-phenyl)-acetamide and 2-ethynyl-pyridine respectively 
(Scheme 5.3).  These gave the 72 and 71-like triazolo-ester cyclohexane analogues 131 and 
132.   
 
O
N3O
MeO
O
O
N3O
O
NO
MeO
O
O
NO
N
N
N
N
N
N
H
O
129 130
131 132
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M copper sulfate-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
2-ethynyl-pyridine
1.1 M Ascorbic acid / H2O
0.3 M copper sulfate-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
69% 62%
9% Overall Yield
11.8% Overall Yield
 
Scheme 5.3: Synthesis of the cis-4-triazolo-ester cyclohexane analogues 131, 132.  
N-(3-Ethynyl-phenyl)-acetamide was added to 5:1 ethanol and water, followed by the 
71-like azidoester 129.  1.1 M ascorbic acid in water and 0.3 M copper sulfate in water were 
added and the solution was shaken at 37 ⁰C for 12 hours.  After purification by 
chromatography on silica gel, this gave a 69% yield of the cis 71-like triazoloester 
cyclohexane analogue 131.  
 2-Ethynyl-pyridine was added to the 72-like azidoester 130 in 5:1 ethanol and water, 
followed by 1.1 M ascorbic acid in water and 0.3 M copper sulfate in water.  After the 
solution was shaken for 12 hours at 37 ⁰C, the cis 72-like triazoloester cyclohexane analogue 
132 was purified by chromatography on silica gel with a 62% yield. 
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Neither of the 72 nor the cis 71-like triazoloester cyclohexane analogue compounds 
131,132 showed activity against a range of Gram positive pathogens. 
 
5.3 Synthesis of the Trans-4-azidomethyl-cyclohexanol scaffold 
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Scheme 5.4: Synthesis of the trans-4-azidomethyl-cyclohexanol scaffold 139. 
With same lack of inversion of stereochemistry in the production of 72 and 71, the 
trans-4-azidomethyl-cyclohexanol scaffold 139 was synthesized with a similar series of 
synthetic steps (Scheme 5.4).  Trans-4-hydroxy-cyclohexane-1-carboxylic acid 133 was 
added to 5% sulfuric acid in methanol and refluxed for 5 hours to give 4-hydroxy-
cyclohexanecarboxylic acid methyl ester 134.  The product was purified by chromatography 
on silica gel and gave 90% yield.  The secondary alcohol of the methyl ester was protected 
by a THP group.  The methyl ester analogue was added to methylene chloride at room 
temperature, followed by DHP and pTsOH.  The solution was stirred for 5 hours and the 
THP protected product 135 was purified by chromatography on silica gel to give a 73 % 
yield.  The methyl ester analogue 135 was reduced by lithium aluminum hydride in THF at 
room temperature for 5 hours, which gave the primary alcohol product 136 at an 86.8% yield 
after purification by chromatography on silica gel.  The primary alcohol 136 was tosylated by 
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the addition of the product to pyridine, followed by pTsCl at room temperature for 5 hours.  
The tosylate product 137 was purified by chromatography on silica gel which resulted in a 
69% yield.  Sodium azide in DMF was added to the tosylate product and the solution was 
warmed to 80 ⁰C for 5 hours which gave an 83.7% yield of 138 after purification by 
chromatography on silica gel.  The trans-4-azidomethyl-cyclohexanol scaffold 139 was 
produced by the deprotection of the THP group on the secondary alcohol with 6 M HCl in 
water and methanol at room temperature for 5 hours.  An 81.7 % yield of 139 was achieved 
after purification by chromatography on silica gel. 
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Scheme 5.5: Synthesis of the trans-4-azidomethyl-ester cyclohexane analogue scaffolds 140, 
141. 
 
Methyl 4-chloro-4-oxobutryate was added to the trans-4-azidomethyl-cyclohexanol 
scaffold 139 in pyridine at room temperature and stirred for 3 hours to give the trans-71-like 
azidoester cyclohexane analogue 140.  After purification by chromatography on silica gel, a 
53% yield was achieved (Scheme 5.5). 
Benzoyl chloride was added to the trans-4-azidomethyl-cyclohexanol scaffold 139 in 
pyridine at room temperature for 3 hours.  The product was purified by chromatography on 
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silica gel and gave a 71% yield of the trans-72-like azidoester cyclohexane analogue 141 
(Scheme 5.5). 
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Scheme 5.6: Synthesis of the trans-4-triazoloester cyclohexane analogues 142, 143. 
The trans-71-azidoester cyclohexane analogue 140 was added to N-(3-ethynyl-
phenyl)-acetamide in 5:1 ethanol and water followed by 1.1 M ascorbic acid in water and 0.3 
M copper sulfate in water.  The solution was stirred at 37 ⁰C for 12 hours which gave the 
trans-71-triazoloester cyclohexane analogue 142 with a 73% yield after purification by 
chromatography on silica gel (Scheme 5.6). 
2-Ethynyl-pyridine was added to the trans-72-azidoester cyclohexane analogue 141 
in 5:1 ethanol in water.  1.1 M Ascorbic acid in water was added, followed by 0.3 M copper 
sulfate in water at 37 ⁰C for 12 hours.  Purification by chromatography on silica gel gave the 
trans-72-triazoloester cyclohexane analogue 143 with a 79% yield (Scheme 5.6).   
No biological activity was exerted by either the 72 or 71-like trans triazoloester 
analogues 142,143. 
89 
 
 
5.4 Synthesis of the Cis-(4-azido-cyclohexyl)-methanol scaffold  
 
In order to cover the range of structures possible with the cyclohexane scaffold, two 
other scaffolds were synthesized (Schemes 5.7 and 5.10).  These scaffolds are the cis and 
trans cyclohexanes with the azide directly connected to the ring.  These syntheses involved 
an inversion of stereochemistry as the alcohol is substituted with an azide. 
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Scheme 5.7: Synthesis of the cis-(4-azido-cyclohexyl)-methanol scaffold 148.  
Cis-(4-Azido-cyclohexyl)-methanol scaffold 148 was synthesized from trans-4-
hydroxy-cyclohexane-1-carboxylic acid 133 (Scheme 5.7).  Trans-4-hydroxy-cyclohexane-1-
carboxylic acid 133 was reduced by lithium aluminum hydride and purified by 
chromatography on silica gel gave a 21% yield of trans-4-hydroxymethyl-cyclohexanol 144.  
The trans diol analogue 144 was added to DMF at 0⁰C, followed by TBDMSCl, and 
imidazole.  The solution was allowed to warm to room temperature as the solution was 
stirred for 12 hours.  This kinetic based reaction gave the silyl protection of the primary 
alcohol almost exclusively.  The percent yield of 145 was 57% after chromatography on 
silica gel.  The secondary alcohol was then tosylated by the addition of the protected diol to 
pyridine at room temperature, followed by pTsCl.  The solution was stirred for 12 hours, and 
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the tosylate product 146 was partially purified by chromatography on silica gel.  Bimolecular 
nucleophilic substitution occurred on the secondary tosylated alcohol by the addition of the 
tosylated product to DMF, followed by sodium azide.  The solution was warmed to 80 ⁰C 
and stirred for 12 hours.  The cis azido product 147 was purified by chromatography on silica 
gel, giving a 54.4% yield over 2 steps.  Deprotection of the primary alcohol with pTsOH in 
water and acetic acid at room temperature for 24 hours and purification by chromatography 
on silica gel gave the cis-(4-azido-cyclohexyl)-methanol scaffold 148 with a 43% yield.  
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Scheme 5.8: Synthesis of the cis-4-azidoester cyclohexane analogue scaffolds 149, 150. 
Methyl 4-chloro-4-oxobutryate was added to the cis-(4-azido-cyclohexyl)-methanol 
scaffold 148 in pyridine and stirred at room temperature for 3 hours to give the cis-71-like 
azidoester cyclohexane analogue 149.  Purification by chromatography on silica gel gave a 
78.4% yield (Scheme 5.8). 
Benzoyl chloride was added to the cis-(4-azido-cyclohexyl)-methanol scaffold 148 in 
pyridine and stirred at room temperature for 3 hours.  The cis-72-like azidoester cyclohexane 
analogue 150 was purified by chromatography on silica gel, which gave an 83% yield 
(Scheme 5.8) 
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Scheme 5.9: Synthesis of the cis-4-triazoloester cyclohexane analogues 151, 152. 
Cis-71-like azidoester cyclohexane analogue 149 was added to N-(3-ethynyl-phenyl)-
acetamide in 5:1 ethanol and water followed by 1.1 M ascorbic acid in water and 0.3 M 
copper sulfate in water.  The solution was shaken at 37 ⁰C for 12 hours which gave an 80.7% 
yield after purification by chromatography on silica gel of the cis-71-like-triazoloester 
cyclohexane analogue 151 (Scheme 5.9). 
Cis-72-like azidoester cyclohexane analogue 150 was added to 2-ethynyl-pyridine in 
5:1 ethanol and water.  1.1 M Ascorbic acid in water and 0.3 M copper sulfate in water was 
added and the solution was shaken for 12 hours at 37 ⁰C.  The cis-72-like-triazoloester 
cyclohexane analogue 152 was purified by chromatography on silica gel which gave an 80% 
yield (Scheme 5.9). 
Unexpectedly, 152 did show activity against B. subtilis.  The assayed showed that 152 
had an IC99 of 125 µM against B. subtilis. 
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5.5 Synthesis of the Trans-(4-azido-cyclohexyl)-methanol scaffold 
 
The final scaffold for the synthesis of the 72 and 71 triazoloester cyclohexane 
analogues was the trans-(4-azido-cyclohexyl)-methanol scaffold 157 (Scheme 5.10).  As 
with the previous syntheses, the synthetic scheme involves an inversion of stereochemistry, 
therefore, the trans scaffold is synthesized from the cis stereoisomer. 
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Scheme 5.10: Synthesis of the Trans-(4-azido-cyclohexyl)-methanol scaffold 157. 
Cis-4-hydroxy-cyclohexane-1-carboxylic acid 122 was added to THF at 0 ⁰C, 
followed by lithium aluminum hydride.  The solution was allowed to warm to room 
temperature over 12 hours and the cis diol product 153 was purified by chromatography on 
silica gel to give a 76% yield.  The primary alcohol of the diol was then protected by a silyl 
group by the addition of the diol to DMF at 0 ⁰C, followed by TBDMSCl and imidazole.  
The solution was warmed to room temperature over 12 hours.  Purification by 
chromatography on silica gel gave a 52% yield of 154, due to the kinetic nature of the 
reaction.  The silyl protected product 154 was then added to pyridine at room temperature, 
followed by pTsCl and stirred for 5 hours which gave the tosylate 155 with a 91.6% yield 
after purification by chromatography on silica gel.  The tosylate 155 was then added to DMF 
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with sodium azide and warmed to 80 ⁰C for 5 hours which after purification by 
chromatography on silica gel gave a 64.5% yield of the azido product 156.  The scaffold 157 
was obtained after purification with a 69.2% yield after the deprotection of the primary 
alcohol with 6 M HCl in water and methanol at room temperature for 5 hours (Scheme 5.10).  
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Scheme 5.11: Synthesis of the trans-4-azidoester cyclohexane analogue scaffolds 158, 159. 
Methyl 4-chloro-4-oxobutyrate was added to the trans-(4-azido-cyclohexyl)-methanol 
scaffold 157 in pyridine at room temperature and stirred for 3 hours, which gave a 61% yield 
of the trans-71-like azidoester cyclohexane analogue 158 (Scheme 5.11).  The product was 
purified by chromatography on silica gel. 
Benzoyl chloride was added to the trans-(4-azido-cyclohexyl)-methanol scaffold 157 
in pyridine at room temperature and stirred for 3 hours (Scheme 5.11).  Purification by 
chromatography on silica gel gave a 72.6% yield of the trans-72-like azidoester cyclohexane 
analogue 159. 
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Scheme 5.12: Synthesis of the trans-4-triazoloester cyclohexane analogues 160, 161. 
Trans-71-like azidoester cyclohexane analogue 158 was added to 5:1 ethanol in 
water, followed by N-(3-ethynyl-phenyl)-acetamide.  1.1 M Ascorbic acid in water and 0.3 M 
copper sulfate in water were added and the solution was shaken at 37 ⁰C for 12 hours.  
Purification by chromatography on silica gel gave a 79.6% yield of the trans-71-like 
triazoloester cyclohexane analogue product 160 (Scheme 5.12). 
Trans-72-like azidoester cyclohexane analogue 159 was added to 5:1 ethanol in 
water, followed by 2-ethynyl-pyridine, 1.1 M ascorbic acid in water, and 0.3 M copper 
sulfate in water.  The solution was shaken at 37 ⁰C for 12 hours and the product was purified 
by chromatography on silica to give the trans-72-like triazoloester cyclohexane analogue 161 
(Scheme 5.12). 
None of the compounds showed any significant biological activity. 
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5.6 Synthesis of alternate cyclohexane-based scaffolds 
 
The four cyclohexane scaffolds synthesized and the 72 and 71-like products made, 
illustrated that the methyl nonactate analogue subunit is important for the biological activity 
of 72 and 71.  More cyclohexane scaffolds were made on a large scale to illustrate this point.  
Both cis and trans versions of the azidocarboxylic acid scaffolds 164, 167 were synthesized 
and sent to the appropriate groups for further synthesis and studies.  The secondary alcohol 
underwent a bimolecular nucleophilic substitution reaction resulting in an inversion in 
stereochemistry.  
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Scheme 5.13: Synthesis of the cis-4-azido-cyclohexane-carboxylic acid scaffold 164. 
The cis-4-azido-cyclohexane-carboxylic acid scaffold 164 was synthesized from the 
trans-4-hydroxy-cyclohexanecarboxylic acid methyl ester 134 (Scheme 5.13).  The 
secondary alcohol was tosylated with pTsCl in pyridine at room temperature and stirred for 5 
hours.  The tosylate 162 was purified by chromatography on silica gel and gave a 78% yield.  
The tosylate 162 was substituted with sodium azide in DMF at 80 ⁰C for 5 hours and the 
product was then purified by chromatography on silica gel.  The reaction gave an 89% yield 
of 163.  The methyl ester was saponified overnight with 2.5 M lithium hydroxide in a water, 
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methanol, and THF solution and followed by 1 M HCl in water.  Purification of the product 
by chromatography on silica gel gave a 91.5% yield of 164.   
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Scheme 5.14: Synthesis of the trans-4-azido-cyclohexane-carboxylic acid scaffold 167. 
The trans-4-azido-cyclohexane-carboxylic acid scaffold 167 was synthesized from 
the cis-4-hydroxy-cyclohexanecarboxylic acid methyl ester 123 (Scheme 5.14).  The 
secondary alcohol was tosylated in pyridine with pTsCl at room temperature which was 
stirred for 5 hours and gave a 67.4% yield of the tosylate 165 after purification by 
chromatography on silica gel.  Trans-4-azido-cyclohexane-carboxylic acid methyl ester 166 
was made by the nucleophilic substitution of the tosylate 165 with sodium azide in DMF at 
80 ⁰C for 5 hours.  Purification by chromatography on silica gel gave a 77.5% yield of the 
azide 166.  Saponification of the methyl ester by 2.5 M lithium hydroxide in a water, 
methanol, and THF mixture followed by the addition of 1 M HCl in water gave a 91% yield 
of the trans-4-azido-cyclohexanecarboxylic acid 167 after purification by chromatography on 
silica gel.      
Using the cis-(164) and trans-substituted (167) azidoacids, the medicinal chemistry 
group at Promiliad Biopharma was able to generate 246 derivatives of the general structure. 
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Figure 5.2:  General structure of the triazoloamide cyclohexane analogues. 
 
Of these compounds, the following three had more than marginal activity against 
Gram-positive pathogens (Table 5.1). 
Designation Compound B. subtilis S. aureus 
18-C-12 
N
N
ON N
O
 
250 250 
18-C-5 
N
N
ON N
N
 
250 250 
18-G-3 
N
N
ON N
O
 
250 250 
 
Table 5.1:  MIC (µM) Values for cyclohexane analogues for B. subtilis and S. aureus.  
 
5.7 Conclusions 
 
The synthesis of the cyclohexane, cis and trans, with alternating alcohol and azide 
groups attached to the ring or a single methylene away from the ring was greatly important in 
establishing the essential nature of the nonactic acid analogue moiety for the activity of 
compounds described earlier (Chapter 3).  Despite the activity of 152, the rest of the eight 
member library was inactive.  It should also be noted that 152 is only bactericidal against B. 
subtilis, a model Gram-positive bacteria and not a human pathogen.  No biological activity 
was shown against S. aureus, S. aureus (MRSA), or E. faecalis (VRE).  Though the chemical 
moieties were similar, with similar spacing to that of the nonactic acid central moiety, no 
significant activity was measured in the trans or the cis forms.  Though this does not in and 
of itself prove that the nonactic acid moiety is responsible for the biological activity seen in 
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72 and 71, it does suggest the importance of this chirally rich, natural product derived 
analogue to the activity of these compounds against these antibiotic resistant strains.   
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CHAPTER 6 
 
OTHER NONACTIC ACID BASED STRUCTURES 
 
 
 
6.1 Introduction 
 
Though nonactin is an antibiotic, it is a poor drug.[247]  Synthesis of nonactin 
analogue structures may be beneficial in developing a nonactin derivative that is less 
hydrophobic and more soluble.[247]  The development of nonactin analogues was attempted 
using the azidoalcohol scaffolds synthesized from methyl nonactate 55 and methyl 
homononactate 97 and the linker compounds: isophthaloyl chloride, terephthaloyl chloride, 
1,3-diethynylbenzene, and 1,4-diethynylbenzene (Figure 6.1). 
Nonactin, 40
Linker Linker
Nonactin Analogues
+
+
+
+
_ _
 
Figure 6.1:  Cartoon of Nonactin Structure vs. Nonactin Analogue Structure. 
Two units of the azidoalcohol scaffold are coupled with either isophthaloyl chloride 
or terephthaloyl chloride via an esterification reaction producing a bis-ester compound 168, 
169, 170.  Two units of the azidoalcohol scaffold were coupled with either 1,3-
100 
 
diethynylbenzene or 1,4-diethynylbenzene via the Huisgen 1,3-dipolar cycloaddition reaction 
under Sharpless conditions giving a bis-triazole product 171, 172, 173.  The final step in 
these syntheses would be coupling the bis-ester compounds with 1,3-diethynylbenzene or 
1,4-diethynylbenzene to make a bis-ester bis-triazole macrolide.  Likewise, the bis-triazole 
dimers would be coupled with isophthaloyl chloride or terephthaloyl chloride to produce a 
bis-triazole bis-ester macrolide. 
The first step in the synthesis of these macrolides was the synthesis of dimers in order 
to work out the coupling conditions necessary for their formation (Scheme 6.1 and 6.2).   
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Scheme 6.1:  Overall synthesis of dimer compounds from terephthaloyl chloride and 
isophthaloyl chloride. 
 
Terephthaloyl chloride and isophthaloyl chloride were used to synthesize bis-ester 
bis-triazole dimer-like compounds of 72 and 71 (Scheme 6.1).  Azidoalcohol nonactic 
analogue scaffolds 55 and 97 were used in conjunction with the dichlorides, terephthaloyl 
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chloride and isophthaloyl chloride, to synthesize bis-ester bis-azide scaffolds which were 
then used to synthesize the dimer compounds (Scheme 6.1).  
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Scheme 6.2:  Overall scheme of dimer compounds from 1,3-diethynylbenzene and 1,4-
diethynylbenzene. 
 
 A second set of scaffolds were synthesized with two molecules of the azidoalcohol 
scaffolds, 55 and 97, in conjunction with 1,3-ethynyl benzene and 1,4-ethynyl benzene 
(Scheme 6.2).  Under Sharpless conditions this gave bis-triazole bis-hydroxy dimer 
compounds.  These hydroxyl groups were then esterified with methyl 4-chloro-4-oxobutyrate 
and benzoyl chloride to make dimer-like compounds of 72 and 71 (Scheme 6.2).   
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6.2 Synthesis of dimer-like derivatives of nonactic acid analogue azideester and 
triazoloalcohol scaffolds 
 
Cl
OO
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O
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N3N3
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N3
py, r.t., 24 h
50.8%
168
97
 
 
Scheme 6.3: Synthesis of Terephthalic acid bis-{1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-
furan-2-ylmethyl]-propyl} ester scaffold 168. 
 
Terephthalic acid bis-{1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-
propyl} ester 168 was synthesized by the addition of 97 to terephthaloyl chloride in pyridine 
at room temperature.  The solution was stirred for 24 hours and the product was purified by 
chromatography on silica gel.  This gave a 50.8% yield of the 1,4-bis-esterazido product 168 
(Scheme 6.3). 
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Scheme 6.4: Synthesis of Terephthalic acid bis-{2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-
furan-2-yl]-1-methyl ethyl} ester scaffold 169. 
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Terephthalic acid bis-{2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl 
ethyl} ester 169 was synthesized by the addition of 55 to terephthaloyl chloride in pyridine at 
room temperature and stirred for 3 days.  Purification of the 1,4-bis-esterazido product 169 
by chromatography on silica gel gave a 26.7% yield (Scheme 6.4).     
ClCl
O O
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Scheme 6.5: Synthesis of Isophthalic acid bis-{2-[5-{2-azido-1-methyl-ethyl)-tetrahydro-
furan-2-yl]-1-methyl-ethyl} ester scaffold 170. 
 
Isophthalic acid bis-{2-[5-{2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-
ethyl} ester 170 was synthesized by the addition of isophthaloyl chloride to 55 in pyridine at 
room temperature and stirred for 3 days.  The 1,3-bis-esterazido product 170 was obtained 
with a 25.3% yield after purification by chromatography on silica gel (Scheme 6.5). 
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Scheme 6.6: Synthesis of 1,4-bis-triazolo-bis-alcohol homononactic acid analogue scaffold 
171. 
 
The 1,4-bis-triazolo alcohol 171 was synthesized by the addition of 97 to 5:1 ethanol 
in water, followed by 1,4-diethynylbenzene.  1.1 M Ascorbic acid in water and 0.3 M copper 
sulfate in water were added and the mixture was shaken at 37 ⁰C for 3 days.  An 85% yield 
of 171 of the product was obtained after purification by chromatography on silica gel 
(Scheme 6.6).  
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Scheme 6.7: Synthesis of the 1,4-bis-triazolo-bis-alcohol nonactic acid analogue scaffold 
172. 
 
The 1,4-bis-triazoloalcohol 172 was synthesized by the addition of 1,4-
diethynylbenzene to 5:1 ethanol in water, followed by 55.  1.1 M Ascorbic acid in water and 
0.3 M copper sulfate in water were added and the mixture was shaken for 12 hours at 37 ⁰C 
to give the product 172 after purification by chromatography on silica gel with an 88% yield 
(Scheme 6.7). 
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Scheme 6.8: Synthesis of 1,3-bis-triazolo-bis-alcohol homononactic acid analogue scaffold 
173. 
 
The 1,3-bis-triazolo-bis-alcohol 173 was synthesized by the addition of 1,3-
diethynylbenzene to 5:1 ethanol in water followed by 97.  1.1 M Ascorbic acid in water and 
0.3 M copper sulfate in water were added.  The solution was shaken for 12 hours at 37 ⁰C 
and the product 173 was purified by chromatography on silica gel.  This resulted in an 85.4% 
yield (Scheme 6.8). 
None of the dimer-like scaffolds synthesized for this library had any significant 
antimicrobial activity. 
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6.3 Synthesis of dimer-like derivatives of 72 and 71 
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Figure 6.2: Terephthalic acid bis-[1-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-
methyl-ethyl}-tetrahydro-furan-2-ylmethyl)-propyl] ester 174. 
 
Dimer 174 was synthesized by the addition of 168 to 5:1 ethanol in water followed by 
N-(3-ethynyl-phenyl)-acetamide.  1.1 M Ascorbic acid in water and 0.3 M copper sulfate in 
water were added and the solution was shaken at 37 ⁰C for 12 hours.  Compound 174 was 
purified by chromatography on silica gel and resulted in a 70% yield (Figure 6.2). 
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Figure 6.3: Terephthalic acid bis-(1-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-
ethyl-tetrahydro-furan-2-ylmethyl}-propyl) ester 175. 
 
The 1,4-bis-ester-bis-triazole homomethyl nonactic acid analogue 175 was 
synthesized by the addition of 168 to 5:1 ethanol in water.  2-Ethynyl-pyridine was added 
with 1.1 M ascorbic acid in water and 0.3 M copper sulfate in water and the solution was 
shaken for 12 hours at 37 ⁰C and gave a 57.7% yield of 175 after purification by 
chromatography on silica gel (Figure 6.3). 
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Figure 6.4: Synthesis of Terephthalic acid bis-(1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-
[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl) ester 176.  
 
2-Ethynyl-pyridine was added to 169 in 5:1 ethanol in water followed by 1.1 M 
ascorbic acid in water and 0.3 M copper sulfate in water.  The solution was stirred at room 
temperature for 12 hours.  Purification by chromatography on silica gel gave 176 (Figure 
6.4). 
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Figure 6.5: Synthesis of Isophthalic acid bis-(1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-
[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl) ester 177. 
 
The 1,3-bis-ester-bis-triazole nonactic acid analogue 177 was synthesized by the 
addition of 2-ethynyl-pyridine to 5:1 ethanol in water followed by 170 .  1.1 M Ascorbic acid 
in water and 0.3 M copper sulfate in water were added, and the solution was stirred at room 
temperature for 12 hours.  Purification of 177 by chromatography on silica gel gave an 85% 
yield (Figure 6.5).  
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Figure 6.6: Synthesis of 1,4-bis-triazole-bis-ester homononactic acid analogue 178. 
 
Methyl 4-chloro-4-oxobutyrate was added to 171 in pyridine at room temperature.  
The solution was stirred for 12 hours and the product was purified by chromatography on 
silica gel which gave a 33.7% yield of 178 (Figure 6.6). 
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Figure 6.7: Synthesis of 1,4-bis-triazole-bis-ester homononactic acid analogue 179. 
Benzoyl chloride was added to 171 in pyridine at room temperature and the solution 
was stirred for 12 hours.  The reaction gave a 60% yield of 179 after purification by 
chromatography on silica gel (Figure 6.7). 
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Figure 6.8: Synthesis of 1,3-bis-triazole-bis-ester homononactic acid analogue 180. 
Compound 173 was added to pyridine, followed by methyl 4-chloro-4-oxobutyrate.  
The solution was stirred for 12 hours at room temperature and 180 was purified by 
chromatography on silica gel to give a 47.8% yield (Figure 6.8). 
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Figure 6.9: Synthesis of 1,3-bis-triazole-bis-ester homononactic acid analogue 181. 
Compound 173 was added to pyridine, followed by benzoyl chloride and stirred for 
12 hours at room temperature which gave a 65.4% yield of 181 after purification by 
chromatography on silica gel (Figure 6.9). 
For this library of eight 72 and 71-like dimeric compounds, no significant 
antibacterial activity was observed in Gram-positive or Gram-negative bacteria.  No 
antibacterial activity was reported for any of the scaffold precursors.   
 
6.4 Conclusions 
 
The dimeric compounds showed no antimicrobial activity in the Alamar blue assays.  
This may indicate the specific nature of the target site and the conformation of 72 and 71 in 
respect to their interaction in order to elicit the bactericidal activity.  Due to the demands of 
the synthesis of the nonactate and homononactate scaffolds and the limited material available 
at the time of synthesis, no macrolides were synthesized. 
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CHAPTER 7 
 
 
FEEDING STUDIES 
 
 
 
7.1 Nonactin biosynthesis competitive inhibitor in Streptomyces griseus 
 
Nonactin 40 is ineffective as a therapeutic due to its high hydrophobicity and 
insufficient solubility.  Making libraries of this structure could yield more effective antibiotic 
and antitumor agents and solve the pharmacodynamic properties.  The structure of nonactin 
40, however, presents a serious challenge to any structural modification for the purpose of 
synthesizing analogues and derivatization. 
Nonactin 40 is a macrotetrolide which is assembled in vivo by Streptomyces griseus 
ETH A7796 from nonactic acid subunits.  The resulting structure provides no easily 
modifiable chemical groups for easy synthetic transformations.  Total synthesis of the 
macrotetrolide in which a chemical handle could be introduced is impractical.  Precursor-
directed biosynthesis derivatives may be a straightforward way to generate nonactin 
derivatives (Scheme 7.1). 
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Scheme 7.1:  Overall synthesis for nonactic acid analogues. 
As the natural production of nonactin is high (5-10 g/L), precursor directed 
biosynthesis should give detectable levels of analogs.  Additionally, S. griseus or genetically 
modified strains of S. griseus in which nonactic acid production has been blocked, can 
convert nonactic acid into nonactin 40.  This observation suggests that nonactic acid 
analogues may be added to these fermentative cultures and incorporated into nonactin-like 
structures, therefore, resulting in a biosynthesis of nonactin analogues with readily available 
synthetic handles for post-fermentative generation of nonactin analogues via synthesis. 
The nonactin biosynthesis inhibitor 186 was synthesized from furan 182 as an 
analogue of nonactic acid.[247]  Initially, this compound was sought after as a methyl 
nonactic acid analogue subunit with a chemically reactive handle for a later modification by 
synthesis.  If the nonactic acid analogue subunits were incorporated into nonactin analogue 
structures, the unreduced furan could be used in alkylation or epoxidation, followed by 
addition reactions to make derivatives of nonactin 40.   
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Scheme 7.2: Synthesis of the Nonactin Biosynthesis Inhibitor 186. 
 
Furan 182 was added to THF, was cooled to 0 ⁰C and n-butyl lithium was added.  
After 2 hours of stirring at 0 ⁰C, propylene oxide was added and the solution warmed to room 
temperature over 12 hours.  The 1-furan-2-yl-propan-2-ol product 183 was purified by 
distillation and gave a 65.6% yield.  This secondary alcohol of this product was then 
acetylated by acetic anhydride with pyridine at room temperature for 2 hours.  The acetic 
acid 2-furan-2-yl-1-methyl-ethyl ester product 184 was given at a 78.8% yield after 
purification by distillation.  Alkylation of the furan ring with ethyl (dl)-2-iodopropionate 
produced the 2,5-substituted furan product 185.  The purified acetylated compound 184 was 
added to DMSO, followed by Fe2(SO4)3-H2O and ethyl (dl)-2-iodopropionate.[248]  Triethyl 
borane in THF was added and the solution was stirred for 45 minutes.[248]  A second 
addition of triethyl borane in THF was added and was stirred for an additional 45 
minutes.[248]  The 2,5-substituted furan nonactic acid analogue 185 was produced with a 
10.9% yield after purification by chromatography on silica gel.  Saponification of the bis-
ester compound by 2.5 M LiOH in water, methanol, and THF at room temperature overnight, 
followed by the addition of 1 M HCl until the solution had a pH of 2, gave 186 after 
purification by chromatography on silica gel with an 81% yield (Scheme 7.2).  
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Two fermentative cultures of S. griseus ETH A7796 were prepared from the same 
vegetative culture and grown under standard conditions for 48 hours.[247]  The unreduced 
nonactic acid analogue 186 (56 mg in 0.5 mL of ethanol) was added to one of the 
fermentative cultures after inoculation after 48 hours.[247]  A blank sample (0.5 mL of 
ethanol) was added to the second fermentative cultures as a control culture.[247]  The 
macrotetrolide mixture produced from the fermentative cultures which were allowed to grow 
for 96 hours, were isolated according to standard protocols and analyzed with HPLC and LC-
MS (TOF).[247]      
The nonactin biosynthesis inhibitor 186 was tested against the aforementioned 
bacterial and fungal species, but it was shown to have no significant activity. 
The first addition of the compound 186 to the fermentative culture did not result in 
the production of nonactin analogues.  A far lower production of macrotetrolides than in the 
control fermentative cultures was also noted.  Though the study did not result in the desired 
product, the much lower production of nonactin 40 proved to be of interest. 
A second feeding study showed that the addition of the compound 186 did not affect 
biomass production, which was shown from the amount of mycelia recovered from each 
culture.  The approximate wet weight of biomass of the experimental and control cultures 
was determined and shown to be approximately equal. 
Secondly the data obtained from the reverse-phase HPLC quantification of the 
macrotetrolides present in the experimental culture (i.e. compound 186 added), revealed that 
nonactin 40 production in the fermentative cultures was reduced by more than 90% if either 
10 mM or 1 mM of 186 was added.  A concentration of 0.01 mM of the compound resulted 
in no inhibition of nonactin 40 production and a concentration of 0.1 mM gave an 
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intermediate amount of nonactin 40 compared to that of the control culture.  Despite the 
lower levels of inhibition, MS and LC-MS analysis of the fermentative cultures showed no 
production of nonactin analogues.  An IC50 value of about 100 µM was obtained for the 
nonactin biosynthesis inhibitor 186.[247]   
It has also been noted that the amount of phenazines, which are produced alongside 
macrotetrolides, did not diminish and remained unaffected by any amount of the inhibitor 
186.  Nonactic acid subunit production was unaffected as well.  This leads to the hypothesis 
that the inhibitor only inhibits the assembly of nonactin 40 itself from its nonactic acid 
subunits.[247]      
 
7.2 Nonactic acid derivatives for feeding studies to Streptomyces griseus 
 
Having demonstrated the inhibition of nonactin biosynthesis by 186 we decided to 
generate additional analogues of 186.  Where 186 did not become incorporated, we hoped for 
better results with analogues of 186. 
 
 
Scheme 7.3: Synthesis of a nonactic acid derivative 191.  
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Compound 187 was synthesized by the addition of ethylene oxide to an anion 
generated from furan and purified by distillation to give a 29.7% yield.  The primary alcohol 
187 was acetylated with the addition of the alkylation product 187 to pyridine in THF at 
room temperature followed by acetic anhydride and stirred for 2 hours.  The product 188 was 
purified by distillation to give a 78.3% yield.  The 2,5-dialkylated bis-ester furan 189 was 
synthesized from the acetylated product 188 which was added to DMSO at room 
temperature, followed by Fe2(SO4)3-H2O and ethyl (dl)-2-iodopropionate.  Air was blown 
through the solution, followed by the addition of 1.0 M Et3B / THF.  The solution was stirred 
for 45 minutes followed by a second addition of 1.0 M Et3B / THF and stirred for 2 hours.  A 
7.8% yield of the product 189 was purified by chromatography on silica gel.  Compound 189 
was reduced by 5% rhodium on carbon under 500 psi of hydrogen for 5 hours to give 190.  
Purification of the tetrahydrofuran product 190 by chromatography on silica gel gave a 
61.5% yield.  The bis-ester product 190 was saponified by 2.5 M LiOH / H2O / MeOH / THF 
(1:2:3) over 24 hours and followed by 1.0 M HCl resulting in a 32.4% yield of the nonactic 
acid analogue 191 after purification by chromatography on silica gel.(Scheme 7.3)     
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Scheme 7.4: Synthesis of a nonactic acid derivative 194. 
 
The nonactic acid analogue 194 was synthesized from furan (Scheme 7.4).  Furan 182 
was added to THF at 0 ⁰C followed by n-butyl lithium and stirred for 1 hour.  Ethylene oxide 
in THF was added at 0 ⁰C and the solution was warmed to room temperature over 12 hours.  
0.1 M HCl was added to the solution which was stirred for 10 minutes.  The product 187 was 
purified by distillation to give a 29.7% yield and added to pyridine in THF, followed by 
acetic anhydride at room temperature and stirred for 2 hours to give 78.3% yield of the 
acetylated product 188 after distillation.  The acetylated product 188 was alkylated to give 
the 2,5-dialkylated-bis-ester furan product 192 by the addition to DMSO at room temperature 
followed by Fe2(SO4)3-H2O and ethyl-iodoacetate.  Air was bubbled through the solution 
followed by 1.0 M Et3B / THF.  The solution was stirred for 45 minutes followed by a second 
addition of 1.0 M Et3B / THF.  The solution was stirred for 2 hours and gave a 14.5% yield 
of the 2,5-dialkylated furan product 192 after purification by chromatography on silica gel.  
The furan was reduced by 5% Rh/C under 500 psi of hydrogen in ethyl acetate at room 
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temperature and stirred for 24 hours.  The product 193 was given after purification by 
chromatography on silica gel to give a 51.4% yield.  The reduced furan bis-ester product 193 
was saponified by 2.5 M LiOH / H2O / MeOH / THF (1:2:3) and followed by 1.0 M HCl.  
Purification by chromatography on silica gel gave a 52.4% yield of the nonactic acid 
analogue 194 (Scheme 7.4).   
 
 
Scheme 7.5: Synthesis of a nonactic acid derivative 197. 
 
Furan 182 was added to THF at 0 ⁰C and followed by n-butyl lithium and stirred for 2 
hours.  Propylene oxide was added to the solution and warmed to room temperature over 12 
hours.  0.1 M HCl was added to the solution and the alkylated product 183 was given with 
65.6% yield after purification by distillation.  The secondary alcohol 183 was acetylated by 
acetic anhydride in THF with pyridine at room temperature for 2 hours.  Distillation gave 
78.8% of the acetylated product 184 which was added to DMSO, followed by Fe2(SO4)3-H2O 
and ethyl-iodoacetate at room temperature.  1.0 M Et3B / THF was added and air was 
bubbled through the solution.  After 45 minutes, a second addition of 1.0 M Et3B / THF was 
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added and the solution was stirred for an additional 2 hours.  The 2,5-dialkylated furan bis-
ester 195 was purified by chromatography on silica gel giving a 16.5% yield.  The product 
195 was added to ethyl acetate at room temperature followed by 5% Rh/C.  The solution was 
stirred for 24 hours under 500 psi of hydrogen.  The reduced furan product 196 was produced 
with a 28.3% yield after purification by chromatography on silica gel.  Saponification of the 
bis-ester with 2.5 M LiOH / H2O / MeOH / THF (1:2:3) for 24 hours followed by 1.0 M HCl 
and gave the nonactic acid analogue 197 after purification by chromatography on silica gel 
with a 57.5% yield.(Scheme 7.5) 
 
 
Scheme 7.6: Synthesis of a nonactic acid derivative 200. 
 
Homononactic acid analogue 200 was synthesized from furan 182 (Scheme 7.6).  1,2-
Epoxy-butane was added to an anion generated from the furan and the solution was stirred 
for 12 hours at 0 ⁰C and the alkylated furan product 198 was purified by distillation and gave 
a 51.4% yield.  The secondary alcohol was acetylated with the addition of the alkylated furan 
198 to THF, followed by acetic anhydride and pyridine at room temperature and the solution 
was stirred for 20 hours.  The product 199 was distilled and gave an 88.8% yield.  The 
acetylated product 199 was added to DMSO at room temperature, followed by Fe2(SO4)3-
H2O and ethyl (dl)-2-iodopropionate.  Air was bubbled through the solution and 1.0 M Et3B / 
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THF was added.  The solution was stirred for 45 minutes followed by a second addition of 
1.0 M Et3B / THF with stirring for 2 hours.  The dialkylated product was purified by 
chromatography on silica gel and added to 2.5 M LiOH / H2O / MeOH / THF (1:2:3) with 
stirring overnight.  1.0 M HCl / H2O was added and the unreduced homononactic acid 
analogue 200 was purified by chromatography on silica gel to give a 5% yield over 2 steps.  
No significant antibacterial activity was noted for any of the nonactic acid analogues 
186, 191, 194, 197 or 200.  
 It was decided to not attempt feeding studies in wild type S. griseus, but to wait for 
the construction of a ∆nonS/∆nonS‟ mutant blocked in the early stages of nonactin 
biosynthesis.  The mutant strain of S. griseus would be unable to produce nonactic acid, but 
still have the ability to make nonactin if nonactic acid were added into the fermentation.   The 
advantage of using the mutant strain is that it prevents the naturally produced nonactic acid 
from competing with the nonactic acid analogues.  This is especially important considering 
the low overall yields of the nonactic acid analogues.  Construction of this mutant is still 
being sought.      
 
7.3 Conclusion 
 
 The feeding study experiments intended to create analogues of nonactin in vivo in 
Streptomyces griseus fermentations were only partially successful.  The synthesis of all 
compounds intended to be fed into the cultures were performed successfully, including 
compound 186.  When compound 186 was added, the production of nonactin 40 was 
inhibited.  Since the only difference between nonactic acid and the nonactin biosynthesis 
inhibitor 186 was the unreduced furan, it is very likely that the unreduced furan caused this 
inhibition.  Though analogues of nonactin were not synthesized, the production of the 
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nonactin biosynthesis inhibitor 186 did show a limit to the modifications allowed to nonactic 
acid.     
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CHAPTER 8 
 
 
SYNTHESIS OF CHEMICALLY DIVERSE MOIETIES FOR TRIAZOLO-ESTER 
DIVERSITY 
 
 
 
8.1 Introduction 
 
 We have already described the synthesis of libraries based upon the nonactate 
scaffold and synthetic analogues thereof, such as cis and trans-cyclohexane derivatives.  
While these libraries have generally relied upon commercially available acyl halides and 
alkynes to diversify the scaffold there are some limitations to relying upon commercial 
sources.  For example, while many hundreds of acyl halides can be purchased, very few 
alkynes are available and those that are have poor structural diversity.  A significant 
component of the experimental work in this thesis involved the generation of additional 
chemical entities for library construction.  The routes, strategies, and methods for the 
synthesis of useful additional building blocks, while tangential to the larger questions studied 
herein, need to be archived for future reference.  This last chapter serves that purpose. 
 
8.2 Synthesis of racemic phenyl substituted allyl and vinyl secondary alcohols 
 
R H
O
R
OH
MgBr
Et2O, 0
 o
C, 30 min
201 202  
Scheme 8.1:  General synthesis of racemic phenyl substituted allyl secondary alcohols 202. 
The Grignard reaction with the allyl magnesium bromide produced five phenyl 
substituted allyl secondary alcohols 202.  4-Isopropylbenzaldehyde, p-tolualdehyde, 4-
bromobenzaldehyde, 3-benzyloxybenzaldehyde, and 4-(diethyl-amino)-benzaldehyde were 
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added to allyl magnesium bromide at 0 ⁰C and the solutions were stirred for 30 minutes 
(Scheme 8.1).  The secondary alcohols 203-207 were purified by chromatography on silica 
gel (Figure 8.1). 
OH
203
OH
204
Br
OH
205
OH
206
N
OH
207
O
 
Figure 8.1: Racemic phenyl substituted allyl secondary alcohols library. 
 
R H
O
R
OH
MgBr
THF, 0
 o
C, 12 h
208 209  
Scheme 8.2:  General synthesis of racemic phenyl substituted vinyl secondary alcohols 209. 
In the second set of precursors, phenyl substituted vinyl secondary alcohols 209 were 
synthesized, which were then used in Sharpless epoxidation reactions to generate the (S)-
alcohols (Scheme 8.2 and 8.3).  p-Tolualdehyde, 4-isopropylbenzaldehyde, 4-(diethyl-
amino)benzaldehyde, 2,3-dimethoxybenzaldehyde, 3-benzyloxybenzaldehyde, 4-
bromobenzaldehyde, 3-phenoxybenzaldehyde, 4-ethoxybenzaldehyde, 4-ethylbenzaldehyde, 
2-naphthaldehyde, and 3,5-di-tert-butyl-4-hydroxybenzaldehyde were each added to a 
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solution of THF and vinyl magnesium bromide at 0 ⁰C.  The solution was stirred for 12 
hours, and the products 210-220 (Figure 8.2) purified by chromatography on silica gel. 
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Figure 8.2: Racemic phenyl substituted vinyl secondary alcohols library. 
 
 
R
OH
R
OH
1. Diethyl (-)-tartrate, Ti(iPrO)4,
    CH2Cl2, sieves, -20 
o
C, 30 min.
2. t-BuOOH / DCM, -20 
o
C to r.t., 24 h
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min
209 221
 
Scheme 8.3: General synthesis of synthesis of (S)-phenyl substituted vinyl secondary 
alcohols 221. 
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Sharpless epoxidation was used as a kinetic resolution to generate the (S)-phenyl 
substituted vinyl secondary alcohols 221 from the racemic starting materials 209 (Scheme 
8.3).[249]  Each stereochemically pure product was synthesized by the addition of its 
racemic precursor to methylene chloride at -20 ⁰C with molecular sieves, followed by diethyl 
(–)-tartrate and Ti(iPrO)4.[249]  The solution was stirred for 30 minutes, after which t-
BuOOH in methylene chloride was added to the -20 ⁰C solution.[249]  The solution was 
allowed to warm to room temperature over a 24 hours period.[249]  Ferrous sulfate and d-(–
)-tartaric acid with water were added and the solution stirred for 30 minutes.[249]  The 
alcohol products were purified from the epoxides by chromatography on silica gel.  The five 
stereochemically pure compounds 222-226 are featured in Figure 8.3.     
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Figure 8.3: (S)-phenyl substituted vinyl secondary alcohols. 
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8.3 Synthesis of racemic phenyl substituted allyl and vinyl terminal alkyne ethers 
 
R
OH
R
O
1. 60% NaH / Mineral oil,
    HMPA, THF, r.t., 1 hr
2. 80% Propargyl bromide
    w/v in toluene, 24 h
209 227  
Scheme 8.4:  General synthesis of racemic phenyl substituted vinyl terminal alkyne ethers 
227. 
 
The racemic phenyl substituted vinyl terminal alkyne ethers 227 were synthesized by 
the addition of the corresponding racemic phenyl substituted vinyl alcohols 209 to THF at 
room temperature.  Sodium hydride was added followed by HMPA and the solution was 
stirred for 1 hour, after which propargyl bromide was added.  The solution was stirred for 12 
hours and the racemic phenyl substituted vinyl terminal alkyne ethers 228-234 (Figure 8.4) 
were purified by chromatography on silica gel.(Scheme 8.4) 
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Figure 8.4: Racemic phenyl substituted vinyl terminal alkyne ethers. 
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R
OH
R
O
1. 60% NaH / Mineral oil,
    HMPA, THF, r.t., 1 hr
2. 80% Propargyl bromide
    w/v in toluene, 24 h
202 235  
Scheme 8.5: General synthesis of racemic phenyl substituted allyl terminal alkyne ethers 
235. 
 
Though only the vinyl alcohols could be used in the Sharpless epoxidations to 
separate out the stereoisomers, the allyl terminal alkyne ethers 235 allow for greater chain 
length for the formation of macrolides using the Grubbs metathesis.  The racemic phenyl 
substituted allyl terminal alkyne ethers 236-240 (Figure 8.5) were synthesized via the 
addition of the corresponding phenyl substituted allyl alcohol 202 to THF at room 
temperature followed by sodium hydride and HMPA which was stirred for 1 hour.  Propargyl 
bromide was added and the solution was stirred at room temperature for 24 hours (Scheme 
8.5).  
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Figure 8.5: Racemic phenyl substituted allyl terminal alkyne ethers library. 
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8.4 Synthesis of N-(3-Ethynyl-phenyl)-acetamide derivatives 
 
NH2 N
H
R Cl
O
py, r.t., 12 h
R
O
241 242  
 
Scheme 8.6:  Synthesis of N-(3-ethynyl-phenyl)-amides. 
 
The 3-ethynylaniline alkyne 241 provides an excellent moiety for the formation of 
triazoles.  The free amine provides an easily modifiable chemical point for the synthesis of 
amides and carbamates and the possible future synthesis of secondary amines.  Modification 
of the amine is necessary as the primary amine interferes with triazole formation in the 1,3-
dipolar cycloaddition under Sharpless conditions as it complexes to Cu. 
The N-(3-ethynyl-phenyl)-amides 242 (Figure 8.6) were synthesized by the addition 
of 3-ethynylaniline 241 to pyridine at room temperature.  Acetic anhydride or an acyl 
chloride was added to the solution followed by stirring for 12 hours (Scheme 8.6).  The 
products 243-249 (Figure 8.6) were purified by chromatography on silica gel in high yields. 
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Figure 8.6: The N-(3-ethynyl-phenyl)-amides library. 
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Scheme 8.7:  Synthesis of (3-ethynyl-phenyl)-carbamic acid allyl ester 250. 
3-Ethynylaniline 241 was added to pyridine at room temperature followed by allyl 
chloroformate (Scheme 8.7).  The solution was stirred for 12 hours and the (3-ethynyl-
phenyl)-carbamic acid allyl ester product 250 was obtained with a 75% yield after 
purification by chromatography on silica gel. 
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Scheme 8.8: Synthesis of (3-ethynyl-phenyl)-carbamic acid isobutyl ester 251. 
(3-Ethynyl-phenyl)-carbamic acid isobutyl ester 251 was synthesized by the addition 
of 3-ethynylaniline 241 to pyridine at room temperature.  Isobutyl chloroformate was added 
and the solution stirred for 12 hours (Scheme 8.8).  Purification by chromatography on silica 
gel of the product 251 gave a 96.8% yield.  
 
8.5 Biological activity of chemical diverse moieties for triazolo-ester diversity 
 
All precursors were assayed for biological activity.  Among these chemically diverse 
groups, 248 had an MIC of 62 µM against B. subtilis.   
 
8.6 Conclusions 
 
No compound in these libraries showed any significant biological activity, with the 
exception of 248, nor did the acyl chlorides or the alkynes used in the previous library.  This 
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lack of activity highlights the necessity of the nonactic acid subunit to the active compounds.  
However, the importance of chemical diversity has been shown through the synthesis of the 
triazolo-ester nonactic acid analogue library.  The synthesis of these new moieties for the 
creation of expanded triazoloester libraries was largely successful and the compounds were 
produced for the most part in good to excellent yields and relatively inexpensively.  The 
vinyl alcohols were readily separated from the vinyl epoxides via column chromatography. 
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CHAPTER 9 
 
 
SUMMATION 
 
 
 
 Combinatorial libraries were synthesized from racemic, and plus and minus methyl 
nonactate 45, 46, 48 the products of methanolysis of nonactin 40.  The racemic triazoloester 
library made from the azidoalcohol 55, revealed 2 active compounds from the 10 (Figure 3.2) 
that were tested for activity.  These compounds, 72 and 71, showed activity against, among 
other species, methicillin-resistant Staphylococcus aureus and vancomycin-resistant 
Enterococcus faecalis (Table 3.2).  The individual enantiomers of 72 and 71, 88, 90, 81, and 
79 were synthesized.  The plus enantiomers, 88 and 90, were shown to exhibit biological 
activity (Table 3.2).  81 and 79 gave no significant biological activity against any of the test 
organisms (Table 3.2).  Regiochemistry of the triazole was also considered.  It was found that 
the 1,4-regioisomer was the active isomer.  The 1,5-triazoles 91 and 92 were not bactericidal.  
Research into the homononactate equivalent versions of 72 and 71, 104 and 103 was begun, 
but was not completed.  None of the intermediate compounds showed any activity of note.         
 The necessity of the nonactic acid subunit for activity was examined by the synthesis 
of the trans and cis cyclohexane analogues of 72 and 71, 141, 140, 132, 131, 152, 151, 161, 
160.  The chemical moieties were essentially the same in these analogues.  None of the eight 
analogues synthesized possessed activity against MRSA or VRE.  This study suggests that 
the nonactic acid subunit itself is important for activity. 
 The dimer library of 72 and 71 compounds and bis-triazole library synthesized from 
the bis-azide nonactic acid analogue scaffold 115 were not bactericidal. Several series of 
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chemical moieties, including enantiomerically pure moieties were synthesized for future 
library purposes in an effort to expand the chemical diversity of the triazoloester libraries. 
The last of the projects entailed the biosynthesis of nonactin analogues via the 
construction of nonactic acid analogues to be used in feeding studies.  The biosynthesis of the 
nonactin analogues remains incomplete due to developmental delays of the ∆nonS/∆nonS’-
double knock out of Streptomyces griseus.  However it was discovered that nonactic acid 
with an unreduced furan ring 186 inhibited the production of nonactin 40, at an IC50 of 100 
µM.      
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CHAPTER 10 
 
 
EXPERIMENTAL SECTION 
 
 
 
10.1 General Methods 
 
Reagents were obtained from various chemical companies (TCI, Sigma-Aldrich, 
Acros, and Fischer Scientific) and were used both with and without prior purification.  
Tetrahydrofuran (THF) was distilled from sodium and benzophenone.  Dichloromethane was 
distilled from calcium hydride (CaH2).  Dimethylformamide (DMF) and dimethyl sulfoxide 
(DMSO) were used as bought from the chemical supplier without further purification.  
Pyridine (Py), used as both a solvent and a base, was purified via distillation under vacuum 
from potassium hydroxide (KOH).  Anhydrous diethyl ether was used as received from the 
chemical supplier.  para-Toluenesulfonyl chloride (pTsCl) was purified via crystallization 
from benzene.  3,4-Dihydro-2H-pyran (DHP) was used without distillation as were acyl 
chlorides and acetylenes.   
Aqueous reagents used deionized water.  All reactions that did not involve aqueous 
reagents, other than para-toluenesulfonic acid monohydrate (pTsOH-H2O), were run under 
anhydrous conditions in an argon atmosphere.  A hydrogen (H2) atmosphere was used in the 
Pd/C catalytic reduction reactions.  In anhydrous reactions, all glassware was flame-dried 
and/or oven dried.  Reactions involving shaking were performed in the innOva 4000 
Incubator Shaker of New Brunswick Scientific and the New Brunswick Scientific Classic 
Series C24 Incubator Shaker.  Thin-layer chromatography plates were aluminum-backed 
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with silica gel 60 F254.  Silica gel (230-400 mesh) from Silicycle was used in all column 
chromatography purifications. 
Characterization of synthesized compounds was performed on the following 
instruments: Varian Unity Plus 400 MHz spectrometer was used to obtain proton and carbon 
nuclear magnetic resonance (NMR) spectra.  Infrared spectra (IR) were obtained using the 
Nicolet Nexus 670 FT-IR using the SMART MIRacle attachment.  Mass spectra (MS) and 
high-resolution mass spectra (HRMS) were obtained with a Micromass LCT electrospray 
ionization (ESI) spectrometer in conjunction with a Waters 2790 Separations Module.  The 
Alamar-Blue Assay, performed by Adrienne E. Smith, Erin S. Bolstad, and Brooke Martin 
was used to obtain the IC50 and MIC values for each compound in bacterial and cytotoxicity 
assays.                       
 
10.2 Library of Compounds 
O OMe
OOTHP
O OMe
OOH DHP, pTsOH-H2O
CH2Cl2, r.t., 5 h  
 
51: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propionic acid 
methyl ester 51.  Racemic methyl nonactate 45 (0.624 g, 2.9 mmol) was added to 
CH2Cl2 (15 mL) followed by DHP (1.3 mL, 14.4 mmol) and pTsOH-H2O (6.0 mg, 
0.03 mmol).  The solution was stirred for 5 hours at room temperature.  The solution 
was dried (MgSO4) and evaporated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:4) to give a clear oil 51 (0.86 g, 
99%).  Rf = 0.44 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.73 (m, 
0.5H), 4.62 (m, 0.5H), 3.92 (m, 4H), 3.67 (m, 3H), 3.46 (m, 1H), 2.50 (sextet, J = 
14.0, 7.1, 7.0 Hz, 1H), 1.96 (m, 2H), 1.65 (m, 10H), 1.23 (m, 2H), and 1.10 (m, 4H); 
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13
C NMR (100 MHz, CDCl3) δ 175.4, 99.8, 94.5, 80.4, 80.3, 77.3, 77.0, 76.4, 72.6, 
68.0, 63.0, 62.0, 51.54, 51.51, 45.4, 45.4, 44.1, 43.8, 31.5, 31.3, 31.1, 31.0, 28.6, 28.5, 
25.51, 25.46, 22.7, 20.2, 19.5, 19.4, 13.4, and 13.3; IR (ATR) 2941, 2873, 1739, 
1456, 1436, 1375, 1352, 1260, 1200, 1163, 1118, 1063, 1021, 992, 942, 905, 869, and 
813 cm
-1
; ESI-TOF-MS m/z calcd for C16H28O5Na
+
: 323.18; found 323.35.   
O OH
OTHP
O OMe
OTHP O LiAlH4
THF, 0 
o
C to r.t., 5h  
 
52: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propan-1-ol 52.  
51 (0.841 g, 2.8 mmol) was added to THF (30 mL) followed by LiAlH4 (0.425 g, 11.2 
mmol) at 0 ºC.  The solution was allowed to warm to room temperature and stirred for 
5 hours.  Water (0.43 mL) was added to the solution, followed by 3.0 M NaOH/H2O 
(0.85 mL) and then with water (0.43 mL).  Sodium sulfate was then added.  After 5 
minutes the solution was filtered and the filtrate evaporated.  The residue was purified 
by chromatography on silica gel in EtOAc-hexanes (1:1) to give a clear oil 52 (0.576 
g, 75.5%).  Rf = 0.46 (EtOAc-hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 4.62 (m, 
0.5H), 4.57 (m, 0.5H), 4.07 (m, 1H), 3.86 (m, 2H), 3.52 (m, 4H), 1.92 (m, 2H), 1.60 
(m, 11H), 1.19 (d, J = 6.3 Hz, 2H), 1.06 (d, J = 6.0 Hz, 2H), and 0.75 (t, J = 6.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 99.7, 95.3, 85.6, 85.3, 76.6, 76.3, 72.3, 68.6, 
68.3, 68.0, 62.9, 62.5, 43.9, 43.6, 41.0, 40.8, 31.0, 30.98, 30.7, 30.4, 30.2, 25.32, 
25.28, 22.5, 20.1, 19.8, 19.5, and 13.5; IR (ATR) 3467, 2939, 2874, 1454, 1374, 
1352, 1261, 1201, 1116, 1075, 1021, 991, 943, 905, 869, and 811 cm
-1
; ESI-TOF-MS 
m/z calcd for C15H28O4Na
+
: 295.19; found 295.34.   
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O OTs
OTHP
O
OTHP
pTsCl
Py, r.t., 5 h
OH
 
 
53: Toluene-4-sulfonic acid 2-{5-[2-(tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-
furan-2-yl}-propyl ester 53.  52 (0.576 g, 2.1 mmol) was added to pyridine (10 mL) 
followed by pTsCl (0.806 g, 4.2 mmol) at room temperature and the resultant solution 
was stirred for 5 hours.  Water (50 mL) was added and the solution extracted with 
ethyl acetate (3 × 100 mL).  The organic layer was then washed with a saturated 
solution of copper sulfate (2 × 50 mL) and then with saturated ammonium chloride 
solution (2 × 50 mL).  The organic layer was dried (Na2SO4) and evaporated.  The 
residue was purified by chromatography on silica gel in EtOAc-hexanes (1:4) to give 
a clear oil 53 (0.718 g, 79.6%).  Rf = 0.41 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.78 (m, 2H), 7.33 (m, 2H), 4.73 (m, 0.5H), 4.60 (m, 0.5), 4.13 (m, 
1H), 3.87 (m, 4H), 3.50 (m, 2H), 2.44 (s, 3H), 1.88 (m, 4H), 1.55 (m, 9H), 1.20 (m, 
2H), 1.07 (m, 1H), and 0.89 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
144.6, 144.5, 133.0, 129.7, 129.7, 127.9, 99.8, 94.6, 80.0, 79.6, 76.3, 76.2, 73.2, 73.1, 
72.8, 72.5, 67.9, 65.2, 63.0, 62.0, 44.1, 43.8, 43.2, 38.8, 38.5, 31.4, 31.2, 31.1, 31.0, 
30.6, 29.12, 29.08, 28.98, 25.5, 25.4, 23.4, 22.6, 21.6, 20.2, 19.5, 19.4, 13.4, and 13.3; 
IR (ATR) 2941, 2875, 1739, 1599, 1454, 1359, 1291, 1188, 1176, 1118, 1097, 1075, 
1021, 992, 962, 940, 812, 792, 706, and 666 cm
-1
; ESI-TOF-MS m/z calcd for 
C22H34O6SNa
+
: 449.20; found 449.40.  
O N3
OTHP
O OTs
OTHP NaN3
DMF, 80 
o
C, 5 h  
 
54: 2-{2-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethoxy}-
tetrahydro-pyran 54.  53 (0.718 g, 1.7 mmol) was added to DMF (7 mL) followed by 
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NaN3 (0.547 g, 8.4 mmol).  The solution was warmed to 80 °C and stirred for 5 hours.  
The solution was cooled to room temperature and water (25 mL) was added.  The 
solution was washed with diethyl ether (3 × 50 mL).  The organic layers were 
collected, dried (MgSO4), and evaporated.  The residue was purified by 
chromatography on silica gel in EtOAc-hexanes (1:9) to give a clear oil 54 (0.404 g, 
80.6%).  Rf = 0.7 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.74 (m, 
0.5H), 4.64 (m, 0.5H), 3.93 (m, 3H), 3.49 (m, 3H), 3.25 (m, 1H), 1.95 (m, 2H), 1.61 
(m, 10H), 1.23 (d, J = 6.3 Hz, 2H), 1.11 (d, J = 6.0 Hz, 2H), and 0.91 (d, J = 6.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 99.8, 94.4, 80.7, 80.6, 76.2, 76.0, 72.5, 67.9, 
62.9, 61.9, 55.1, 44.1, 43.9, 39.49, 3.47, 31.5, 31.3, 31.1, 31.0, 29.2, 25.5, 25.4, 22.7, 
20.1, 19.41, 19.39, and 14.4; IR (ATR) 2939, 2875, 2096, 1453, 1380, 1351, 1282, 
1201, 1115, 1075, 1021, 992, 942, 905, 870, and 813 cm
-1
; ESI-TOF-MS m/z calcd 
for C15H27N3O3Na
+
: 320.20; found 320.37.   
O N3
OH
O N3
OTHP
6 M HCl / MeOH
r.t., 3 h  
 
55: 1-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-propan-2-ol 55.  54 (0.404 g, 
1.4 mmol) was added to 6 M HCl/MeOH (10 mL) and stirred at room temperature for 
3 hours.  A saturated solution of sodium bicarbonate was added until no gas evolved.  
The solution was then washed with ethyl acetate (3 × 50 mL).  The organic phases 
were collected, dried (MgSO4), and evaporated.  The residue was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give a light yellow clear oil 
55 (0.218 g, 75.4%).  Rf = 0.54 (EtOAc-hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) 
δ 3.93 (m, 1H), 3.85 (m, 1H), 3.47 (m, 1H), 3.30 (m, 1H), 3.18 (s, 1H), 3.12 (m, 1H), 
1.83 (m, 2H), 1.51 (m, 5H), 1.05 (d, J = 6.3 Hz, 3H), and 0.80 (d, J = 6.9 Hz, 3H); 
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13
C NMR (100 MHz, CDCl3) δ 80.8, 76.3, 64.7, 54.7, 43.5, 38.9, 30.5, 28.8, 23.2, and 
14.0; IR (ATR) 3404, 2966, 2934, 2095, 1460, 1380, 1282, 1067, and 937 cm
-1
; ESI-
TOF-MS m/z calcd for C10H19N3O2Na
+
: 236.14; found 236.28.   
O
O
N3
O
O N3
OH O
O O
py, THF, r.t., 12 h
 
 
57: Acetic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl ester 
57.  55 (35.0 mg, 0.2 mmol) was added to THF (1 mL) followed by pyridine (2 mL) 
and acetic anhydride (2 mL).  The solution was stirred for 12 hours at room 
temperature.  Ethyl acetate (50 mL) was added and the solution was washed with 
saturated copper sulfate solution (2 × 20 mL) and saturated ammonium chloride 
solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:9) to give 57 (32.3 mg, 
76.9%).  Rf = 0.63 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.99 (m, 
1H), 3.84 (m, 1H), 3.54 (m, 1H), 3.46 (m, 1H), 3.24 (m, 1H), 2.01 (s, 3H), 1.94 (m, 
1H), 1.72 (m, 2H), 1.52 (m, 2H), 1.24 (d, J = 6.3 Hz, 3H), and 0.93 (d, J = 6.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 170.6, 80.8, 76.0, 69.1, 55.0, 42.4, 39.4, 31.3, 
29.2, 21.4, 20.6, and 14.4  
O
O
N3
O
O N3
OH
Cl
O
py, 37 
o
C, 5 h
 
 
58: 2,2-Dimethyl-propionic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-
methyl-ethyl ester 58.  55 (35.0 mg, 0.2 mmol) was added to pyridine (2 mL) 
followed by trimethylacetyl chloride (0.2 mL, 1.6 mmol).  The solution was then 
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shaken at 37 °C for 5 hours.  Ethyl acetate (50 mL) was added and the solution was 
washed with saturated copper sulfate solution (2 × 20 mL) and saturated ammonium 
chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:9) to give 58 (32.0 
mg, 65.7%).  Rf = 0.80 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.96 
(m, 1H), 3.83 (m, 1H), 3.53 (m, 1H), 3.47 (m, 1H), 3.23 (m, 1H), 1.93 (m, 2H), 1.72 
(m, 3H), 1.51 (m, 2H), 1.21 (d, J = 6.2 Hz, 3H), 1.18 (s, 9H), and 0.92 (d, J = 6.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 177.9, 80.8, 76.1, 68.8, 55.1, 42.5, 39.4, 31.4, 
29.2, 27.2, 27.1, 20.5, and 14.4 
O
O
N3
O
O N3
OH Cl
O
py, 37 
o
C, 5 h
 
     
59: Pent-4-enoic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-
ethyl ester 59.  55 (35.0 mg, 0.2 mmol) was added to pyridine (2 mL) followed by 4-
pentenoyl chloride (0.2 mL, 1.6 mmol).  The solution was shaken at 37 °C for 5 
hours.  Ethyl acetate (50 mL) was added and the solution was washed with saturated 
copper sulfate solution (2 × 20 mL) and saturated ammonium chloride solution (2 × 
20 mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:9) to give 59 (24.7 mg, 51.0%).  
Rf = 0.73 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 5.81 (m, 1H), 5.02 
(m, 2H), 3.84 (m, 1H), 3.55 (m, 1H), 3.47 (m, 1H), 3.24 (m, 1H), 2.37 (m, 4H), 1.95 
(m, 2H), 1.72 (m, 3H), 1.53 (m, 3H), 1.24 (d, J = 6.4 Hz, 3H), and 0.93 (d, J = 6.8 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.5, 136.7, 115.4, 80.8, 76.0, 69.1, 55.1, 
42.5, 39.4, 33.8, 31.3, 29.2, 28.9, 20.7, and 14.4  
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O N3
O
O
MeO
OO N3
OH
methyl 4-chloro-4-oxobutyrate
r.t., 12 h
 
 
60: Succinic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester methyl ester 60.  55 (0.119 g, 0.6 mmol) was added to pyridine (3 mL) followed 
by methyl 4-chloro-4-oxobutyrate (0.2 mL, 1.6 mmol).  The solution was stirred at 
room temperature overnight.  Chloroform (50 mL) was added and the solution was 
washed with saturated copper sulfate solution (2 × 20 mL) and then with saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:4) 
to give 60 (0.109 g, 63.5%).  Rf = 0.43 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 5.03 (m, 1H), 3.84 (m, 1H), 3.69 (s, 3H), 3.55 (m, 1H), 3.46 (m, 1H), 3.24 
(m, 1H), 2.61 (m, 4H), 1.95 (m, 2H), 1.72 (m, 3H), 1.52 (m, 2H), 1.25 (d, J = 6.2 Hz, 
3H), and 0.93 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 173.1, 172.8, 80.8, 
76.0, 69.6, 55.1, 51.8, 42.4, 39.5, 31.3, 29.4, 29.2, 28.9, 20.6, and 14.4; IR (ATR) 
3954, 2360, 2097, 1731, 1438, 1363, 1269, 1162, 1065, 997, and 846 cm
-1
; ESI-TOF-
MS m/z calcd for C15H25N3O5Na
+
: 350.17; found 350.21.    
O N3
O
O
O N3
OH
benzoyl chloride
r.t., 12 h
 
 
61: Benzoic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester 61.  55 (0.119 g, 0.6 mmol) was added to pyridine (3 mL) followed by benzoyl 
chloride (0.18 mL, 1.6 mmol).  The solution was stirred at room temperature 
overnight.  Chloroform (50 mL) was added and the solution was washed with 
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saturated copper sulfate solution (2 × 20 mL) and then with saturated ammonium 
chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:19) to give 61 
(0.128 g, 77.6%).  Rf = 0.75 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 
8.03 (m, 2H), 7.55 (m, 1H), 7.43 (m, 2H), 5.28 (m, 1H), 3.94 (m, 1H), 3.54 (m, 1H), 
3.47 (m, 1H), 3.21 (m, 1H), 1.95 (m, 3H), 1.83 (m, 1H), 1.72 (m, 1H), 1.54 (m, 2H), 
1.38 (d, J = 6.2 Hz, 3H), and 0.92 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
166.0, 132.7, 130.8, 129.5, 128.3, 80.8, 76.1, 69.8, 55.0, 42.6, 39.4, 31.4, 29.2, 20.8, 
and 14.4; IR (ATR) 2972, 2877, 2096, 1715, 1603, 1585, 1451, 1381, 1356, 1314, 
1274, 1175, 1109, 1069, 1026, and 711 cm
-1
; ESI-TOF-MS m/z calcd for 
C17H23N3O3H
+
: 318.18; found 318.23.    
O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
63: Acetic acid 2-{5-[2-(4-tert-butyl-[1,2,3]triazol-1-yl)-1-methyl-ethyl]-tetrahydro-
furan-2-yl}-1-methyl-ethyl ester 63.  57 (16.2 mg, 0.06 mmol) was added to 5:1 
EtOH/H2O (1.5 mL) followed by 3,3-dimethyl-1-butyne (98%, 79.0 µL, 0.6 mmol).  
Ascorbic acid/H2O (1.1 M, 127.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.1 
mL, 0.03 mmol) were added and the solution was shaken at 37 °C for 12 hours.  
Saturated sodium bicarbonate solution (20 mL) was added and the solution was 
washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:1) to give 63 (18.0 mg, 84.1%).  Rf = 0.38 (EtOAc-
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hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.30 (s, 1H), 5.09 (m, 1H), 4.51 (m, 
1H), 4.22 (m, 1H), 3.85 (m, 1H), 3.43 (m, 1H), 2.03 (s, 3H), 1.99 (m, 3H), 1.80 (m, 
1H), 1.70 (m, 1H), 1.53 (m, 2H), 1.34 (s, 9H), 1.26 (d, J = 6.2 Hz, 3H), and 0.83 (d, J 
= 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.6, 119.55, 119.52, 80.8, 76.0, 
68.9, 53.1, 42.4, 40.3, 31.3, 30.7, 30.4, 29.4, 21.4, 20.7, and 14.3  
O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
64: Acetic acid 2-{5-[2-(4-cyclopentylmethyl-[1,2,3]triazol-1-yl)-1-methyl-ethyl]-
tetrahydro-furan-2-yl}-1-methyl-ethyl ester 64.  57 (16.2 mg, 0.06 mmol) was added 
to 5:1 EtOH/H2O (1.5 mL) followed by 3-cyclopentyl-1-propyne (98%, 84.0 µL, 0.6 
mmol).  Ascorbic acid/H2O (1.1 M, 127.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 
M, 0.1 mL, 0.03 mmol) were added and the solution was shaken at 37 °C for 12 
hours.  Saturated sodium bicarbonate solution (20 mL) was added and the solution 
was washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:1) to give 64 (9.4 mg, 41.0%).  Rf = 0.37 (EtOAc-
hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.35 (s, 1H), 5.10 (m, 1H), 4.52 (m, 
1H), 4.26 (m, 1H), 3.85 (m, 1H), 3.40 (m, 1H), 2.71 (d, J = 7.3 Hz, 2H), 2.19 (m, 
1H), 2.04 (s, 3H), 2.00 (m, 2H), 1.66 (m, 9H), 1.25 (d, J = 6.3 Hz, 3H), 1.23 (m, 4H), 
and 0.82 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.6, 122.1, 80.8, 76.0, 
68.9, 53.2, 42.4, 40.3, 40.0, 32.4, 31.6, 31.3, 29.7, 29.5, 25.1, 21.4, 20.7, and 14.4  
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O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
65: Pent-4-enoic acid 2-{5-[2-(4-tert-butyl-[1,2,3]triazol-1-yl)-1-methyl-ethyl]-
tetrahydro-furan-2-yl}-1-methyl-ethyl ester 65.  59 (22.3 mg, 0.08 mmol) was added 
to 5:1 EtOH/H2O (1.5 mL) followed by 3,3-dimethyl-1-butyne (98%, 94.0 µL, 0.8 
mmol).  Ascorbic acid/H2O (1.1 M, 151.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 
M, 126.0 µL, 0.04 mmol) were added and the solution was shaken at 37 °C for 12 
hours.  Saturated sodium bicarbonate solution (20 mL) was added and the solution 
was washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:1) to give 65 (10.1 mg, 35.6%).  Rf = 0.50 (EtOAc-
hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.31 (s, 1H), 5.81 (m, 1H), 5.06 (m, 
3H), 4.52 (m, 1H), 4.22 (m, 1H), 3.85 (m, 1H), 3.43 (m, 1H), 2.38 (m, 4H), 1.97 (m, 
3H), 1.80 (m, 1H), 1.70 (m, 1H), 1.54 (m, 1H), 1.35 (s, 9H), 1.26 (d, J = 6.3 Hz, 3H), 
and 0.83 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.5, 136.7, 119.5, 
115.4, 80.8, 76.0, 68.9, 53.1, 42.5, 40.3, 33.8, 31.3, 30.7, 30.4, 29.4, 28.9, 20.8, and 
14.3  
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O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
66: 2,2-Dimethyl-propionic acid 2-{5-[2-(4-cyclopentylmethyl-[1,2,3]triazol-1-yl)-1-
methyl-ethyl]-tetrahydro-furan-2-yl}-1-methyl-ethyl ester 66.  58 (27.6 mg, 0.09 
mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by 3-cyclopentyl-1-propyne 
(98%, 122.0 µL, 0.9 mmol).  Ascorbic acid/H2O (1.1 M, 185.0 µL, 0.2 mmol) and 
CuSO4-5H2O/H2O (0.3 M, 155.0 µL, 0.05 mmol) were added and the solution was 
shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was 
added and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
phases were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:1) to give 66 (17.2 mg, 
46.0%).  Rf = 0.50 (EtOAc-hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.35 (s, 
1H), 5.07 (m, 1H), 4.51 (m, 1H), 4.26 (m, 1H), 3.83 (m, 1H), 3.38 (m, 1H), 2.71 (d,  J 
= 7.4 Hz, 2H), 2.18 (m, 1H), 1.97 (m, 4H), 1.66 (m, 11H), 1.24 (d, J = 6.2 Hz, 3H), 
1.18 (s, 9H), and 0.82 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 178.0, 
147.5, 122.0, 80.7, 76.1, 68.5, 53.1, 42.5, 40.3, 40.0, 38.7, 32.4, 31.6, 31.4, 29.5, 27.1, 
25.1, 20.6, and 14.3  
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O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
67: Pent-4-enoic acid 2-{5-[2-(4-cyclopentylmethyl-[1,2,3]triazol-1-yl)-1-methyl-ethyl]-
tetrahydro-furan-2-yl}-1-methyl-ethyl ester 67.  59 (22.3 mg, 0.08 mmol) was added 
to 5:1 EtOH/H2O (1.5 mL) followed by 3-cyclopentyl-1-propyne (98%, 100.0 µL, 0.8 
mmol).  Ascorbic acid/H2O (1.1 M, 151.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 
M, 126.0 µL, 0.04 mmol) were added and the solution was shaken at 37 °C for 12 
hours.  Saturated sodium bicarbonate solution (20 mL) was added and the solution 
was washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:1) to give 67 (11.0 mg, 36.0%).  
1
H NMR (400 MHz, 
CDCl3) δ 7.36 (s, 1H), 5.82 (m, 1H), 5.12 (m, 1H), 5.03 (m, 1H), 4.52 (m, 1H), 4.27 
(m, 1H), 3.84 (m, 1H), 3.39 (m, 1H), 2.72 (d, J = 7.4 Hz, 2H), 2.38 (m, 4H), 2.19 (m, 
1H), 1.97 (m, 1H), 1.65 (m, 9H), 1.26 (d, J = 6.3 Hz, 3H), 1.23 (m, 4H), and 0.82 (d, 
J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.5, 136.6, 122.1, 115.4, 80.7, 
76.0, 68.8, 53.2, 42.5, 40.3, 40.0, 33.8, 32.4, 32.4, 31.6, 31.3, 29.7, 29.5, 29.0, 25.1, 
20.8, and 14.4  
O
O
N
O
N
N
O
O
N3
O
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
MeOMeO
O
F
F
O
 
 
68: Succinic acid 2-(5-{2-[4-(4-fluoro-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester methyl ester 68.  60 (22.4 mg, 0.07 mmol) 
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was added to 5:1 EtOH/H2O (1.5 mL) followed by 1-ethynyl-4-fluorobenzene (78.0 
µL, 0.7 mmol).  Ascorbic acid/H2O (1.1 M, 137.0 µL, 0.2 mmol) and CuSO4-
5H2O/H2O (0.3 M, 114.0 µL, 0.04 mmol) were added and the solution was shaken at 
37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and 
the solution was washed with ethyl acetate (3 × 50 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 68 (17.7 mg, 57.8%).  
Rf = 0.38 (EtOAc-hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.88 (m, 3H), 7.11 
(t, J = 8.7 Hz, 2H), 5.23 (m, 1H), 4.55 (m, 1H), 4.43 (m, 1H), 3.83 (m, 1H), 3.65 (s, 
3H), 3.40 (m, 1H), 2.63 (m, 4H), 1.98 (m, 3H), 1.82 (m, 1H), 1.67 (m, 2H), 1.53 (m, 
2H), 1.26 (d, J = 6.4 Hz, 3H), and 0.90 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 172.7, 171.8, 127.5, 127.4, 120.9, 115.7, 115.5, 80.4, 75.9, 69.1, 53.2, 51.8, 
42.5, 40.4, 31.2, 29.7, 29.4, 28.9, 20.8, and 14.5 
O
O
N
O
N
N
O
O
N3
O
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
NHAc
 
 
69: 2,2-Dimethyl-propionic acid 2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-
1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl ester 69.  58 (27.6 mg, 0.09 
mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by N-(3-ethynyl-pyridine)-
acetamide (147.0 mg, 0.9 mmol).  Ascorbic acid/H2O (1.1 M, 185.0 µL, 0.2 mmol) 
and CuSO4-5H2O/H2O (0.3 M, 155.0 µL, 0.05 mmol) were added and the solution 
was shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) 
was added and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
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phases were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel (100% EtOAc) to give 69 (32.4 mg, 76.6%).  
Rf = 0.51 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 7.98 (s, 1H), 7.91 (s, 1H), 
7.81 (s, 1H), 7.76 (d, J = 8.1 Hz, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.34 (t, J = 7.9 Hz, 
1H), 5.09 (m, 1H), 4.53 (m, 1H), 4.39 (m, 1H), 3.81 (m, 1H), 3.41 (m, 1H), 2.17 (s, 
3H), 1.98 (m, 3H), 1.81 (m, 1H), 1.58 (m, 3H), 1.20 (m, 12H), and 0.89 (d, J = 6.9 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 178.3, 168.6, 138.6, 131.2, 129.5, 121.3, 
119.5, 116.7, 80.7, 76.2, 68.7, 53.5, 42.5, 40.4, 38.8, 31.3, 29.8, 27.1, 24.6, 20.6, and 
14.6 
O
O
N
O
N
N
O
O
N3
O
N-(3-ethynyl-phenyl)acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
NHAc
 
 
70: Benzoic acid 2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester 70.  61 (31.7 mg, 0.01 mmol) was added 
to 5:1 EtOH/H2O (1.5 mL) followed by N-(3-ethynyl-pyridine)-acetamide (159.0 µL, 
1.0 mmol).  Ascorbic acid/H2O (1.1 M, 200.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O 
(0.3 M, 165.0 µL, 0.05 mmol) were added and the solution was shaken at 37 °C for 
12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and the solution 
was washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel (100% EtOAc) to give 70 (43.5 mg, 91.4%).  Rf = 0.49 (100% EtOAc); 
1
H 
NMR (400 MHz, CDCl3) δ 8.03 (m, 3H), 7.91 (m, 1H), 7.84 (s, 1H), 7.77 (m, 1H), 
7.56 (m, 2H), 7.44 (m, 2H), 7.32 (m, 1H), 5.44 (m, 1H), 4.51 (m, 1H), 4.40 (m, 1H), 
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3.92 (m, 1H), 3.38 (m, 1H), 2.14 (s, 3H), 1.98 (m, 4H), 1.81 (m, 1H), 1.55 (m, 2H), 
1.37 (d, J = 6.3 Hz, 3H), and 0.87 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
168.7, 166.3, 146.9, 138.7, 132.9, 131.2, 130.6, 129.49, 129.46, 128.4, 121.5, 121.3, 
119.4, 116.7, 80.6, 76.0, 69.5, 53.4, 42.5, 40.3, 31.3, 29.8, 24.6, 20.9, and 14.6  
O N
O
O
MeO
O
O N3
O
O
MeO
O
N
N
NHAc
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
71: Succinic acid 2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester methyl ester 71.  60 (21.0 mg, 0.1 mmol) 
was added to 5:1 EtOH/H2O (1.5 mL) followed by N-(3-ethynyl-phenyl)-acetamide 
(102.0 mg, 0.6 mmol).  Ascorbic acid/H2O (1.1 M, 128.0 µL, 0.1 mmol) and CuSO4-
5H2O/H2O (0.3 M, 106.0 µL, 0.03 mmol) were added and the solution was shaken at 
37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and 
the solution washed with ethyl acetate (3 × 50 mL).  The organic layers were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (4:1) to give 71 (25.2 mg, 80.8%).  
Rf = 0.38 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 7.91 (s, 1H), 
7.77 (m, 2H), 7.65 (d, J = 7.8 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 5.18 (m, 1H), 4.52 
(m, 1H), 4.40 (m, 1H), 3.82 (m, 1H), 3.64 (s, 3H), 3.38 (m, 1H), 2.63 (s, 4H), 2.17 (s, 
3H), 1.97 (m, 3H), 1.81 (m, 1H), 1.66 (m, 1H), 1.51 (m, 2H), 1.24 (d, J = 6.3 Hz, 
3H), and 0.89 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.8, 172.0, 
168.6, 146.9, 138.6, 131.4, 129.5, 121.4, 121.2, 119.4, 116.6, 80.6, 75.9, 69.4, 53.3, 
51.8, 42.4, 40.3, 31.2, 29.8, 29.5, 29.0, 24.5, 20.7, and 14.6; IR (ATR) 3311, 3130, 
2974, 2099, 1730, 1693, 1618, 1592, 1569, 1534, 1488, 1438, 1406, 1369, 1316, 
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1222, 1163, 1045, 997, 884, 847, 792, 757, and 694 cm
-1
; ESI-TOF-MS m/z calcd for 
C25H34N4O6H
+
: 487.26; found 487.27.    
O
O
O
N N
N
N
O
O
O
N3
2-ethynyl-pyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
72: Benzoic acid 1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-
tetrahydro-furan-2-yl}-ethyl ester 72.  61 (10.18 mg, 0.03 mmol) was added to 5:1 
EtOH/H2O (1.5 mL) followed by 2-ethynyl-pyridine (98+%, 33.0 µL, 0.3 mmol).  
Ascorbic acid/H2O (1.1 M, 64.0 µL, 0.07 mmol) and CuSO4-5H2O/H2O (0.3 M, 53.0 
µL, 0.02 mmol) were added and the solution was shaken at 37 °C for 12 hours.  
Saturated sodium bicarbonate solution (20 mL) was added and the solution was 
washed with ethyl acetate (2 × 50 mL).  The organic layers were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (4:1) to give 72 (12.2 mg, 90.4%).  Rf = 0.19 (EtOAc-
hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 8.56 (m, 1H), 8.16 (m, 2H), 8.05 (m, 
2H), 7.75 (m, 1H), 7.54 (m, 1H), 7.43 (m, 2H), 7.21 (m, 1H), 5.36 (m, 1H), 4.64 (m, 
1H), 4.32 (m, 1H), 3.98 (m, 1H), 3.51 (m, 1H), 2.00 (m, 4H), 1.86 (m, 1H), 1.58 (m, 
2H), 1.40 (d, J = 6.3 Hz, 3H), and 0.85 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 166.0, 150.4, 149.3, 148.1, 136.8, 132.7, 130.7, 129.5, 128.3, 122.9, 122.6, 
120.2, 80.7, 76.3, 69.6, 53.5, 42.6, 40.4, 31.4, 29.6, 20.8, and 14.3; IR (ATR) 3133, 
3065, 2972, 2954, 2935, 2877, 2100, 1736, 1708, 1600, 1593, 1569, 1544, 1472, 
1455, 1430, 1420, 1382, 1356, 1319, 1275, 1260, 1235, 1201, 1155, 1108, 1070, 
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1060, 1031, 844, 790, and 718 cm
-1
; ESI-TOF-MS m/z calcd for C24H28N4O3H
+
: 
421.22; found 421.24.    
O OMe
OOTHP
O OMe
OOH DHP, pTsOH-H2O
CH2Cl2, r.t., 5 h
 
 
73: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propionic acid 
methyl ester 73.  Methyl (–)–nonactate 48 (0.704 g, 3.3 mmol) was added to 
methylene chloride (13 mL) followed by DHP (1.5 mL, 16.3 mmol) and pTsOH-H2O 
(6.0 mg, 0.03 mmol).  The solution was stirred at room temperature for 5 hours.  The 
solution was evaporated to a residue which was purified by chromatography on silica 
gel in EtOAc-hexanes (1:9) to give 73 (0.824 g, 84.4%).  
1
H NMR (400 MHz, CDCl3) 
δ 4.73 (m, 0.5H), 4.62 (m, 0.5H), 3.92 (m, 4H), 3.67 (m, 3H), 3.46 (m, 1H), 2.50 (m, 
1H), 1.96 (m, 2H), 1.65 (m, 10H), 1.22 (m, 2H), and 1.09 (m, 4H); 
13
C NMR (100 
MHz, CDCl3) δ 175.41, 175.38, 99.8, 94.5, 80.4, 80.3, 77.3, 77.0, 76.65, 76.4, 72.6, 
68.0, 63.0, 62.0, 51.54, 5.51, 45.44, 45.36, 44.1, 43.8, 31.5, 31.3, 31.1, 31.0, 28.6, 
28.5, 25.5, 25.4, 22.6, 20.2, 19.5, 19.4, 13.4, and 13.3; IR (ATR) 2941, 2873, 1739, 
1456, 1436, 1375, 1352, 1260, 1200, 1163, 1118, 1063, 1021, 992, 942, 905, 869, and 
812 cm
-1
; ESI-TOF-MS m/z calcd for C16H28O5Na
+
: 323.18; found 323.24.    
O OH
OTHP
O OMe
OOTHP LiAlH4
THF, r.t., 12 h  
 
74: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propan-1-ol 74.  
73 (0.824 g, 2.8 mmol) was added to THF (30 mL) followed by (0.208 g, 5.5 mmol) 
of lithium aluminum hydride at room temperature and then the solution was stirred 
overnight.  Water (5.5 mL) was added, followed by 3.0 M NaOH/H2O (11 mL) and 
then water (5.5 mL).  The solution was filtered and evaporated to a residue which was 
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purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 74 (0.708 g, 
94.8%).  
1
H NMR (400 MHz, CDCl3) δ 4.66 (m, 0.5H), 4.60 (m, 0.5H), 4.12 (m, 1H), 
3.88 (m, 2H), 3.54 (m, 4H), 1.96 (m, 2H), 1.65 (m, 11H), 1.23 (m, 2H), 1.10 (m, 2H), 
and 0.78 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 99.9, 95.4, 85.9, 85.6, 76.7, 76.5, 
72.5, 68.8, 68.5, 68.1, 63.1, 62.7, 44.0, 43.7, 41.1, 40.9, 31.12, 31.09, 30.73, 30.7, 
30.5, 30.4, 25.41, 25.37, 22.6, 20.2, 19.9, 19.6, and 13.6; IR (ATR) 3467, 2939, 2874, 
1454, 1374, 1352, 1261, 1201, 1116, 1075, 1021, 991, 943, 905, 869, 811 cm
-1
; ESI-
TOF-MS m/z calcd for C15H28O4Na
+
: 295.19; found  295.24.    
O OTs
OTHP
O OH
OTHP pTsCl, py
r.t., 5 h
 
 
75: Toluene-4-sulfonic acid 2-{5-[2-(tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-
furan-2-yl}-propyl ester 75.  74 (0.708 g, 2.6 mmol) was added to pyridine (2.1 mL, 
26.0 mmol) followed by pTsCl (0.992 g, 5.2 mmol) and then the solution was stirred 
at room temperature for 5 hours.  Ethyl acetate (50 mL) was added and the solution 
was washed with saturated copper sulfate solution (2 × 20 mL) and then saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:3) 
to give 75 (0.961 g, 86.6%).  
1
H NMR (400 MHz, CDCl3) δ 7.77 (m, 2H), 7.33 (m, 
2H), 4.72 (m, 0.5H), 4.59 (m, 0.5H), 4.13 (m, 1H), 3.85 (m, 4H), 3.48 (m, 2H), 2.43 
(s, 3H), 1.68 (m, 13H), 1.17 (m, 2H), 1.07 (m, 1H), and 0.89 (m, 3H); 
13
C NMR (100 
MHz, CDCl3) δ 144.51, 144.45, 133.0, 129.7, 127.9, 99.8, 94.6, 80.0, 79.62, 79.60, 
76.7, 76.3, 76.2, 73.2, 73.1, 72. 8, 72.5, 67.9, 65.2, 63.0, 62.0, 44.1, 43.8, 43.2, 38.81, 
38.8, 38.5, 31.4, 31.2, 31.1, 31.0, 30.6, 29.1, 29.07, 29.0, 25.5, 25.4, 25.37, 22.6, 21.6, 
20.2, 19.5, 19.4, 13.41, and 13.39; IR (ATR) 2941, 2875, 1739, 1599, 1454, 1359, 
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1291, 1188, 1176, 1118, 1097, 1075, 1021, 992, 962, 940, 812, 792, and 666 cm
-1
; 
ESI-TOF-MS m/z calcd for C22H34O6SNa
+
: 449.20; found 449.26.   
O N3
OTHP
O OTs
OTHP NaN3
DMF, 100 
o
C, 3 h  
 
76: 2-{2-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethoxy}-
tetrahydro-pyran 76.  75 (0.961 g, 2.3 mmol) was added to DMF (10 mL) followed 
by sodium azide (1.464 g, 22.5 mmol) and the solution was then warmed to 100 °C 
and stirred for 3 hours.  Once cooled, water (50 mL) was added and the solution was 
washed with diethyl ether (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:9) to give 76 (0.479 g, 71.6%).  
1
H NMR (400 MHz, 
CDCl3) δ 4.75 (m, 0.5H), 4.66 (m, 0.5H), 3.94 (m, 3H), 3.50 (m, 3H), 3.26 (m, 1H), 
1.95 (m, 2H), 1.64 (m, 10H), 1.25 (m, 2H), 1.12 (m, 2H), and 0.93 (m, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ 99.8, 94.5, 80.70, 80.67, 76.3, 76.1, 72.6, 67.9, 62.9, 62.0, 55.1, 
44.2, 43.9, 39.53, 39.51, 31.5, 31.4, 31.1, 31.0, 29.3, 25.5, 25.45, 22.7, 20.2, 19.5, and 
14.4; IR (ATR) 2939, 2875, 2096, 1453, 1380, 1351, 1282, 1201, 1115, 1075, 1021, 
992, 942, 905, 870, and 813 cm
-1
; ESI-TOF-MS m/z calcd for C15H27N3O3Na
+
: 
320.20; found 320.25.    
O N3
OH
O N3
OTHP 6 M HCl / MeOH
r.t., 3 h
 
 
77: 1-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-propan-2-ol 77.  76 (0.479 g, 1.6 
mmol) was added to 6 M HCl/MeOH (5 mL) and the solution was stirred for 3 hours 
at room temperature.  Saturated sodium bicarbonate solution was added until no gas 
evolved and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
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phases were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 77 (0.268 g, 
78%).  
1
H NMR (400 MHz, CDCl3) δ 4.06 (m, 2H), 3.60 (m, 1H), 3.42 (m, 1H), 3.27 
(m, 1H), 2.75 (s, 1H), 1.96 (m, 2H), 1.67 (m, 5H), 1.20 (d, J = 6.4 Hz, 3H), and 0.94 
(d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 81.3, 76.8, 65.3, 55.1, 43.1, 39.2, 
30.6, 29.2, 23.3, and 14.4; IR (ATR) 3404, 2966, 2934, 2095, 1460, 1380, 1282, 1067, 
and 937 cm
-1
; ESI-TOF-MS m/z calcd for C10H19N3O2H
+
: 214.16; found 214.20.    
O N3
O
O
MeO
OO N3
OH
methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
 
 
78: Succinic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester methyl ester 78.  77 (0.134 g, 0.6 mmol) was added to pyridine (1 mL) followed 
by methyl 4-chloro-4-oxobutyrate (97%, 155.0 µL, 1.3 mmol) and the solution was 
then stirred for 3 hours at room temperature.  Ethyl acetate (50 mL) was added and 
the solution was washed with saturated copper sulfate solution (2 × 20 mL) and then 
saturated ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated 
to a residue which was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 78 (0.150 g, 73%).  
1
H NMR (400 MHz, CDCl3) δ 5.01 (m, 1H), 3.82 
(m, 1H), 3.66 (s, 3H), 3.53 (m, 1H), 3.44 (m, 1H), 3.22 (m, 1H), 2.58 (m, 4H), 1.92 
(m, 2H), 1.71 (m, 3H), 1.49 (m, 2H), 1.22 (d, J = 6.4 Hz, 3H), and 0.91 (d, J = 6.9 
Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 171.6, 80.8, 75.9, 69.6, 55.0, 51.7, 
42.4, 39.4, 31.2, 29.4, 29.1, 28.9, 20.5, and 14.4; IR (ATR) 2973, 2879, 2097, 1732, 
1438, 1363, 1268, 1162, 1065, 997, 883, and 846 cm
-1
; ESI-TOF-MS m/z calcd for 
C15H25N3O5Na
+
: 350.17; found 350.22.    
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O
O
MeO
O
N
N
NHAc
O N3
O
O
MeO
O
N-(3-ethynyl-phenyl)acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 oC, 12 h  
 
79: Succinic acid 2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester methyl ester 79.  78 (0.150 g, 0.5 mmol) 
was added to 5:1 EtOH/H2O (6 mL) followed by N-(3-ethynyl-pyridine)-acetamide 
(0.729 g, 4.6 mmol).  Ascorbic acid/H2O (1.1 M, 0.9 mL, 1.0 mmol) and CuSO4-
5H2O/H2O (0.3 M, 0.8 mL, 0.2 mmol) were added and the solution was shaken at 37 
°C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and the 
solution was washed with ethyl acetate (3 × 50 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (4:1) to give 79 (0.215 g, 96.5%).  
1
H 
NMR (400 MHz, CDCl3) δ 8.11 (s, 1H), 7.89 (s, 1H), 7.75 (m, 2H), 7.62 (d, J = 7.8 
Hz, 1H), 7.33 (m, 1H), 5.16 (m, 1H), 4.51 (m, 1H), 4.38 (m, 1H), 3.81 (m, 1H), 3.62 
(s, 3H), 3.38 (m, 1H), 2.61 (s, 4H), 2.15 (s, 3H), 1.95 (m, 3H), 1.79 (m, 1H), 1.64 (m, 
1H), 1.50 (m, 2H), 1.22 (d, J = 6.4 Hz, 3H), and 0.86 (d, J = 6.9 Hz, 3H); 
13
C NMR 
(100 MHz, CDCl3) δ 172.8, 172.0, 168.7, 146.9, 138.7, 131.3, 129.5, 121.4, 121.2, 
119.4, 116.6, 80.6, 75.9, 69.4, 53.3, 51.8, 42.3, 40.3, 31.2, 29.7, 29.5, 28.9, 24.5, 20.7, 
and 14.6; IR (ATR) 3311, 3130, 2974, 2100, 1730, 1693, 1618, 1592, 1569, 1534, 
1488, 1438, 1406, 1369, 1316, 1222, 1163, 1045, 997, 884, 847, 792, 757, and 694 
cm
-1
; ESI-TOF-MS m/z calcd for C25H34N4O6H
+
: 487.26; found 487.27.    
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O
O
O N3
OH
benzoyl chloride
py, r.t., 3 h
 
 
80: Benzoic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester 80.  77 (0.134 g, 0.6 mmol) was added to pyridine (1 mL) followed by benzoyl 
chloride (146.0 µL, 1.3 mmol).  The solution was stirred for 3 hours at room 
temperature.  Ethyl acetate (50 mL) was added and the solution was washed with 
saturated copper sulfate solution (2 × 20 mL) and then saturated ammonium chloride 
solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:9) to give 80 (0.193 g, 
96.7%).  
1
H NMR (400 MHz, CDCl3) δ 8.03 (d, J = 7.0 Hz, 2H), 7.53 (m, 1H), 7.43 
(t, J = 7.9 Hz, 2H), 5.28 (m, 1H), 3.93 (m, 1H), 3.53 (m, 1H), 3.46 (m, 1H), 3.20 (m, 
1H), 1.94 (m, 3H), 1.82 (m, 1H), 1.71 (m, 1H), 1.54 (m, 2H), 1.38 (d, J = 6.4 Hz, 
3H), and 0.92 (d, J = 6.7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 165.9, 132.7, 
130.5, 129.4, 128.2, 80.8, 76.1, 69.7, 55.0, 42.5, 39.4, 31.4, 29.2, 20.7, and 14.4; IR 
(ATR) 2972, 2877, 2096, 1715, 1602, 1585, 1451, 1381, 1356, 1314, 1274, 1175, 
1109, 1069, 1026, 935, and 711 cm
-1
; ESI-TOF-MS m/z calcd for C17H23N3O3H
+
: 
318.18; found 318.23.    
O N
O
O
N
N
N
O N3
O
O
2-ethynyl-pyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
81: Benzoic acid 1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-
tetrahydro-furan-2-yl}-ethyl ester 81.  80 (0.166 g, 0.5 mmol) was added to 5:1 
EtOH/H2O (6 mL) followed by 2-ethynylpyridine (98%, 0.53 mL, 5.2 mmol).  
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Ascorbic acid/H2O (1.1 M, 1.0 mL, 1.2 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.9 
mL, 0.3 mmol) were added and the solution was shaken at 37 °C for 12 hours.  
Saturated sodium bicarbonate solution (20 mL) was added and the solution was 
washed with ethyl acetate (3 × 50 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (4:1) to give 81 (0.147 g, 67%).  
1
H NMR (400 MHz, 
CDCl3) δ 8.53 (m, 1H), 8.13 (m, 2H), 8.03 (m, 2H), 7.72 (m, 1H), 7.51 (m, 1H), 7.40 
(m, 2H), 7.17 (m, 1H), 5.34 (m, 1H), 4.61 (m, 1H), 4.30 (m, 1H), 3.96 (m, 1H), 3.48 
(m, 1H), 1.98 (m, 4H), 1.84 (m, 1H), 1.55 (m, 2H), 1.37 (d, J = 6.4 Hz, 3H), and 0.82 
(d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 165.9, 150.4, 149.3, 148.1, 136.7, 
132.7, 130.6, 129.4, 128.2, 122.8, 122.6, 120.1, 80.6, 76.2, 69.5, 53.4, 42.5, 40.4, 
31.3, 29.5, 20.8, and 14.2; IR (ATR) 3133, 3065, 2972, 2954, 2910, 2877, 2100, 
1736, 1708, 1599, 1593, 1569, 1544, 1472, 1455, 1430, 1420, 1382, 1356, 1319, 
1275, 1260, 1235, 1201, 1155, 1108, 1070, 1031, 844, 790, and 718 cm
-1
; ESI-TOF-
MS m/z calcd for C24H28N4O3H
+
: 421.22; found 421.24.    
O OMe
OOTHP
O OMe
OOH DHP, pTsOH-H2O
r.t., 5 h
 
 
82: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propionic acid 
methyl ester 82.  Methyl (+)-nonactate 46 (567.0 mg, 2.6 mmol) was added to 
methylene chloride (10 mL) followed by DHP (1.2 mL, 13.1 mmol) and pTsOH-H2O 
(50.0 mg, 0.3 mmol).  The solution was stirred for 5 hours at room temperature.  The 
solution was evaporated to a residue which was partially purified by chromatography 
on silica gel in EtOAc-hexanes (1:19) to give 82.  The semi-pure material was used in 
the following reaction.  
1
H NMR (400 MHz, CDCl3) δ 4.72 (m, 0.5H), 4.61 (m, 
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0.5H), 3.92 (m, 4H), 3.66 (m, 3H), 3.46 (m, 1H), 2.49 (m, 1H), 1.95 (m, 2H), 1.60 (m, 
10H), 1.20 (m, 2H), and 1.08 (m, 4H); 
13
C NMR (100 MHz, CDCl3) δ 175.39, 
175.36, 99.8, 94.5, 80.34, 80.25, 77.3, 77.0, 76.7, 76.6, 76.4, 72.6, 68.0, 62.9, 62.0, 
51.52, 51.48, 45.4, 45.3, 44.0, 43.8, 31.5, 31.3, 31.1, 31.0, 28.53, 28.51, 25.5, 25.4, 
22.6, 20.1, 19.43, 19.38, 13.33, and 13.28; IR (ATR) 2942, 2873, 1739, 1456, 1437, 
1376, 1353, 1261, 1200, 1164, 1121, 1075, 1021, 992, 904, 869, and 812 cm
-1
; ESI-
TOF-MS m/z calcd for C16H28O5Na
+
: 323.18; found 323.22.    
O OH
OTHP
O OMe
OTHP O LiAlH4
THF, r.t., 12 h  
 
83: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-furan-2-yl}-propan-1-ol 83.  
Semi-pure material 82 was added to THF (20 mL) followed by lithium aluminum 
hydride (0.3 g, 7.9 mmol) at room temperature and the solution was then stirred for 
12 hours.  Water (0.3 mL) was added, followed by 3.0 M NaOH/H2O (0.6 mL) and 
then water (0.3 mL).  The solution was filtered and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 83 
(0.477 g, 66.9%).  
1
H NMR (400 MHz, CDCl3) δ 4.67 (m, 1H), 4.61 (m, 1H), 4.13 
(m, 1H), 3.90 (m, 2H), 3.55 (m, 4H), 1.97 (m, 2H), 1.65 (m, 11H), 1.24 (m, 2H), 1.11 
(m, 2H), and 0.79 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 99.9, 95.5, 85.9, 85.7, 
76.8, 76.52, 72.5, 68.9, 68.6, 68.1, 63.1, 62.7, 44.0, 43.7, 41.1, 40.9, 31.1, 31.1, 30.74, 
30.72, 30.6, 30.5, 25.4, 25.4, 22.6, 20.2, 20.0, 19.6, and 13.7; IR (ATR) 3464, 2939, 
2874, 1454, 1374, 1352, 1261, 1201, 1116, 1075, 1021, 991, 943, 905, 869, and 811 
cm
-1
; ESI-TOF-MS m/z calcd for C15H28O4Na
+
: 295.19; found 295.24.    
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O OTs
OTHP
O OH
OTHP
pTsCl
py, r.t., 12 h  
 
84: Toluene-4-sulfonic acid 2-{5-[2-(tetrahydro-pyran-2-yloxy)-propyl]-tetrahydro-
furan-2-yl}-propyl ester 84.  83 (0.452 g, 1.7 mmol) was added to pyridine (2 mL) 
followed by pTsCl (0.633 g, 3.3 mmol).  The solution was stirred for 12 hours at 
room temperature.  Ethyl acetate (50 mL) was added and the solution was washed 
with saturated copper sulfate solution (2 × 20 mL) and then saturated ammonium 
chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 84 
(0.520 g, 73.4%).  
1
H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.2 Hz, 2H), 7.33 (d, J 
= 8.2 Hz, 2H), 4.73 (m, 0.5H), 4.60 (m, 0.5H), 4.13 (m, 1H), 3.89 (m, 4H), 3.50 (m, 
2H), 2.44 (s, 3H), 1.72 (m, 13H), 1.18 (m, 2H), 1.07 (m, 1H), and 0.90 (m, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ 144.6, 129.74, 129.7, 127.9, 99.8, 94.6, 80.0, 79.7, 76.7, 
76.3, 76.2, 73.2, 73.1, 72.8, 72.5, 67.9, 65.3, 63.0, 62.0, 44.1, 43.8, 43.2, 38.8, 38.5, 
31.4, 31.3, 31.1, 31.0, 30. 6, 29.12, 29.08, 29.0, 25.5, 25.4, 23.4, 22.6, 21.6, 20.2, 
19.5, 19.4, 13.42, 13.4, and 13.3; IR (ATR) 2941, 1599, 1455, 1359, 1188, 1176, 
1097, 1075, 1021, 991, 962, 940, 813, and 667 cm
-1
; ESI-TOF-MS m/z calcd for 
C22H34O6SNa
+
: 449.20; found 449.25.    
O N3
OTHP
O OTs
OTHP NaN3
DMF, 80 
o
C, 5 h  
 
85: 2-{2-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethoxy}-
tetrahydro-pyran 85.  84 (494.0 mg, 1.2 mmol) was added to DMF (3.5 mL) followed 
by sodium azide (376.0 mg, 5.8 mmol).  The solution was warmed to 80 °C and 
stirred for 5 hours.  Once cooled to room temperature, water (20 mL) was added and 
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the solution was washed with diethyl ether (3 × 50 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:9) to give 85 (0.275 g, 79.9%).  
1
H 
NMR (400 MHz, CDCl3) δ 4.75 (m, 1H), 4.66 (m, 1H), 3.96 (m, 3H), 3.51 (m, 3H), 
3.26 (m, 1H), 1.96 (m, 2H), 1.65 (m 10H), 1.25 (m, 2H), 1.13 (m, 2H), and 0.93 (m, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 99.8, 94.5, 80.72, 80.7, 76.3, 76.1, 72.6, 68.0, 
63.0, 62.0, 55.2, 44.2, 43.9, 39.5, 31.5, 31.4, 31.1, 31.0, 29.3, 25.5, 25.46, 22.7, 20.2, 
19.5, and 14.4; IR (ATR) 2939, 2875, 2096, 1453, 1380, 1351, 1282, 1201, 1115, 
1075, 1021, 992, 941, 905, 870, and 813 cm
-1
; ESI-TOF-MS m/z calcd for 
C15H27N3O3Na
+
: 320.20; found 320.25.    
O N3
OH
O N3
OTHP 6 M HCl / H2O / MeOH
r.t., 12  h
 
 
86: 1-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-propan-2-ol 86.  85 (0.249 g, 
0.9 mmol) was added to 6 M HCl/H2O/MeOH (10 mL) and the solution was stirred 
for 12 hours at room temperature.  Saturated sodium bicarbonate solution was added 
until no gas evolved and the solution was washed with ethyl acetate (3 × 50 mL).  The 
organic phases were collected, dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 86 
(0.120 g, 67%).  
1
H NMR (400 MHz, CDCl3) δ 4.07 (m, 2H), 3.61 (m, 1H), 3.43 (m, 
1H), 3.27 (m, 1H), 2.73 (s, 1H), 1.96 (m, 2H), 1.66 (m, 5H), 1.21 (d, J = 6.2 Hz, 3H), 
and 0.94 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 81.3, 76.8, 65.3, 55.1, 
43.0, 39.2, 30.7, 29.2, 23.3, and 14.4; IR (ATR) 3411, 2967, 2934, 2878, 2095, 1460, 
1379, 1282, 1067, and 937 cm
-1
; ESI-TOF-MS m/z calcd for C10H19N3O2H
+
: 214.16; 
found 214.18.    
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87: Benzoic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester 87.  86 (46.0 mg, 0.2 mmol) was added to pyridine (1 mL) followed by benzoyl 
chloride (50.0 µL, 0.4 mmol).  The solution was stirred for 3 hours at room 
temperature.  Ethyl acetate (50 mL) was added and the solution was washed with 
saturated copper sulfate solution (2 × 20 mL) and then saturated ammonium chloride 
solution (2 × 20 mL), dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:9) to give 87 (53.1 mg, 
77.5%).  
1
H NMR (400 MHz, CDCl3) δ 8.04 (m, 2H), 7.55 (m, 1H), 7.43 (m, 2H), 
5.28 (m, 1H), 3.94 (m, 1H), 3.54 (m, 1H), 3.47 (m, 1H), 3.21 (m, 1H), 1.95 (m, 3H), 
1.83 (m, 1H), 1.72 (m, 1H), 1.55 (m, 2H), 1.39 (d, J = 6.4 Hz, 3H), and 0.93 (d, J = 
6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 166.0, 132.7, 130.8, 129.5, 128.3, 80.8, 
76.1, 69.8, 55.0, 42.6, 39.4, 31.4, 29.2, 20.8, and 14.4; IR (ATR) 2972, 2877, 2096, 
1715, 1602, 1585, 1451, 1381, 1356, 1314, 1274, 1175, 1109, 1069, 1026, 935, and 
711 cm
-1
; ESI-TOF-MS m/z calcd for C17H23N3O3H
+
: 318.18; found 318.23.    
O N
O
O
N
N
N
O N3
O
O
2-ethynyl-pyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
88: Benzoic acid 1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-
tetrahydro-furan-2-yl}-ethyl ester 88.  87 (32.8 mg, 0.1 mmol) was added to 5:1 
EtOH/H2O (2.5 mL) followed by 2-ethynylpyridine (98%, 21.0 µL, 0.2 mmol).  
Ascorbic acid/H2O (1.1 M, 207.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 M, 
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172.0 µL, 0.05 mmol) were added and the solution was shaken at 37 °C for 12 hours.  
Saturated sodium bicarbonate solution (20 mL) was added and the solution was 
washed with ethyl acetate (3 × 50 mL).  The organic layers were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (4:1) to give 88 (32.3 mg, 74.4%).  
1
H NMR (400 MHz, 
CDCl3) δ 8.55 (m, 1H), 8.14 (m, 2H), 8.04 (m, 2H), 7.74 (m, 1H), 7.52 (m, 1H), 7.41 
(m, 2H), 7.19 (m 1H), 5.34 (m, 1H), 4.62 (m, 1H), 4.30 (m, 1H), 3.97 (m, 1H), 3.49 
(m, 1H), 1.99 (m, 4H), 1.85 (m, 1H), 1.57 (m, 2H), 1.38 (d, J = 6.4 Hz, 3H), and 0.83 
(d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 166.0, 150.4, 149.3, 148.1, 136.8, 
132.7, 130.7, 129.5, 128.3, 122.8, 122.6, 120.2, 80.7, 76.3, 69.6, 53.5, 42.6, 40.4, 
31.3, 29.5, 20.8, and 14.3; IR (ATR) 3133, 3065, 2971, 2954, 2934, 2854, 2099, 
1708, 1600, 1593, 1569, 1544, 1472, 1454, 1430, 1420, 1382, 1356, 1319, 1275, 
1260, 1235, 1201, 1155, 1141, 1108, 1070, 1069, 1039, 844, 789, and 718 cm
-1
; ESI-
TOF-MS m/z calcd for C24H28N4O3H
+
: 421.22; found 421.28.     
O N3
O
O
MeO
OO N3
OH
methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
 
 
89: Succinic acid 2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-ethyl 
ester methyl ester 89.  86 (46.0 mg, 0.2 mmol) was added to pyridine (1 mL) followed 
by methyl 4-chloro-4-oxobutyrate (53.0 µL, 0.4 mmol).  The solution was stirred for 
3 hours at room temperature.  Ethyl acetate (50 mL) was added and the solution was 
washed with saturated copper sulfate solution (2 × 20 mL) and then saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:3) 
162 
 
to give 89 (46.7 mg, 66.1%).  
1
H NMR (400 MHz, CDCl3) δ 5.02 (m, 1H), 3.83 (m, 
1H), 3.68 (s, 3H), 3.54 (m, 1H), 3.46 (m, 1H), 3.23 (m, 1H), 2.60 (m, 4H), 1.94 (m, 
2H), 1.72 (m, 3H), 1.50 (m, 2H), 1.24 (d, J = 6.2 Hz, 3H), and 0.93 (d, J = 6.9 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 172.8, 171.7, 80.8, 75.9, 69.6, 55.1, 51.8, 42.4, 
39.4, 31.3, 29.4, 29.2, 29.0, 20.6, and 14.4; IR (ATR) 2973, 2879, 2097, 1732, 1438, 
1363, 1268, 1162, 1065, 997, 883, and 846 cm
-1
; ESI-TOF-MS m/z calcd for 
C15H25N3O5Na
+
: 350.17; found 350.21.    
O N
O
O
MeO
O
N
N
NHAc
O N3
O
O
MeO
O
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 oC, 12 h  
 
90: Succinic acid 2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester methyl ester 90.  89 (26.7 mg, 0.08 mmol) 
was added to 5:1 EtOH/H2O (2 mL) followed by N-(3-ethynyl-pyridine)-acetamide 
(26.0 mg, 0.2 mmol).  Ascorbic acid/H2O (1.1 M, 163.0 µL, 0.2 mmol) and CuSO4-
5H2O/H2O (0.3 M, 136.0 µL, 0.04 mmol) were added and the solution was shaken at 
37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and 
the solution was washed with ethyl acetate (3 × 50 mL).  The organic layers were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (4:1) to give 90 (32.1 mg, 80.9%).  
1
H NMR (400 MHz, CDCl3) δ 8.08 (s, 1H), 7.90 (s, 1H), 7.77 (m, 2H), 7.63 (m, 1H), 
7.35 (m, 1H), 5.17 (m, 1H), 4.52 (m, 1H), 4.39 (m, 1H), 3.82 (m, 1H), 3.64 (s, 3H), 
3.39 (m, 1H), 2.63 (s, 4H), 2.16 (s, 3H), 1.97 (m, 3H), 1.80 (m, 1H), 1.66 (m,1H), 
1.51 (m, 2H), 1.23 (d, J = 6.4 Hz, 3H), and 0.88 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 
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MHz, CDCl3) δ 172.8, 172.0, 168.7, 146.9, 138.7, 131.3, 129.5, 121.4, 121.2, 119.4, 
116.6, 80.6, 75.9, 69.4, 53.3, 51.8, 42.3, 40.3, 31.2, 29.7, 29.5, 29.0, 24.5, 20.7, and 
14.6; IR (ATR) 3309, 3130, 2930, 1729, 1676, 1618, 1592, 1568, 1534, 1488, 1438, 
1406, 1368, 1316, 1221, 1163, 1120, 1045, 997, 884, 847, 792, 694, and 666 cm
-1
; 
ESI-TOF-MS m/z calcd for C25H34N4O6H
+
: 487.26; found 487.32.    
O
O
O
N N
N
O
O
O
N3
1. benzoyl chloride
    py, r.t., 3 h 
2. 2-ethynyl-pyridine
    1.1 M Ascorbic acid / H2O
    0.3 M CuSO4-5H2O / H2O
    5:1 EtOH / H2O 
    100 
o
C, 12 h
N
 
 
91: Benzoic acid 1-methyl-2-{5-[1-methyl-2-(5-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-
tetrahydro-furan-2-yl}-ethyl ester 91.  55 (110.0 mg, 0.5 mmol) was added to 
pyridine (3 mL) followed by benzoyl chloride (0.6 mL, 5.2 mmol).  The solution was 
stirred at room temperature for 3 hours.  Ethyl acetate (50 mL) was added and the 
solution washed with saturated copper sulfate solution (2 × 20 mL) and saturated 
sodium bicarbonate solution (2 × 20 mL), dried (Na2SO4), concentrated to a residue 
and was partially purified by chromatography on silica gel in EtOAc-hexanes (1:3) to 
give 61.  Semi-pure product 61 was added to 5:1 EtOH/H2O (1.5 mL) followed by 2-
ethynyl-pyridine (98+%, 0.53 mL, 5.2 mmol).  Ascorbic acid/H2O (1.1 M, 1.0 mL, 
1.1 mmol) and CuSO4-5H2O/H2O (0.3M, 0.9 mL, 0.3 mmol) were added and the 
solution was heated on a hot plate at 100 °C and stirred for 12 hours.  Once the 
solution was cool, saturated sodium bicarbonate solution (20 mL) was added and the 
solution was washed with ethyl acetate (3 × 50 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
164 
 
chromatography on silica gel in EtOAc-hexanes (4:1) to give 91 (0.150 g, 69%).  Rf = 
0.55 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.56 (m, 1H), 8.17 (m, 2H), 8.05 
(m, 2H), 7.76 (m, 1H), 7.54 (m, 1H), 7.42 (m, 2H), 7.21 (m, 1H), 5.35 (m, 1H), 4.63 
(m, 1H), 4.32 (m, 1H), 3.98 (m, 1H), 3.50 (m, 1H), 2.01 (m, 4H), 1.86 (m, 1H), 1.58 
(m, 2H), 1.39 (d, J = 6.4 Hz, 3H), and 0.84 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 166.2, 150.6, 149.5, 137.1, 133.0, 131.0, 129.8, 128.5, 123.2, 122.9, 120.5, 
81.0, 76.5, 69.8, 53.8, 42.8, 40.7, 31.6, 29.8, 21.1, and 14.5; IR (ATR) 3132, 2955, 
2924, 2854, 2099, 1709, 1600, 1461, 1420, 1381, 1357, 1319, 1275, 1201, 1155, 
1108, 1070, 1044, 1031, 844, 790, 749, and 718 cm
-1
; ESI-TOF-MS m/z calcd for 
C24H28N4O3H
+
: 421.22; found 421.28.    
O
O
O
N N
N    N-(3-ethynyl-phenyl)acetamide
    1.1 M Ascorbic acid / H2O
    0.3 M CuSO4-5H2O / H2O
    5:1 EtOH / H2O 
    100 
o
C, 12 h
MeO
O
AcHN
O
O
N3
O
MeO
O
 
 
92: Succinic acid 2-(5-{2-[5-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl ester methyl ester 92.  60 (113.0 mg, 0.4 mmol) 
was added to 5:1 EtOH/H2O (1.5 mL) followed by N-(3-ethynyl-pyridine)-acetamide 
(550.0 mg, 3.5 mmol).  Ascorbic acid/H2O (1.1 M, 0.7 mL, 0.8 mmol) and CuSO4-
5H2O/H2O (0.3 M, 0.6 mL, 0.2 mmol) were added and the solution was heat on a hot 
plate at 100 °C and stirred for 12 hours.  Once the solution was cool, saturated 
sodium bicarbonate solution (20 mL) was added and the solution was washed with 
ethyl acetate (3 × 50 mL).  The organic phases were collected, dried (Na2SO4), and 
concentrated to a residue, which were purified by chromatography on silica gel in 
EtOAc-hexanes (4:1) to give 92 (0.145 g, 86.3%).  Rf = 0.38 (100% EtOAc); 
1
H 
165 
 
NMR (400 MHz, CDCl3) δ 7.92 (s, 1H), 7.79 (m, 2H), 7.73 (s, 1H), 7.67 (d, J = 7.8 
Hz, 1H), 7.43 (t, J = 7.9 Hz, 1H), 5.19 (m, 1H), 4.53 (m, 1H), 4.43 (m, 1H), 3.86 (m, 
1H), 3.65 (s, 3H), 3.39 (m, 1H), 2.64 (s, 4H), 2.18 (s, 3H), 1.98 (m, 3H), 1.82 (m, 
1H), 1.67 (m, 1H), 1.52 (m, 2H), 1.25 (d, J = 6.4 Hz, 3H), and 0.91 (d, J = 6.8 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 172.8, 172.0, 168.6, 146.9, 138.7, 131.4, 129.5, 
121.4, 121.2, 119.43, 119.41, 116.6, 80.6, 75.9, 69.4, 53.3, 51.8, 42.4, 40.3, 31.2, 
29.7, 29.5, 29.0, 24.5, 20.7, and 14.6; IR (ATR) 3305, 3130, 2970, 2100, 1728, 1678, 
1618, 1592, 1569, 1536, 1488, 1439, 1409, 1369, 1317, 1219, 1164, 1046, 997, 885, 
847, 792, 754, and 693 cm
-1
; ESI-TOF-MS m/z calcd for C25H34N4O6H
+
: 487.26; 
found 487.31.   
O OH
OTHP
O OMe
OH O
1. DHP, pTsOH-H2O
    CH2Cl2, r.t., 5 h
    
2. LiAlH4, THF, r.t., 12 h  
 
94: 2-{5-[2-(Tetrahydro-pyran-2-yloxy)-butyl]-tetrahydro-furan-2-yl}-propan-1-ol 94.  
Methyl homononactate 93 (0.534 g, 2.3 mmol) was added to methylene chloride (9.3 
mL) followed by DHP (1.1 mL, 11.6 mmol) and pTsOH-H2O (4.5 mg, 0.02 mmol).  
The solution was stirred for 5 hours at room temperature.  The solution was 
evaporated to a residue and partially purified by column chromatography on silica gel 
in EtOAc-hexanes (1:19) to give the semi-pure intermediate product.  The semi-pure 
material was added to THF (25 mL) followed by lithium aluminum hydride (0.353 g, 
9.3 mmol).  The reaction was stirred at room temperature overnight.  Water (0.4 mL) 
was added followed by 3.0 M NaOH/H2O (0.8 mL) and then water (0.4 mL).  The 
solution was filtered and evaporated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 94 (0.484 g, 72.9%).  
1
H 
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NMR (400 MHz, CDCl3) δ 4.60 (m, 1H), 4.11 (m, 1H), 3.90 (m, 2H), 3.58 (m, 3H), 
3.45 (m, 1H), 2.12 (s, 1H), 1.96 (m, 2H), 1.78 (m, 1H), 1.58 (m, 12H), and 0.83 (m, 
6H); 
13
C NMR (100 MHz, CDCl3) δ 99.6, 97.2, 86.0, 85.7, 77.6, 77.2, 76.8, 74.2, 
69.0, 68.7, 63.3, 41.3, 41.1, 41.0, 40.6, 31.4, 31.3, 31.1, 31.0, 30.8, 28.9, 26.5, 25.62, 
25.59, 20.46, 20.42, 13.85, 13.82, 9.8, and 9.0; IR (ATR) 3461, 2940, 2876, 1463, 
1380, 1352, 1201, 1115, 1076, 1022, 999, 902, 868, 810, and 754 cm
-1
; ESI-TOF-MS 
m/z calcd for C16H30O4Na
+
: 309.20; found 309.11.    
O OTs
OTHP
O OH
OTHP pTsCl, py
CH2Cl2, r.t., 12 h  
 
95: Toluene-4-sulfonic acid 2-{5-[2-(tetrahydro-pyran-2-yloxy)-butyl]-tetrahydro-furan-
2-yl}-propyl ester 95.  94 (0.426 g, 1.5 mmol) was added to methylene chloride (3 
mL) was added to pyridine (1.2 mL, 14.9 mmol) and pTsCl (0.567 g, 3.0 mmol).  The 
solution was stirred overnight at room temperature.  Ethyl acetate (50 mL) was added 
and the solution was washed with saturated copper sulfate solution (2 × 20 mL) and 
then saturated ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 95 (0.512 g, 78.2%).  
1
H NMR (400 MHz, CDCl3) δ 
7.76 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 8.1 Hz, 2H), 4.62 (m, 1H), 4.12 (m, 1H), 3.91 
(m, 3H), 3.54 (m, 3H), 2.42 (m, 4H), 1.70 (m, 14H), and 0.85 (m, 6H); 
13
C NMR (100 
MHz, CDCl3) δ 144.6, 144.5, 132.9, 129.7, 129.67, 127.8, 99.3, 96.1, 94.6, 80.0, 
79.60, 79.55, 76.9, 76.8, 76.5, 76.1, 73.8, 73.2, 73.1, 72.8, 70.3, 62.9, 62.87, 62.4, 
41.0, 40.9, 40.4, 38.8, 31.4, 31.3, 25.9, 25.5, 21.6, 20.1, 19.8, 13.4, 9.97, 9.52, and 
8.6; IR (ATR) 2940, 2876, 1738, 1599, 1464, 1359, 1188, 1176, 1118, 1097, 1075, 
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1022, 1001, 963, 902, 812, 667, and 554 cm
-1
; ESI-TOF-MS m/z calcd for 
C23H36O6SNa
+
: 463.21; found 463.03.    
O N3
OTHP
O OTs
OTHP NaN3
DMF, 100 
o
C, 24 h  
 
96: 2-{1-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-propoxy}-tetrahydro-
pyran 96.  95 (0.450 g, 1.0 mmol) was added to DMF (10 mL) followed by sodium 
azide (0.332 g, 5.1 mmol).  The solution was warmed to 100 °C and stirred for 24 
hours.  Once cooled to room temperature, water (25 mL) was added and the solution 
was extracted with diethyl ether (3 × 50 mL).  The organic phases were collected, 
dried (Na2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in EtOAc-hexanes (1:9) to give 96 (0.269 g, 84.5%).  
1
H NMR (400 
MHz, CDCl3) δ 4.67 (m, 1H), 4.02 (m, 1H), 3.89 (m, 2H), 3.79 (m, 1H), 3.70 (m, 
1H), 3.50 (m, 3H), 3.25 (m, 1H), 1.95 (m, 2H), 1.80 (m, 1H), 1.68 (m, 2H), 1.53 (m, 
8H), and 0.88 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 99.4, 96.1, 80.7, 80.6, 76.9, 
76.4, 76.1, 73.8, 62.9, 62.4, 55.14, 55.12, 41.0, 40.6, 39.5, 31.6, 31.5, 31.1, 31.0, 29.3, 
28.9, 25.9, 25.5, 20.1, 19.8, 14.4, 9.58, and 8.7; IR (ATR) 2941, 2876, 2096, 1462, 
1381, 1351, 1282, 1201, 1115, 1075, 1022, 1002, 903, 869, and 812 cm
-1
; ESI-TOF-
MS m/z calcd for C16H29N3O3Na
+
: 334.21; found 334.10.    
O N3
OH
O N3
OTHP 6 M HCl / H2O / MeOH
r.t., 3 h
 
 
97: 1-[5-(2-Azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-butan-2-ol 97.  96 (0.215 g, 0.7 
mmol) was added to 6 M HCl/H2O/MeOH (5 mL) and the solution was stirred at 
room temperature for 3 hours.  Saturated sodium bicarbonate solution was added until 
no gas evolved and the solution was washed with ethyl acetate (3 × 50 mL).  The 
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organic phases were collected, dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 97 
(0.103 g, 70%).  
1
H NMR (400 MHz, CDCl3) δ 4.07 (m, 1H), 3.70 (m 1H), 3.57 (m, 
1H), 3.40 (m, 1H), 3.23 (m, 1H), 2.81 (s, 1H), 1.93 (m, 2H), 1.58 (m, 7H), and 0.90 
(m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 81.2, 76.9, 70.4, 55.0, 40.9, 39.1, 30.6, 30.1, 
29.1, 14.3, and 9.97; IR (ATR) 3412, 2965, 2936, 2876, 2096, 1462, 1381, 1282, 
1069, and 883 cm
-1
; ESI-TOF-MS m/z calcd for C11H21N3O2H
+
: 228.17; found 
228.09.    
O
O
N3
O
O
OH
N3
O
O O
py, 37 
o
C, 12 h
 
 
98: Acetic acid 1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-propyl ester) 
98.  97 (36.0 mg, 0.2 mmol) was added to pyridine (2 mL) followed by acetic 
anhydride (0.15 mL, 1.6 mmol).  The solution was shaken at 37 °C for 12 hours.  
Ethyl acetate (50 mL) was added and the solution was washed with saturated copper 
sulfate solution (2 × 20 mL) and then saturated ammonium chloride solution (2 × 20 
mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:4) to give 98 (28.4 mg, 66.7%).  
1
H NMR (400 MHz, CDCl3) δ 4.93 (m, 1H), 3.84 (m, 1H), 3.55 (m, 1H), 3.48 (m, 
1H), 3.23 (m, 1H), 2.04 (m, 3H), 1.88 (m, 2H), 1.60 (m, 7H), and 0.92 (m, 6H); 
13
C 
NMR (100 MHz, CDCl3) δ 170.7, 80.8, 76.2, 73.4, 55.1, 40.0, 39.4, 31.3, 29.2, 27.5, 
21.3, 14.4, and 9.4 
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O
O
N3
O
O
OH
N3
Cl
O
py, r.t., 24 h
 
 
99: 2,2-Dimethyl-propionic acid 1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-
ylmethyl]-propyl ester 99.  97 (42.6 mg, 0.2 mmol) was added to pyridine (5 mL) 
followed by trimethylacetyl chloride (230.0 µL, 1.9 mmol).  The solution was stirred 
for 24 hours at room temperature.  Ethyl acetate (50 mL) was added and the solution 
was washed with saturated copper sulfate solution (2 × 20 mL) and then saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:9) 
to give 99 (46.8 mg, 80.6%).  
1
H NMR (400 MHz, CDCl3) δ 4.89 (m, 1H), 3.81 (m, 
1H), 3.54 (m, 1H), 3.48 (m, 1H), 3.22 (m, 1H), 1.93 (m, 2H), 1.60 (m, 7H), 1.18 (s, 
9H), and 0.89 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 178.0, 80.7, 76.3, 73.0, 55.1, 
40.1, 39.4, 38.8, 31.4, 29.2, 27.4, 27.2, 14.4, and 9.2 
O
O
N3
O
O
OH
N3
Cl
O
py, 37 
o
C, 12 h
 
 
100: Pent-4-enoic acid 1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-propyl 
ester 100.  97 (36.0 mg, 0.2 mmol) was added to pyridine (2 mL) followed by 4-
pentenoyl chloride (0.18 mL, 1.6 mmol).  The solution was shaken at 37 °C for 12 
hours.  Ethyl acetate (50 mL) was added and the solution was washed with saturated 
copper sulfate solution (2 × 20 mL) and then saturated ammonium chloride solution 
(2 × 20 mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:9) to give 100 (32.4 mg, 66.1%).  
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1
H NMR (400 MHz, CDCl3) δ 5.81 (m, 1H), 5.00 (m, 2H), 3.83 (m, 1H), 3.54 (m, 
1H), 3.48 (m, 1H), 3.23 (m, 1H), 2.38 (m, 4H), 1.93 (m, 2H), 1.60 (m, 7H), 1.25 (m, 
1H), and 0.90 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 172.6, 136.8, 115.4, 80.8, 
76.1, 73.4, 55.1, 40.1, 39.4, 33.8, 31.3, 29.2, 28.9, 27.5, 14.4, and 9.4 
O N3
O
O
MeO
OO
OH methyl 4-chloro-4-oxobutyrate
py, 37 
o
C, 12 h
N3
 
 
101: Succinic acid 1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-propyl 
ester methyl ester 101.  97 (36.0 mg, 0.2 mmol) was added to pyridine (2 mL) 
followed by methyl 4-chloro-4-oxobutyrate (0.2 mL, 1.6 mmol).  The solution was 
shaken at 37 °C for 12 hours.  Ethyl acetate (50 mL) was added and the solution was 
washed with saturated copper sulfate solution (2 × 20 mL) and then saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:3) 
to give 101 (35.7 mg, 66.1%).  
1
H NMR (400 MHz, CDCl3) δ 4.96 (m, 1H), 3.82 (m, 
1H), 3.68 (s, 3H), 3.54 (m, 1H), 3.47 (m, 1H), 3.23 (m 1H), 2.62 (m, 4H), 1.94 (m, 
2H), 1.60 (m, 7H), and 0.92 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 172.8, 171.8, 
80.8, 80.5, 76.1, 73.9, 67.2, 61.8, 55.1, 51.8, 40.0, 39.8, 39.4, 38.1, 31.3, 31.1, 29.3, 
29.2, 29.1, 28.94, 28.9, 28.6, 27.5, 27.2, 14.4, 13.4, 10.4, and 9.3 
O
O
O
N3
O
OH
N3
benzoyl chloride
py, 37 
o
C, 12 h
 
 
102: Benzoic acid 1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-propyl ester 
102.  97 (36.0 mg, 0.2 mmol) was added to pyridine (2 mL) followed by benzoyl 
chloride (0.18 mL, 1.6 mmol).  The solution was shaken at 37 °C for 12 hours.  Ethyl 
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acetate (50 mL) was added and the solution was washed with saturated copper sulfate 
solution (2 × 20 mL) and then saturated ammonium chloride solution (2 × 20 mL), 
dried (Na2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in EtOAc-hexanes (1:9) to give 102 (21.5 mg, 41.0%).  
1
H NMR (400 
MHz, CDCl3) δ 8.05 (m, 2H), 7.55 (m, 1H), 7.44 (m, 2H), 5.21 (m, 1H), 3.92 (m, 
1H), 3.53 (m, 1H), 3.47 (m, 1H), 3.19 (m, 1H), 1.92 (m, 4H), 1.74 (m, 3H), 1.57 (m, 
2H), and 0.94 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 166.1, 132.7, 130.7, 129.5, 
128.3, 80.8, 76.3, 74.0, 55.1, 40.1, 39.4, 31.4, 29.2, 27.7, 14.4, and 9.4 
O
OH
OHO
OH
OMe
O LiAlH4
THF, reflux, 3 h  
 
113: 2-[5-(2-Hydroxy-propyl)-tetrahydro-furan-2-yl]-propan-1-ol 113.  Methyl nonactate 
45 (1.072 g, 5.0 mmol) was added to THF (50 mL) followed by lithium aluminum 
hydride (0.376 g, 9.9 mmol).  The solution was refluxed for 3 hours.  Once cooled to 
room temperature, water (0.4 mL) was added followed by 3.0 M NaOH/H2O (0.8 
mL) and then water (0.4 mL).  The solution was filtered and evaporated to a residue 
to give 113 (0.933 g, 99%).  
1
H NMR (400 MHz, CDCl3) δ 4.08 (m, 1H), 3.97 (m, 
1H), 3.60 (m, 3H), 3.03 (s, 1H), 1.96 (m, 2H), 1.62 (m, 6H), 1.18 (d, J = 6.2 Hz, 3H), 
and 0.82 (d, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 84.8, 76.9, 67.7, 65.1, 
44.1, 40.9, 30.4, 30.1, 23.8, and 13.6; IR (ATR) 3367, 2964, 2932, 2877, 1461, 1414, 
1374, 1234, 1036, 938, 825, and 753 cm
-1
  
O
OTs
OTsO
OH
OH
pTsCl, DMAP
py, r.t., 12 h  
 
114: Bis-tosylated nonactate diol 114.  113 (0.207 g, 1.1 mmol) was added to pyridine (10 
mL) followed by DMAP (0.134 g, 1.1 mmol) and pTsCl (1.05 g, 5.5 mmol).  The 
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solution was stirred at room temperature overnight.  Ethyl acetate (100 mL) was 
added and the solution was washed with saturated copper sulfate solution (2 × 50 mL) 
and then saturated ammonium chloride solution (2 × 50 mL), dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:1) to give 114 (0.213 g, 39%). 
O
N3
N3O
OTs
OTs
NaN3
DMF, 80 
o
C, 12 h  
 
115: 2-(2-Azido-1-methyl-ethyl)-5-(2-azido-propyl)-tetrahydro-furan 115.  114 (0.213 g, 
0.4 mmol) was added to DMF (2 mL) followed by sodium azide (0.279 g, 4.3 mmol).  
The solution was warmed to 80 °C and stirred for 12 hours.  Once the solution was 
cooled to room temperature, water (20 mL) was added and the solution was washed 
with diethyl ether (3 × 50 mL).  The organic phases were collected, dried (Na2SO4), 
and concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:9) to give 115 (82.3 mg, 80.5%).  Rf = 0.63 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 3.90 (m, 1H), 3.58 (m, 2H), 3.45 (m, 1H), 3.28 
(m, 1H), 1.98 (m, 2H), 1.78 (m, 2H), 1.53 (m, 3H), 1.29 (d, J = 6.5 Hz, 3H), and 0.94 
(d, J = 6.7 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 81.0, 76.0, 55.4, 55.0, 42.0, 39.4, 
31.2, 29.1, 19.2, and 14.4; IR (ATR) 2970, 2937, 2877, 2093, 1461, 1380, 1253, 
1091, 1041, 885, and 649 cm
-1
; ESI-TOF-MS m/z calcd for C10H18N6ONa
+
: 261.14; 
found 261.19.    
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O
N
N
N
N
N
NO
N3
N3 1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
117: 4-tert-butyl-1-(1-15-(1-(4-tert-butyl-1H-1,2,3-triazol-1-yl)propane-2-
yl)tetrahydrofran-2-yl)propan-2-yl)-1H-1,2,3-triazole 117.  115 (10.0 mg, 0.04 
mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by 3,3-dimethyl-1-butyne 
(98%, 52.0 µL, 0.4 mmol).  Ascorbic acid/H2O (1.1 M, 168.0 µL, 0.2 mmol) and 
CuSO4-5H2O/H2O (0.3 M, 140.0 µL, 0.04 mmol) were added and the solution was 
shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was 
added and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
layers were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel (100% EtOAc) to give 117 (4.2 mg, 24.9%). 
O
N3
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
O
N
N
N
N
N
N
 
 
118: 4-(cyclopenylmethyl)-1-(1-15-(1-(1-(4-(cyclopentylmethyl)-1H-1,2,3-triazol-1-
yl)propane-2-yl)tetrahydrofuran-2-yl)propan-2-yl)-1H-1,2,3-triazole 118.  115 (10.0 
mg, 0.04 mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by 3-cyclopentyl-1-
propyne (98%, 55.0 µL, 0.4 mmol).  Ascorbic acid/H2O (1.1 M, 168.0 µL, 0.2 mmol) 
and CuSO4-5H2O/H2O (0.3 M, 140.0 µL, 0.04 mmol) were added and the solution 
was shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) 
was added and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
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layers were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in 100% EtOAc to give 118 (10.7 mg, 
56.0%).  
O
N3
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
O
N
N
N
N
N
N
F
F
F
 
 
119: 4-(4-fluorophenyl)-1-(1-(5-(1-(4-(4-(fluorophenyl)-1H-1,2,3-triazol-1-yl)propane-2-
yl)tetrahydrofuran-2-yl) propane-2-yl)-1H-1,2,3-triazole 119.  115 (10.0 mg, 0.04 
mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by 1-ethynyl-4-fluorobenzene 
(48.0 µL, 0.4 mmol).  Ascorbic acid/H2O (1.1 M, 168.0 µL, 0.2 mmol) and CuSO4-
5H2O/H2O (0.3 M, 140.0 µL, 0.04 mmol) were added and the solution was shaken at 
37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was added and 
the solution was washed with ethyl acetate (3 × 50 mL).  The organic layers were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in 100% EtOAc to give 119 (12.3 mg, 61.2%).  
1
H 
NMR (400 MHz, CDCl3) δ 7.79 (m, 5H), 7.70 (m, 1H), 7.08 (m, 4H), 4.87 (m, 1H), 
4.43 (m, 1H), 4.14 (m, 1H), 3.91 (m,1H), 3.45 (m, 1H), 2.18 (m, 1H), 2.07 (m 2H), 
1.97 (m, 2H), 1.65 (d,  J = 6.8 Hz, 3H), 1.55 (m, 2H), and 0.83 (d, J = 6.9 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 163.8, 161.3, 127.4, 127.3, 127.2, 127.1, 115.91, 
115.87, 115.69, 115.65, 81.5, 76.6, 55.7, 53.4, 43.4, 40.5, 31.3, 29.4, 21.4, and 14.5  
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O
N3
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
O
N
N
N
N
N
N
N
N
N
 
 
120: 2-(1-(1-(5-(1-(4-(pyridine-2-yl)-1H-1,2,3-triazol-1-yl)propan-2-yl)tetrahydrofuran-2-
yl)propan-2-yl)-1H-1,2,3-triazol-4-yl)pyridine 120.  115 (10.0 mg, 0.04 mmol) was 
added to 5:1 EtOH/H2O (1.5 mL) followed by 2-ethynylpyridine (98%, 42.0 µL, 0.4 
mmol).  Ascorbic acid/H2O (1.1 M, 168.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 
M, 140.0 µL, 0.04 mmol) were added and the solution was shaken at 37 °C for 12 
hours.  Saturated sodium bicarbonate solution (20 mL) was added and the solution 
was washed with ethyl acetate (3 × 50 mL).  The organic layers were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in 100% EtOAc to give 120 (11.8 mg, 63.4%).  
1
H NMR (400 MHz, CDCl3) 
δ 8.58 (m, 1H), 8.52 (m, 1H), 8.28 (s, 1H), 8.15 (m, 2H), 7.78 (m, 1H), 7.72 (m, 1H), 
7.23 (m, 1H), 7.16 (m, 1H), 4.92 (m, 1H), 4.47 (m, 1H), 4.22 (m, 1H), 3.88 (m, 1H), 
3.48 (m, 1H), 2.30 (m, 2H), 2.00 (m, 4H), 1.66 (d, J = 6.9 Hz, 3H), 1.53 (m, 2H), and 
0.81 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 149.0, 137.2, 123.0, 122.8, 
122.7, 120.4, 120.3, 120.2, 81.2, 76.3, 55.6, 53.4, 43.2, 40.2, 31.2, 29.3, 21.3, and 
14.3  
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O
N3
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
O
N
N
N
N
N
N
AcHN
NHAc
N
H
O
 
 
121: N-(3-{1-[2-(5-{2-[4-(3-Acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-
tetrahydro-furan-2-yl)-1-methyl-ethyl]-1H-[1,2,3]triazol-4-yl}-phenyl)-acetamide 
121.  115 (10.0 mg, 0.04 mmol) was added to 5:1 EtOH/H2O (1.5 mL) followed by 
N-(3-ethynyl-phenyl)-acetamide (67.0 mg, 0.4 mmol).  Ascorbic acid/H2O (1.1 M, 
168.0 µL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 M, 140.0 µL, 0.04 mmol) were 
added and the solution was shaken at 37 °C for 12 hours.  Saturated sodium 
bicarbonate solution (20 mL) was added and the solution was washed with ethyl 
acetate (3 × 50 mL).  The organic layers were collected, dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
100% EtOAc to give 121 (23.1 mg, 99.1%).  
1
H NMR (400 MHz, CDCl3) δ 8.65 (s, 
1H), 8.43 (s, 1H), 7.94 (s, 1H), 7.85 (s, 1H), 7.77 (s, 1H), 7.61 (m, 3H), 7.47 (m, 2H), 
7.31 (m, 1H), 7.19 (m, 1H), 4.74 (m, 1H), 4.24 (m, 1H), 4.00 (m, 1H), 3.88 (m, 1H), 
3.36 (m, 1H), 2.56 (m, 1H), 2.12 (m, 9H), 1.90 (m, 1H), 1.60 (d, J = 6.8 Hz, 3H), 1.49 
(m, 2H), and 0.75 (d, J = 6.8 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 169.3, 138.8, 
130.8, 129.5, 129.47, 121.4, 121.1, 120.0, 119.6, 117.5, 116.8, 82.0, 56.4, 53.7, 43.1, 
40.4, 31.4, 29.5, 24.5, 24.4, 21.6, and 14.6  
HO
OMe
O
HO
OH
O
5% H2SO4  / MeOH
reflux, 5 h
 
 
123: 4-Hydroxy-cyclohexanecarboxylic acid methyl ester 123.  Cis-4-hydroxycyclohexane-
1-carboxylic acid 122 (5.0 g, 34.7 mmol) was added to 5% H2SO4/MeOH (100 mL) 
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and the solution was stirred at room temperature then refluxed for 5 hours.  Saturated 
sodium bicarbonate solution was added until no more gas evolved and the solution 
was then washed with ethyl acetate (3 × 100 mL).  The organic phases were collected, 
dried (Na2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in EtOAc-hexanes (1:1) to give 123 (4.611 g, 84%).  Rf = 0.19 (EtOAc-
hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 3.80 (m, 1H), 3.60 (s, 3H), 2.32 (m, 
2H), 1.89 (m, 2H), and 1.58 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 175.7, 66.5, 
51.4, 41.0, 31.8, and 23.5; IR (ATR) 3407, 2937, 2867, 1729, 1435, 1237, 1198, 
1169, 1137, 1067, 1033, 964, 911, 893, 839, 821, and 755 cm
-1
; ESI-TOF-MS m/z 
calcd for C8H14O3H
+
: 159.10; found 159.06.    
THPO
OMe
O
HO
OMe
O
DHP, pTsOH-H2O
CH2Cl2, r.t., 12 h
 
 
124: 4-(Tetrahydro-pyran-2-yloxy)-cyclohexanecarboxylic acid methyl ester 124.  123 (1.0 
g, 6.3 mmol) was added to methylene chloride (20 mL) followed by DHP (2.9 mL, 
63.2 mmol) and pTsOH-H2O (12.0 mg, 0.1 mmol).  The solution was stirred at room 
temperature for 12 hours then evaporated to give a residue which was partially 
purified by chromatography on silica gel in EtOAc-hexanes (1:19) to give semi-pure 
124.  The semi-pure product was used in the following reduction reaction.  
1
H NMR 
(400 MHz, CDCl3) δ 4.61 (m, 1H), 3.82 (m, 1H), 3.75 (m, 1H), 3.41 (m, 1H), 2.31 
(septet, J = 5.6, 3.906 Hz, 1H), and 1.66 (m, 15H); 
13
C NMR (100 MHz, CDCl3) δ 
175.7, 96.3, 70.2, 62.4, 51.3, 41.4, 31.1, 30.7, 28.2, 25.4, 24.0, 23.6, and 19.6; IR 
(ATR) 2941, 2868, 1733, 1441, 1341, 1234, 1200, 1160, 1134, 1118, 1076, 1030, 
1020, and 996 cm
-1
; ESI-TOF-MS m/z calcd for C13H22O4Na
+
: 265.14; found 265.01.    
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THPO
OH
THPO
OMe
O
LiAlH4, THF
 r.t., 12 h
 
 
125: [4-(Tetrahydro-pyran-2-yloxy)-cyclohexyl]-methanol 125.  124 was added to THF 
(30 mL) followed by lithium aluminum hydride (0.720 g, 19.0 mmol) at room 
temperature and allowed to stir overnight.  Water (0.8 mL) was added, followed by 
3.0 M NaOH/H2O (1.6 mL), followed by water (0.8 mL) and sodium sulfate.  The 
solution was filtered and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 125 (1.219 g, 90% over 
2 steps).  Rf = 0.23 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.63 (m, 
1H), 3.87 (m, 2H), 3.45 (d, J = 6.0 Hz, 3H), 1.81 (m, 4H), 1.66 (m, 1H), 1.50 (m, 
9H), and 1.35 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 96.6, 70.8, 67.6, 62.7, 39.1, 
31.3, 30.7, 28.2, 25.5, 24.0, 23.7, and 19.9; IR (ATR) 3360, 3103, 2925, 2858, 1442, 
1350, 1200, 1120, 1076, 1019, and 997 cm
-1
; ESI-TOF-MS m/z calcd for 
C12H22O3Na
+
: 237.15; found 237.09.   
THPO
OTs
THPO
OH
pTsCl, py
 r.t., 12 h
 
 
126: Toluene-4-sulfonic acid 4-(tetrahydro-pyran-2-yloxy)-cyclohexylmethyl ester 126.  
125 (1.108, 5.2 mmol) was added to pyridine (20 mL), followed by pTsCl (1.971 g, 
10.4 mmol) and the solution was stirred for 12 hours at room temperature.  Ethyl 
acetate (100 mL) was added and the solution washed with saturated copper sulfate 
solution (2 × 100 mL) and then washed with saturated ammonium chloride solution 
(2 × 100 mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 126 (1.32 g, 69.1%).  
1
H 
NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2H), 7.33 (d, J = 7.9 Hz, 2H), 4.59 
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(m, 1H), 3.85 (m, 2H), 3.84 (d, J = 7.0 Hz, 2H), 3.45 (m, 1H), 2.44 (s, 3H), 1.74 (m, 
5H), and 1.39 (m, 10H); 
13
C NMR (100 MHz, CDCl3) δ 144.6, 133.1, 129.8, 127.8, 
96.8, 74.6, 70.2, 62.8, 36.1, 31.5, 31.3, 30.4, 28.0, 25.5, 23.6, 23.3, 22.9, 21.6, and 
20.0; IR (ATR) 2936, 2861, 1599, 1443, 1359, 1175, 1126, 1098, 1076, 1021, 997, 
and 937 cm
-1
; ESI-TOF-MS m/z calcd for C19H28O5SNa
+
: 391.16; found 391.02.   
THPO
N3
THPO
OTs
NaN3
DMF, 80 
o
C, 5 h  
 
127: 2-(4-Azidomethyl-cyclohexyloxy)-tetrahydro-pyran 127.  126 (1.211 g, 3.3 mmol) was 
added to DMF (15 mL) followed by sodium azide (1.07 g, 16.4 mmol).  The solution 
was warmed to 80 °C and stirred for 5 hours.  Once the solution had cooled to room 
temperature, water (50 mL) was added and the solution washed with diethyl ether (3 
× 50 mL).  The organic layers were collected, dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:9) 
to give 127 (0.646 g, 82.2%).  
1
H NMR (400 MHz, CDCl3) δ 4.629 (m, 1H), 3.875 
(m, 2H), 3.46 (m, 1H), 3.14 (d, J = 6.8 Hz, 2H), 1.82 (m, 3H), and 1.50 (m, 12H); 
13
C 
NMR (100 MHz, CDCl3) δ 96.7, 70.2, 62.7, 57.1, 36.9, 31.3, 30.7, 28.2, 25.5, 25.0, 
24.7, and 19.9; IR (ATR) 2929, 2860, 2094, 1443, 1348, 1275, 1200, 1121, 1076, 
1092, 1021, and 997 cm
-1
; ESI-TOF-MS m/z calcd for C12H21N3O2Na
+
: 262.15; 
found 262.09.  
HO
N3
THPO
N3
6 M HCl / H2O / MeOH
r.t., 3 h
 
 
128: 4-Azidomethyl-cyclohexanol 128.  127 (0.543 g, 2.3 mmol) was added to 6 M 
HCl/H2O/MeOH (10 mL) and the solution was stirred at room temperature for 3 
hours.  Saturated sodium bicarbonate solution was added to the solution until no gas 
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evolved.  The solution was washed with ethyl acetate (3 × 50 mL) and the organic 
phases collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 128 (0.318 g, 90.3%).  
1
H NMR (400 MHz, CDCl3) δ 3.98 (m, 1H), 3.15 (d, J = 6.6 Hz, 2H), 1.71 (m, 3H), 
and 1.51 (m, 7H); 
13
C NMR (100 MHz, CDCl3) δ 66.1, 57.0, 36.7, 31.7, and 24.2; IR 
(ATR) 3332, 2928, 2860, 2092, 1446, 1359, 1260, 1126, 1068, 1034, and 975 cm
-1
  
O
N3
HO
N3
methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
O
MeO
O  
 
129: Succinic acid 4-azidomethyl-cyclohexyl ester methyl ester 129.  128 (0.208 g, 1.4 
mmol) was added to pyridine (3 mL) followed by methyl 4-chloro-4-oxobutyrate 
(1.65 mL, 13.4 mmol).  The solution was stirred at room temperature for 3 hours.  
Ethyl acetate (50 mL) was added and the solution was washed with saturated copper 
sulfate solution (2 × 20 mL) then with saturated ammonium chloride solution (2 × 20 
mL).  The solution was dried (Na2SO4) and concentrated to a residue which as 
purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 129 (0.199 
g, 55%).  
1
H NMR (400 MHz, CDCl3) δ 5.03 (m, 1H), 3.67 (s, 3H), 3.16 (d, J = 6.4 
Hz, 2H), 2.61 (s, 4H), 1.87 (m, 2H), 1.55 (m, 5H), and 1.28 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 172.7, 171.5, 69.6, 57.2, 51.8, 36.8, 29.5, 29.0, 28.9, and 24.7; IR 
(ATR) 2940, 2860, 2096, 1728, 1438, 1363, 1264, 1159, 1118, 1036, and 983 cm
-1
; 
ESI-TOF-MS m/z calcd for C12H19N3O4H
+
: 270.15; found 270.06.   
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O
N3
HO
N3
benzoyl chloride
py, r.t., 3 h
O
 
 
130: Benzoic acid 4-azidomethyl-cyclohexyl ester 130.  128 (0.208 g, 1.4 mmol) was added 
to pyridine (3 mL) followed by benzoyl chloride (1.55 mL, 13.4 mmol).  The solution 
was stirred at room temperature for 3 hours.  Ethyl acetate (50 mL) was added and the 
solution was washed with saturated copper sulfate solution (2 × 20 mL) and then with 
saturated ammonium chloride solution (2 × 20 mL).  The solution was dried (Na2SO4) 
and concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 130 (0.283 g, 81%).  
1
H NMR (400 MHz, CDCl3) δ 8.05 
(m, 1H), 7.56 (m, 1H), 7.45 (m, 2H), 5.29 (m, 1H), 3.23 (d, J = 6.2 Hz, 2H), 2.05 (m, 
2H), 1.67 (m, 5H), and 1.47 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 165.7, 132.8, 
130.8, 129.4, 128.3, 69.7, 57.3, 37.0, 29.2, and 25.0; IR (ATR) 2938, 2860, 2095, 
1712, 1602, 1584, 1450, 1274, 1108, 1069, 1026, and 710 cm
-1
; ESI-TOF-MS m/z 
calcd for C14H17N3O2H
+
: 260.14; found 260.08.   
O
N
O
N3
OO
MeO
O
MeO
O
N
N
NHAc
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
131: Succinic acid 4-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-ylmethyl]-cyclohexyl ester 
methyl ester 131.  129 (0.199 g, 0.7 mmol) was added to 5:1 EtOH/H2O (10 mL) 
followed by N-(3-ethynyl-phenyl)-acetamide (0.235 g, 1.5 mmol).  Ascorbic 
acid/H2O (1.1 M, 1.5 mL, 1.6 mmol) and CuSO4-5H2O/H2O (0.3 M, 1.2 mL, 0.4 
mmol) were added and the solution was shaken at 37 °C for 12 hours.  Saturated 
sodium bicarbonate (50 mL) was added and the solution extracted with ethyl acetate 
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(3 × 50 mL).  The organic phases were collected, dried (Na2SO4), and concentrated to 
a residue which was purified by chromatography on silica gel in 100% EtOAc to give 
131 (0.217 g, 69%).  Rf = 0.37 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.00 (s, 
2H), 7.71 (s, 1H), 7.56 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 7.5 Hz, 1H), 7.30 (t, J = 7.9 
Hz, 1H), 5.02 (s, 1H), 4.22 (d, J = 7.3 Hz, 2H), 3.68 (s, 3H), 2.63 (s, 4H), 2.16 (s, 
3H), 1.98 (m, 1H), 1.87 (m, 2H), 1.48 (m, 4H), and 1.34 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 172.8, 171.5, 168.8, 147.2, 138.7, 131.2, 129.5, 121.3, 120.3, 119.4, 
116.9, 69.3, 55.8, 51.8, 37.5, 29.4, 28.9, 28.8, 24.6, and 24.5; IR (ATR) 3351, 2949, 
2865, 2633, 2539, 2431, 2362, 2265, 2098, 1736, 1713, 1687, 1641, 1615, 1566, 
1532, 1480, 1450, 1374, 1351, 1304, 1282, 1247, 1220, 1172, 1049, 1007, and 991 
cm
-1
; ESI-TOF-MS m/z calcd for C22H28N4O5H
+
: 429.21; found 429.04.   
O
N
O
N3 OO N
N
N
2-ethynylpyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
132: Benzoic acid 4-(4-pyridin-2-yl-[1,2,3]triazol-1-ylmethyl)-cyclohexyl ester 132.  130 
(0.283 g, 1.1 mmol) was added to 5:1 EtOH/H2O (10 mL) followed by 2-ethynyl-
pyridine (0.225 µL, 2.2 mmol).  Ascorbic acid/H2O (1.1 M, 2.2 mL, 2.4 mmol) and 
CuSO4-H2O/H2O (0.3 M, 1.8 mL, 0.6 mmol) were added.  The solution was shaken at 
37 °C for 12 hours.  Saturated sodium bicarbonate (50 mL) was added and the 
solution extracted with ethyl acetate (3 × 50 mL).  The organic phases were collected, 
dried (N2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in 100% EtOAc to give 132 (0.244 g, 62%).  Rf = 0.51 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.55 (m, 1H), 8.17 (d, J = 7.9 Hz, 2H), 8.14 (s, 1H), 
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8.00 (d, J = 8.2 Hz, 2H), 7.75 (t, J = 7.8 Hz, 1H), 7.52 (t, J = 7.5 Hz, 1H), 7.40 (t, J = 
7.3, 2H), 7.20 (t, J = 6.2 Hz, 1H), 5.26 (s, 1H), 7.20 (d, 2H), 2.05 (m, 3H), and 1.55 
(m, 6H); 
13
C NMR (100 MHz, CDCl3) δ ; IR (ATR) 2929, 2860, 2633, 2538, 2444, 
2266, 2098, 1721, 1607, 1599, 1471, 1449, 1427, 1368, 1278, 1266, 1119, 1046, 793, 
and 710 cm
-1
; ESI-TOF-MS m/z calcd for C21H22N4O2H
+
: 363.18; found 363.04.   
HO
OH
O
HO
OMe
O
5% H2SO4 / MeOH
reflux, 5 h  
 
134: 4-Hydroxy-cyclohexanecarboxylic acid methyl ester 134.  Trans-4-hydroxy-
cyclohexane-1-carboxylic acid 133 (5.0 g, 34.7 mmol) was added to 5% 
H2SO4/MeOH (100 mL) and the solution was stirred and refluxed for 5 hours.  
Saturated sodium bicarbonate solution was added until no gas evolved and the 
solution was extracted with ethyl acetate (3 × 100 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 134 (4.94 g, 90%).  Rf = 
0.14 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 3.61 (s, 3H), 3.53 (pentet, 
J = 6.6, 4.028 Hz, 1H), 2.335 (s, 1H), 2.20 (m, 1H), 1.95 (m, 4H), 1.43 (m, 2H), and 
1.23 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 176.0, 69.5, 51.5, 42.0, 34.3, and 27.0; 
IR (ATR) 3374, 2938, 2861, 1731, 1453, 1405, 1367, 1280, 1238, 1193, 1171, 1064, 
959, 898, and 754 cm
-1
; ESI-TOF-MS m/z calcd for C8H14O3H
+
: 159.10 ; found 
159.03.   
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HO
OMe
O
THPO
OMe
O
DHP, pTsOH-H2O
CH2Cl2, r.t., 5 h
 
 
135: 4-(Tetrahydro-pyran-2-yloxy)-cyclohexanecarboxylic acid methyl ester 135.  134 (1.0 
g, 6.3 mmol) was added to methylene chloride (20 mL) followed by DHP (2.9 mL, 
31.6 mmol) and pTsOH-H2O (12.0 mg, 0.06 mmol).  The solution was stirred at room 
temperature for 5 hours.  The solution was evaporated to a residue which was purified 
by chromatography on silica gel in EtOAc-hexanes (1:9) to give 135 (1.11 g, 73%).  
Rf = 0.57 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.66 (m, 1H), 3.85 
(m, 1H), 3.61 (s, 3H), 3.54 (m, 1H), 3.44 (m, 1H), 2.21 (m, 1H), 1.99 (m, 4H), 1.78 
(m, 1H), 1.65 (m, 1H), 1.40 (m, 7H), and 1.18 (m, 1H); 
13
C NMR (100 MHz, CDCl3) 
δ 175.9, 96.7, 73.8, 62.6, 51.4, 42.2, 32.5, 31.1, 30.7, 27.3, 27.0, 25.3, and 19.8; IR 
(ATR) 2939, 2864, 1734, 1453, 1354, 1309, 1248, 1172, 1134, 1118, 1063, 1022, and 
987 cm
-1
; ESI-TOF-MS m/z calcd for C13H22O4Na
+
: 265.14; found 265.01.   
THPO
OMe
O
THPO
OH
LiAlH4, THF
r.t., 5 h
 
 
136: [4-(Tetrahydro-pyran-2-yloxy)-cyclohexyl]-methanol 136.  135 (1.0 g, 4.1 mmol) was 
added to THF (30 mL) followed by lithium aluminum hydride (0.471 g, 12.4 mmol).  
The solution was stirred at room temperature for 5 hours.  Water (0.5 mL) was added, 
followed by 3.0 M NaOH/H2O (1.0 mL), and then water (0.5 mL) again.  The mixture 
was filtered and evaporated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:1) to give 136 (0.769 g, 86.8%).  Rf = 0.14 (EtOAc-
hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.68 (m, 1H), 3.87 (m, 1H), 3.48 (m, 
2H), 3.37 (d, J = 6.4 Hz, 2H), 2.10 (s, 1H), 2.01 (m, 2H), 1.79 (m, 3H), 1.65 (m, 1H), 
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1.42 (m, 6H), 1.18 (m, 1H), and 0.94 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 96.6, 
75.0, 67.7, 62.6, 39.6, 32.9, 31.1, 27.8, 27.5, 25.4, and 19.8; IR (ATR) 3386, 2930, 
2859, 1737, 1452, 1353, 1261, 1200, 1116, 1076, 1056, 1023, 970, 902, 867, 809, and 
753 cm
-1
; ESI-TOF-MS m/z calcd for C12H22O3Na
+
: 237.15; found 237.10.   
THPO
OH
THPO
OTs
pTsCl, py
r.t., 5 h
 
 
137: Toluene-4-sulfonic acid 4-(tetrahydro-pyran-2-yloxy)-cyclohexylmethyl ester 137.  
136 (0.641 g, 3.0 mmol) was added to pyridine (10 mL) followed by p-
toluenesulfonyl chloride (0.855 g, 4.5 mmol).  The solution was stirred at room 
temperature for five hours.  Ethyl acetate (100 mL) was added and the solution 
washed with saturated copper sulfate solution (2 × 50 mL) and then with saturated 
ammonium chloride solution (2 × 50 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in EtOAc-hexanes (1:1) 
to give 137 (0.764 g, 69.3 %).  
1
H NMR (400 MHz, CDCl3) δ 7.75 (d, J = 8.4 Hz, 
2H), 7.32 (d, J = 7.9 Hz, 2H), 4.66 (m, 1H), 3.86 (m, 1H), 3.79 (d, J = 6.5 Hz, 2H), 
3.47 (m, 2H), 2.42 (s, 3H), 1.99 (m, 2H), 1.75 (m, 3H), 1.61 (m, 1H), 1.49 (m, 4H), 
1.28 (m, 1H), 1.14 (m, 1H), and 0.94 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 144.6, 
132.9, 129.7, 127.7, 96.7, 74.5, 74.3, 62.7, 36.4, 32.5, 31.1, 30.7, 27.3, 27.1, 25.3, 
21.5, and 19.8; IR (ATR) 2938, 2866, 1597, 1452, 1351, 1292, 1189, 1178, 1023, 
950, and 810 cm
-1
; ESI-TOF-MS m/z calcd for C19H28O5SNa
+
: 391.16; found 391.04.   
THPO
OTs
THPO
N3
NaN3
DMF, 80 
o
C, 5 h  
 
138: 2-(4-Azidomethyl-cyclohexyloxy)-tetrahydro-pyran 138.  137 (0.406 g, 1.1 mmol) was 
added to DMF (5 mL) followed by sodium azide (0.292 g, 4.5 mmol).  The solution 
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was warmed to 80 °C and stirred for 5 hours.  After cooling to room temperature, 
water (25 mL) was added and the solution washed with diethyl ether (3 × 50 mL).  
The organic phases were collected, dried (Na2SO4), and concentrated to a residue 
which was purified by chromatography on silica gel in EtOAc-hexanes (1:9) to give 
138 (0.221g, 83.7%).  
1
H NMR (400 MHz, CDCl3) δ 4.69 (m, 1H), 3.88 (m, 1H), 
3.50 (m, 2H), 3.11 (d, J = 6.9 Hz, 2H), 2.03 (m, 2H), 1.80 (m, 3H), 1.68 (m, 1H), 1.51 
(m, 5H), 1.36 (m, 1H), 1.20 (m, 1H), and 1.02 (m, 2H); 
13
C NMR (100 MHz, CDCl3) 
δ 96.7, 74.6, 62.7, 57.3, 37.3, 32.8, 31.1, 31.0, 28.8, 28.5, 25.4, and 19.9; IR (ATR) 
2935, 2860, 2095, 1738, 1453, 1354, 1275, 1200, 1076, 1056, 1030, and 978 cm
-1
; 
ESI-TOF-MS m/z calcd for C12H21N3O2Na
+
: 262.15; found 262.09.   
THPO
N3
HO
N3
6 M HCl / H2O / MeOH
r.t., 5 h  
 
139: 4-Azidomethyl-cyclohexanol 139.  138 (0.162 g, 0.7 mmol) was added to 6 M 
HCl/H2O/MeOH (5 mL) and the solution was stirred for 5 hours at room temperature.  
Saturated sodium bicarbonate solution was added until no gas evolved and the 
solution was washed with ethyl acetate (3 × 50 mL).  The organic phases were 
collected, dried, and concentrated to a residue which was purified by chromatography 
on silica gel in EtOAc-hexanes (1:3) to give 139 (85.8 mg, 81.7%).  
1
H NMR (400 
MHz, CDCl3) δ 3.54 (m, 1H), 3.13 (d, J = 6.6 Hz, 2H), 1.99 (m, 2H), 1.86 (s, 1H), 
1.80 (m, 2H), 1.51 (m, 1H), 1.25 (m, 2H), and 1.03 (m, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ 70.5, 57.2, 37.0, 34.7, and 28.5; IR (ATR) 3332, 2929, 2857, 2360, 2094, 
1454, 1360, 1273, 1200, 1046, and 1014 cm
-1 
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HO
N3
O
N3methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
O
MeO
O  
 
140: Succinic acid 4-azidomethyl-cyclohexyl ester methyl ester 140.  139 (83.5 mg, 0.5 
mmol) was added to pyridine (5 mL) followed by methyl 4-chloro-4-oxybutyrate 
(0.65 mL, 5.4 mmol).  The solution was stirred at room temperature for 3 hours.  
Ethyl acetate (50 mL) was added and the solution was washed with saturated copper 
sulfate solution (2 × 20 mL) and then with saturated ammonium chloride solution (2 
× 20 mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 140 (76.4 mg, 53%).  
1
H NMR (400 MHz, CDCl3) δ 4.66 (septet, J = 6.7, 4.4 Hz, 1H), 3.67 (s, 3H), 3.13 (d, 
J = 6.7 Hz, 2H), 2.58 (m, 4H), 2.00 (m, 2H), 1.83 (m, 2H), 1.53 (m, 1H), 1.34 (m, 
2H), and 1.08 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 171.6, 73.1, 57.0, 51.7, 
36.9, 30.8, 29.4, 28.9, and 28.2; IR (ATR) 2944, 2864, 2097, 1730, 1438, 1355, 1269, 
1159, 1023, and 1001 cm
-1
; ESI-TOF-MS m/z calcd for C12H19N3O4H
+
: 270.15; 
found 270.06.   
HO
N3
O
N3benzoyl chloride
py, r.t., 3 h
O
 
 
141: Benzoic acid 4-azidomethyl-cyclohexyl ester 141.  139 (83.5 mg, 0.5 mmol) was 
added to pyridine (5 mL) followed by benzoyl chloride (0.62 mL, 5.4 mmol).  The 
solution was stirred at room temperature for 3 hours.  Ethyl acetate (50 mL) was 
added and the solution was washed with saturated copper sulfate solution (2 × 20 mL) 
and then with saturated ammonium chloride solution (2 × 20 mL), dried (Na2SO4), 
and concentrated to a residue which was purified by chromatography on silica gel in 
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EtOAc-hexanes (1:3) to give 141 (100.1 mg, 71%).  
1
H NMR (400 MHz, CDCl3) δ 
8.04 (m, 2H), 7.55 (m, 1H), 7.43 (m, 2H), 4.92 (m, 1H), 3.18 (d, J = 6.6 Hz, 2H), 2.16 
(m, 2H), 1.90 (m, 2H), 1.56 (m, 3H), and 1.19 (m, 2H); 
13
C NMR (100 MHz, CDCl3) 
δ 165.9, 132.7, 130.6, 129.5, 128.2, 73.3, 57.0, 37.0, 30.9, and 28.3; IR (ATR) 2939, 
2863, 2095, 1712, 1601, 1584, 1451, 1315, 1271, 1176, 1112, 1070, 1025, and 991 
cm
-1
 
O
N
O
N3
OO N
N
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
MeO
O
MeO
O NHAc
 
 
142: Succinic acid 4-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-ylmethyl]-cyclohexyl ester 
methyl ester 142.  140 (76.4 mg, 0.3 mmol) was added to 5:1 EtOH/H2O (10 mL) 
followed by N-(3-ethynyl-phenyl)-acetamide (90.0 mg, 0.6 mmol).  Ascorbic 
acid/H2O (1.1 M, 0.57 mL, 0.6 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.47 mL, 0.2 
mmol) were added and the solution was shaken at 37 °C for 12 hours.  Saturated 
sodium bicarbonate solution (25 mL) was added and the solution extracted with ethyl 
acetate (3 × 50 mL).  The organic layers were collected, dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
100% EtOAc to give 142 (89.0 mg, 73%).  
1
H NMR (400 MHz, CDCl3) δ 8.33 (s, 
1H), 7.99 (s, 1H), 7.68 (s, 1H), 7.53 (m, 2H), 7.30 (m, 1H), 4.63 (m, 1H), 4.15 (d, J = 
7.2, 2H), 3.65 (s, 2H), 2.58 (m, 4H), 2.14 (s, 3H), 1.95 (m, 2H), 1.87 (m, 1H), 1.66 
(m, 2H), 1.26 (m, 3H), and 1.08 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 
171.7, 168.9, 147.2, 138.8, 131.0, 129.4, 121.2, 120.4, 119.5, 116.9, 77.2, 72.8, 55.5, 
51.7, 37.5, 30.5, 29.3, 28.8, 28.1, and 24.4; IR (ATR) 3527, 3352, 2939, 1728, 1678, 
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1618, 1592, 1568, 1532, 1486, 1439, 1367, 1308, 1274, 1217, 1163, 1023, and 999 
cm
-1
; ESI-TOF-MS m/z calcd for C22H28N4O5H
+
: 429.21; found 429.05.   
O
N
O
N3 OO N
N
N
2-ethynylpyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
143: Benzoic acid 4-(4-pyridin-2-yl-[1,2,3]triazol-1-ylmethyl)-cyclohexyl ester 143.  141 
(100.1 mg, 0.4 mmol) was added to 5:1 EtOH/H2O (10 mL) followed by 2-ethynyl-
pyridine (98+%, 78.0 µL, 0.8 mmol).  Ascorbic acid/H2O (1.1 M, 0.77 mL, 0.9 
mmol) and CuSO4-5H2O/H2O (0.3 M, 0.64 mL, 0.2 mmol) were added and the 
solution was shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (25 
mL) was added and the solution extracted with ethyl acetate (3 × 50 mL).  The 
organic layers were collected, dried (Na2SO4), and concentrated to a residue which 
was purified by chromatography on silica gel in 100% EtOAc to give 143 (111.0 mg, 
79%).  Rf = 0.45 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.57 (d, J = 4.8 Hz, 
1H), 8.18 (d, J = 7.9 Hz, 1H), 8.12 (s, 1H), 8.00 (d, J = 7.2 Hz, 2H), 7.77 (m, 1H), 
7.52 (m, 1H), 7.40 (m, 2H), 7.22 (m, 1H), 4.92 (m, 1H), 4.29 (d, J = 7.2 Hz, 2H), 2.14 
(m, 2H), 2.02 (m, 1H), 1.80 (m, 2H), 1.48 (m, 2H), and 1.25 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 165.9, 150.2, 149.3, 148.2, 136.9, 132.8, 130.5, 129.4, 128.2, 122.8, 
122.3, 120.2, 72.9, 55.7, 37.7, 30.7, and 28.2; IR (ATR) 2946, 2866, 2099, 1705, 
1604, 1452, 1284, and 1121 cm
-1
; ESI-TOF-MS m/z calcd for C21H22N4O2H
+
: 
363.18; found 363.04.   
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HO
OH
HO
OH
O
LiAlH4
THF, r.t., 12 h
 
 
144: 4-Hydroxymethyl-cyclohexanol 144.  Trans-4-hydroxy-cyclohexane-1-carboxylic 
acid 133 (4.01 g, 27.8 mmol) was added to THF (140 mL) followed by lithium 
aluminum hydride (3.163 g, 83.4 mmol).  The solution was stirred for 12 hours at 
room temperature.  Water (3.2 mL) was added, followed by 3.0 M NaOH/H2O (6.4 
mL), and then water (3.2 mL).  The mixture was filtered and evaporated to a residue 
which was purified by chromatography on silica gel in MeOH-chloroform (1:19) to 
give 144 (0.745 g, 21%).  Rf = 0.30 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 
3.57 (m, 1H), 3.46 (d, J = 6.2 Hz, 2H), 2.02 (m, 2H), 1.83 (m, 2H), 1.62 (s, 1H), 1.45 
(m, 2H), 1.27 (m, 2H), and 1.02 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 71.0, 68.0, 
39.5, 35.0, and 27.5; IR (ATR) 3271, 2940, 2922, 2862, 1460, 1363, 1297, 1258, 
1048, 1055, and 976 cm
-1
 
HO
OTBDMS
HO
OH TBDMSCl, imidazole
DMF, 0 
o
C to r.t., 12 h  
 
145: 4-(tert-Butyl-dimethyl-silanyloxymethyl)-cyclohexanol 145.  144 (0.50 g, 3.9 mmol) 
was added to DMF (7 mL) at 0 °C followed by imidazole (0.288 g, 4.2 mmol).  
TBSCl (0.579 g, 3.9 mmol) was added and the solution was stirred and slowly 
allowed to return to room temperature for 12 hours.  Water (25 mL) was added and 
the solution extracted with diethyl ether (3 × 100 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 145 (0.534 g, 57%).  IR 
(ATR) 3346, 2928, 2898, 2856, 1471, 1453, 1388, 1360, 1255, 1111, 1077, 833, and 
773 cm
-1
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TsO
OTBDMS
HO
OTBDMS pTsCl, py
r.t., 12 h  
 
146: Toluene-4-sulfonic acid 4-(tert-butyl-dimethyl-silanyloxymethyl)-cyclohexyl ester 
146.  145 (1.05 g, 4.3 mmol) was added to pyridine (4 mL) followed by pTsCl (1.64 
g, 8.6 mmol) and the solution was stirred for 12 hours at room temperature.  Ethyl 
acetate (100 mL) was added and the solution washed with saturated copper sulfate 
solution (2 × 50 mL) and then with saturated ammonium chloride solution (2 × 50 
mL), dried (Na2SO4), and concentrated to a residue which was partially purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 146.  The semi-pure 
product was used directly in the following reaction.  ESI-TOF-MS m/z calcd for 
C20H34O4SSiNa
+
: 421.18; found 420.99.   
N3
OTBDMS
TsO
OTBDMS NaN3
DMF, 80 
o
C, 12 h  
 
147: (4-Azido-cyclohexylmethoxy)-tert-butyl-dimethyl-silane 147.  146 (1.72 g, 4.3 mmol) 
was added to DMF (13 mL) followed by (1.4 g, 21.5 mmol) sodium azide.  The 
solution was stirred at 80 °C for 12 hours.  Water (50 mL) was added and the solution 
was extracted with diethyl ether (3 × 100 mL).  The organic phases were collected, 
dried (Na2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in EtOAc-hexanes (1:9) to give 147 (0.631 g, 54.4% over 2 steps).  Rf = 
0.57 (EtOAc-hexanes (1:19)); IR (ATR) 2928, 2891, 2856, 2099, 1471, 1447, 1253, 
1107, 1090, 1068, 835, and 774  cm
-1
.   
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N3
OH
N3
OTBDMS pTsOH-H2O
Acetic acid, H2O, r.t., 24 h  
 
148: (4-Azido-cyclohexyl)-methanol 148.  147 (0.586 g, 2.2 mmol) was added to water (1 
mL) followed by acetic acid (9.8 mL) and pTsOH-H2O (62.0 mg, 0.3 mmol).  The 
solution was stirred at room temperature for 24 hours.  Saturated sodium bicarbonate 
solution was added until no gas evolved.  The solution was extracted with ethyl 
acetate (3 × 50 mL).  The organic phases were collected, dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 148 (145 mg, 42.9%).  IR (ATR) 2932, 2860, 2097, 
1738, 1448, 1365, 1233, and 1029 cm
-1
 
N3
O
N3
OH methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
O
O
OMe
 
 
149: Succinic acid 4-azido-cyclohexylmethyl ester methyl ester 149.  148 (57.0 mg, 0.4 
mmol) was added to pyridine (5 mL) followed by methyl 4-chloro-4-oxobutyrate (0.5 
mL, 3.7 mmol).  The solution was stirred at room temperature for 3 hours.  Ethyl 
acetate (50 mL) was added and the solution was washed with saturated copper sulfate 
solution (2 × 20 mL) and then with saturated ammonium chloride solution (2 × 20 
mL).  The solution was dried (Na2SO4) and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 149 (77.5 
mg, 78.4 %). 
N3
O
N3
OH benzoyl chloride
py, r.t., 3 h
O
 
 
150: Benzoic acid 4-azido-cyclohexylmethyl ester 150.  148 (57.0 mg, 0.4 mmol) was 
added to pyridine (5 mL) followed by benzoyl chloride (0.4 mL, 3.7 mmol).  The 
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solution was stirred at room temperature for 3 hours.  Ethyl acetate (50 mL) was 
added and the solution was washed with saturated copper sulfate solution (2 × 20 mL) 
and then with saturated ammonium chloride solution (2 × 20 mL), dried (Na2SO4), 
and concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 150 (79.2 mg, 83.2 %).  IR (ATR) 3062, 2931, 2858, 
2100, 1784, 1725, 1599, 1451, 1209, 1172, 1036, 1013, 993, and 700 cm
-1
 
N
O
N3
O
O
O
OMe
O
OMe
ON
N
AcHN
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
151: Succinic acid 4-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-cyclohexylmethyl ester 
methyl ester 151.  149 (77.5 mg, 0.3 mmol) was added 5:1 EtOH/H2O (7 mL) 
followed by N-(3-ethynyl-phenyl)-acetamide (92.0 mg, 0.6 mmol).  Ascorbic 
acid/H2O (1.1 M, 0.58 mL, 0.6 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.48 mL, 0.2 
mmol) were added and the solution was shaken at 37 °C for 12 hours.  Saturated 
sodium bicarbonate (20 mL) was added and the solution washed with ethyl acetate (3 
× 50 mL).  The organic phases were collected, dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in 100% EtOAc to give 
151 (99.5 mg, 80.7%).  Rf = 0.37 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.25 
(s, 1H), 7.95 (s, 1H), 7.77 (s, 1H), 7.55 (d, J = 7.8 Hz, 2H), 7.30 (t, J = 7.9 Hz, 1H), 
4.52 (pentet, J = 3.8, 3.7 Hz, 1H), 4.035 (d, J = 7.3 Hz, 2H), 3.66 (s, 3H), 2.62 (s, 
4H), 2.16 (m, 2H), 2.14 (s, 3H), 1.97 (m, 3H), 1.68 (m, 2H), and 1.58 (m, 2H) ; 
13
C 
NMR (100 MHz, CDCl3) δ 172.74, 172.2, 168.9, 146.9, 138.7, 131.2, 129.4, 121.2, 
119.4, 118.5, 116.8, 77.2, 66.7, 57.7, 51.8, 33.3, 29.0, 28.8, 28.7, 24.7, and 24.4; IR 
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(ATR) 3301, 2949, 2861, 1729, 1690, 1678, 1618, 1592, 1567, 1532, 1482, 1440, 
1367, 1160, 998, 791, and 751 cm
-1
; ESI-TOF-MS m/z calcd for C22H28N4O5H
+
: 
429.21; found 428.99.  
N
O
N3
O
O
O
N
N
N
2-ethynyl-pryridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
152: Benzoic acid 4-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-cyclohexylmethyl ester 152.  150 
(79.2 mg, 0.3 mmol) was added to 5:1 EtOH/H2O (7 mL) followed by 2-ethynyl-
pyridine (98+%, 63.0 µL, 0.6 mmol).  Ascorbic acid/H2O (1.1 M, 0.61 mL, 0.7 
mmol) and CuSO4-5H2O/H2O (0.3 M, 0.50 mL, 0.2 mmol) were added and the 
solution was shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate (20 mL) 
was added and the solution washed with ethyl acetate (3 × 50 mL).  The organic 
phases were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in 100% EtOAc to give 152 (88.2 mg, 
79.7%).  Rf = 0.53 (100% EtOAc); 
1
H NMR (400 MHz, CDCl3) δ 8.58 (m, 1H), 8.33 
(s, 1H), 8.23 (d, J = 7.9 Hz, 1H), 8.03 (m, 2H), 7.82 (m, 1H), 7.55 (m, 1H), 7.42 (m, 
2H), and 7.26 (m, 1H), 4.67 (pentet, J = 3.8, 3.296 Hz, 1H), 4.29 (d, J = 7.2 Hz, 2H), 
2.37 (m, 2H), 2.12 (m, 3H), 1.83 (m, 2H), and 1.72 (m, 2H); 
13
C NMR (100 MHz, 
CDCl3) δ 166.4, 132.9, 130.1, 129.5, 128.4, 122.8, 120.3, 67.1, 57.7, 33.8, 28.8, and 
24.8; IR (ATR) 2952, 2855, 1716, 1599, 1449, 1426, 1272, 1116, 786, and 706 cm
-1
; 
ESI-TOF-MS m/z calcd for C21H22N4O2H
+
: 363.18; found 362.99.   
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HO
OH
HO
OH
O
LiAlH4, THF, 0 
o
C
0 
o
C to r.t., 12 h  
 
153: 4-Hydroxymethyl-cyclohexanol 153.  Cis-4-hydroxy-cyclohexane-1-carboxylic acid 
122 (4.01 g, 27.8 mmol) was added to THF (140 mL) at 0 °C followed by lithium 
aluminum hydride (3.17 g, 83.5 mmol).  The solution was stirred overnight and 
allowed to warm to room temperature.  Water (3.2 mL) was added, followed by 3.0 
M NaOH/H2O (6.4 mL), and then water (3.2 mL).  The solution was filtered and 
evaporated to a residue which was purified by chromatography on silica gel in 
MeOH-chloroform (1:19) to give 153 (2.76 g, 76%).  Rf = 0.32 (100% EtOAc); IR 
(ATR) 3315, 2924, 2859, 1442, 1372, 1255, 1126, 1022, 976, and 931 cm
-1
 
HO
OTBDMS
HO
OH TBDMSCl, imidazole
DMF, 0 
o
C to r.t., 12 h  
 
154: 4-(tert-Butyl-dimethyl-silanyloxymethyl)-cyclohexanol 154.  153 (0.50 g, 3.9 mmol) 
was added to DMF (7 mL) at 0 °C followed by imidazole (0.288 g, 4.2 mmol) and 
TBSCl (0.58g, 3.9 mmol).  The solution was allowed to slowly warm to room 
temperature while stirring overnight.  Water (50 mL) was added and the solution was 
extracted with diethyl ether (3 × 100 mL).  The organic phases were collected, dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:3) to give 154 (485 mg, 52%).  
1
H NMR (400 MHz, 
CDCl3) δ 3.98 (s, 1H), 3.43 (d, J = 6.1 Hz, 2H), 1.69 (m, 2H), 1.52 (m, 6H), 1.35 (m, 
2H), 0.88 (s, 10H), and 0.03 (s, 5H); 
13
C NMR (100 MHz, CDCl3) δ 67.7, 67.0, 39.1, 
32.0, 25.9, 23.4, 18.4, and 5.4; IR (ATR) 3333, 2927, 2886, 2855, 1471, 1253, 1108, 
1078, 1032, 979, 940, 896,, 833, and 771 cm
-1
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TsO
OTBDMS
HO
OTBDMS pTsCl
py, r.t., 5 h  
 
155: Toluene-4-sulfonic acid 4-(tert-butyl-dimethyl-silanyloxymethyl)-cyclohexyl ester 
155.  154 (1.9 g, 7.8 mmol) was added to pyridine (7 mL) followed by pTsCl (2.964 
g, 15.6 mmol).  The solution was stirred for 5 hours at room temperature.  Ethyl 
acetate (100 mL) was added and the solution was washed with saturated copper 
sulfate solution (2 X 50 mL) and then with saturated ammonium chloride solution (2 
X 50 mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 155 (2.84 g, 91.6%).  Rf 
= 0.72 (EtOAc-hexanes (1:3)); IR (ATR) 2929, 2885, 2859, 1598, 1470, 1348, 1247, 
1187, 1170, 1129, 1092, 904, 831, 815, 775, and 676 cm
-1
 
N3
OTBDMS
TsO
OTBDMS NaN3
DMF, 80 
o
C, 5 h  
 
156: (4-Azido-cyclohexylmethoxy)-tert-butyl-dimethyl-silane 156.  155 (2.733 g, 6.9 mmol) 
in DMF (20 mL) followed by sodium azide (2.23 g, 34.3 mmol).  The solution was 
warmed to 80 °C and stirred for 5 hours.  Once cool, water (50 mL) was added to the 
solution which was then washed with diethyl ether (3 × 100 mL).  The organic phases 
were collected, dried (Na2SO4), and concentrated to a residue which was then purified 
by chromatography on silica gel in EtOAc-hexanes (1:9) to give 156 (1.192 g, 
64.5%).  Rf = 0.57 (EtOAc-hexanes (1:19)); 
1
H NMR (400 MHz, CDCl3) δ 3.40 (d, J 
= 6.2 Hz, 2H), 3.20 (m, 1H), 2.02 (m, 2H), 1.84 (m, 2H), 1.43 (m, 1H), 1.32 (m, 2H), 
1.00 (m, 2H), 0.88 (s, 10H), and 0.03 (s, 5H); 
13
C NMR (100 MHz, CDCl3) δ 67.8, 
60.4, 39.3, 31.2, 27.8, 25.9, 18.3, and -5.42; IR (ATR) 2930, 2857, 2090, 1471, 1389, 
1360, 1253, 1109, 1074, 1024, 834, and 774 cm
-1
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N3
OH
N3
OTBDMS 6 M HCl / H2O / MeOH
r.t., 5 h  
 
157: (4-Azido-cyclohexyl)-methanol 157.  156 (1.109 g, 4.1 mmol) was added to THF (2 
mL) followed by 6 M HCl/H2O/MeOH (10 mL).  The solution was stirred at room 
temperature for five hours.  Saturated sodium bicarbonate solution was added until no 
gas evolved and the solution was washed with ethyl acetate (3 × 50 mL).  The organic 
phases were collected, dried (Na2SO4), and concentrated to a residue which was 
purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 157 (0.442 
g, 69.2%).  
1
H NMR (400 MHz, CDCl3) δ 3.88 (d, J = 6.5 Hz, 2H), 3.23 (m, 1H), 
2.04 (s, 1H), 2.03 (m, 2H), 1.85 (m, 2H), 1.62 (m, 1H), 1.33 (m, 2H), and 1.06 (m, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 171.1, 68.6, 59.9, 35.9, 30.9, 27.8, and 20.9; IR 
(ATR) 2936, 2860, 2089, 1739, 1453, 1365, 1237, 1038, and 989 cm
-1
  
N3
O
N3
OH methyl 4-chloro-4-oxobutyrate
py, r.t., 3 h
O
OMe
O
 
 
158: Succinic acid 4-azido-cyclohexylmethyl ester methyl ester 158.  157 (26.0 mg, 0.2 
mmol) was added to pyridine (5 mL) followed by methyl 4-chloro-4-oxobutyrate (0.2 
mL, 1.7 mmol).  The solution was stirred at room temperature for 3 hours.  Ethyl 
acetate (50 mL) was added and the solution was washed with saturated copper sulfate 
solution (2 × 20 mL) and then with saturated ammonium chloride solution (2 × 20 
mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 158 (27.5 mg, 61%).  
1
H NMR (400 MHz, CDCl3) δ 3.90 (d, J = 6.5 Hz, 2H), 3.67 (s, 3H), 3.22 (pentet, J = 
7.5, 4.150 Hz, 1H), 2.61 (s, 4H), 2.02 (m, 2H), 1.83 (m, 2H), 1.61 (m, 1H), 1.32 (m, 
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2H), and 1.05 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.6, 172.1, 68.8, 59.8, 51.8, 
35.9, 30.9, 29.0, 28.8, and 27.7; IR (ATR) 2935, 2860, 2091, 1732, 1438, 1361, 1158, 
and 993 cm
-1
; ESI-TOF-MS m/z calcd for C12H19N3O4H
+
: 270.15; found 270.04.   
N3
O
N3
OH benzoyl chloride
py, r.t., 3 h
O
 
 
159: Benzoic acid 4-azido-cyclohexylmethyl ester 159.  157 (26.0 mg, 0.2 mmol) was 
added to pyridine (5 mL) followed by benzoyl chloride (0.2 mL, 1.7 mmol).  The 
solution was stirred at room temperature for 3 hours.  Ethyl acetate (50 mL) was 
added and the solution was washed with saturated copper sulfate solution (2 × 20 mL) 
and then with saturated ammonium chloride solution (2 × 20 mL), dried (Na2SO4), 
and concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 159 (31.5 mg, 72.6%).  
1
H NMR (400 MHz, CDCl3) δ 
8.04 (m, 2H), 7.56 (m, 1H), 7.44 (m, 2H), 4.15 (d, J = 6.5 Hz, 2H), 3.27 (pentet, J = 
7.4, 4.150 Hz, 1H), 2.07 (m, 2H), 1.96 (m, 2H), 1.79 (m, 1H), 1.38 (m, 2H), and 1.17 
(m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 166.4, 132.9, 130.1, 129.5, 128.3, 68.9, 59.9, 
36.1, 31.0, and 27.9; IR (ATR) 2936, 2860, 2089, 1713, 1452, 1315, 1267, 1175, 
1120, 1070, 1025, 984, and 956 cm
-1
 
N
O
N3
O
O
O
OMe
O
OMe
ON
N
AcHN
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
160: Succinic acid 4-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-cyclohexylmethyl ester 
methyl ester 160.  158 (27.5 mg, 0.1 mmol) was added to 5:1 EtOH/H2O (3 mL) 
followed by N-(3-ethynyl-phenyl)-acetamide (33.0 mg, 0.2 mmol).  Ascorbic 
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acid/H2O (1.1 M, 0.2 mL, 0.2 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.2 mL, 0.05 
mmol) were added and the solution was shaken at 37 °C for 12 hours.  Saturated 
sodium bicarbonate solution (20 mL) was added and washed with ethyl acetate (3 × 
50 mL).  The organic phases were collected, dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gel in 100% EtOAc to give 
160 (34.8 mg, 79.6%).  
1
H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 8.01 (s, 1H), 7.70 
(s, 1H), 7.51 (m, 2H), 7.26 (m, 1H), 4.34 (m, 1H), 3.92 (d, J = 6.4 Hz, 2H), 3.65 (s, 
3H), 2.62 (s, 4H), 2.18 (m, 2H), 2.10 (s, 3H), 1.89 (m, 2H), 1.70 (m, 3H), and 1.16 
(m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 172.1, 169.1, 146.8, 138.8, 131.1, 
129.2, 121.0, 119.4, 117.8, 116.8, 68.6, 59.7, 51.7, 35.8, 32.3, 28.9, 28.7, 27.9, and 
24.3; IR (ATR) 3283, 2941, 1731, 1671, 1617, 1592, 1568, 1533, 1403, 1439, 1370, 
1160, and 996 cm
-1
; ESI-TOF-MS m/z calcd for C22H28N4O5H
+
: 429.21; found 
428.97.   
N
O
N3
O
O
O
N
N
N
2-ethynyl-pryridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
161: Benzoic acid 4-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-cyclohexylmethyl ester 161.  159 
(31.5 mg, 0.1 mmol) was added to 5:1 EtOH/H2O (3 mL) followed by 2-ethynyl-
pyridine, 98% (25.0 µL, 0.3 mmol).  Ascorbic acid/H2O (1.1 M, 0.25 mL, 0.3 mmol) 
and CuSO4-5H2O/H2O (0.3 M, 0.2 mL, 0.06 mmol) were added and the solution was 
shaken at 37 °C for 12 hours.  Saturated sodium bicarbonate solution (20 mL) was 
added and washed with ethyl acetate (3 × 50 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
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chromatography on silica gel in 100% EtOAc to give 161 (32.8 mg, 74.5%).  
1
H 
NMR (400 MHz, CDCl3) δ 8.54 (m, 1H), 8.16 (s, 1H), 8.15 (m, 1H), 8.03 (m, 2H), 
7.73 (m, 1H), 7.54 (t, J = 7.5 Hz, 1H), 7.42 (m, 2H), 7.18 (m, 1H), 4.51 (m, 1H), 4.19 
(d, J = 6.5 Hz, 2H), 2.33 (m, 2H), 2.06 (m, 2H), 1.88 (m, 3H), and 1.35 (m, 2H); 
13
C 
NMR (100 MHz, CDCl3) δ 166.3, 150.3, 149.2, 147.8, 136.8, 132.9, 130.0, 129.4, 
128.3, 122.7, 120.0, 119.6, 68.7, 59.8, 36.1, 32.1, and 28.2; IR (ATR) 3145, 2941, 
2855, 2094, 1718, 1603, 1451, 1438, 1417, 1275, 1176, 1118, 1045, 789, and 702 cm
-
1
; ESI-TOF-MS m/z calcd for C21H22N4O2H
+
: 363.18; found 363.01.   
TsO
OMe
O
HO
OMe
O
pTsCl
py, r.t., 5 h
 
 
162: 4-(Toluene-4-sulfonyloxy)-cyclohexanecarboxylic acid methyl ester 162.  134 (0.50 g, 
3.2 mmol) was added to pyridine (5 mL) followed by pTsCl (0.663 g, 3.5 mmol) was 
added and the solution stirred for 5 hours at room temperature.  Ethyl acetate (100 
mL) was added and the solution washed with saturated copper sulfate solution (3 × 50 
mL) and then with saturated ammonium chloride solution (3 × 50 mL), dried 
(Na2SO4), and concentrated to a residue which was purified by chromatography on 
silica gel in EtOAc-hexanes (1:3) to give 162 (0.772 g, 78.2%).  
1
H NMR (400 MHz, 
CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.30 (d, J = 7.9 Hz, 2H), 4.37 (m, 1H), 3.60 (s, 
3H), 2.40 (s, 3H), 2.23 (m, 1H), 1.94 (m, 4H), and 1.46 (m, 4H); 
13
C NMR (100 
MHz, CDCl3) δ 174.9, 144.5, 134.2, 129.7, 127.4, 80.2, 51.6, 40.9, 30.9, 26.2, and 
21.5; IR (ATR) 3001, 2951, 2905, 2866, 2836, 1729, 1597, 1451, 1431, 1365, 1312, 
1192, 1174, 1043, and 952 cm
-1
; ESI-TOF-MS m/z calcd for C15H20O5SH
+
: 313.11; 
found 312.93.   
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N3
OMe
O
TsO
OMe
O
NaN3
DMF, 80 
o
C, 5 h  
 
163: 4-Azido-cyclohexanecarboxylic acid methyl ester 163.  162 (1.193 g, 3.8 mmol) was 
added to DMF (10 mL) followed by sodium azide (1.241 g, 19.1 mmol).  The 
solution was warmed to 80 °C and stirred for 5 hours.  Water (50 mL) was added to 
the solution once it was cooled to room temperature and the solution was washed with 
diethyl ether (3 × 100 mL).  The organic phases were collected, dried (Na2SO4), and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:9) to give 163 (0.624 g, 89.1%).  
1
H NMR (400 MHz, CDCl3) δ 
3.63 (m, 1H), 3.62 (s, 3H), 2.34 (m, 1H), 1.83 (m, 2H), and 1.64 (m, 6H); 
13
C NMR 
(100 MHz, CDCl3) δ 175.0, 57.3, 51.4, 40.8, 28.6, and 23.9; IR (ATR) 2950, 2868, 
2095, 1730, 1435, 1341, 1253, 1230, 1198, 1168, 1141, 1032, and 905 cm
-1
 
N3
OH
O
N3
OMe
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
164: 4-Azido-cyclohexanecarboxylic acid 164.  163 (0.524 g, 2.9 mmol) was added to 2.5 
M LiOH/H2O/MeOH/THF (1:2:3) (10 mL) and the solution was stirred at room 
temperature overnight.  1.0 M HCl/H2O was added until the solution had a pH of 2.  
The solution was washed with ethyl acetate (5 × 100 mL) and the organic phases 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 164 (0.443 g, 91.5%).  
Rf = 0.49 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 12.03 (s, 1H), 3.69 
(m, 1H), 2.44 (m, 1H), 1.91 (m, 2H), and 1.73 (m, 6H); 
13
C NMR (100 MHz, CDCl3) 
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δ 181.6, 57.4, 40.7, 28.6, and 23.8; IR (ATR) 3024, 2934, 2098, 1788, 1709, 1461, 
1444, 1415, 1369 1312, 1233, 1199, and 1026 cm
-1
 
TsO
OMe
O
HO
OMe
O
pTsCl
py, r.t., 5 h
 
 
165: 4-(Toluene-4-sulfonyloxy)-cyclohexanecarboxylic acid methyl ester 165.  123 (1.0 g, 
6.3 mmol) was added to pyridine (10 mL) followed by pTsCl (1.446 g, 7.6 mmol).  
The solution was stirred at room temperature for 5 hours.  Ethyl acetate (100 mL) was 
added and the solution was washed with saturated copper sulfate solution (2 × 50 mL) 
and then with saturated ammonium chloride solution (2 × 50 mL), dried (Na2SO4), 
and concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) to give 165 (1.330 g, 67.4%).  Rf = 0.31 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.77 (d, J = 8.3 Hz, 2H), 7.32 (d, J = 7.9 Hz, 2H), 4.69 
(m, 1H), 3.65 (s, 3H), 2.43 (s, 3H), 2.31 (m, 1H), 1.85 (m, 4H), 1.69 (m, 2H), and 
1.53 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 175.0, 144.4, 134.5, 129.7, 127.5, 78.3, 
51.6, 40.9, 29.7, 23.2, and 21.6; ESI-TOF-MS m/z calcd for C15H20O5SNa
+
: 335.09; 
found 334.95.  
N3
OMe
O
TsO
OMe
O
NaN3
DMF, 80 
o
C, 5 h  
 
166: 4-Azido-cyclohexanecarboxylic acid methyl ester 166.  165 (1.275 g, 4.1 mmol) was 
added to (20 mL) DMF followed by sodium azide (1.327 g, 20.4 mmol).  The 
solution was warmed to 80 °C and stirred for 5 hours.  After cooling to room 
temperature, water (50 mL) was added and the solution was washed with diethyl ether 
(3 × 100 mL).  The organic phases were collected, dried (Na2SO4), and concentrated 
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to a residue which was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 166 (0.58 g, 77.5%).  
1
H NMR (400 MHz, CDCl3) δ 3.59 (s, 3H), 3.22 
(m, 1H), 2.21 (m, 1H), 1.97 (m, 4H), 1.44 (m, 2H), and 1.28 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 175.1, 58.9, 51.4, 41.5, 30.4, and 26.9; IR (ATR) 2949, 2864, 2092, 
1731, 1453, 1435, 1365, 1305, 1254, 1194, 1171, 1118, 1042, 1021, and 898 cm
-1
 
N3
OH
O
N3
OMe
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
167: 4-Azido-cyclohexanecarboxylic acid 167.  166 (0.520 g, 2.8 mmol) was added to 2.5 
M LiOH/H2O/MeOH/THF (1:2:3) (10 mL) and the solution was stirred for 12 hours 
at room temperature.  1.0 M HCl/H2O was added until the solution had a pH of 2 and 
the solution was washed with ethyl acetate (5 × 100 mL).  The organic phases were 
collected, dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 167 (0.437 g, 91%).  Rf 
= 0.44 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 11.82 (s, 1H), 3.30 (m, 
1H), 2.31 (m, 1H), 2.07 (m, 4H), 1.53 (m, 2H), and 1.37 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 181.7, 59.0, 41.6, 30.5, and 26.8; IR (ATR) 3033, 2935, 2862, 2091, 
1693, 1446, 1427, 1360, 1307, 1250, 1213, 1041, 1021, and 939 cm
-1
 
O
OO
O
O O
N3N3
O
ClCl
O
O
OH
N3
py, r.t., 24 h
 
 
168: Terephthalic acid bis-{1-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-ylmethyl]-
propyl} ester 168.  97 (0.168 g, 0.8 mmol) was added to pyridine (2 mL) followed by 
terephthaloyl chloride (75.2 mg, 0.4 mmol) at room temperature.  The solution was 
stirred for 24 hours.  Ethyl acetate (50 mL) was added and the solution was washed 
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consecutively with saturated copper sulfate solution (2 × 25 mL) then saturated 
ammonium chloride solution (2 × 25 mL).  The organic layer was dried (Na2SO4) and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:9) to give 168 (0.110 g, 50.8%).  Rf = 0.85 (EtOAc-hexanes (1:3)).  
1
H NMR (400 MHz, CDCl3) δ 8.10 (s, 4H), 5.23 (m, 2H), 3.91 (m, 2H), 3.53 (m, 2H), 
3.46 (dd, J = 4.1 Hz, 2H), 3.20 (dd, J = 7.4 Hz, 2H), 1.92 (m, 8H), 1.74 (m, 6H), 1.54 
(m, 4H), and  0.94 (m, 12H); 
13
C NMR (100 MHz, CDCl3) δ 165.4, 134.3, 129.5, 
80.8, 76.2, 74.6, 55.1, 40.1, 39.4, 31.4, 29.2, 27.6, 14.4, and 9.4; IR (ATR) 2967, 
2878, 2095, 1715, 1578, 1504, 1461, 1407, 1382, 1267, 1116, 1100, 1067, 1018, 945, 
876, and 730 cm
-1
; ESI-TOF-MS m/z calcd for C30H44N6O6H
+
: 585.34; found 585.41.    
O
OH
N3
py, r.t., 3 days
O
O O
OO O
N3N3
O
Cl Cl
O
 
 
169: Terephthalic acid bis-{2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-
methyl-ethyl} ester 169.  55 (0.100 g, 0.5 mmol) was added to pyridine (2 mL) 
followed by terephthalolyl chloride (0.048 g, 0.2 mmol) at room temperature.  The 
solution was stirred for 3 days.  Ethyl acetate (50 mL) was added followed by a 
saturated copper sulfate solution (2 × 50 mL).  The organic layer was then extracted 
with saturated ammonium chloride solution (2 × 50 mL) and then dried (Na2SO4) and 
concentrated to a residue which was purified by chromatography on silica gel in 
EtOAc-hexanes (1:9) to give 169 (34.8 mg, 26.7%).  Rf = 0.76 (EtOAc-hexanes 
(1:3)).  IR (ATR) 2966, 2934, 2876, 2096, 1717, 1579, 1504, 1461, 1408, 1380, 1268, 
1116, 1101, 1018, 967, 876, and 731 cm
-1
; ESI-TOF-MS m/z calcd for 
C28H40N6O6H
+
: 557.31; found 557.27.    
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O
O
O
O
O O
N3N3
Cl
O
Cl
O
O
OH
N3
py, r.t., 3 days  
 
170: Isophthalic acid bis-{2-[5-(2-azido-1-methyl-ethyl)-tetrahydro-furan-2-yl]-1-methyl-
ethyl} ester 170.  55 (0.100 g, 0.5 mmol) was added to pyridine (2 mL) followed by 
isophthaloyl chloride (0.048 g, 0.2 mmol) at room temperature.  The solution was 
stirred for 3 days.  Ethyl acetate (50 mL) was added followed by a saturated copper 
sulfate solution (2 × 50 mL).  The organic layer was then extracted with saturated 
ammonium chloride solution (2 × 50 mL) and then dried (Na2SO4), and concentrated 
to a residue which was purified by chromatography on silica gel in EtOAc-hexanes 
(1:9) to give 170 (33.0 mg, 25.3%).  Rf = 0.76 (EtOAc-hexanes (1:3)).  
13
C NMR 
(100 MHz, CDCl3) δ 165.3, 133.6, 131.1, 130.6, 128.5, 80.9, 76.0, 70.3, 55.1, 42.5, 
39.4, 31.4, 29.2, 20.8, and 14.4; IR (ATR) 2970, 2877, 2096, 1720, 1609, 1461, 1365, 
1302, 1285, 1235, 1137, 1092, 1073, 938, and 731 cm
-1
; ESI-TOF-MS m/z calcd for 
C28H40N6O6H
+
: 557.31; found 557.37.    
N
NNNN
N
OO
OHHO
O
OH
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 3 days  
 
171: 1-[5-(2-{4-[4-(1-{2-[5-(2-Hydroxy-butyl)-tetrahydro-furan-2-yl]-propyl}-1H-
[1,2,3]triazol-4-yl)-phenyl]-[1,2,3]triazol-1-yl}-1-methyl-ethyl)-tetrahydro-furan-2-
yl]-butan-2-ol 171.  97 (0.100 g, 0.5 mmol) was added to 5:1 EtOH/H2O (3 mL) 
followed by 1,4-diethylbenzene (0.0264 g, 0.2 mmol).  Ascorbic acid/H2O (1.1 M, 
0.84 mL, 0.9 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.7 mL, 0.2 mmol) was added 
and the mixture was shaken for 3 days at 37 
o
C.  Ethyl acetate (50 mL) was added and 
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the solution extracted with saturated sodium bicarbonate solution (2 × 100 mL).  The 
organic layer was dried (Na2SO4) and concentrated to a residue which was purified by 
chromatography on silica gel in 100% EtOAc to give 171 (0.1034 g, 85%).  Rf = 0.67 
(MeOH-chloroform (1:9)).  
1
H NMR (400 MHz, CDCl3) δ 7.90 (m, 4H), 7.84 (s, 2H), 
4.59 (m, 2H), 4.35 (m, 2H), 4.16 (m, 2H), 3.79 (m, 2H), 3.55 (m, 3H), 2.30 (s, 1H), 
2.06 (m, 7H), 1.62 (m, 11H), and 0.88 (m, 12H); 
13
C NMR (100 MHz, CDCl3) δ 
130.3, 126.0, 120.5, 81.2, 77.1, 70.6, 53.5, 41.3, 40.2, 30.8, 30.4, 29.5, 14.4, and 10.0; 
IR (ATR) 3409, 3130, 2965, 2937, 2877, 2242, 1462, 1416, 1371, 1223, 1070, 1047, 
975, 909, 849, 821, 729, 646 cm
-1
; ESI-TOF-MS m/z calcd for C32H48N6O4H
+
: 
581.38; found 581.45.    
N
NNNN
N
O O
HOOH
O
OH
N3
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
172: 1-[5-(2-{4-[4-(1-{2-[5-(2-Hydroxy-propyl)-tetrahydro-furan-2-yl]-propyl}-1H-
[1,2,3]triazol-4-yl)-phenyl]-[1,2,3]triazol-1-yl}-1-methyl-ethyl)-tetrahydro-furan-2-
yl]-propan-2-ol 172.  55 (50.0 mg, 0.3 mmol) was added to 5:1 EtOH/H2O (2 mL), 
followed by 1,4-diethynyl benzene (96%, 15.0 mg, 0.1 mmol).  Ascorbic acid/H2O 
(1.1 M, 0.45 mL, 0.5 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.37 mL, 0.1 mmol) was 
added and the solution was stirred for at 37 °C for 12 hours.  Saturated sodium 
bicarbonate solution (50 mL) was added and the solution was extracted with ethyl 
acetate (3 × 25 mL).  The organic phases were collected, dried (Na2SO4), and 
evaporated to a residue.  The product was purified by chromatography on silica gel 
MeOH-chloroform (1:9) to give 172 (54.3 mg, 88.0%).  Rf = 0.20 (100% EtOAc).  
1
H 
207 
 
NMR (400 MHz, CDCl3) δ 7.88 (s, 4H), 7.84 (s, 2H), 4.57 (m, 2H), 4.34 (m, 2H), 
4.10 (m, 4H), 3.53 (m, 2H), 2.65 (s, 2H), 2.05 (m, 6H), 1.65 (m, 8H), 1.23 (d, J = 6.2 
Hz, 6H), and 0.88 (d, J = 6.8 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 147.2, 130.3, 
126.0, 120.5, 81.1, 76.9, 65.4, 53.5, 43.5, 40.1, 30.8, 29.4, 23.6, and 14.3 
N
N N N N
N
O O OHHO
O N3
OH
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h  
 
173: 1-[5-(2-{4-[3-(1-{2-[5-(2-Hydroxy-butyl)-tetrahydro-furan-2-yl]-propyl}-1H-
[1,2,3]triazol-4-yl)-phenyl]-[1,2,3]triazol-1-yl}-1-methyl-ethyl)-tetrahydro-furan-2-
yl]-butan-2-ol 173.  97 (97.1 mg, 0.4 mmol) was added to 5:1 EtOH/H2O (3 mL) 
followed by 1,3-diethynylbenzene (27 µL, 0.2 mmol).  Ascorbic acid/H2O (1.1 M, 0.8 
mL, 0.9 mmol) and CuSO4-5H2O/H2O (0.3 M, 0.7 mL, 0.2 mmol) was added and the 
mixture was stirred at 37 °C for 12 hours.  Ethyl acetate (50 mL) was added and the 
solution extracted with saturated sodium bicarbonate solution (100 mL), dried 
(Na2SO4), and then concentrated to a residue.  The residue was purified by 
chromatography on silica gel in 100% EtOAc to give 173 (100.9 mg, 85.4%).  Rf = 
0.61 (MeOH-chloroform (1:9)).  
1
H NMR (400 MHz, CDCl3) δ 8.33 (s, 1H), 8.03 (s, 
2H), 7.86 (m, 2H), 7.49 (m, 1H), 4.57 (m, 2H), 4.42 (m, 2H), 4.15 (m, 2H), 3.83 (m, 
2H), 3.51 (m, 2H), 2.45 (s, 2H), 2.05 (m, 10H), 1.60 (m, 8H), and 0.87 (m, 12H); 
13
C 
NMR (100 MHz, CDCl3) δ 129.4, 125.0, 81.1, 76.9, 70.4, 53.6, 41.3, 40.0, 30.8, 29.6, 
14.6, 14.5, and 10.0; IR (ATR) 3401, 3130, 2964, 2935, 2876, 2239, 1619, 1461, 
1384, 1226, 1045, 971, 908, 795, 730, and 695 cm
-1
; ESI-TOF-MS m/z calcd for 
C32H48N6O4H
+
: 581.38; found 581.33.    
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N
N
N
N
NHAc
NHAc
O O
OO O
O N3
N3
N-(3-ethynyl-phenyl)-acetamide
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
37 
o
C, 12 h
 
 
174: Terephthalic acid bis-[1-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-
methyl-ethyl}-tetrahydro-furan-2-ylmethyl)-propyl] ester 174.  168 (21.0 mg, 0.04 
mmol) was added to 5:1 EtOH/H2O (1.5 mL) and ethyl acetate (1 mL) followed by N-
(3-ethynyl-phenyl)-acetamide (17.0 mg, 0.1 mmol).  Ascorbic acid/H2O (1.1 M, 72 
µL, 0.1 mmol) and CuSO4-5H2O/H2O (0.3 M, 60 µL, 0.02 mmol) was added and the 
mixture was shaken at 37 °C for 12 hours.  Ethyl acetate (25 mL) was added to the 
solution and washed with saturated sodium bicarbonate solution (20 mL).  The 
organic phase was dried (Na2SO4) and concentrated to a residue which was purified 
by chromatography on silica gel in 100% EtOAc to give 174 (22.7 mg, 70%).  Rf = 
0.12 (100% EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.13 (m, 4H), 8.00 (s, 2H), 7.87 
(m, 4H), 7.72 (d, J = 7.7 Hz, 2H), 7.58 (d, J = 7.7 Hz, 2H), 7.31 (t, J = 7.9 Hz, 2H), 
5.39 (m, 2H), 4.45 (m, 4H), 3.88 (m, 2H), 3.35 (m, 2H), 2.14 (s, 6H), 1.87 (m, 14H), 
1.54 (m, 3H), 1.25 (m, 1H), 0.95 (m, 6H), and 0.85 (m, 6H); 
13
C NMR (100 MHz, 
CDCl3) δ 168.7, 165.6, 138.6, 134.4, 131.4, 129.6, 129.4, 121.44, 121.42, 119.5, 
116.8, 80.5, 75.9, 74.4, 53.2, 40.2, 40.1, 31.3, 29.7, 27.9, 24.6, 14.5, and 9.5; IR 
(ATR) 3304, 3127, 2962, 2926, 2855, 2243, 1712, 1691, 1678, 1619, 1592, 1567, 
1536, 1484, 1462, 1443, 1406, 1369, 1269, 1167, 1103, 1018, 909, 791, 729, and 693 
cm
-1
; ESI-TOF-MS m/z calcd for C50H62N8O8H
+
: 903.48; found 903.49.    
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37 
o
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175: Terephthalic acid bis-(1-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-
tetrahydro-furan-2-ylmethyl}-propyl) ester 175.  168 (21.0 mg, 0.04 mmol) was 
added to 5:1 EtOH/H2O (1.5 mL) and ethyl acetate (1 mL) followed by 2-ethynyl-
pyridine, 98+% (11.0 µL, 0.1 mmol).  Ascorbic acid/H2O (1.1 M, 72 µL, 0.08 mmol) 
and CuSO4-H2O/H2O (0.3 M, 60 µL, 0.02 mmol) was added and the mixture was 
stirred at room temperature for 12 hours.  Ethyl acetate (25 mL) was added and the 
solution was washed with saturated sodium bicarbonate solution (20 mL).  The 
organic phase was dried (Na2SO4) and concentrated to a residue then purified by 
chromatography on silica gel in 100% EtOAc to give 175 (16.4 mg, 57.7%).  Rf = 
0.29 (100% EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.57 (m, 2H), 8.15 (m, 8H), 7.76 
(m, 2H), 7.21 (m, 2H), 5.32 (m, 2H), 4.64 (m, 2H), 4.34 (m, 2H), 3.94 (m, 2H), 3.49 
(m, 2H), 1.97 (m, 6H), 1.76 (m, 4H), 1.57 (m, 4H), 1.25 (m, 4H), 0.97 (t, J = 7.4 Hz, 
6H), and 0.85 (d, J = 6.9 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 165.4, 150.5, 
149.3, 148.1, 136.8, 134.3, 129.5, 122.9, 122.7, 120.2, 80.7, 76.3, 74.4, 53.5, 40.4, 
40.3, 31.4, 29.6, 27.8, 14.3, and 9.5; IR (ATR) 2968, 2934, 2978, 2243, 1713, 1604, 
1572, 1462, 1421, 1384, 1269, 1204, 1118, 1102, 1040, 1018, 910, 785, and 729 cm
-1
; 
ESI-TOF-MS m/z calcd for C44H54N8O6Na
+
: 813.41; found 813.48.    
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176: Terephthalic acid bis-(1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-
ethyl]-tetrahydro-furan-2-yl}-ethyl) ester 176.  169 (6.5 mg, 0.01 mmol) was added to 
5:1 EtOH/H2O (1.0 mL) and ethyl acetate (1.0 mL) followed by 2-ethynyl-pyridine, 
98+% (4.0 µL, 0.04 mmol).  Ascorbic acid/H2O (1.1 M, 23.0 µL, 0.03 mmol) and 
CuSO4-5H2O/H2O (0.3 M, 20.0 µL, 0.006 mmol) was added and the mixture was 
stirred at room temperature for 12 hours.  Ethyl acetate (25 mL) was added and the 
solution washed with saturated sodium bicarbonate solution (20 mL), dried (Na2SO4), 
concentrated to a residue, and purified by chromatography on silica gel in 100% 
EtOAc to give 176.  Rf = 0.50 (MeOH-chloroform (1:9)).  IR (ATR) 2955, 2916, 
2869, 1738, 1722, 1604, 1461, 1378, 1270, 1230, 1211, 1086, 1086, 908, 786, and 
732 cm
-1
; ESI-TOF-MS m/z calcd for C42H50N8O6Na
+
: 785.38; found 785.45.    
O
O
O
O
O
O
N
N
NN
N N
N
N
O
O
O
O
O
O
N3
N3
2-ethynyl-pyridine
1.1 M Ascorbic acid / H2O
0.3 M CuSO4-5H2O / H2O
5:1 EtOH / H2O
r.t., 12 h
 
 
177: Isophthalic acid bis-(1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-
ethyl]-tetrahydro-furan-2-yl}-ethyl) ester 177.  170 (6.0 mg, 0.01 mmol) was added to 
5:1 EtOH/H2O (1.0 mL) and ethyl acetate (1.0 mL) followed by 2-ethynyl-pyridine, 
98+% (3.0 µL, 0.03 mmol).  Ascorbic acid/H2O (1.1 M, 22.0 µL, 0.03 mmol) and 
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CuSO4-H2O/H2O (0.3 M, 18.0 µL, 0.005 mmol) was added and the mixture was 
stirred at room temperature for 12 hours.  Ethyl acetate (25 mL) was added and the 
solution washed with saturated sodium bicarbonate solution (20 mL).  The organic 
phase was dried (Na2SO4), concentrated to a residue and purified by chromatography 
on silica gel in 100% EtOAc to give 177 (7.0 mg, 85%).  IR (ATR) 2954, 2916, 2869, 
2841, 1722, 1605, 1461, 1377, 1241, 1081, 972, 908, 789, and 734 cm
-1
; ESI-TOF-
MS m/z calcd for C42H50N8O6Na
+
: 785.38; found 785.44.    
N
N N
NN
N
O
O
O
O
O OMe
O
O OMe
O
N
N N
NN
N
O
O
OH
OH
methyl 4-chloro-4-oxobutyrate
py, r.t., 12 h
 
 
178: Succinic acid 1-{5-[2-(4-{4-[1-(2-{5-[2-(3-methoxycarbonyl-propionyloxy)-butyl]-
tetrahydro-furan-2-yl}-propyl)-1H-[1,2,3]triazol-4-yl]-phenyl}-[1,2,3]triazol-1-yl)-1-
methyl-ethyl]-tetrahydro-furan-2-ylmethyl}-propyl ester methyl ester 178.  171 (49.0 
mg, 0.09 mmol) was added to pyridine (1 mL) followed by methyl 4-chloro-4-
oxobutyrate, 97% (43.0 µL, 0.4 mmol).  The solution was stirred at room temperature 
for 12 hours.  Ethyl acetate (25 mL) was added and the solution was washed with 
saturated copper sulfate solution (2 × 20 mL), followed by saturated ammonium 
chloride solution (2 × 20 mL).  The organic phase was dried (Na2SO4) and 
concentrated to a residue then purified by chromatography on silica gel in 100% 
EtOAc to give 178 (23.0 mg, 33.7%).  Rf = 0.71 (100% EtOAc).  
1
H NMR (400 MHz, 
CDCl3) δ 7.93 (m, 6H), 5.15 (m, 1H), 4.58 (m, 1H), 4.45 (m, 1H), 3.83 (m, 1H), 3.66 
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(m, 6H), 3.41 (m, 1H), 2.63 (m, 8H), 1.44 (m, 21H), 1.22 (m, 2H), and 0.88 (m, 12H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 172.0, 130.4, 126.04, 126.0, 121.2, 80.4, 75.9, 
73.5, 53.2, 51.8, 40.3, 40.2, 31.3, 29.7, 29.4, 29.0, 27.8, 14.5, and 9.4; IR (ATR) 
2969, 2879, 2256, 1728, 1438, 1366, 1217, 1161, 1066, 1044, 996, 973, 914, 847, and 
729 cm
-1
; ESI-TOF-MS m/z calcd for C42H60N6O10H
+
: 809.44; found 809.48.    
N
N N
NN
N
O
O
O
O
O
O
N
N N
NN
N
O
O
OH
OH
benzoyl chloride
py, r.t., 12 h
 
 
179: 1,1’-(5,5’-(1,1’-(4,4’-(1,4-phenylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(propane-2,1-
diyl))bis(tetrahydrofuran-5,2-diyl))bis(butane-2,1-diyl)dibenzoate 179.  171 (49.0 
mg, 0.09 mmol) was added to pyridine (1 mL) followed by benzoyl chloride (40.0 
µL, 0.4 mmol).  The solution was stirred at room temperature for 12 hours.  Ethyl 
acetate (25 mL) was added and the solution was washed with saturated copper sulfate 
solution (2 × 20 mL) and then with saturated ammonium chloride solution (2 × 20 
mL), dried (Na2SO4), and concentrated to a residue which was purified by 
chromatography on silica gel in 100% EtOAc to give 179 (40.0 mg, 60%).  Rf = 0.82 
(100% EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 7.98 (m, 10H), 7.50 (m, 6H), 5.42 (m, 
1H), 4.53 (m, 4H), 3.93 (m, 1H), 3.38 (m, 1H), 1.81 (m, 18H), 1.25 (m, 1H), 0.98 (t, J 
= 7.4 Hz, 6H), and 0.90 (d, J = 6.8 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 166.3, 
132.9, 130.5, 130.3, 130.1, 129.5, 128.4, 126.0, 121.3, 80.4, 75.9, 73.5, 53.2, 40.35, 
40.27, 31.3, 29.8, 28.0, 14.5, and 9.6; IR (ATR) 2970, 2878, 2249, 1711, 1602, 1584, 
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1451, 1366, 1314, 1273, 1229, 1176, 1111, 1069, 1026, 973, 909, 804, 730, and 710 
cm
-1
; ESI-TOF-MS m/z calcd for C46H56N6O6H
+
: 789.43; found 789.45.    
N
N
N
N
N
N
O
O
O
O
O
O
OMe
O
OMe
O
N
N
N
N
N
N
O
O
OH
OH
methyl 4-chloro-4-oxobutyrate
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180: Succinic acid 1-{5-[2-(4-{3-[1-(2-{5-[2-(3-methoxycarbonyl-propionyloxy)-butyl]-
tetrahydro-furan-2-yl}-propyl)-1H-[1,2,3]triazol-4-yl]-phenyl}-[1,2,3]triazol-1-yl)-1-
methyl-ethyl]-tetrahydro-furan-2-ylmethyl}-propyl ester methyl ester 180.  173 (36.0 
mg, 0.06 mmol) was added to pyridine (1 mL) followed by methyl 4-chloro-4-
oxobutyrate, 97% (32.0 µL, 0.3 mmol).  The solution was stirred at room temperature 
for 12 hours.  Ethyl acetate (25 mL) was added to the solution and was washed with 
saturated copper sulfate solution (2 × 20 mL) and then washed with saturated 
ammonium chloride solution (2 × 20 mL), dried (Na2SO4), and concentrated to a 
residue which was purified by chromatography on silica gelin 100% EtOAc to give 
180 (24.0 mg. 47.8%).  Rf = 0.71 (100% EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.32 
(m, 1H), 8.02 (s, 1H), 7.88 (m, 2H), 7.48 (m, 1H), 5.11 (m, 1H), 4.60 (m, 1H), 4.42 
(m, 1H), 3.85 (m, 1H), 3.65 (s, 6H), 3.44 (m, 1H), 2.63 (s, 8H), 1.75 (m, 16H), 1.24 
(m, 5H), and 0.88 (m, 15H); 
13
C NMR (100 MHz, CDCl3) δ 172.7, 172.0, 147.2, 
131.3, 125.2, 122.84, 122.78, 121.3, 80.5, 76.0, 73.5, 53.3, 51.8, 40.4, 40.2, 31.3, 
29.7, 29.4, 28.9, 27.8, 14.4, and 9.4; IR (ATR) 2969, 2254, 1729, 1620, 1439, 1366, 
1217, 1162, 1045, 997, 910, 846, 797, and 728 cm
-1
; ESI-TOF-MS m/z calcd for 
C42H60N6O10H
+
: 809.44; found 809.48.    
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181: 1,1’-(5,5’-(1,1’-(4,4’-(1,3-phenylene)bis(1H-1,2,3-triazole-4,1-diyl))bis(propane-2,1-
diyl))bis(tetrahydrofuran-5,2-diyl))bis(butane-2,1-diyl)dibenzoate 181.  173 (36.0 
mg, 0.06 mmol) was added to pyridine (1 mL) followed by benzoyl chloride (29.0 
µL, 0.3 mmol).  The solution was stirred for 12 hours at room temperature.  Ethyl 
acetate (25 mL) was added and the solution was washed with saturated copper sulfate 
solution (2 × 20 mL) and then saturated ammonium chloride solution (2 × 20 mL), 
dried (Na2SO4), and concentrated to a residue which was purified by chromatography 
on silica gel in 100% EtOAc to give 181 (32.0 mg, 65.4%).  Rf = 0.82 (100% EtOAc).  
1
H NMR (400 MHz, CDCl3) δ 8.35 (m, 1H), 8.05 (m, 6H), 7.88 (m, 2H), 7.55 (m, 
2H), 7.43 (m, 5H), 5.38 (m, 2H), 4.56 (m, 2H), 4.41 (m, 2H), 3.93 (m, 2H), 3.40 (m, 
2H), 1.96 (m, 9H), 1.75 (m, 2H), 1.56 (m, 3H), 1.42 (m, 2H), 1.25 (m, 2H), 0.97 (m, 
6H), and 0.85 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 166.3, 132.9, 132.8, 131.3, 
130.6, 130.0, 129.53, 129.49, 128.36, 128.27, 125.3, 80.5, 76.2, 73.6, 53.3, 40.31, 
40.26, 31.3, 29.7, 27.9, 19.3, 14.4, and 9.5; IR (ATR) 2970, 2878, 2249, 1711, 1602, 
1451, 1383, 1314, 1273, 1175, 1111, 1069, 1026, 909, 795, 730, and 710 cm
-1
; ESI-
TOF-MS m/z calcd for C46H56N6O6H
+
: 789.43; found 789.49.    
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o
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o
C
3. 0 
o
C to r.t., 12 h
4. 0.1 M HCl / H2O  
 
183: 1-Furan-2-yl-propan-2-ol 183.  Furan 182 (5.0 mL, 68.8 mmol) was added to THF 
(70 mL), cooled to 0 ºC.  nBuLi in THF (2.37 M, 32.0 mL, 75.6 mmol) was added 
dropwise.  The solution was stirred at 0 ºC for 2 hours followed by the dropwise 
addition of propylene oxide (7.2 mL, 103.1 mmol).  The solution was allowed to 
warm to room temperature overnight.  After 12 hours, 0.1 M HCl/H2O (25 mL) was 
added and the solution was stirred for 10 minutes.  The solution was extracted with 
ethyl acetate (3 × 200 mL) and the organic layer was collected, dried (Na2SO4), and 
evaporated to an oil.  The product was purified by distillation (48 ºC, 15 mmHg) to 
give a clear liquid 183 (5.68 g, 65.6%).  Rf  = 0.29 (EtOAc-hexanes (1:3)); 
1
H NMR 
(400 MHz, CDCl3) δ 7.29 (m, 1H), 6.26 (m, 1H), 6.00 (m, 1H), 4.10 (m, 1H), 3.31 (s, 
1H), 2.70 (m, 2H), and 1.17 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 152.7, 141.3, 
110.1, 106.8, 66.6, 37.6, and 22.5; IR (ATR) 3415, 2971, 2933, 1717, 1507, 1376, 
1080, 1008, and 941 cm
-1
 
O
O
O
O
OH O
O O
THF, py, r.t., 2 h  
 
184: Acetic acid 2-furan-2-yl-1-methyl-ethyl ester 184.  183 (5.7 g, 45.1 mmol) was added 
to THF (15 mL) followed by pyridine (18.4 mL, 225.4 mmol).  Acetic anhydride 
(12.8 mL, 135.2 mmol) was added at room temperature and the solution was then 
stirred for 2 hours.  Ethyl acetate (100 mL) was added to the solution, which was then 
washed with saturated copper sulfate solution (2 × 50 mL) and then with saturated 
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ammonium chloride solution (2 × 50 mL).  The organic layer was dried (Na2SO4) and 
concentrated to an oil.  The product was purified by distillation (96 ºC, 24 mmHg) to 
give slightly yellow oil 184 (5.97 g, 78.8%).  Rf  = 0.50 (EtOAc-hexanes (1:9); 
1
H 
NMR (400 MHz, CDCl3) δ 7.26 (s, 1H), 6.23 (s, 1H), 6.01 (s, 1H), 5.10 (sextet, J = 
12.7, 6.4 Hz, 1H), 2.87 (dd, J = 15.0, 6.5 Hz, 1H), 2.78 (dd, J = 15.0, 6.4 Hz, 1H), 
1.95 (s, 3H), and 1.19 (d, J = 6.4 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.1, 
151.4, 141.2, 110.0, 106.7, 69.0, 34.1, 20.9, and 19.3; IR (ATR) 2982, 2937, 1736, 
1597, 1507, 1456, 1372, 1237, 1147, 1061, 1009, 957, and 934 cm
-1 
O
O
O
O
O
O
O
O
1. Fe2(SO4)3-H2O, 1.0 M Et3B / THF
    Ethyl-(dl)-2-iodopropionate
    DMSO, r.t., air, 45 min
    
2. 1.0 M Et3B / THF, r.t., air, 2 h
 
 
185: 2-[5-(2-Acetoxy-propyl)-furan-2-yl]-propionic acid ethyl ester 185.  184 (30.6 g, 
182.0 mmol) was added to DMSO (250 mL) followed by Fe2(SO4)3-H2O (72.8 g, 
182.0 mmol) and ethyl-(dl)-2-iodopropionate (41.5 g, 182.0 mmol).  Et3B in THF (1.0 
M, 182.0 mL, 182.0 mmol) was added and the solution was stirred for 45 minutes 
while air was bubbled through the solution.  After 45 minutes, Et3B in THF (1.0 M, 
182.0 mL, 182.0 mmol) was added and the solution was stirred for an additional 2 
hours.  Brine solution (200 mL) was added and the solution was extracted with 
diethyl ether (3 × 100 mL).  The organic layers were collected, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:9) to give 185 (5.34 g, 10.9%).  Rf  = 0.56 (EtOAc-hexanes 
(1:3)); 
1
H NMR (400 MHz, CDCl3) δ 6.01 (d, J = 3.3 Hz, 1H), 5.95 (d, J = 2.9 Hz, 
1H), 5.06 (sextet, J = 12.8, 6.6, 6.2 Hz, 1H), 4.10 (q, J = 14.3, 7.3, 7.0, 2H), 3.69 (q, J 
= 7.3 Hz, 1H), 2.73 (dd, J = 15, 6.2 Hz, 1H) 2.73 (dd, J = 15, 6.2 Hz, 1H), 1.96 (s, 
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3H), 1.43 (d, J = 7.3 Hz, 3H), 1.21-1.17 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 
172.5, 170.3, 152.1, 150.7, 107.6, 106.4, 69.2, 60.8, 39.4, 34.3, 21.1, 19.4, 15.6, and 
14.0; IR (ATR) 2983, 2939, 1735, 1559, 1456, 1372, 1236, 1202, 1057, 1016, 954, 
and 786 cm
-1
; ESI-TOF-HRMS m/z calcd for C14H20O5H
+
: 269.1398; found 
269.1389. 
O
OH
OH
O
O
O
O
O
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
186: 2-[5-(2-Hydroxy-propyl)-furan-2-yl]-propionic acid 186.  2.5 M 
LiOH/H2O/MeOH/THF (1:2:3) (40 mL) was added to 185 (2.2 g, 8.2 mmol) and the 
solution was stirred at room temperature overnight.  1.0 M HCl/H2O was added until 
the solution had a pH of 2.  The solution was extracted with ethyl acetate (5 × 50 
mL).  The organic phase was dried (Na2SO4) and evaporated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-MeOH-AcOH 
(194:5:1) to give 186 (1.32 g, 81.0%).  Rf  = 0.74 (EtOAc-MeOH-AcOH (95:4:1)); 
1
H 
NMR (400 MHz, CDCl3) δ 7.40 (s, 2H), 6.05 (d, J = 3.3 Hz, 1H), 5.98 (d, J = 3.3 Hz, 
1H), 4.02 (sextet, J = 12.4, 6.2, 2H), 3.73 (q, J = 7.3 Hz, 1H), 2.68 (d, J = 6.2 Hz, 
2H), 1.46 (d, J = 7.3, 3H), and 1.15 (d, J = 6.2 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 177.3, 151.9, 151.6, 107.6, 106.8, 66.8, 39.1, 37.4, 22.2, and 15.3; ESI-TOF-HRMS 
m/z calcd for C10H14O4H
+
: 199.0970; found 199.0971.   
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O
OH
O
1. 2.37 M nBuLi / THF
    THF, 0 
o
C, 1 h
    
2. ethylene oxide
    THF, 0 
o
C to r.t., 12 h
3. 0.1 M HCl / H2O  
 
187: 2-Furan-2-yl-ethanol 187.  Furan 182 (20.0 mL, 275.0 mmol) was added to THF (150 
mL) and cooled to 0 ºC.  nBuLi in THF (2.37 M, 128.0 mL, 302.5 mmol) was added 
dropwise to the solution.  The solution was stirred for 1 hour and ethylene oxide (14.0 
mL, 275.0 mmol) in THF (50 mL) was added dropwise into solution which was then 
stirred overnight and allowed to warm to room temperature.  0.1 M HCl/H2O (100 
mL) was added to the solution and was stirred for 10 minutes.  The solution was 
extracted with ethyl acetate (3 × 200 mL) and the organic layers collected, dried 
(Na2SO4), and evaporated to an oil.  The product was purified by distillation to give a 
clear oil 187 (9.16 g, 29.7%).  Rf  = 0.23 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 7.33 (m, 1H), 6.30 (m, 1H), 6.10 (m, 1H), 3.87 (t, J = 6.2 Hz, 2H), 2.89 (t, J 
= 6.2 Hz, 2H), and 1.25 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 141.5, 110.3, 106.5, 
61.0, and 31.5; IR (ATR) 3402, 3078, 2929, 1717, 1600, 1507, 1364, 1217, and 1004 
cm
-1
 
O
O
O
O
OH O
O O
py, THF, 25 
o
C, 2 h
 
 
188: Acetic acid 2-furan-2-yl-ethyl ester 188.  187 (9.162 g, 81.7 mmol) was added to THF 
(27 mL) and pyridine (33.3 mL, 408.5 mmol) followed by acetic anhydride (23.2 mL, 
245.1 mmol).  The solution was stirred for 2 hours at 25 ºC.  Ethyl acetate (100 mL) 
was added and the solution was washed with saturated copper sulfate solution (2 × 50 
mL) and then with saturated ammonium sulfate solution (2 × 50 mL).  The organic 
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layer was dried (Na2SO4) and concentrated to an oil.  The product was purified by 
distillation (85 ºC, 10 mmHg) to give 188 (9.85 g, 78.3%).  Rf  = 0.41 (EtOAc-
hexanes (1:9); 
1
H NMR (400 MHz, CDCl3) δ 7.24 (m, 1H), 6.20 (m, 1H), 6.00 (m, 
1H), 4.22 (m, 2H), 2.88 (m, 2H), and 1.96 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
170.6, 151.5, 141.2, 110.0, 106.0, 62.0, 27.4, and 20.4; IR (ATR) 2970, 1738, 1653, 
1600, 1559, 1508, 1456, 1366, 1231, 1147, 1035, and 1009 cm
-1
 
O O
OO
O
O
O
O
1. Fe2(SO4)3-H2O, 1.0 M Et3B / THF
    Ethyl-(dl)-2-iodopropionate
    DMSO, r.t., air, 45 min
    
2. 1.0 M Et3B / THF, r.t., air, 2 h
 
 
189: 2-[5-(2-Acetoxy-ethyl)-furan-2-yl]-propionic acid ethyl ester 189.  188 (30.0 g, 194.7 
mmol) was added to DMSO (250 mL) followed by Fe2(SO4)3-H2O (78.0 g, 194.7 
mmol) and ethyl-(dl)-2-iodopropionate (44.4 g, 194.7 mmol).  Et3B in THF (1.0 M, 
195.0 mL, 194.7 mmol) was then added and the solution was stirred for 45 minutes 
while air was bubbled through the solution.  After 45 minutes, Et3B in THF (1.0 M, 
195.0 mL, 194.7 mmol) was added and the solution was stirred for an additional 2 
hours.  Brine solution (200 mL) was added and the solution was extracted with 
diethyl ether (3 × 100 mL).  The organic layers were collected, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:9) to give a yellowish oil 189 (3.84 g, 7.8%).  Rf  = 0.56 
(EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 6.03 (d, J = 3.1 Hz, 1H), 5.97 
(d, J = 3.2 Hz, 1H), 4.24 (t, J = 6.9 Hz, 2H), 4.12 (q, J = 7.2, 7.1 Hz, 3H), 2.90 (t, J = 
6.9 Hz, 2H), 2.00 (s, 3H), 1.45 (d, J = 7.2 Hz, 3H), and 1.21 (t, J = 7.2 Hz, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ 172.6, 170.8, 152.2, 150.9, 106.9, 106.4, 62.2, 60.9, 39.4, 
220 
 
27.6, 20.8, 15.6, and 14.0; IR (ATR) 2984, 1735, 1653, 1559, 1456, 1367, 1231, 1036 
cm
-1
; ESI-TOF-MS m/z calcd for C13H18O5Na
+
: 277.11; found 277.03.   
O
O
O
O
O
O
O
O
O
O
5% Rh/C, H2, (500 psi)
ethyl acetate, r.t., 5 h
 
 
190: 2-[5-(2-Acetoxy-ethyl)-tetrahydro-furan-2-yl]-propionic acid ethyl ester 190. 189 
(2.001 g, 7.9 mmol) was added to ethyl acetate (10 mL) in a hydrogenator followed 
by 5% Rh/C (0.6 g) and the solution was stirred at room temperature.  The air was 
flushed out with argon, which was then flushed out with hydrogen.  The pressure of 
the hydrogen atmosphere was raised to 500 psi and the solution was stirred for 24 
hours.  The pressure was released and the hydrogen was flushed out with argon.  The 
solution was filtered through Celite and evaporated to a residue.  The product was 
purified by chromatography on silica gel in EtOAc-hexanes (1:4) to give 190 (1.25 g, 
61.5%).  Rf  = 0.50 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.04 (m, 
5H), 3.85 (m, 1H), 2.39 (m, 1H), 1.94 (s, 3H), 1.90 (m, 2H), 1.71 (m, 2H), 1.60 (m, 
1H), 1.43 (m, 1H), and 1.13 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 174.3, 170.8, 
80.0, 76.0, 61.7, 60.0, 45.0, 34.7, 30.8, 28.8, 20.7, 14.0, and 13.8; ESI-TOF-MS m/z 
calcd for C13H22O5H
+
 : 259.15; found 259.08.   
O
OH
OH
O
O
O
O
O
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
191: 2-[5-(2-Hydroxy-ethyl)-tetrahydro-furan-2-yl]-propionic acid 191.  2.5 M 
LiOH/H2O/MeOH/THF (1:2:3) (25 mL) was added to 190 (1.2 g, 4.7 mmol) and the 
solution was stirred for 24 hours at room temperature.  1.0 M HCl/H2O was added 
until the solution had a pH of 2.  The solution was extracted with ethyl acetate (5 × 50 
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mL).  The organic layers were collected, dried (Na2SO4), and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-MeOH-
AcOH (194:5:1) to give 191 (0.283 g, 32.4%).  Rf = 0.76 (EtOAc-MeOH-AcOH 
(95:4:1)); 
1
H NMR (400 MHz, CDCl3) δ 7.65 (s, 1H), 4.13 (m, 2H), 3.98 (m, 2H), 
2.51 (m, 1H), 2.00 (m, 4H), 1.66 (m, 3H), and 1.15 (m, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 179.3, 179.0, 171.2, 80.3, 79.8, 76.6, 76.5, 61.9, 45.1, 44.4, 34.8, 34.7, 30.9, 
30.8, 28.7, 28.5, 20.9, and 13.3 
O
O
O
O
O
O
O
O
1. Fe2(SO4)3-H2O, 1.0 M Et3B / THF
    Ethyl iodoacetate
    DMSO, r.t., air, 45 min
    
2. 1.0 M Et3B / THF, r.t., air, 2 h  
 
192: [5-(2-Acetoxy-ethyl)-furan-2-yl]-acetic acid ethyl ester 192.  188 (32.09 g, 208.3 
mmol) was added to DMSO (300 mL) followed by Fe2(SO4)3-H2O (83.3 g, 208.3 
mmol) and ethyl iodoacetate (45.0 mL, 208.3 mmol).  Et3B in THF (1.0 M, 208.5 mL, 
208.3 mmol) was added and the solution was stirred for 45 minutes while air was 
bubbled through the solution.  After 45 minutes, Et3B in THF (1.0 M, 208.5 mL, 
208.3 mmol) was added and the solution was stirred for an additional 2 hours.  Brine 
solution (200 mL) was added and the solution was extracted with diethyl ether (3 × 
100 mL).  The organic layers were collected, dried (Na2SO4), and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:9) to give 192 (7.25 g, 14.5%).  Rf  = 0.63 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 6.02 (s, 1H), 5.92 (s, 1H), 4.17 (s, 2H), 4.06 (s, 2H), 3.52 (s, 2H), 
2.83 (s, 2H), 1.93 (s, 3H), and 1.15 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.5, 
169.1, 151.0, 146.4, 108.3, 107.0, 61.9, 60.7, 33.8, 27.4, 20.5, and 13.8; IR (ATR) 
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2971, 1736, 1653, 1567, 1368, 1229, 1031, and 788  cm
-1
; ESI-TOF-MS m/z calcd 
for C12H16O5Na
+
: 263.09; found 263.01.   
O
O
O
O
O
O
O
O
O
O
5% Rh/C, H2, (500 psi)
ethyl acetate, r.t., 24 h
 
 
193: [5-(2-Acetoxy-ethyl)-tetrahydro-furan-2-yl]-acetic acid ethyl ester 193.  192 (3.001 g, 
12.5 mmol) was added to ethyl acetate (10 mL) in a hydrogenator followed by 5% 
Rh/C (0.7 g) and the solution was stirred at room temperature.  The air was flushed 
out with argon, which was then flushed out with hydrogen.  The pressure of the 
hydrogen atmosphere was raised to 500 psi and the solution was stirred for 24 hours.  
The pressure was released and the hydrogen was flushed out with argon.  The 
solution was filtered through Celite and evaporated to a residue.  The product was 
purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 193 (1.57 g, 
51.4%).  Rf  = 0.40 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 4.15 (m, 
1H), 4.05 (m, 4H), 3.85 (m, 1H), 2.49 (dd, J = 15.8, 6.87, 6.776 Hz, 1H), 2.35 (dd, J 
= 15.9, 6.501, 6.409 Hz, 1H), 1.95 (m, 2H), 1.94 (s, 3H), 1.74 (m, 2H), 1.50 (m, 2H), 
and 1.17 (t, J = 7.2, 3H); 
13
C NMR (100 MHz, CDCl3) δ 170.9, 170.8, 76.2, 75.2, 
61.7, 60.1, 40.9, 34.8, 30.7, 30.6, 20.7, and 14.0; ESI-TOF-MS m/z calcd for 
C12H20O5H
+
: 245.14; found 245.07.   
O
OH
OH
O
O
O
O
O
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
194: [5-(2-Hydroxy-ethyl)-tetrahydro-furan-2-yl]-acetic acid 194.  2.5 M 
LiOH/H2O/MeOH/THF (1:2:3) (25 mL) was added to 193 (1.454 g, 6.0 mmol) and 
the solution was stirred for 24 hours at room temperature.  1.0 M HCl/H2O was added 
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until the solution had a pH of 2.  The solution was extracted with ethyl acetate (5 × 50 
mL).  The organic layers were collected, dried (Na2SO4), and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-MeOH-
AcOH (194:5:1) to give 194 (0.543 g, 52.4%).  Rf = 0.70 (EtOAc-MeOH-AcOH 
(95:4:1)); 
1
H NMR (400 MHz, CDCl3) δ 8.03 (s, 1H), 4.20 (m, 1H), 4.09 (m, 2H), 
3.93 (m, 1H), 2.55 (m, 1H), 2.45 (m, 1H), 2.00 (m, 3H), 1.78 (m, 2H), and 1.55 (m, 
2H); 
13
C NMR (100 MHz, CDCl3) δ 175.7, 171.2, 76.5, 75.0, 61.8, 40.7, 34.7, 30.73, 
30.68, and 20.8 
O
O
O
O
O
O
O
O
1. Fe2(SO4)3-H2O, 1.0 M Et3B / THF
    Ethyl iodopropionate
    DMSO, 45 min, r.t., air
    
2. 1.0 M Et3B / THF, 2 h, r.t., air  
 
195: [5-(2-Acetoxy-propyl)-furan-2-yl]-acetic acid ethyl ester 195.  184 (30.0 g, 178.4 
mmol) was added to DMSO (250 mL) at room temperature.  Fe2(SO4)3-H2O (71.35 g, 
178.4 mmol) was added followed by ethyl iodoacetate (98%, 21.2 mL, 178.4 mmol).  
Et3B in THF (1.0 M, 178.5 mL, 178.4 mmol) was added and the solution was stirred 
for 45 minutes as air was bubbled through the solution.  After 45 minutes, Et3B in 
THF (1.0 M, 178.5 mL, 178.4 mmol) was added and the solution was stirred for an 
additional 2 hours.  Brine solution (200 mL) was added and the solution was 
extracted with diethyl ether (3 × 100 mL).  The organic layers were collected, dried 
(Na2SO4), and evaporated to a residue.  The product was purified by chromatography 
on silica gel in EtOAc-hexanes (1:9) to give 195 (7.5 g, 16.5%).  IR (ATR) 2982, 
2936, 1735, 1653, 1559, 1457, 1372, 1237, 1031, and 955 cm
-1
; ESI-TOF-MS m/z 
calcd for C13H18O5Na
+
: 277.11; found 277.03.   
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O
O
O
O
O
O
O
O
O
5% Rh/C, H2, (500 psi)
ethyl acetate, r.t., 24 h
 
 
196: [5-(2-Acetoxy-propyl)-tetrahydro-furan-2-yl]-acetic acid ethyl ester 196.  195 (3.024 
g, 11.9 mmol) was added to ethyl acetate (10 mL) followed by 5% Rh/C (0.7 g) and 
the solution stirred at room temperature.  The air was flushed out with argon, which 
was then flushed out with hydrogen.  The pressure of the hydrogen atmosphere was 
raised to 500 psi and the solution was stirred for 24 hours.  The pressure was released 
and the hydrogen was flushed out with argon.  The solution was filtered through 
Celite and evaporated to a residue.  The product was purified by chromatography on 
silica gel in EtOAc-hexanes (1:3) to give 196 (0.87 g, 28.3%).  
1
H NMR (400 MHz, 
CDCl3) δ 4.91 (m, 1H), 4.11 (m, 1H), 4.04 (q, J = 7.2, 7.050 Hz, 2H), 3.78 (m, 1H), 
2.48 (m, 1H), 2.34 (m, 1H), 1.91 (s, 3H), 1.90 (m, 2H), 1.65 (m, 1H), and 1.48 (m, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 170.96, 170.94, 170.32, 170.29, 76.16, 76.13, 
75.07, 75.01, 68.9, 68.5, 60.1, 42.3, 41.8, 40.99, 40.9, 31.0, 30.9, 30.6, 30.5, 21.11, 
21.09, 20.4, and 13.9; ESI-TOF-MS m/z calcd for C13H22O5Na
+
: 281.14; found 
281.05.   
O
OH
OH
O
O
O
O
O
O
1. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
2. 1.0 M HCl / H2O
 
 
197: [5-(2-Hydroxy-propyl)-tetrahydro-furan-2-yl]-acetic acid 197.  2.5 M 
LiOH/H2O/MeOH/THF (1:2:3) (10 mL) was added to 196 (0.493 g, 1.9 mmol) and 
the solution was stirred for 24 hours at room temperature.  1.0 M HCl/H2O was added 
until the solution had a pH of 2.  The solution was extracted with ethyl acetate (5 × 50 
mL).  The organic layers were collected, dried (Na2SO4), and concentrated to a 
225 
 
residue.  The product was purified by chromatography on silica gel in EtOAc-MeOH-
AcOH (194:5:1) to give 197 (0.206 g, 57.5%).  Rf = 0.54 (EtOAc-MeOH-AcOH 
(95:4:1)); 
1
H NMR (400 MHz, CDCl3) δ 5.99 (s, 2H), 4.14 (m, 3H), 2.52 (m, 2H), 
2.04 (m, 2H), 1.62 (m, 2H), and 1.16 (m, 3H); 
13
C NMR (100 MHz, CDCl3) δ 80.0, 
77.1, 76.0, 75.5, 68.0, 65.1, 44.3, 43.0, 30.7, 30.5, 30.4, 31.6, and 23.0; ESI-TOF-MS 
m/z calcd for C9H16O4H
+
: 189.11; found 189.06.   
O
OH
O
1. 2.37 M nBuLi in hexanes
    THF, 0 
o
C, 1 h
    
2. 1,2-epoxy-butane
    0 
o
C to r.t., 12 h
3. 0.1 M HCl / H2O  
 
198: 1-Furan-2-yl-butan-2-ol 198.  Furan 182 (50.0 mL, 687.4 mmol) was added to THF 
(400 mL) and cooled to 0 ºC.  nBuLi in hexanes (2.37 M, 320.0 mL, 756.2 mmol) 
was added dropwise and the solution was stirred at 0 ºC for 1 hour.  1,2-epoxybutane 
(66.0 mL, 756.2 mmol) was added dropwise into solution and the solution was 
allowed to warm to room temperature as it was stirred overnight.  0.1 M HCl/H2O 
(200 mL) was added and the solution was stirred for 10 minutes.  The solution was 
extracted with ethyl acetate (3 × 200 mL) and the organic layers collected, dried 
(Na2SO4), and evaporated to a residue.  The product was purified by distillation under 
vacuum to give a clear oil 198 (49.57 g, 51.4%).  
1
H NMR (400 MHz, CDCl3) δ 7.28 
(s, 1H), 6.25 (s, 1H), 6.05 (s, 1H), 3.75 (s, 1H), 2.73 (m, 2H), 2.36 (s, 1H), 1.46 (s, 
2H), and 0.93 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 152.9, 141.2, 110.1, 106.7, 
71.5, 35.5, 29.3, and 9.7; IR (ATR) 3569, 3438, 3421, 3353, 3084, 2968, 2935, 2879, 
1739, 1597, 1507, 1461, 1378, 1281, 1218, 1171, 1146, 1113, 1079, 1008, and 976 
cm
-1
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O
O
O
O
OH O
O O
THF, py, r.t., 20 h  
 
199: Acetic acid 1-furan-2-ylmethyl-propyl ester 199.  198 (30.0 g, 214.0 mmol) was 
added to THF (44 mL) followed by pyridine (88.0 mL, 1070.1 mmol). Acetic 
anhydride (61.0 mL, 642.0 mmol) was added and the solution was stirred at room 
temperature for 7 hours.  Acetic anhydride (20.0 mL) was added followed by pyridine 
(20.0 mL) and the solution was stirred overnight to complete the reaction.  Ethyl 
acetate (100 mL) was added to the solution which was then washed with saturated 
copper sulfate solution (2 × 100 mL) and then with saturated ammonium chloride 
solution (2 × 100 mL).  The organic phase was then washed with water (100 mL), 
dried (MgSO4), and evaporated to a residue.  The product was purified by distillation 
(92ºC, 9.6 mmHg) to give a clear liquid 199 (34.62 g, 88.8%).  
1
H NMR (400 MHz, 
CDCl3) δ 7.24 (m, 1H), 6.21 (m, 1H), 5.99 (m, 1H), 4.98 (m, 1H), 2.81 (d, J = 6.1 Hz, 
2H), 1.95 (s, 3H), 1.54 (m, 2H), and 0.86 (t, J = 7.5 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 170.3, 151.5, 141.2, 110.0, 106.7, 73.4, 32.1, 26.3, 20.8, and 9.3; IR (ATR) 
2971, 2937, 2883, 1735, 1596, 1507, 1458, 1373, 1236, 1148, 1079, 1011, 966, and 
737 cm
-1
 
O
O
O
1. Fe2(SO4)3-H2O, 1.0 M Et3B / THF
    Ethyl-(dl)-2-iodoproprionate
    DMSO, r.t., air, 45 min
    
2. 1.0 M Et3B / THF, r.t., air, 2 h
3. 2.5 M LiOH / H2O / MeOH / THF (1:2:3)
4. 1.0 M HCl / H2O
O
OH
OH
O
 
 
200: 2-[5-(2-Hydroxy-butyl)-furan-2-yl]-propionic acid 200.  199 (15.0 mL, 82.3 mmol) 
was added to DMSO (200 mL) followed by Fe2(SO4)3-H2O (33.0 g, 82.3 mmol) and 
DL-ethyl-2-iodopropionate (20.0 g, 82.3 mmol).  Et3B in THF (1.0 M, 82.5 mL, 82.3 
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mmol) was added and the solution was stirred for 45 minutes at room temperature 
while air was bubbled through the solution.  After 45 minutes, Et3B in THF (1.0 M, 
82.5 mL, 82.3 mmol) was added and the solution was stirred for an additional 2 
hours.  Brine solution (200 mL) was added and the solution was extracted with 
diethyl ether (3 × 100 mL).  The organic phases were collected, dried (Na2SO4), and 
evaporated to a residue.  The product was purified by chromatography on silica gel in 
EtOAc-hexanes (1:3) which was then added to 2.5 M LiOH/H2O/MeOH/THF (100 
mL) and the solution stirred at room temperature overnight.  1.0 M HCl/H2O was 
added until the solution had a pH of 2.  The solution was then extracted with ethyl 
acetate (5 × 100 mL).  The organic phases were collected, dried (Na2SO4), and 
evaporated to a residue.  The product was purified by chromatography on silica gel in 
EtOAc-MeOH-AcOH (194:5:1) to give 200 (0.882 g, 5% over two steps).  
1
H NMR 
(400 MHz, CDCl3) δ 6.80 (s, 2H), 6.07 (d, J = 3.2 Hz, 1H), 6.01 (d, J = 3.1 Hz, 1H), 
3.77 (m, 2H), 2.77 (m, 1H), 2.66 (m, 1H), 1.48 (d, J = 7.2 Hz, 4H), 1.19 (m, 1H), and 
0.92 (t, J = 7.3 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 177.4, 152.1, 151.6, 107.6, 
106.8, 71.84, 71.81, 39.1, 35.4, 35.3, 29.15, 29.13, 15.4, 15.3, and 9.74; ESI-TOF-MS 
m/z calcd for C11H16O4Na
+
: 235.09; found 235.03.   
OH
H
O
MgBr
Et2O, 0 
o
C, 30 min
 
 
203: 1-(4-Isopropyl-phenyl)-but-3-en-1-ol 203.  Allyl magnesium bromide in Et2O (1.0 M, 
40.5 mL, 40.5 mmol) was chilled to 0 ºC and 4-isopropylbenzaldehyde (5.11 mL, 
33.8 mmol) was added.  The solution was stirred for 30 minutes.  Saturated 
ammonium chloride solution (50 mL) was added and the solution was then extracted 
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with ethyl acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 
mL) and then water (20 mL).  The solution was then dried (Na2SO4) and concentrated 
to a residue.  The product was purified by chromatography on silica gel in EtOAc-
hexanes (3:17) to give 203.  Rf  = 0.65 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 7.24 (m, 4H), 5.81 (m, 1H), 5.12 (m, 2H), 4.68 (s, 1H), 2.91 (m, 1H), 2.50 
(s, 2H), 2.25 (s, 1H), and 1.27 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 148.4, 141.6, 
135.0, 126.7, 126.1, 118.3, 73.5, 43.9, 34.1, and 24.3; IR (ATR) 3385, 3077, 2960, 
2933, 2903, 2871, 1726, 1641, 1615, 1512, 1461, 1417, 1246, 1048, 999, 913, and 
831 cm
-1
 
OH
H
O
MgBr
Et2O, 0 
o
C, 30 min  
 
204: 1-p-Tolyl-but-3-en-1-ol 204.  Allyl magnesium bromide in Et2O (1.0 M, 50.0 mL, 
50.0 mmol) was chilled to 0 ºC and p-tolualdehyde (97%, 4.93 mL, 41.6 mmol) was 
added.  The solution was stirred for 30 minutes.  Saturated ammonium chloride 
solution (50 mL) was added and the solution was then extracted with ethyl acetate (3 
× 20 mL).  The organic layer was washed with brine solution (20 mL) and then water 
(20 mL).  The solution was then dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (3:17) to 
give 204.  Rf  = 0.54 (EtOAc-hexanes (1:3)); 
13
C NMR (100 MHz, CDCl3) δ 140.9, 
137.0, 134.6, 128.9, 125.7, 117.9, 73.1, 60.3, and 43.7; IR (ATR) 3369, 3076, 3007, 
2978, 2923, 1903, 1641, 1514, 1432, 1306, 1247, 1179, 1108, 1045, 998, 914, 872, 
and 816 cm
-1
 
229 
 
Br
OH
Br
H
O
MgBr
Et2O, 0 
o
C, 30 min  
 
205: 1-(4-Bromo-phenyl)-but-3-en-1-ol 205.  Allyl magnesium bromide in Et2O (1.0 M, 
32.43 mL, 32.4 mmol) was chilled to 0 ºC and 4-bromobenzaldehyde (5.0 g, 27.0 
mmol) was added.  The solution was stirred for 30 minutes.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(3:17) to give 205.  Rf  = 0.47 (EtOAc-hexanes (1:3)); 
13
C NMR (100 MHz, CDCl3) δ 
142.9, 133.9, 131.2, 127.5, 121.0, 118.4, 72.5, and 43.6; IR (ATR) 3428, 3077, 2980, 
2934, 2904, 1724, 1641, 1593, 1488, 1403, 1374, 1244, 1098, 1045, 1010, 917, 871 
and 824 cm
-1
 
OH
H
O
MgBr
Et2O, 0 
o
C, 30 min
O O
 
 
206: 1-(3-Benzyloxy-phenyl)-but-3-en-1-ol 206.  Allyl magnesium bromide in Et2O (1.0 M, 
28.3 mL, 28.3 mmol) was chilled to 0 ºC and 3-benzyloxybenzaldehyde (5.0 g, 23.6 
mmol) was added.  The solution was stirred for 30 minutes.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 206.  Rf  = 0.47 (EtOAc-hexanes (1:3));  
13
C NMR (100 MHz, CDCl3) δ 
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159.1, 146.0, 137.2, 134.7, 129.7, 128.8, 128.2, 127.8, 118.7, 118.5, 114.1, 112.6, 
73.4, 70.2, and 44.0; IR (ATR) 3429, 3068, 3032, 2979, 2904, 1736, 1641, 1600, 
1585, 1487, 1448, 1376, 1317, 1248, 1154, 1041, 1027, 994, 916, and 873 cm
-1
 
OH
H
O
MgBr
Et2O, 0 
o
C, 30 min NN
 
 
207: 1-(4-Diethylamino-phenyl)-but-3-en-1-ol 207.  Allyl magnesium bromide in Et2O (1.0 
M, 33.9 mL, 33.9 mmol) was chilled to 0 °C and 4-(diethyl-amino)-benzaldehyde 
(99%, 5.0 g, 28.2 mmol) was added.  The solution was stirred for 30 minutes.  
Saturated ammonium chloride solution (50 mL) was added and the solution was then 
extracted with ethyl acetate (3 × 20 mL).  The organic layer was washed with brine 
solution (20 mL) and then water (20 mL).  The solution was then dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:3) to give 207.  Rf  = 0.46 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.19 (m, 2H), 6.66 (m, 2H), 5.83 (m, 1H), 5.13 (m, 2H), 4.60 (m, 
1H), 3.35 (m, 4H), 2.51 (m, 2H), 2.14 (s, 1H), and 1.16 (m, 6H); 
13
C NMR (100 
MHz, CDCl3) δ 147.2, 135.1, 130.5, 127.0, 117.4, 111.5, 73.2, 44.2, 43.3, and 12.4; 
IR (ATR) 3414, 3075, 2973, 2932, 2899, 1739, 1640, 1613, 1567, 1520, 1467, 1448, 
1397, 1374, 1355, 1265, 1196, 1153, 1045, 1011, 912, and 814 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h  
 
210: 1-p-Tolyl-prop-2-en-1-ol 210.  Vinyl magnesium bromide in THF (1.0 M, 49.9 mL, 
50.0 mmol) was chilled to 0 ºC and p-tolualdehyde (97%, 5.0 g, 41.6 mmol) was 
added.  The solution was stirred for 12 hours.  Saturated ammonium chloride solution 
231 
 
(50 mL) was added and the solution was then extracted with ethyl acetate (3 × 20 
mL).  The organic layer was washed with brine solution (20 mL) and then water (20 
mL).  The solution was then dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (3:17) to 
give 210 (6.1 g, 98.9%).  Rf  = 0.57 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 7.20 (m, 4H), 6.02 (m, 1H), 5.31 (m, 1H), 5.13 (m, 2H), 2.34 (s, 3H), and 
2.02 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 140.3, 139.7, 137.2, 129.0, 126.2, 114.6, 
74.9, and 21.0; IR (ATR) 3367, 3078. 3020, 2981, 2922, 2870, 1907, 1724, 1641, 
1513, 1422, 1375, 1247, 1196, 1178, 1107, 1041, 1020, 988, 923, 848, 815, and 773 
cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h
 
 
211: 1-(4-Isopropyl-phenyl)-prop-2-en-1-ol 211.  Vinyl magnesium bromide in THF (1.0 
M, 40.5 mL, 40.5 mmol) was chilled to 0 ºC and 4-isopropylbenzaldehyde (5.0 g, 
33.8 mmol) was added.  The solution was stirred for 12 hours.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with of brine solution (20 mL) 
and then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(3:17) to give 211 (5.31 g, 89.3%).  Rf  = 0.55 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.25 (m, 4H), 6.04 (m, 1H), 5.34 (m, 1H), 5.17 (m, 2H), 2.90 (m, 
1H), 2.04 (s, 1H), and 1.24 (m, 6H); 
13
C NMR (100 MHz, CDCl3) δ 148.5, 140.2, 
140.0, 126.6, 126.3, 114.8, 75.1, 33.8, and 24.0; IR (ATR) 3349, 3082, 3015, 2960, 
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2929, 2870, 1641, 1614, 1512, 1461, 1420, 1383, 1363, 1292, 1248, 1200, 1110, 
1055, 1017, 988, 922, and 827 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h NN
 
 
212: 1-(4-Diethylamino-phenyl)-prop-2-en-1-ol 212.  Vinyl magnesium bromide in THF 
(1.0 M, 33.9 mL, 33.9 mmol) was chilled to 0 ºC and 4-(diethyl-amino)-benzaldehyde 
(99%, 5.0 g, 28.2 mmol) was added.  The solution was stirred for 12 hours.  Saturated 
ammonium chloride solution (50 mL) was added and the solution was then extracted 
with ethyl acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 
mL) and then water (20 mL).  The solution was then dried (Na2SO4) and concentrated 
to a residue.  The product was purified by chromatography on silica gel in EtOAc-
hexanes (3:17) to give 212 (3.96 g, 68.4%).  Rf  = 0.39 (EtOAc-hexanes (1:3)); 
1
H 
NMR (400 MHz, CDCl3) δ 7.20 (m, 2H), 6.66 (m, 2H), 6.06 (m, 1H), 5.33 (m, 1H), 
5.11 (m, 2H), 3.34 (m, 4H), 2.03 (s, 1H), and 1.16 (m, 6H); 
13
C NMR (100 MHz, 
CDCl3) δ 147.7, 140.9, 129.7, 128.0, 114.2, 112.0, 75.2, 44.6, and 12.8; IR (ATR) 
3384, 3076, 2971, 2931, 2871, 1611, 1567, 1519, 1466, 1449, 1397, 1374, 1355, 
1264, 1187, 1153, 1095, 1077, 988, 919, and 811 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h OMe
OMe
OMe
OMe  
 
213: 1-(2,3-Dimethoxy-phenyl)-prop-2-en-1-ol 213.  Vinyl magnesium bromide in THF 
(1.0 M, 36.11 mL, 36.1 mmol) was chilled to 0 ºC and 2,3-dimethoxybenzaldehyde 
(5.0 g, 30.1 mmol) was added.  The solution was stirred for 12 hours.  Saturated 
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ammonium chloride solution (50 mL) was added and the solution was then extracted 
with ethyl acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 
mL) and then water (20 mL).  The solution was then dried (Na2SO4) and concentrated 
to a residue.  The product was purified by chromatography on silica gel in EtOAc-
hexanes (3:17) to give 213 (2.2 g, 37.6%).  Rf  = 0.32 (EtOAc-hexanes (1:3)); 
1
H 
NMR (400 MHz, CDCl3) δ 7.04 (t, J = 8.0 Hz, 1H), 6.91 (d, J = 7.8 Hz, 1H), 6.85 (d, 
J = 8.2 Hz, 1H), 6.08 (m, 1H), 5.42 (m, 1H), 5.31 (m, 1H), 5.16 (m, 1H), 3.85 (s, 6H), 
and 2.82 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 152.5, 146.4, 140.2, 136.2, 124.2, 
119.2, 114.4, 111.8, 71.1, 60.9, and 55.7; IR (ATR) 3427, 3083, 2939, 2905, 2835, 
1737, 1640, 1586, 1479, 1430, 1264, 1219, 1170, 1065, 1003, 923, 872, 809, 787, and 
748 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h
OO
 
 
214: 1-(3-Benzyloxy-phenyl)-prop-2-en-1-ol 214.  Vinyl magnesium bromide in THF (1.0 
M, 28.27 mL, 28.3 mmol) was chilled to 0 ºC and 3-benzyloxybenzaldehyde (5.0 g, 
23.6 mmol) was added.  The solution was stirred for 12 hours.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL). The solution was then dried (Na2SO4) and concentrate to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(3:7) to give 214 (4.84 g, 85.5%).  Rf  = 0.37 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.34 (m, 5H), 7.03 (m, 1H), 6.96 (m, 1H), 6.89 (m, 1H), 6.03 (m, 
1H), 5.35 (m, 1H), 5.19 (m, 1H), 5.16 (m, 1H), 5.06 (m, 3H), and 2.00 (s, 1H); 
13
C 
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NMR (100 MHz, CDCl3) δ 159.0, 144.3, 140.0, 136.9, 129.6, 128.6, 128.0, 127.5, 
118.8, 115.2, 114.1, 112.7, 75.2, and 70.0; IR (ATR) 3386, 3065, 3032, 2978, 2871, 
1737, 1598, 1584, 1486, 1446, 1380, 1317, 1257, 1153, 1026, 991, 923, 878, 773, 
735, and 696 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h BrBr  
 
215: 1-(4-Bromo-phenyl)-prop-2-en-1-ol 215.  Vinyl magnesium bromide in THF (1.0 M, 
32.5 mL, 32.4 mmol) was chilled to 0 ºC and 4-bromobenzaldehyde (5.0 g, 27.0 
mmol) was added.  The solution was stirred for 12 hours.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 215 (2.5 g, 43.4%).  Rf  = 0.41 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.43 (d, J = 8.3 Hz, 2H), 7.19 (d, J = 8.4 Hz, 2H), 5.94 (m, 1H), 5.27 
(m, 1H), 5.15 (m, 1H), 5.07 (m, 1H), and 3.11 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 
141.6, 139.8, 131.4, 128.0, 121.3, 115.4, and 74.4; IR (ATR) 3346, 3081, 2978, 2878, 
1907, 1642, 1592, 1486, 1402, 1292, 1248, 1192, 1100, 1071, 1040, 1010, 988, 926, 
843, and 816 cm
-1
  
OH
H
O
MgBr
THF, 0 
o
C, 12 h
PhOPhO
 
 
216: 1-(3-Phenoxy-phenyl)-prop-2-en-1-ol 216.  Vinyl magnesium bromide in THF (1.0 
M, 30.3 mL, 30.3 mmol) was chilled to 0 ºC and 3-phenoxybenzaldehyde (5.0 g, 25.2 
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mmol) was added.  The solution was stirred for 12 hours.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 216 (4.75 g, 83.2%).  Rf  = 0.42 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.31 (m, 3H), 7.02 (m, 6H), 6.01 (m, 1H), 5.31 (m, 1H), 5.17 (m, 
1H), 5.15 (m, 1H), and 2.72 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 157.3, 157.0, 
144.8, 140.0, 129.6, 123.2, 121.0, 118.8, 117.8, 116.7, 115.2, and 74.8; IR (ATR) 
3386, 3075, 2980, 2878, 1712, 1583, 1484, 1443, 1375, 1242, 1211, 1163, 1141, 
1072, 1043, 1023, 990, 926, 821, 751, 700, and 692 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h OO  
 
217: 1-(4-Ethoxy-phenyl)-prop-2-en-1-ol 217.  Vinyl magnesium bromide in THF (1.0 M, 
39.9 mL, 39.9 mmol) was chilled to 0 ºC and 4-ethoxybenzaldehyde (5.0 g, 33.3 
mmol) was added.  The solution was stirred for 12 hours.  Saturated ammonium 
chloride solution (50 mL) was added and the solution was then extracted with ethyl 
acetate (3 × 20 mL).  The organic layer was washed with brine solution (20 mL) and 
then water (20 mL).  The solution was then dried (Na2SO4) and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:3) to give 217 (5.61 g, 94.5%).  Rf  = 0.37 (EtOAc-hexanes (1:3)); 
1
H NMR (400 
MHz, CDCl3) δ 7.24 (d, J = 8.8 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 6.01 (m, 1H), 5.29 
(m, 1H), 5.14 (m, 1H), 5.10 (m, 1H), 3.99 (q, J = 7.0 Hz, 2H), 2.47 (s, 1H), and 1.38 
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(t, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 158.4, 140.4, 134.7, 127.6, 114.5, 
114.3, 74.7, 63.3, and 14.7; IR (ATR) 3388, 3077, 2980, 2930, 2879, 1893, 1725, 
1641, 1611, 1585, 1510, 1478, 1393, 1302, 1241, 1173, 1115, 1045, 989, 921, and 
826 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h  
 
218: 1-(4-Ethyl-phenyl)-prop-2-en-1-ol 218.  Vinyl magnesium bromide in THF (1.0 M, 
44.7 mL, 44.7 mmol) was chilled to 0 ºC and 4-ethylbenzaldehyde (5.0 g, 37.3 mmol) 
was added.  The solution was stirred for 12 hours.  Saturated ammonium chloride 
solution (50 mL) was added and the solution was then extracted with ethyl acetate (3 
× 20 mL).  The organic layer was washed with brine solution (20 mL) and then water 
(20 mL).  The solution was then dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 
218 (5.53 g, 91.4%).  Rf  = 0.50 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) 
δ 7.29 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.3 Hz, 2H), 6.05 (m, 1H), 5.34 (m, 1H), 5.19 
(m, 1H), 5.16 (m, 1H), 2.67 (q, J = 7.6 Hz, 2H), 2.33 (s, 1H), and 1.26 (t, J = 7.6 Hz, 
3H); 
13
C NMR (100 MHz, CDCl3) δ 143.7, 140.3, 139.9, 127.9, 126.3, 114.7, 75.0, 
28.5, and 15.5; IR (ATR) 3369, 3083, 3014, 2965, 2931, 2873, 1908, 1641, 1614, 
1512, 1455, 1418, 1282, 1249, 1197, 1178, 1110, 1018, 988, 923,  and 826 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h  
 
219: 1-Naphthalen-2-yl-prop-2-en-1-ol 219.  Vinyl magnesium bromide in THF (1.0 M, 
38.5 mL, 38.4 mmol) was chilled to 0 ºC and 2-naphthaldehyde (3.0 g, 19.2 mmol) 
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was added.  The solution was stirred for 12 hours.  Saturated ammonium chloride 
solution (50 mL) was added and the solution was then extracted with ethyl acetate (3 
× 20 mL).  The organic layer was washed with brine solution (20 mL) and then water 
(20 mL).  The solution was then dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (1:3) to give 
219 (2.84 g, 82.2%).  Rf  = 0.42 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) 
δ 7.82 (m, 4H), 7.48 (m, 3H), 6.11 (m, 1H), 5.38 (m, 1H), 5.31 (m, 1H), 5.22 (m, 
1H)and 3.18 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 140.2, 140.0, 133.2, 132.8, 
128.1, 127.9, 127.5, 126.0, 125.7, 124.8, 124.5, 115.0, and 75.1; IR (ATR) 3369, 
3056, 3017, 2978, 2877, 1709, 1639, 1601, 1508, 1361, 1270, 1203, 1164, 1125, 
1039, 988, 926, 856, 819, 780, 762, and 744 cm
-1
 
OH
H
O
MgBr
THF, 0 
o
C, 12 h HOHO
 
 
220: 2,6-Di-tert-butyl-4-(1-hydroxy-allyl)-phenol 220.  Vinyl magnesium bromide in THF 
(1.0 M, 47.0 mL, 46.9 mmol) was chilled to 0 ºC and 3,5-di-tert-butyl-4-
hydroxybenzaldehyde (5.0 g, 21.4 mmol) was added.  The solution was stirred for 12 
hours.  Saturated ammonium chloride solution (50 mL) was added and the solution 
was then extracted with ethyl acetate (3 × 20 mL).  The organic layer was washed 
with brine solution (20 mL) and then water (20 mL).  The solution was then dried 
(Na2SO4) and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:4) to give 220 (3.5 g, 62.5%).  Rf  
= 0.55 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.18 (s, 2H), 6.09 (m, 
1H), 5.37 (m,1H), 5.22 (s, 1H), 5.19 (m, 1H), 5.12 (m, 1H), 2.07 (s, 1H), and 1.45 (s, 
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18H); 
13
C NMR (100 MHz, CDCl3) δ 153.5, 140.4, 135.9, 133.2, 123.2, 114.4, 75.7, 
34.4, and 30.2; IR (ATR) 3636, 3542, 3430, 3076, 3076, 2956, 2910, 2871, 1643, 
1592, 1433, 1391, 1362, 1317, 1234, 1205, 1155, 1119, 1032, 993, 927, and 885 cm
-1
 
OHOH
1. Diethyl (-)-tartrate, Ti(iPrO)4,
    CH2Cl2, sieves, -20 
o
C, 30 min
2. t-BuOOH/DCM, -20 
o
C to r.t., 24 h     
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min  
 
222: 1-(4-Ethyl-phenyl)-prop-2-en-1-ol 222.  218 (3.5 g, 21.5 mmol) was added to CH2Cl2 
(5.4 mL), followed by 13 x 2µ sieves (1.2 g).  Diethyl (–)-tartrate (0.67 g, 3.2 mmol) 
and Ti(iPrO)4 (0.61 g, 2.2 mmol) were added and the solution was cooled to -20 ºC.  
After 30 minutes, t-BuOOH in DCM (4.408 M, 2.92 mL, 12.9 mmol) was added and 
the reaction was stirred and allowed to warm to room temperature for 24 hours.  
Ferrous sulfate (9.0 g) was then added followed by d-(–)-tartaric acid (3.0 g) and 
water (100 mL).  The solution was stirred for 30 minutes.  The solution was extracted 
with ethyl acetate (3 × 10 mL) and the organic layer was dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:3) to give 222 (1.31 g, 37.4%).  Rf  = 0.43 (EtOAc-hexanes 
(1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.29 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 
2H), 6.05 (m, 1H), 5.34 (m, 1H), 5.18 (m, 1H), 5.15 (m, 1H), 2.67 (q, J = 7.6 Hz, 
2H), and 1.26 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 143.6, 140.3, 139.9, 
127.9, 126.3, 114.6, 75.0, 28.4, and 15.5; IR (ATR) 3368, 3083, 3014, 2965, 2932, 
2873, 1640, 1614, 1512, 1456, 1418, 1375, 1282, 1249, 1197, 1179, 1110, 1018, 988, 
923, and 826 cm
-1
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OHOH
1. Diethyl (-)-tartrate, Ti(iPrO)4,       
     CH2Cl2, sieves, -20 
o
C, 30 min
2. t-BuOOH/DCM, -20 
o
C to r.t., 24 h     
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min
OMe
OMe
OMe
OMe
 
 
223: 1-(2,3-Dimethoxy-phenyl)-prop-2-en-1-ol 223.  213 (1.0 g, 5.2 mmol) was added to 
CH2Cl2 (20.6 mL), followed by 13 x 2µ sieves (1.0 g).  Diethyl (–)-tartrate (0.16 g, 
0.8 mmol) and Ti(iPrO)4 (0.15 g, 0.5 mmol) were added and the solution was cooled 
to -20 ºC.  After 30 minutes, t-BuOOH in DCM (4.408 M, 0.7 mL, 3.1 mmol) was 
added and the reaction was stirred and allowed to warm to room temperature for 24 
hours.  Ferrous sulfate (3.0 g) was then added followed by d-(–)-tartaric acid (1.0 g) 
and water (100 mL).  The solution stirred for 30 minutes.  The solution was extracted 
with ethyl acetate (3 × 10 mL) and the organic layer was dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:3) to give 223 (0.245 g, 24.5%).  Rf  = 0.27 (EtOAc-hexanes 
(1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.02 (t, J = 8.0 Hz, 1H), 6.91 (m, 1H), 6.83 (m, 
1H), 6.07 (m, 1H), 5.43 (m, 1H), 5.30 (m, 1H), 5.15 (m, 1H), 3.83 (s, 6H), and 2.96 
(s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 152.4, 146.2, 140.1, 136.2, 124.1, 119.1, 
114.3, 111.7, 70.8, 60.8, and 55.6; IR (ATR) 3428, 3078, 2936, 2836, 1640, 1586, 
1479, 1430, 1263, 1219, 1169, 1065, 1003, 922, 871, 809, 787, and 748 cm
-1
 
OHOH
1. Diethyl (-)-tartrate, Ti(iPrO)4,           
     CH2Cl2, sieves, -20 
o
C, 30 min
2. t-BuOOH/DCM, -20 
o
C to r.t., 24 h       
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min  
 
224: 1-(4-Isopropyl-phenyl)-prop-2-en-1-ol 224.  211 (3.0 g, 17.0 mmol) was added to 
CH2Cl2 (50 mL), followed by 13 x 2 µ sieves (3.0 g).  Diethyl (–)-tartrate (0.53 g, 2.6 
mmol) and Ti(iPrO)4 (0.5 g, 1.7 mmol) were added and the solution was cooled to -20 
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ºC.  After 30 minutes, t-BuOOH in DCM (4.408 M, 2.3 mL, 10.2 mmol) was added 
and the reaction was stirred for 24 hours and allowed to warm to room temperature.  
Ferrous sulfate (9.0 g) was then added followed by d-(–)-tartaric acid (3.0 g) and 
water (100 mL).  The solution stirred for 30 minutes.  The solution was extracted with 
ethyl acetate (3 × 10 mL) and the organic layer was dried (Na2SO4) and concentrated 
to a residue.  The product was purified by chromatography on silica gel in EtOAc-
hexanes (3:17) to give 224 (0.855 g, 28.5%).  Rf = 0.50 (EtOAc-hexanes (1:3)); 
1
H 
NMR (400 MHz, CDCl3) δ 7.31 (d, J = 8.3 Hz, 2H), 7.23 (d, J = 8.2 Hz, 2H), 6.05 
(m, 1H); 5.35 (m, 1H), 5.19 (m, 1H), 5.15 (m, 1H), 2.93 (septet, J = 6.9 Hz, 1H), 2.66 
(s, 1H), and 1.28 (d, J = 7.0 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 148.2, 140.3, 
140.0, 126.5, 126.3, 114.6, 75.0, 33.7, and 23.9; IR (ATR) 3369, 3082, 3014, 2960, 
2928, 2870, 1641, 1614, 1512, 1460, 1419, 1383, 1363, 1292, 1201, 1180, 1109, 
1055, 1017, 988, 922, and 827 cm
-1
  
OHOH
1. Diethyl (-)-tartrate, Ti(iPrO)4,                  
     CH2Cl2, sieves, -20 
o
C, 30 min
2. t-BuOOH/DCM, -20 
o
C to r.t., 24 h        
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min
OO
 
 
225: 1-(3-Benzyloxy-phenyl)-prop-2-en-1-ol 225.  214 (1.84 g, 7.7 mmol) was added to 
CH2Cl2 (30 mL), followed by 13 x 2 µ sieves (2.0 g).  Diethyl (–)-tartrate (0.20 mL, 
1.2 mmol) and Ti(iPrO)4 (0.23 mL, 0.8 mmol) were added and the solution was 
cooled to -20 ºC.  After 30 minutes, t-BuOOH in DCM (4.408 M, 1.04 mL, 4.6 
mmol) was added and the reaction was stirred for 24 hours and allowed to warm to 
room temperature.  Ferrous sulfate (6.0 g) was then added followed by d-(–)-tartaric 
acid (2.0 g) and water (100 mL).  The solution stirred for 30 minutes.  The solution 
was extracted with ethyl acetate (3 × 10 mL) and the organic layer was dried 
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(Na2SO4) and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:4) to give 225 (0.864 g, 47.0%).  
Rf  = 0.33 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.36 (m, 5H), 7.06 
(m, 1H), 6.98 (m, 1H), 6.91 (m, 1H), 6.04 (m, 1H), 5.35 (m, 1H), 5.19 (m, 1H), 5.14 
(m, 1H), 5.06 (m, 3H), and 2.92 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 158.8, 144.4, 
140.1, 136.8, 129.4, 128.4, 127.8, 127.4, 118.8, 114.9, 113.8, 112.6, 74.9, and 69.8; 
IR (ATR) 3406, 3065, 3032, 2978, 2871, 1734, 1598, 1584, 1486, 1446, 1380, 1317, 
1257, 1153, 1122, 1081, 1026, 992, 881, 774, 735, and 696 cm
-1
 
OHOH
1. Diethyl (-)-tartrate, Ti(iPrO)4,                   
     CH2Cl2, sieves, -20 
o
C, 30 min
2. t-BuOOH/DCM, -20 
o
C to r.t., 24 h        
3. Ferrous sulfate, d-(-)-tartaric acid,
    H2O, 30 min
PhOPhO
 
 
226: 1-(3-Phenoxy-phenyl)-prop-2-en-1-ol 226.  216 (3.0 g, 13.3 mmol) was added to 
CH2Cl2 (50 mL), followed by 13 x 2 µ sieves (3.0 g).  Diethyl (–)-tartrate (0.41 g, 2.0 
mmol) and Ti(iPrO)4 (0.38 g, 1.3 mmol) were added and the solution was cooled to -
20 ºC.  After 30 minutes, t-BuOOH in DCM (4.408 M, 1.8 mL, 8.0 mmol) was added 
and the reaction stirred for 24 hours and allowed to warm to room temperature.  
Ferrous sulfate (9.0 g) was then added followed by d-(–)-tartaric acid (3.0 g) and 
water (100 mL).  The solution was stirred for 30 minutes.  The solution was extracted 
with ethyl acetate (3 × 10 mL) and the organic layer was dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:3) to give 226 (0.859 g, 28.6%).  Rf  = 0.40 (EtOAc-hexanes 
(1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.33 (m, 3H), 7.06 (m, 5H), 6.92 (m, 1H), 6.01 
(m, 1H), 5.33 (m, 1H), 5.19 (m, 1H), 5.14 (m, 1H), and 2.47 (s, 1H); 
13
C NMR (100 
MHz, CDCl3) δ 157.3, 157.0, 144.7, 139.8, 129.74, 129.67, 123.2, 121.0, 118.8, 
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117.8, 116.7, 115.3, and 74.9; IR (ATR) 3348, 3069, 2980, 2876, 1864, 1583, 1484, 
1443, 1242, 1211, 1163, 1140, 1072, 1023, 989, 926, 821, 780, 751, and 691 cm
-1
  
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h  
 
228: 1-Methyl-4-(1-prop-2-ynyloxy-allyl)-benzene 228.  Sodium hydride in mineral oil 
(60%, 0.272 g, 6.8 mmol) was added to dry THF (10 mL) followed by 210 (0.503 g, 
3.4 mmol).  HMPA (1.2 mL, 6.8 mmol) was added to the solution which was stirred 
for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.6 mL, 6.8 
mmol) was added and the solution was stirred overnight.  Saturated ammonium 
chloride solution (20 mL) was added and the solution was extracted with chloroform 
(3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(3:17) to give 228 (0.351g, 55.5%).  Rf  = 0.77 (EtOAc-hexanes (1:9)); 
1
H NMR (400 
MHz, CDCl3) δ 7.30 (d, J = 7.7 Hz, 2H), 7.22 (d, J = 7.4 Hz, 2H), 6.00 (m, 1H), 5.32 
(m, 2H), 5.06 (d, J = 6.4 Hz, 1H), 4.16 (m, 2H), 2.47 (m, 1H), and 2.40 (s, 3H); 
13
C 
NMR (100 MHz, CDCl3) δ 137.9, 137.5, 136.8, 129.1, 127.0, 116.8, 80.9, 79.7, 74.2, 
55.0, and 21.0; IR (ATR) 3292, 3023, 2921, 2856, 1738, 1642, 1612, 1513, 1442, 
1414, 1365, 1304, 1259, 1217, 1180, 1108, 1068, 1021, 991, 926, 849, and 815 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h
OMe
OMeOMe
OMe  
 
229: 1,2-Dimethoxy-3-(1-prop-2-ynyloxy-allyl)-benzene 229.  Sodium hydride in mineral 
oil (60%, 0.045 g, 1.1 mmol) was added to dry THF (10 mL) followed by 213 (0.110 
g, 0.6 mmol).  HMPA (0.2 mL, 1.1 mmol) was then added to the solution which was 
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stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.1 
mL, 1.1 mmol) was added and the solution was stirred overnight.  Saturated 
ammonium chloride solution (20 mL) was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (3:17) to give 229 (30.2 mg, 22.9%).  Rf  = 0.34 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.07 (t, J = 7.9 Hz, 1H), 6.98 (d, J = 7.9 Hz, 
1H), 6.85 (d, J = 8.1 Hz, 1H), 5.97 (m, 1H), 5.48 (d, J = 6.5 Hz, 1H), 5.30 (d, J = 17.1 
Hz, 1H), 5.21 (d, J = 10.3 Hz, 1H), 4.12 (m, 2H), 3.85 (m, 6H), and 2.41 (m, 1H); 
13
C 
NMR (100 MHz, CDCl3) δ 152.6, 146.9, 137.6, 133.8, 124.3, 119.2, 116.8, 111.7, 
79.9, 75.2, 74.2, 60.9, 55.7, and 55.4; IR (ATR) 3287, 2970, 2918, 2849, 1738, 1587, 
1480, 1431, 1365, 1264, 1219, 1170, 1060, 1005, and 927 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h
PhOPhO
 
 
230: 1-Phenoxy-3-(1-prop-2-ynyloxy-allyl)-benzene 230.  Sodium hydride in mineral oil 
(60%, 0.177 g, 4.5 mmol) was added to dry THF (10 mL) followed by 216 (0.502 g, 
2.2 mmol).  HMPA (0.8 mL, 4.5 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.4 
mL, 4.5 mmol) was added and the solution was stirred overnight.  Saturated 
ammonium chloride solution (20 mL) was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 230 (0.301 g, 51.4%).  Rf  = 0.60 (EtOAc-hexanes 
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(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.38 (m, 2H), 7.17 (m, 2H), 7.08 (m, 2H), 6.99 
(m, 1H), 5.98 (m, 1H), 5.36 (m, 2H), 5.09 (d, J = 6.9 Hz, 1H), 4.22 (m, 2H), and 2.49 
(m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 157.2, 156.9, 142.0, 137.3, 129.6, 129.7, 
123.1, 121.7, 118.7, 118.0, 117.5, 117.4, 80.6, 79.5, 74.5, and 55.1; IR (ATR) 3293, 
3065, 2856, 1738, 1583, 1484, 1443, 1244, 1211, 1163, 1067, 1023, 990, 930, 884, 
835, 782, 753, and 692 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h BrBr  
 
231: 1-Bromo-4-(1-prop-2-ynyloxy-allyl)-benzene 231.  Sodium hydride in mineral oil 
(60%, 0.158 g, 4.0 mmol) was added to dry THF (10 mL) followed by 215 (0.422 g, 
2.0 mmol).  HMPA (0.7 mL, 4.0 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.4 
mL, 4.0 mmol) was added and the solution was stirred overnight.  Saturated 
ammonium chloride solution (20 mL) was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 231 (0.23 g, 46.3%).  Rf  = 0.71 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.48 (d, J = 8.5 Hz, 2H), 7.24 (d, J = 8.3 Hz, 
2H), 5.88 (m, 1H), 5.30 (m, 2H), 5.00 (d, J = 6.9 Hz, 1H), 4.14 (m, 2H), and 2.46 (m, 
1H); 
13
C NMR (100 MHz, CDCl3) δ 139.0, 137.2, 131.5, 128.7, 121.7, 117.8, 80.3, 
79.4, 74.6, and 55.2; IR (ATR) 3297, 3082, 2982, 2855, 1726, 1591, 1486, 1404, 
1264, 1069, 1011, 990, 929, and 817 cm
-1
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OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h  
 
232: 1-Ethyl-4-(1-prop-2-ynyloxy-allyl)-benzene 232.  Sodium hydride in mineral oil 
(60%, 0.224 g, 5.6 mmol) was added to dry THF (10 mL) followed by 218 (0.454 g, 
2.8 mmol).  HMPA (1.0 mL, 5.6 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.5 
mL, 5.6 mmol) was added and the solution was stirred overnight.  Saturated 
ammonium chloride solution (20 mL) was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 232 (0.447 g, 79.8%).  Rf  = 0.77 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.36 (d, J = 8.1 Hz, 2H), 7.26 (d, J = 8.2 Hz, 
2H), 6.025 (m, 1H), 5.34 (m, 2H), 5.09 (d, J = 6.7 Hz, 1H), 4.19 (m, 2H), 2.71 (q, J = 
7.6, 2H), 2.485 (m, 1H), and 1.31 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 
143.7, 137.8, 137.0, 127.8, 127.0, 116.7, 80.8, 79.7, 74.2, 54.9, 28.4, and 15.4; IR 
(ATR) 3292, 3012, 2966, 2933, 2873, 1727, 1669, 1612, 1513, 1442, 1417, 1360, 
1266, 1068, 1020, 990, and 827 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h  
 
233: 2-(1-Prop-2-ynyloxy-allyl)-naphthalene 233.  Sodium hydride in mineral oil (60%, 
0.217 g, 5.4 mmol) was added to dry THF (10 mL) followed by 219 (0.5 g, 2.7 
mmol).  HMPA (1.0 mL, 5.4 mmol) was then added to the solution which was stirred 
for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.5 mL, 5.4 
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mmol) was added and the solution was stirred overnight.  Saturated ammonium 
chloride solution (20 mL) was added and the solution was extracted with chloroform 
(3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and concentrated to a 
residue.  The product was purified by chromatography on silica gel in EtOAc-hexanes 
(1:19) to give 233 (0.307 g, 50.9%).  Rf  = 0.63 (EtOAc-hexanes (1:9)); 
1
H NMR (400 
MHz, CDCl3) δ 7.95 (m, 4H), 7.60 (m, 3H), 6.18 (m, 1H), 5.48 (m, 2H), 5.34 (d, J = 
6.6 Hz, 1H), 4.31 (m, 2H), and 2.61 (m, 1H); 
13
C NMR (100 MHz, CDCl3) δ 137.6, 
137.1, 133.0, 132.9, 128.2, 127.8, 127.5, 126.0, 125.8, 124.7, 117.2, 81.0, 79.7, 77.2, 
74.5, and 55.1; IR (ATR) 3294, 3056, 3017, 2983, 2854, 1738, 1601, 1509, 1359, 
1067, 991, 928, 857, 820, and 746 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 1 h
EtO EtO  
 
234: 1-Ethoxy-4-(1-prop-2-ynyloxy-allyl)-benzene 234.  Sodium hydride in mineral oil 
(60%, 0.225 g, 5.6 mmol) was added to dry THF (10 mL) followed by 217 (0.501 g, 
2.8 mmol).  HMPA (1.0 mL, 5.6 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.5 
mL, 5.6 mmol) was added and the solution was stirred overnight.  Saturated 
ammonium chloride solution (20 mL) was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated, dried (Na2SO4), and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 234 (0.256 g, 42.1%).  Rf  = 0.71 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.28 (d, J = 8.7 Hz, 2H), 6.89 (d, J = 8.6 Hz, 
2H), 5.965 (m, 1H), 5.27 (m, 2H), 4.99 (d, J = 6.6 Hz, 1H), 4.12 (m, 2H), 4.01 (q, J = 
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7.0 Hz, 2H), 2.46 (m, 1H), and 1.41 (t, J = 7.0 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) 
δ 158.5, 137.9, 131.6, 128.2, 116.5, 114.2, 80.5, 79.7, 74.2, 63.1, 54.8, and 14.6; IR 
(ATR) 3289, 2981, 2901, 1738, 1610, 1585, 1511, 1478, 1442, 1393, 1303, 1240, 
1174, 1115, 1067, 1047, 991, 923, and 826 cm
-1
  
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 24 h
OO
 
 
236: 1-Benzyloxy-3-(1-prop-2-ynyloxy-but-3-enyl)-benzene 236.  Sodium hydride in 
mineral oil (60%, 0.159 g, 4.0 mmol) was added to dry THF (10 mL) followed by 206 
(0.504 g, 2.0 mmol).  HMPA (0.7 mL, 4.0 mmol) was then added to the solution 
which was stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene 
(80%, 0.4 mL, 4.0 mmol) was added and the solution was stirred overnight.  
Saturated ammonium chloride solution (20 mL) was added and the solution was 
extracted with chloroform (3 × 20 mL).  The organic layer was separated, dried 
(Na2SO4), and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:19) to give 236 (0.339 g, 58.5%).  
Rf  = 0.68 (EtOAc-hexanes (1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.38 (m, 6H), 7.01 
(m, 1H), 6.96 (m, 2H), 5.81 (m, 1H), 5.11 (m, 4H), 4.57 (m, 1H), 4.16 (dd, J = 2.5, 
2.4 Hz, 1H), 3.90 (dd, J = 2.4 Hz, 1H), 2.66 (m, 1H), 2.49 (m, 1H), and 2.44 (t, J = 
2.4 Hz, 1H); 
13
C NMR (100 MHz, CDCl3) δ 158.9, 142.2, 136.8, 134.3, 129.4, 128.5, 
127.9, 127.5, 119.6, 117.0, 114.3, 113.1, 80.2, 79.8, 74.2, 69.8, 55.5, and 42.0; IR 
(ATR) 3285, 3065, 3032, 2977, 2940, 2906, 2881, 1590, 1445, 1384, 1355, 1320, 
1248, 1167, 1158, 1078, 1013, 992, and 924 cm
-1
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OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 24 h NN
 
 
237: Diethyl-[4-(1-prop-2-ynyloxy-but-3-enyl)-phenyl]-amine 237.  Sodium hydride in 
mineral oil (60%, 0.186 g, 4.7 mmol) was added to dry THF (10 mL) followed by 207 
(0.511 g, 2.3 mmol).  HMPA (0.8 mL, 4.7 mmol) was then added to the solution 
which was stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene 
(80%, 0.4 mL, 4.7 mmol) was added and the solution was stirred overnight.  
Saturated ammonium chloride solution (20 mL) was added and the solution was 
extracted with chloroform (3 × 20 mL).  The organic layer was separated, dried 
(Na2SO4), and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:19) to give 237 (0.205 g, 34.2%).  
Rf  = 0.68 (EtOAc-hexanes (1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.18 (d, J = 8.7 Hz, 
2H), 6.68 (d, J = 8.8 Hz, 2H), 5.83 (m, 1H), 5.08 (m, 2H), 4.46 (m, 1H), 4.11 (m, 
1H), 3.88 (m, 1H), 3.38 (q, J = 7.1 Hz, 4H), 2.68 (m, 1H), 2.48 (m, 1H), 2.41 (m, 
1H), and 1.19 (t, J = 7.1 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 147.5, 135.1, 128.2, 
126.4, 116.4, 111.3, 80.2, 80.0, 73.7, 54.8, 44.2, 41.8, and 12.5; IR (ATR) 3295, 
3075, 2971, 2933, 2898, 1738, 1612, 1520, 1398, 1375, 1355, 1265, 1187, 1154, 
1073, 1011, 914, and 814 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 24 h BrBr  
 
238: 1-Bromo-4-(1-prop-2-ynyloxy-but-3-enyl)-benzene 238.  Sodium hydride in mineral 
oil (60%, 0.180 g, 4.5 mmol) was added to dry THF (10 mL) followed by 205 (0.510 
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g, 2.3 mmol).  HMPA (0.8 mL, 4.5 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.4 
mL, 4.5 mmol) was added and the solution was stirred overnight.  20 mL of saturated 
ammonium chloride solution was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated and dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 238 (0.287 g, 48.2%).  Rf  = 0.79 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.47 (d, J = 8.5 Hz, 2H), 7.19 (d, J = 8.4 Hz, 
2H), 5.73 (m, 1H), 5.04 (m, 2H), 4.53 (m, 1H), 4.11 (dd, J = 2.4 Hz, 1H), 3.85 (dd, J 
= 2.4 Hz, 1H), 2.59 (m, 1H), and 2.41 (m, 2H); 
13
C NMR (100 MHz, CDCl3) δ 139.5, 
133.8, 131.5, 128.6, 121.6, 117.4, 79.5, 79.4, 74.4, 55.5, and 41.8; IR (ATR) 3298, 
3078, 2978, 2903, 2855, 1738, 1642, 1592, 1485, 1442, 1408, 1344, 1229, 1070, 
1010, 917, and 822 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 24 h  
 
239: 1-Methyl-4-(1-prop-2-ynyloxy-but-3-enyl)-benzene 239.  Sodium hydride in mineral 
oil (60%, 0.247 g, 6.2 mmol) was added to dry THF (10 mL) followed by 204 (0.500 
g, 3.1 mmol).  HMPA (1.1 mL, 6.2 mmol) was then added to the solution which was 
stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene (80%, 0.6 
mL, 6.2 mmol) was added and the solution was stirred overnight.  20 mL of saturated 
ammonium chloride solution was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated and dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
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in EtOAc-hexanes (1:19) to give 239 (72.2 mg, 11.7%).  Rf  = 0.82 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.205 (m, 4H), 5.78 (m, 1H), 5.06 (m, 2H), 4.53 
(m, 1H), 4.11 (dd, J = 2.5 Hz, 1H), 3.86 (dd, J = 2.4 Hz, 1H), 2.64 (m, 1H), 2.45 (m, 
1H), 2.41 (t, J = 2.4 Hz, 1H), and 2.36 (s, 3H); 
13
C NMR (100 MHz, CDCl3) δ 137.6, 
137.4, 134.6, 129.1, 126.9, 116.9, 80.1, 79.9, 74.0, 55.3, 42.0, and 21.1; IR (ATR) 
3297, 3077, 3012, 2979, 2923, 2856, 1741, 1641, 1514, 1442, 1347, 1235, 1078, 
1020, 996, 916, and 816 cm
-1
 
OOH
1. NaH, HMPA, THF, r.t., 1h
2. Propargyl bromide, r.t., 24 h
 
 
240: 1-Isopropyl-4-(1-prop-2-ynyloxy-but-3-enyl)-benzene 240.  Sodium hydride in 
mineral oil (60%, 0.214 g, 5.4 mmol) was added to dry THF (10 mL) followed by 203 
(0.510 g, 2.7 mmol).  HMPA (1.0 mL, 5.4 mmol) was then added to the solution 
which was stirred for 1 hour at room temperature.  Propargyl bromide w/v in toluene 
(80%, 0.5 mL, 5.4 mmol) was added and the solution was stirred overnight.  20 mL of 
saturated ammonium chloride solution was added and the solution was extracted with 
chloroform (3 × 20 mL).  The organic layer was separated and dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:19) to give 240 (0.359 g, 58.7%).  Rf  = 0.85 (EtOAc-hexanes 
(1:9)); 
1
H NMR (400 MHz, CDCl3) δ 7.25 (m, 4H), 5.82 (m, 1H), 5.08 (m, 2H), 4.56 
(m, 1H), 4.12 (dd, J = 2.4 Hz, 1H), 3.87 (dd, J = 2.3 Hz, 1H), 2.93 (m, 1H), 2.65 (m, 
1H), 2.47 (m, 1H), 2.39 (t, J = 2.4 Hz, 1H), and 1.28 (d, J = 7.0 Hz, 6H); 
13
C NMR 
(100 MHz, CDCl3) δ 148.3, 137.8, 134.6, 126.8, 126.3, 116.7, 80.0, 79.8, 74.0, 55.2, 
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42.0, 33.7, and 23.9; IR (ATR) 3302, 3078, 3014, 2961, 2904, 2870, 1738, 1642, 
1510, 1461, 1422, 1364, 1298, 1229, 1078, 1018, 996, 916, and 831 cm
-1
 
N
H
O
NH2
O
O O
Py, r.t., 12 h
 
 
243: N-(3-Ethynyl-phenyl)-acetamide 243.  3-Ethynylaniline 241 (2 mL, 19.1 mmol) was 
added to pyridine (20 mL).  Acetic anhydride (5.4 mL, 57.4 mmol) was added and the 
solution was stirred for 12 hours at room temperature.  Water (10 mL) was added to 
the solution which was then extracted with ethyl acetate (3 × 10 mL).  The organic 
layer was separated and washed with saturated copper sulfate solution (3 × 10 mL) 
and then with saturated ammonium chloride solution (3 × 10 mL).  The organic layer 
was dried (Na2SO4) and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:1) to give 243 (2.78 g, 91.3%).  Rf  
= 0.46 (EtOAc-hexanes (1:1)); 
1
H NMR (400 MHz, CDCl3) δ 8.23 (s, 1H), 7.64 (s, 
1H), 7.48 (m, 1H), 7.20 (m, 2H), 3.03 (s, 1H), and 2.13 (s, 3H); 
13
C NMR (100 MHz, 
CDCl3) δ 169.1, 138.0, 128.9, 127.9, 123.5, 122.6, 120.6, 83.1, 77.4, and 24.3; IR 
(ATR) 3301, 3203, 1666, 1605, 1584, 1554, 1482, 1425, 1402, 1371, 1308, 1210, 
1256, 1156, 1017, 880, and 786 cm
-1
; ESI-TOF-MS m/z calcd for C10H9NOH
+
: 
160.08; found 160.05.    
N
H
O
NH2
Cl
O
Py, r.t., 12 h
 
 
244: N-(3-Ethynyl-phenyl)-2,2-dimethyl-propionamide 244.  3-Ethynylaniline 241 (0.100 
g, 0.9 mmol) was added to pyridine (3 mL).  Trimethylacetyl chloride (99%, 0.3 mL, 
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2.6 mmol) was added and the solution was stirred for 12 hours at room temperature.  
Water (10 mL) was added to the solution which was then extracted with ethyl acetate 
(3 × 10 mL).  The organic layer was separated and washed with saturated copper 
sulfate solution (3 × 10 mL) and then with saturated ammonium chloride solution (3 
× 10 mL).  The organic layer was dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (3:17) to 
give 244 (0.149 g, 86.6%).  Rf  = 0.78 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 7.64 (s, 1H), 7.53 (m, 2H), 7.21 (m, 2H), 3.04 (s, 1H), and 1.28 (s, 9H); 
13
C 
NMR (100 MHz, CDCl3) δ 176.8, 138.0, 128.7, 127.7, 123.6, 122.5, 120.7, 83.1, 
77.3, 39.5, and 27.4; IR (ATR) 3303, 3283, 2968, 2931, 2870, 1656, 1579, 1524, 
1472, 1415, 1368, 1293, 1186, 923, 866, 789, 692, 651, and 627 cm
-1
; ESI-TOF-MS 
m/z calcd for C13H15NOH
+
: 202.12; found 201.99.   
N
H
O
NH2
Cl
O
Py, r.t., 12 h
 
 
245: Pent-4-enoic acid (3-ethynyl-phenyl)-amide 245.  3-Ethynylaniline 241 (0.100 g, 0.9 
mmol) was added to pyridine (3 mL).  Pentenoyl chloride (98%, 0.3 mL, 2.6 mmol) 
was added and the solution was stirred for 12 hours at room temperature.  Water (10 
mL) was added to the solution which was then extracted with ethyl acetate (3 × 10 
mL).  The organic layer was separated and washed with saturated copper sulfate 
solution (3 × 10 mL) and then with saturated ammonium chloride solution (3 × 10 
mL).  The organic layer was dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (1:4) to give 
245 (0.101 g, 59.4%).  Rf  = 0.58 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) 
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δ 7.925 (s, 1H), 7.635 (s, 1H), 7.52 (m, 1H), 7.22 (m, 2H), 5.83 (m, 1H), 5.05 (m, 
2H), 3.04 (s, 1H), and 2.44 (m, 4H); 
13
C NMR (100 MHz, CDCl3) δ 171.1, 137.9, 
136.6, 128.9, 127.9, 123.4, 122.6, 120.6, 115.9, 83.1, 77.4, 36.5, and 29.3; IR (ATR) 
3284, 3079, 2978, 2918, 1660, 1602, 1584, 1536, 1482, 1425, 1406, 1367, 1294, 
1237, 994, 920, 873, and 791 cm
-1
; ESI-TOF-MS m/z calcd for C13H13NOH
+
: 200.11; 
found 199.99.   
N
H
O
NH2
Cl
O
Py, r.t., 12 h
MeO
OMe
O
O
 
 
246: N-(3-Ethynyl-phenyl)-succinamic acid methyl ester 246.  3-Ethynylaniline 241 (0.100 
g, 0.9 mmol) was added to pyridine (3 mL).  Methyl 4-chloro-4-oxobutyrate (97%, 
0.3 mL, 2.6 mmol) was added and the solution was stirred for 12 hours at room 
temperature.  Water (10 mL) was added to the solution which was then extracted with 
ethyl acetate (3 × 10 mL).  The organic layer was separated and washed with 
saturated copper sulfate solution (3 × 10 mL) and then with saturated ammonium 
chloride solution (3 × 10 mL).  The organic layer was dried (Na2SO4) and 
concentrated to a residue.  The product was purified by chromatography on silica gel 
in EtOAc-hexanes (1:3) to give 246 (0.139 g, 70.6%).  Rf  = 0.19 (EtOAc-hexanes 
(1:3)); 
1
H NMR (400 MHz, CDCl3) δ 7.82 (s, 1H), 7.64 (s, 1H), 7.52 (m, 1H), 7.22 
(m, 2H), 3.71 (s, 3H), 3.05 (s, 1H), 2.75 (m, 2H), and 2.66 (m, 2H); 
13
C NMR (100 
MHz, CDCl3) δ 173.7, 169.8, 137.8, 128.9, 127.9, 123.1, 122.7, 120.2, 83.1, 77.4, 
52.1, 32.0, and 29.1; IR (ATR) 3361, 3282, 3104, 3029, 3004, 2970, 2953, 1727, 
1738, 1692, 1605, 1550, 1480, 1325, 1171, 884, 805, and 695 cm
-1
; ESI-TOF-MS m/z 
calcd for C13H13NO3H
+
: 232.10; found 231.98.   
254 
 
N
H
O
NH2
Cl
O
Py, r.t., 12 h
 
 
247: N-(3-Ethynyl-phenyl)-benzamide 247.  3-Ethynylaniline 241 (0.100 g, 0.9 mmol) was 
added to pyridine (3 mL).  Benzoyl chloride (0.1 mL, 1.0 mmol) was added and the 
solution was stirred for 12 hours at room temperature.  Water (10 mL) was added to 
the solution which was then extracted with ethyl acetate (3 × 10 mL).  The organic 
layer was separated and washed with saturated copper sulfate solution (3 × 10 mL) 
and then with saturated ammonium chloride solution (3 × 10 mL).  The organic layer 
was dried (Na2SO4) and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:4) to give 247 (0.130 g, 68.8%).  
Rf  = 0.58 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 8.00 (s, 1H), 7.83 
(d, J = 7.2 Hz, 2H), 7.75 (s, 1H), 7.67 (m, 1H), 7.52 (m, 1H), 7.44 (m, 2H), 7.27 (m, 
2H), and 3.06 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 165.9, 137.9, 134.6, 131.9, 
129.0, 128.7, 128.2, 127.0, 123.6, 122.8, 120.8, 83.1, and 77.5; IR (ATR) 3278, 1645, 
1612, 1579, 1547, 1424, 1296, 1253, and 798 cm
-1
; ESI-TOF-MS m/z calcd for 
C15H11NOH
+
: 222.09; found 221.99.   
N
H
O
NH2
Cl
O
Py, r.t., 12 h
 
 
248: Octanoic acid (3-ethynyl-phenyl)-amide 248.  3-Ethynylaniline 241 (0.100 g, 0.9 
mmol) was added to pyridine (3 mL).  Octanoyl chloride (99%, 0.5 mL, 2.6 mmol) 
was added and the solution was stirred for 12 hours at room temperature.  Water (10 
mL) was added to the solution which was then extracted with ethyl acetate (3 × 10 
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mL).  The organic layer was separated and washed with saturated copper sulfate 
solution (3 × 10 mL) and then with saturated ammonium chloride solution (3 × 10 
mL).  The organic layer was dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (3:17) to 
give 248 (0.197 g, 94.7%).  Rf  = 0.69 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 8.20 (s, 1H), 7.66 (s, 1H), 7.54 (m, 1H), 7.20 (m, 2H), 3.02 (s, 1H), 2.33 (m, 
2H), 1.65 (m, 2H), 1.25 (m, 8H), and 0.85 (m, 3H); IR (ATR) 3267, 2953, 2924, 
2855, 1710, 1645, 1606, 1583, 1535, 1424, 1284, 1105, and 883 cm
-1
; ESI-TOF-MS 
m/z calcd for C16H21NOH
+
: 244.17; found 244.04.  
N
H
O
NH2
Cl
O
Py, r.t., 12 h
 
 
249: N-(3-Ethynyl-phenyl)-propionamide 249.  3-Ethynylaniline 241 (0.100 g, 0.9 mmol) 
was added to pyridine (3 mL).  Propionyl chloride (0.3 mL, 2.6 mmol) was added and 
the solution was stirred for 12 hours at room temperature.  Water (10 mL) was added 
to the solution which was then extracted with ethyl acetate (3 × 10 mL).  The organic 
layer was separated and washed with saturated copper sulfate solution (3 × 10 mL) 
and then with saturated ammonium chloride solution (3 × 10 mL).  The organic layer 
was dried (Na2SO4) and concentrated to a residue.  The product was purified by 
chromatography on silica gel in EtOAc-hexanes (1:3) to give 249 (0.139 g, 93.9%).  
Rf  = 0.39 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) δ 8.10 (s, 1H), 7.66 (s, 
1H), 7.52 (m, 1H), 7.20 (m, 2H), 3.04 (s, 1H), 2.36 (q, J = 7.6, 7.508 Hz, 2H), and 
1.19 (t, J = 7.6 Hz, 3H); 
13
C NMR (100 MHz, CDCl3) δ 172.8, 138.0, 128.8, 127.7, 
123.4, 122.5, 120.6, 83.1, 77.3, 30.5, and 9.6; IR (ATR) 3248, 3143, 3082, 2983, 
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2971, 2938, 1650, 1607, 1579, 1547, 1476, 1462, 1417, 1378, 1282, 1221, 1074, 949, 
888, and 788 cm
-1
; ESI-TOF-MS m/z calcd for C11H11NOH
+
: 174.09; found 174.00.   
N
H
O
O
NH2
O Cl
O
Py, r.t., 12 h
 
 
250: (3-Ethynyl-phenyl)-carbamic acid allyl ester 250.  3-Ethynylaniline 241 (0.100 g, 0.9 
mmol) was added to pyridine (3 mL).  Allyl chloroformate (97%, 0.3 mL, 2.6 mmol) 
was added and the solution was stirred for 12 hours at room temperature.  Water (10 
mL) was added to the solution which was then extracted with ethyl acetate (3 × 10 
mL).  The organic layer was separated and washed with saturated copper sulfate 
solution (3 × 10 mL) and then with saturated ammonium chloride solution (3 × 10 
mL).  The organic layer was dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (1:4) to give 
250 (0.129 g, 75.0%).  Rf  = 0.58 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, CDCl3) 
δ 7.53 (s, 1H), 7.42 (m, 1H), 7.22 (m, 2H), 6.95 (s, 1H), 5.94 (m, 1H), 5.30 (m, 2H), 
4.66 (m, 2H), and 3.06 (s, 1H); 
13
C NMR (100 MHz, CDCl3) δ 153.2, 137.8, 132.2, 
129.0, 127.1, 122.7, 122.0, 119.2, 118.3, 83.1, 77.4, and 65.9; IR (ATR) 3295, 3087, 
2950, 1708, 1606, 1586, 1536, 1487, 1432, 1408, 1216, 1171, 1060, 996, 933, and 
788 cm
-1
; ESI-TOF-MS m/z calcd for C12H11NO2H
+
: 202.09; found 202.00.   
N
H
O
O
NH2
O Cl
O
Py, r.t., 12 h
 
 
251: (3-Ethynyl-phenyl)-carbamic acid isobutyl ester 251.  3-Ethynylaniline 241 (0.100 g, 
0.9 mmol) was added to pyridine (3 mL).  Isobutyl chloroformate (98%, 0.4 mL, 2.6 
257 
 
mmol) was added and the solution was stirred for 12 hours at room temperature.  
Water (10 mL) was added to the solution which was then extracted with ethyl acetate 
(3 × 10 mL).  The organic layer was separated and washed with saturated copper 
sulfate solution (3 × 10 mL) and then with saturated ammonium chloride solution (3 
× 10 mL).  The organic layer was dried (Na2SO4) and concentrated to a residue.  The 
product was purified by chromatography on silica gel in EtOAc-hexanes (3:17) to 
give 251 (0.179 g, 96.8%).  Rf  = 0.81 (EtOAc-hexanes (1:3)); 
1
H NMR (400 MHz, 
CDCl3) δ 7.52 (s, 1H), 7.42 (s, 1H), 7.23 (t, J = 7.9 Hz, 1H), 7.17 (d, J = 7.7 Hz, 1H), 
6.87 (s, 1H), 3.95 (d, J = 6.6 Hz, 2H), 3.05 (s, 1H), 1.96 (nonet, J = 13.4, 6.7 Hz, 1H), 
and 0.95 (d, J = 6.7 Hz, 6H); 
13
C NMR (100 MHz, CDCl3) δ 153.6, 138.0, 128.9, 
126.9, 122.7, 122.0, 119.1, 83.2, 77.3, 73.9, 71.4, 27.9, and 19.0; IR (ATR) 3298, 
2963, 2875, 1702, 1606, 1586, 1536, 1488, 1471, 1431, 1410, 1285, 1268, 1217, 
1172, 1062, 998, 978, 938, 886, 788, 770, 686, and 623 cm
-1
; ESI-TOF-MS m/z calcd 
for C13H15NO2H
+
: 218.12; found 218.02.   
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APPENDIX 
 
 
 
11.1 Spectra for (±)-1,4-Regioisomer, 72 
 
O
O
N
O
N
N
N
72, Racemic 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
1
H NMR: 
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N
72, Racemic 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
13
C NMR: 
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N
72, Racemic 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
Infrared Spectrum: 
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11.2 Spectra for (–)-1,4-Regioisomer, 81 
 
O
O
N
O
N
N
N
81, Minus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
1
H NMR: 
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81, Minus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
13
C NMR: 
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81, Minus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
Infrared Spectrum: 
 
 
 
264 
 
 
 
 
O
O
N
O
N
N
N
81, Minus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester
 
Mass Spectrum: 
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11.3 Spectra for (+)-1,4-Regioisomer, 88 
 
O
O
N
O
N
N
N
88, Plus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
1
H NMR: 
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88, Plus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
13
C NMR: 
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88, Plus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
Infrared Spectrum: 
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88, Plus 1,4-Regioisomer
Benzoic acid 
1-methyl-2-{5-[1-methyl-2-(4-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl ester  
 
Mass Spectrum: 
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11.4 Spectra for (±)-1,4-Regioisomer, 71 
 
O
O
N
O
MeO
O
N
N
NHAc
71, Racemic 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
1
H NMR: 
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NHAc
71, Racemic 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
13
C NMR: 
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NHAc
71, Racemic 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
Infrared Spectrum: 
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11.5 Spectra for (–)-1,4-Regioisomer, 79 
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NHAc
79, Minus 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
1
H NMR: 
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79, Minus 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
13
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79, Minus 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
Infrared Spectrum: 
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79, Minus 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
Mass Spectrum: 
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11.6 Spectra for (+)-1,4-Regioisomer, 90 
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90, Plus 1,4-Regioisomer
Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
1
H NMR: 
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Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
13
C NMR: 
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Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
Infrared Spectrum: 
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Succinic acid 
2-(5-{2-[4-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl 
ester methyl ester
 
Mass Spectrum: 
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11.7 Spectra for (±)-1,5-Regioisomer, 91 
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Benzoic acid 1-methyl-2-{5-[1-methyl-2-(5-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl 
ester
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Benzoic acid 1-methyl-2-{5-[1-methyl-2-(5-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl 
ester
 
13
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Benzoic acid 1-methyl-2-{5-[1-methyl-2-(5-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl 
ester
 
Infrared Spectrum: 
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Benzoic acid 1-methyl-2-{5-[1-methyl-2-(5-pyridin-2-yl-[1,2,3]triazol-1-yl)-ethyl]-tetrahydro-furan-2-yl}-ethyl 
ester
 
Mass Spectrum: 
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11.8 Spectra for (±)-1,5-Regioisomer, 92 
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92, Plus 1,5-Regioisomer
Succinic acid 
2-(5-{2-[5-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl ester 
methyl ester
 
1
H NMR: 
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92, Plus 1,5-Regioisomer
Succinic acid 
2-(5-{2-[5-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl ester 
methyl ester
 
13
C NMR: 
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Succinic acid 
2-(5-{2-[5-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl ester 
methyl ester
 
Infrared Spectrum: 
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Succinic acid 
2-(5-{2-[5-(3-acetylamino-phenyl)-[1,2,3]triazol-1-yl]-1-methyl-ethyl}-tetrahydro-furan-2-yl)-1-methyl-ethyl ester 
methyl ester
 
Mass Spectrum: 
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11.9 Spectra for Nonactin Biosynthesis Competitive Inhibitor, 186 
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186, Nonactin Biosynthesis Inhibitor
2-[5-(2-Hydroxy-propyl)-furan-2-yl]-propionic acid  
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186, Nonactin Biosynthesis Inhibitor
2-[5-(2-Hydroxy-propyl)-furan-2-yl]-propionic acid  
 
13
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186, Nonactin Biosynthesis Inhibitor
2-[5-(2-Hydroxy-propyl)-furan-2-yl]-propionic acid  
 
Infrared Spectrum: 
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2-[5-(2-Hydroxy-propyl)-furan-2-yl]-propionic acid  
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